Green tea (Camellia sinensis) for the prevention of cancer by Filippini, Tommaso et al.
Cochrane
Library
 
Cochrane Database of Systematic Reviews
  Green tea (Camellia sinensis) for the prevention of cancer (Review)  
  Filippini T, Malavolti M, Borrelli F, Izzo AA, Fairweather-Tait SJ, Horneber M, Vinceti M  
  Filippini T, Malavolti M, Borrelli F, Izzo AA, Fairweather-Tait SJ, Horneber M, Vinceti M. 
Green tea (Camellia sinensis) for the prevention of cancer. 
Cochrane Database of Systematic Reviews 2020, Issue 3. Art. No.: CD005004. 
DOI: 10.1002/14651858.CD005004.pub3.
 
  www.cochranelibrary.com  
Green tea (Camellia sinensis) for the prevention of cancer (Review) 
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
T A B L E   O F   C O N T E N T S
HEADER......................................................................................................................................................................................................... 1
ABSTRACT..................................................................................................................................................................................................... 1
PLAIN LANGUAGE SUMMARY....................................................................................................................................................................... 2
SUMMARY OF FINDINGS.............................................................................................................................................................................. 4
BACKGROUND.............................................................................................................................................................................................. 9
OBJECTIVES.................................................................................................................................................................................................. 10
METHODS..................................................................................................................................................................................................... 10
RESULTS........................................................................................................................................................................................................ 12
Figure 1.................................................................................................................................................................................................. 13
Figure 2.................................................................................................................................................................................................. 17
Figure 3.................................................................................................................................................................................................. 19
Figure 4.................................................................................................................................................................................................. 20
Figure 5.................................................................................................................................................................................................. 21
Figure 6.................................................................................................................................................................................................. 22
Figure 7.................................................................................................................................................................................................. 23
Figure 8.................................................................................................................................................................................................. 24
Figure 9.................................................................................................................................................................................................. 25
Figure 10................................................................................................................................................................................................ 26
Figure 11................................................................................................................................................................................................ 27
Figure 12................................................................................................................................................................................................ 28
Figure 13................................................................................................................................................................................................ 29
Figure 14................................................................................................................................................................................................ 30
Figure 15................................................................................................................................................................................................ 31
Figure 16................................................................................................................................................................................................ 32
Figure 17................................................................................................................................................................................................ 33
Figure 18................................................................................................................................................................................................ 34
Figure 19................................................................................................................................................................................................ 35
DISCUSSION.................................................................................................................................................................................................. 38
AUTHORS' CONCLUSIONS........................................................................................................................................................................... 40
ACKNOWLEDGEMENTS................................................................................................................................................................................ 40
REFERENCES................................................................................................................................................................................................ 41
CHARACTERISTICS OF STUDIES.................................................................................................................................................................. 59
DATA AND ANALYSES.................................................................................................................................................................................... 176
Analysis 1.1. Comparison 1 Experimental studies: highest versus lowest green tea exposure, Outcome 1 Prostate cancer
incidence................................................................................................................................................................................................
177
Analysis 1.2. Comparison 1 Experimental studies: highest versus lowest green tea exposure, Outcome 2 Gynaecological cancer
incidence................................................................................................................................................................................................
177
Analysis 1.3. Comparison 1 Experimental studies: highest versus lowest green tea exposure, Outcome 3 Non-melanoma skin
cancer incidence...................................................................................................................................................................................
177
Analysis 2.1. Comparison 2 Nonexperimental studies: highest versus lowest green tea exposure, Outcome 1 Any cancer
incidence................................................................................................................................................................................................
182
Analysis 2.2. Comparison 2 Nonexperimental studies: highest versus lowest green tea exposure, Outcome 2 Any cancer
mortality.................................................................................................................................................................................................
183
Analysis 2.3. Comparison 2 Nonexperimental studies: highest versus lowest green tea exposure, Outcome 3 Oral cancer........... 183
Analysis 2.4. Comparison 2 Nonexperimental studies: highest versus lowest green tea exposure, Outcome 4 Oral, pharyngeal
and laryngeal cancer.............................................................................................................................................................................
184
Analysis 2.5. Comparison 2 Nonexperimental studies: highest versus lowest green tea exposure, Outcome 5 Pharyngeal
cancer.....................................................................................................................................................................................................
184
Analysis 2.6. Comparison 2 Nonexperimental studies: highest versus lowest green tea exposure, Outcome 6 Any gut cancer....... 185
Analysis 2.7. Comparison 2 Nonexperimental studies: highest versus lowest green tea exposure, Outcome 7 Oesophageal
cancer.....................................................................................................................................................................................................
185
Analysis 2.8. Comparison 2 Nonexperimental studies: highest versus lowest green tea exposure, Outcome 8 Stomach cancer...... 186
Green tea (Camellia sinensis) for the prevention of cancer (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
i
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Analysis 2.9. Comparison 2 Nonexperimental studies: highest versus lowest green tea exposure, Outcome 9 Liver cancer.......... 187
Analysis 2.10. Comparison 2 Nonexperimental studies: highest versus lowest green tea exposure, Outcome 10 Pancreatic
cancer.....................................................................................................................................................................................................
188
Analysis 2.11. Comparison 2 Nonexperimental studies: highest versus lowest green tea exposure, Outcome 11 Biliary tract
cancer.....................................................................................................................................................................................................
189
Analysis 2.12. Comparison 2 Nonexperimental studies: highest versus lowest green tea exposure, Outcome 12 Colorectal
cancer.....................................................................................................................................................................................................
189
Analysis 2.13. Comparison 2 Nonexperimental studies: highest versus lowest green tea exposure, Outcome 13 Colon cancer...... 190
Analysis 2.14. Comparison 2 Nonexperimental studies: highest versus lowest green tea exposure, Outcome 14 Rectal cancer...... 191
Analysis 2.15. Comparison 2 Nonexperimental studies: highest versus lowest green tea exposure, Outcome 15 Nasopharyngeal
carcinoma..............................................................................................................................................................................................
192
Analysis 2.16. Comparison 2 Nonexperimental studies: highest versus lowest green tea exposure, Outcome 16 Lung cancer....... 193
Analysis 2.17. Comparison 2 Nonexperimental studies: highest versus lowest green tea exposure, Outcome 17 Breast cancer...... 194
Analysis 2.18. Comparison 2 Nonexperimental studies: highest versus lowest green tea exposure, Outcome 18 Gynaecological
cancer.....................................................................................................................................................................................................
194
Analysis 2.19. Comparison 2 Nonexperimental studies: highest versus lowest green tea exposure, Outcome 19 Endometrial
cancer.....................................................................................................................................................................................................
195
Analysis 2.20. Comparison 2 Nonexperimental studies: highest versus lowest green tea exposure, Outcome 20 Ovarian cancer.... 196
Analysis 2.21. Comparison 2 Nonexperimental studies: highest versus lowest green tea exposure, Outcome 21 Prostate cancer.... 196
Analysis 2.22. Comparison 2 Nonexperimental studies: highest versus lowest green tea exposure, Outcome 22 Renal cancer...... 197
Analysis 2.23. Comparison 2 Nonexperimental studies: highest versus lowest green tea exposure, Outcome 23 Urinary tract
cancer.....................................................................................................................................................................................................
197
Analysis 2.24. Comparison 2 Nonexperimental studies: highest versus lowest green tea exposure, Outcome 24 Hematopoietic
cancer.....................................................................................................................................................................................................
198
Analysis 2.25. Comparison 2 Nonexperimental studies: highest versus lowest green tea exposure, Outcome 25 Leukaemia........ 199
Analysis 2.26. Comparison 2 Nonexperimental studies: highest versus lowest green tea exposure, Outcome 26 Lymphoma........ 199
Analysis 2.27. Comparison 2 Nonexperimental studies: highest versus lowest green tea exposure, Outcome 27 Multiple
myeloma................................................................................................................................................................................................
200
Analysis 2.28. Comparison 2 Nonexperimental studies: highest versus lowest green tea exposure, Outcome 28 Non-melanoma
skin cancer.............................................................................................................................................................................................
200
Analysis 2.29. Comparison 2 Nonexperimental studies: highest versus lowest green tea exposure, Outcome 29 Thyroid cancer.... 200
Analysis 2.30. Comparison 2 Nonexperimental studies: highest versus lowest green tea exposure, Outcome 30 Brain cancer....... 201
ADDITIONAL TABLES.................................................................................................................................................................................... 201
APPENDICES................................................................................................................................................................................................. 272
WHAT'S NEW................................................................................................................................................................................................. 275
CONTRIBUTIONS OF AUTHORS................................................................................................................................................................... 275
DECLARATIONS OF INTEREST..................................................................................................................................................................... 275
SOURCES OF SUPPORT............................................................................................................................................................................... 275
DIFFERENCES BETWEEN PROTOCOL AND REVIEW.................................................................................................................................... 275
Green tea (Camellia sinensis) for the prevention of cancer (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
ii
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
[Intervention Review]
Green tea (Camellia sinensis) for the prevention of cancer
Tommaso Filippini1, Marcella Malavolti1, Francesca Borrelli2, Angelo A Izzo2, Susan J Fairweather-Tait3, Markus Horneber4, Marco
Vinceti1,5
1Research Center in Environmental, Nutritional and Genetic Epidemiology (CREAGEN), Department of Biomedical, Metabolic and Neural
Sciences, University of Modena and Reggio Emilia, Modena, Italy. 2Department of Pharmacy, School of Medicine and Surgery, University
of Naples 'Federico II', Naples, Italy. 3Norwich Medical School, University of East Anglia, Norwich, UK. 4Department of Internal Medicine,
Division of Oncology and Hematology, Paracelsus Medical University, Klinikum Nuremberg, Nuremberg, Germany. 5Department of
Epidemiology, Boston University School of Public Health, Boston, USA
Contact address: Marco Vinceti, Research Center in Environmental, Nutritional and Genetic Epidemiology (CREAGEN), Department
of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Via Campi 287, Modena, 41125, Italy.
marco.vinceti@unimore.it.
Editorial group: Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group
Publication status and date: New search for studies and content updated (no change to conclusions), published in Issue 3, 2020.
Citation: Filippini T, Malavolti M, Borrelli F, Izzo AA, Fairweather-Tait SJ, Horneber M, Vinceti M. Green tea (Camellia
sinensis) for the prevention of cancer. Cochrane Database of Systematic Reviews 2020, Issue 3. Art. No.: CD005004. DOI:
10.1002/14651858.CD005004.pub3.
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
This review is an update of a previously published review in the Cochrane Database of Systematic Reviews (2009, Issue 3).Tea is one of
the most commonly consumed beverages worldwide. Teas from the plant Camellia sinensis can be grouped into green, black and oolong
tea, and drinking habits vary cross-culturally. C sinensis contains polyphenols, one subgroup being catechins. Catechins are powerful
antioxidants, and laboratory studies have suggested that these compounds may inhibit cancer cell proliferation. Some experimental and
nonexperimental epidemiological studies have suggested that green tea may have cancer-preventative eGects.
Objectives
To assess possible associations between green tea consumption and the risk of cancer incidence and mortality as primary outcomes, and
safety data and quality of life as secondary outcomes.
Search methods
We searched eligible studies up to January 2019 in CENTRAL, MEDLINE, Embase, ClinicalTrials.gov, and reference lists of previous reviews
and included studies.
Selection criteria
We included all epidemiological studies, experimental (i.e. randomised controlled trials (RCTs)) and nonexperimental (non-randomised
studies, i.e. observational studies with both cohort and case-control design) that investigated the association of green tea consumption
with cancer risk or quality of life, or both.
Data collection and analysis
Two or more review authors independently applied the study criteria, extracted data and assessed methodological quality of studies. We
summarised the results according to diagnosis of cancer type.
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Main results
In this review update, we included in total 142 completed studies (11 experimental and 131 nonexperimental) and two ongoing studies.
This is an additional 10 experimental and 85 nonexperimental studies from those included in the previous version of the review.
Eleven experimental studies allocated a total of 1795 participants to either green tea extract or placebo, all demonstrating an overall high
methodological quality based on 'Risk of bias' assessment. For incident prostate cancer, the summary risk ratio (RR) in the green tea-
supplemented participants was 0.50 (95% confidence interval (CI) 0.18 to 1.36), based on three studies and involving 201 participants
(low-certainty evidence). The summary RR for gynaecological cancer was 1.50 (95% CI 0.41 to 5.48; 2 studies, 1157 participants; low-
certainty evidence). No evidence of eGect of non-melanoma skin cancer emerged (summary RR 1.00, 95% CI 0.06 to 15.92; 1 study, 1075
participants; low-certainty evidence). In addition, adverse eGects of green tea extract intake were reported, including gastrointestinal
disorders, elevation of liver enzymes, and, more rarely, insomnia, raised blood pressure and skin/subcutaneous reactions. Consumption
of green tea extracts induced a slight improvement in quality of life, compared with placebo, based on three experimental studies.
In nonexperimental studies, we included over 1,100,000 participants from 46 cohort studies and 85 case-control studies, which were on
average of intermediate to high methodological quality based on Newcastle-Ottawa Scale 'Risk of bias' assessment. When comparing the
highest intake of green tea with the lowest, we found a lower overall cancer incidence (summary RR 0.83, 95% CI 0.65 to 1.07), based on three
studies, involving 52,479 participants (low-certainty evidence). Conversely, we found no association between green tea consumption and
cancer-related mortality (summary RR 0.99, 95% CI 0.91 to 1.07), based on eight studies and 504,366 participants (low-certainty evidence).
For most of the site-specific cancers we observed a decreased RR in the highest category of green tea consumption compared with the
lowest one. AKer stratifying the analysis according to study design, we found strongly conflicting results for some cancer sites: oesophageal,
prostate and urinary tract cancer, and leukaemia showed an increased RR in cohort studies and a decreased RR or no diGerence in case-
control studies.
Authors' conclusions
Overall, findings from experimental and nonexperimental epidemiological studies yielded inconsistent results, thus providing limited
evidence for the beneficial eGect of green tea consumption on the overall risk of cancer or on specific cancer sites.
Some evidence of a beneficial eGect of green tea at some cancer sites emerged from the RCTs and from case-control studies, but their
methodological limitations, such as the low number and size of the studies, and the inconsistencies with the results of cohort studies, limit
the interpretability of the RR estimates. The studies also indicated the occurrence of several side eGects associated with high intakes of
green tea. In addition, the majority of included studies were carried out in Asian populations characterised by a high intake of green tea,
thus limiting the generalisability of the findings to other populations. Well conducted and adequately powered RCTs would be needed to
draw conclusions on the possible beneficial eGects of green tea consumption on cancer risk.
P L A I N   L A N G U A G E   S U M M A R Y
Green tea for the prevention of cancer
Background
There is a high consumption worldwide of green tea (Camellia sinensis), that contains polyphenols which have a powerful antioxidant
activity that can prevent the formation of free radicals that may cause damage and cell death. Therefore it has been suggested that green
tea might reduce cancer risk, a theory that has been tested through a number of studies on human populations, which examined the link
between green tea consumption and cancer.
The aim of the review
We assessed the association between green tea consumption and the risk of developing cancer in epidemiologic studies.
Main findings
In this review we included 142 studies with more than 1.1 million participants looking for an association between green tea consumption
and cancers of the digestive tract and the female reproductive system, breast, prostate, kidney and urinary tract, nasopharynx, lung, blood,
skin, thyroid and brain. The majority of the studies were of medium to high quality in terms of how they were conducted. Overall, the
evidence from the studies showed that the consumption of green tea consumption to reduce the risk of cancer was inconsistent.
Some studies suggested a beneficial eGect on cancer risk, while others indicated no eGect, and even suggested a slightly increased cancer
risk. In particular, results from experimental studies suggested that green tea extract supplementation yielded a decreased risk for prostate
cancer, but increased risk for gynaecological cancers. For non-melanoma skin cancer no diGerence in cancer cases emerged. Green tea
supplementation seemed to slightly improve quality of life compared with placebo, although it was associated with some adverse eGects
including gastrointestinal disorders, higher levels of liver enzymes, and, more rarely, insomnia, raised blood pressure and skin reactions.
In nonexperimental studies, comparing people consuming the highest amount of green tea to those in the lowest category of consumption,
we found an indication of a lower occurrence of new cases of overall types of cancer, while no diGerence emerged for lethal cases. However,
results according to the type of cancer and study design were inconsistent.
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What are the conclusions?
A beneficial eGect of green tea consumption on cancer prevention remains unproven so far. Caution is advised regarding supplementation
with high-dose green tea extracts due to the possible adverse eGects.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings for the main comparison.   Green tea extract supplementation compared with placebo for preventing cancer: experimental
studies
Green tea extract supplementation compared with placebo for cancer prevention: experimental studies
Patient or population: adults (aged at least 18 years)
Settings: outpatients
Intervention: green tea extract supplementation
Comparison: placebo
Anticipated absolute effects* (95% CI)
(studies)
Outcomes Relative ef-
fect
(95% CI)
Placebo Green tea
extract
supplemen-
tation
Difference
No of par-
ticipants
(studies)
Certainty
of the evi-
dence
(GRADE)
Comments/explanations
Prostate
cancer inci-
dence
RR 0.50
(0.18 to
1.36)
22.0% 11.7%
(4.4 to 28.7)
10.3% fewer
(17.6 fewer
to 6.7 more)
201
(3 RCTs)
⊕⊕⊝⊝
Low
Very large effects, but all participants were at high risk of
prostate cancer at the time of recruitment, with high-grade
prostatic intraepithelial neoplasia and/or atypical small aci-
nar proliferation less than 3 months before, thus the indi-
rectness in transferring the results to the general population,
high imprecision of the summary estimates based on only
201 participants and 32 cases, and high inconsistency be-
tween study results
Gynaeco-
logical can-
cer inci-
dence
RR 1.50
(0.41 to
5.48)
0.9% 1.3%
(0.4 to 4.6)
0.4% more
(0.5 fewer to
3.7 more)
1157
(2 RCTs)
⊕⊕⊝⊝
Low
Large effects, but high imprecision of the summary RR and
high inconsistency of results due to contradictory findings
from two available studies.
Non-
melanoma
skin cancer
incidence
RR 1.00
(0.06 to
15.92)
0.2% 0.2%
(0.0 to 2.9)
0.0% fewer
(0.0 fewer to
2.7 more)
1075
(1 RCT)
⊕⊕⊝⊝
Low
Very high imprecision based on only one study and no large
effect detected.
Quality of
life
Not es-
timable
- - - - Not as-
sessed
Due to the large number of different scales used it was not
possible to the overall certainty of evidence.
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The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
 
 
Summary of findings 2.   Highest compared with lowest green tea exposure for preventing cancer: primary outcomes in nonexperimental studies
Highest compared with lowest green tea exposure for preventing cancer in nonexperimental studies
Patient or population: adults (aged at least 18 years)
Setting: outpatient
Intervention: highest green tea exposure
Comparison: lowest green tea exposure
Outcomes
(number of studies)
Relative effect
(95% CI)
Number of participants
(number of cases)
Certainty of
the evidence
(GRADE)
Comments
Any cancer incidence
(3 studies)
RR 0.83 (0.65 to 1.07) 52,479 
(4962 cases)
⊕⊕⊝⊝
Low
Largea but imprecise effect. Similar but imprecise effect
from the 2 cohort studies (RR 0.81, 95% CI 0.50 to 1.32)
Any cancer mortality
(8 studies)
RR 0.99 (0.91 to 1.07) 504,366 
(21,439 cases)
⊕⊕⊝⊝
Low
Not a large effect. All cohort studies
The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
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aUpgrading criteria for nonexperimental studies considered are: large eGect estimates.
 
 
Summary of findings 3.   Highest compared with lowest green tea exposure for preventing cancer: individual cancer types in nonexperimental studies
Highest compared with lowest green tea exposure for preventing cancer in nonexperimental studies
Patient or population: adults (aged at least 18 years)
Setting: outpatient
Intervention: highest green tea exposure
Comparison: lowest green tea exposure
Outcomes
(Number of stud-
ies)
Relative ef-
fect
(95% CI)
Number of
participants
(number of
cases)
Certainty of
the evidence
(GRADE)
Comments
Oral cancer risk
(5 studies)
RR 0.71 (0.62
to 0.82
55,977
(2343 cases)
⊕⊕⊝⊝
Low
Large effecta, but possible serious risk of bias due to case-control studies. Smaller but more im-
precise effect from the single cohort study (RR 0.44, 95% CI 0.19 to 1.04)
Any gut cancer
risk
(7 studies)
RR 0.78 (0.59
to 1.02)
70,299
(3191 cases)
⊕⊕⊝⊝
Low
Large effecta, but possible serious risk of bias due to case-control studies. Smaller but more im-
precise decreased risk for cohort studies alone (RR 0.86, 95% CI 0.27 to 2.79; 2 studies)
Oesophageal can-
cer risk
(13 studies)
RR 0.81 (0.64
to 1.04)
74,895
(4595 cases)
⊕⊝⊝⊝
Very low
Large effecta, but possible serious risk of bias due to case-control studies. Possible publication
bias. Increased though highly imprecise risk from the single cohort study (RR 1.67, 95% CI 0.88 to
3.16)
Stomach cancer
risk
(18 studies)
RR 0.86 (0.74
to 1.01)
438,595
(10,183 cases)
⊕⊝⊝⊝
Very low
Large effecta, but possible serious risk of bias due to case-control studies. Null risk from cohort
studies alone (RR 0.99, 95% CI 0.85 to 1.14; 7 studies)
Liver cancer risk
(6 studies)
RR 0.88 (0.68
to 1.14)
198,885
(1284 cases)
⊕⊕⊝⊝
Low
Small but imprecise effect. Mostly cohort studies showing similar but smallest risk (RR 0.93, 0.71
to 1.20; 5 studies)
Pancreatic cancer
risk
(9 studies)
RR 0.88 (0.70
to 1.10)
326,564
(2386 cases)
⊕⊕⊝⊝
Low
Small but imprecise effect. Possible serious risk of bias due to case-control studies. Null risk for
only cohort studies (RR 1.04, 95% CI 0.84 to 1.30; 6 studies)
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Colorectal cancer
risk
(16 studies)
RR 0.84 (0.74
to 0.96)
610,295
(8601 cases)
⊕⊕⊝⊝
Low
Large effecta, but possible serious risk of bias due to case-control studies. Null risk for cohort
studies alone (RR 1.00, 95% CI 0.92 to 1.08; 9 studies)
Colon cancer risk
(10 studies)
RR 0.89 (0.80
to 0.98)
389,974
(4118 cases)
⊕⊕⊝⊝
Low
Large effecta, but possible serious risk of bias due to case-control studies. Smaller but more im-
precise decreased risk for cohort studies alone (RR 0.93, 95% CI 0.82 to 1.05; 6 studies)
Rectal cancer risk
(9 studies)
RR 0.89 (0.75
to 1.05)
356,851
(2679 cases)
⊕⊕⊝⊝
Low
Small effect. Smaller but more imprecise effect from only cohort studies (RR 0.92, 95% CI 0.77 to
1.09, 5 studies)
Lung cancer risk
(17 studies)
RR 0.88 (0.76
to 1.02)
269,565
(9180 cases)
⊕⊝⊝⊝
Very low
Small effect, but possible serious risk of bias due to case-control studies. Null risk for cohort
studies alone (RR 1.02, 95% CI 0.79 to 1.31; 6 studies)
Breast cancer risk
(14 studies)
RR 0.88 (0.75
to 1.02)
250,822
(9378 cases)
⊕⊝⊝⊝
Very low
Small effect, but possible serious risk of bias due to case-control studies. Null risk for cohort
studies alone (RR 1.01, 95% CI 0.86 to 1.19; 5 studies)
Gynaecological
cancer risk
(10 studies)
RR 0.69 (0.57
to 0.83)
66,738
(5506 cases)
⊕⊕⊝⊝
Low
Large effecta, but possible serious risk of bias due to case-control studies. Similar but more im-
precise effect from the single cohort study (RR 0.75, 95% CI 0.43 to 1.30)
Endometrial can-
cer risk
(5 studies)
RR 0.77 (0.65
to 0.91)
60,416
(2835 cases)
⊕⊕⊝⊝
Low
Large effect, but possible serious risk of bias due to case-control studies. Smaller but imprecise
effect from the single cohort study (RR 0.75, 95% CI 0.43 to 1.30)
Ovarian cancer
risk
(5 studies)
RR 0.64 (0.45
to 0.90)
6,322
(2671 cases)
⊕⊕⊝⊝
Low
Large effecta, but possible serious risk of bias due to all case-control studies
Prostate cancer
risk
(13 studies)
RR 0.73 (0.56
to 0.94)
127,239
(2926 cases)
⊕⊝⊝⊝
Very low
Large effecta, but possible serious risk of bias due to case-control studies. Increased though im-
precise risk for cohort studies alone (RR 1.09, 95% CI 0.89 to 1.32; 5 studies). Possible publication
bias
Urinary tract can-
cer risk
(7 studies)
RR 1.04 (0.79
to 1.37)
156,039
(2235 cases)
⊕⊝⊝⊝
Very low
Small and imprecise effect. Increased but imprecise effect from cohort studies alone (RR 1.24,
95% CI 0.87 to 1.76; 3 studies)
The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
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CI: confidence interval; RR: risk ratio
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
aUpgrading criteria for nonexperimental studies considered are: large eGect estimates.
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B A C K G R O U N D
This review is an update of a previously published Cochrane review
(Boehm 2009).
Description of the intervention
Tea (Camellia sinensis) is the most highly consumed manufactured
drink in the world (FAO 2018). Between 2007 and 2016, world
tea production grew by an average annual rate of 4.4%. Global
tea consumption was 5.53 million tonnes in 2016 with an annual
growth rate of 4.5% between 2007 and 2016. Three-quarters of
global production is consumed locally, driven particularly by China,
India and other emerging economies (FAO 2018). In high-income
countries, consumption is much lower, being generally one-fiKh of
that found in low- and middle-income countries. Tea consumption
has stabilised in recent years, with a few exceptions (FAO 2015), for
example between 1990 and 2014, total tea consumption increased
in the USA by about 38% (USDA 2018).
Brewed tea is obtained from the infusion of leaves and buds
of Camellia sinensis. The most commonly consumed types of
tea are green and black tea. Approximately 20% of the world's
Camellia sinensis consumption is in the form of green tea; the
other 80% is black (FAO 2015). Tea is characterised by the
manufacturing process that the leaves undergo aKer harvesting.
Green tea is made by processing fresh leaves using heat or hot
steam immediately aKer collection, thus minimising any oxidation
processes. Conversely, in black tea, the leaves undergo several
treatments, including withering by blowing air, preconditioning,
'cut-tear-curl', fermentation and final drying, which result in an
oxidised tea (Preedy 2014). Depending on these processes, the
degree of oxidation may vary greatly, thus influencing the content
of antioxidant compounds (Preedy 2014).
Due to the high content of antioxidant compounds, a great deal of
attention has been given to green tea with regard to the possible
prevention of chronic diseases and cancer (Eisenstein 2019; Yang
2019), as well as possible beneficial eGects on cardiovascular
disease, insulin sensitivity and lipid profiles (Liu 2013b; Yang 2019;
Yu 2017).
How the intervention might work
Pharmacology of Camellia sinensis
The active ingredients of green tea include polyphenols most
of which are flavonols, commonly known as catechins. These
account for 30% to 40% of the extractable solids of dried green
tea leaves. Other active ingredients are alkaloids, such as caGeine
and theobromine, carbohydrates, and minerals and other trace
elements, such as fluoride and aluminium (Coppock 2016; Filippini
2019; Milani 2019; Yang 2019). Green tea contains higher amounts
of catechins than black tea (Peluso 2017), and green tea processing
prevents oxidation (Chen 2007). AKer fermentation from green to
black tea, about 15% of catechins remain unchanged while the rest
of the catechins are converted to theaflavins, which are polyphenol
pigments and thearubigins (Blumenthal 2003). Brewing conditions,
including water temperature and infusion time, influence the
antioxidant capacity of green tea (Sharpe 2016).
The catechins found in green tea include epigallocatechin-3-gallate
(EGCG), epigallocatechin, epicatechin-3-gallate and epicatechin,
gallocatechins and gallocatechin gallate. EGCG is the predominant
and most studied catechin in green tea (Peluso 2017; Yang 2019),
as it is a powerful antioxidant believed to be an important
determinant of the therapeutic qualities of green tea (Chen 2019;
Gao 2016; Peluso 2017). It is suggested that EGCG works by
suppressing the formation of new blood vessels (angiogenesis) and
regulating their permeability, thereby cutting oG the blood supply
to cancerous cells (Demeule 2002; Diniz 2017; Maiti 2003; Rashidi
2017; Yang 2019). In vitro studies and in vivo animal models have
shown EGCG to be a potent chemo-preventative agent (Liao 2001;
Shirakami 2018; Xu 2019).
Green tea catechins have also been shown to decrease plasma
lipid peroxide and malondialdehyde concentrations, to increase
plasma ascorbate concentrations, to decrease non-haem iron
absorption, and increase the resistance of low-density lipoproteins
to oxidation (Williamson 2005). It is recognised that most classes
of catechins are suGiciently well absorbed to have the potential
to induce biological eGects, since they cross the intestinal barrier
and reach concentrations in the blood stream that have been
shown in vitro to exert eGects (Liao 2001; Manach 2005; Scalbert
2000). They are reported to be rapidly absorbed and eliminated
in humans. Peak plasma concentrations were observed between
one to three hours aKer oral administration and reached total
catechin concentrations in the sub- or low-μM range, and with a
half-life of two to four hours. Parent flavonoids are deglycosylated
during digestion, are absorbed in the small intestine, and
appear in the blood as phase II metabolites (Williamson 2018).
Pharmacokinetic studies show that the flavonoid epicatechin is
absorbed in the small intestine with a number of structural-related
epicatechin metabolites (SREM) attaining sub-μmol/L peak plasma
concentrations (Cmax) approximately one hour aKer ingestion
(Borges 2018). The SREMs are excreted in urine over a 24-hour
period in amounts corresponding to 20% of epicatechin intake.
If unabsorbed along the small intestine epicatechin undergoes
microbiota-mediated conversions in the colon, which, being
absorbed, appear in plasma as phase II metabolites with a Cmax
of 5.8 hours aKer consumption, and they are excreted in quantities
equivalent to 42% of the ingested epicatechin (Borges 2018).
Possible mechanisms of action of Camellia sinensis
polyphenols
Green tea polyphenols inhibit cell proliferation and viability, and
have been shown (primarily in in vitro and ex vivo studies)
to exert a powerful antioxidant activity (Ahmad 1999; Romano
2013; Schröder 2019; Yang 1993; Yang 1997). Several mechanisms
have been proposed for the potential anticancer activity of green
tea catechins (Yang 2019). Their polyphenolic structure allows
electron delocalisation, conferring the ability to quench free
radicals. EGCG, has been shown to reduce reactive oxygen species,
such as superoxide radical, singlet oxygen, hydroxyl radical,
peroxyl radical, nitric oxide, nitrogen dioxide and peroxynitrite
(Sang 2011). Tea polyphenols are also strong chelators of metal
ions, thus hampering the formation of reactive oxygen species.
Several hypotheses have been put forward to explain a possible
cancer-preventive activity of catechins (Fujiki 1999; Yang 2019),
including counteraction of tumour growth, invasion, metastasis
and cell transformation, as well as inhibiting the interaction of
tumour promoters, hormones and various growth factors with their
receptors (Beltz 2006; Peluso 2017; Rahmani 2015; Rashidi 2017;
Yang 2019). However, although in vitro and animal mechanistic
studies indicate that flavonoids have anticancer properties, much
of the evidence is derived from culture studies using unmetabolised
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flavonoids, and the simple antioxidant hypothesis is no longer
an acceptable explanation (Kerimi 2018). In animal models,
where high doses of green tea extracts and constituents have
been used, strong evidence for the cancer-preventive activity
of tea constituents has been noted (Yang 2009; Yang 2011b).
However, because of diGerences in endogenous metabolism and
gut microflora, animal studies produce data that may not be
necessarily be extrapolated to humans (Borges 2016).
Why it is important to do this review
Many reviews have been undertaken in recent years to examine
the association between green tea consumption and cancer risk.
Examples include a meta-analysis that concluded that there is
a dose-response relationship between green tea consumption
and prevention of prostate cancer when more than seven cups
of tea are consumed per day (Guo 2017). Another recent dose-
response meta-analysis reported a relationship between green tea
drinking and prevention of liver cancer, with the downward trend
being most obvious when the consumption was increased to four
cups per day (Ni 2017). Similarly, dose-response analysis of green
tea consumption and biliary tract cancer suggested that the risk
decreased by 4% with each additional cup of tea per day, especially
in women (Xiong 2017). A systematic review examining the eGect
of green tea on risk of breast cancer suggested a protective eGect
(Gianfredi 2018), whereas another was inconclusive (Najaf 2018).
With regard to gastric cancer, the eGect of green tea may be
temperature-dependent, with high-dose, long-term consumption
reducing the risk, whereas very high-temperature green tea may
possibly increase the risk of gastric cancer (Huang 2017).
Since several additional experimental and nonexperimental
epidemiological studies have become available since the previous
version of this Cochrane Review, we undertook an update to assess
the relationship between peoples' green tea or EGCG consumption
and cancer risk.
O B J E C T I V E S
To assess possible associations between green tea consumption
and the risk of cancer incidence and mortality as primary outcomes,
and safety data and quality of life as secondary outcomes.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included studies in which participants consumed green tea
orally, either as drinkable tea or as extracts. Studies used one of the
following designs.
• Experimental studies: randomised controlled trials (RCTs)• Nonexperimental studies: both cohort and case-control
observational studies
We did not consider case-series, case reports and other studies
without a comparator, editorials, reviews, animal studies and in
vitro studies for this review.
Types of participants
Adult participants (18 years of age and older).
Types of interventions
We were interested in studies that focused on the consumption
of green tea, either as part of an intervention (experimental)
study or measured in a nonexperimental study. The exposure
variable was the consumption of green tea or green tea extract
(only monotherapy preparations for oral consumption in liquid,
powder or tablet form). We excluded studies that used green tea
extract supplementation as part of a multi-component preparation
if they did not include a study arm using green tea extracts in
monotherapy.
We defined green tea as non-fermented tea leaves, and studies had
to mention that green tea, non-fermented tea or 'matsu-cha', as it
is called in Asia, had been consumed. We considered any method of
quantifying this variable (e.g. direct recording, recall questionnaire)
as potentially valid. We excluded studies that did not distinguish
the type of tea (e.g. black tea versus green tea) or did not report
quantitative data of at least two diGerent amounts or frequencies
of green tea consumption.
We excluded pharmacokinetic-type studies because they were
unlikely to contribute useful data on long-term eGects of green tea.
Only studies reporting the duration of green tea consumption in
their summary were included.
Types of outcome measures
Primary outcomes
The primary outcome measures were:
• the number of participants developing cancer (incidence);• the number of participants dying from cancer (mortality).
Results from nonexperimental epidemiological studies had to
include an estimate of the risk ratio (RR), or suGicient data for us to
calculate it.
We used the following categories to combine and analyse diGerent
types of cancer.
• Gastrointestinal cancers: including oral cancer, pharyngeal
cancer, laryngeal cancer, oesophageal cancer, stomach cancer,
liver cancer, pancreatic cancer, biliary tract cancer, and
colorectal cancer• Respiratory tract cancer: including nasopharyngeal cancer, lung
cancer, and mesothelioma• Breast cancer• Urogenital tract cancers: including prostate cancer, endometrial
cancer, ovarian cancer, renal cancer, and urinary tract cancer• Haematological cancers: including haematopoietic cancer,
leukaemia, lymphoma, and multiple myeloma• All other types of cancer
Secondary outcomes
Safety data and data on quality of life
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Search methods for identification of studies
Electronic searches
For the original review we searched the following electronic
databases from inception to January 2009 to retrieve studies for
potential inclusion: the Cochrane Central Register of Controlled
Trials (CENTRAL), MEDLINE (Ovid), Embase (Ovid), Amed, CancerLit,
PsychInfo and Phytobase.
For this update we searched the following electronic databases up
to January 2019:
• the Cochrane Central Register of Controlled Trials (CENTRAL;
2019, Issue 1) in the Cochrane Library (Appendix 1);• MEDLINE via Ovid (January 2009 to January week 1, 2019)
(Appendix 2);• Embase via Ovid (January 2009 to 2019 Week 1) (Appendix 3).
Searching other resources
We systematically checked references from published studies for
further studies. We specifically screened the reference list from
studies retrieved in full text, and also from previous systematic
reviews and meta-analysis on the topic, including non-English
papers, though we assumed that some of the articles from Asian
countries would not be retrievable via Western medical databases.
We obtained all relevant non-English articles and a Japanese/
Chinese Cochrane collaborator acted as a filter for study selection.
Publications in languages other than English were translated in-
house or by using relevant services. Finally, we also checked for
other relevant studies in the clinical trials registry ClinicalTrials.gov
up to January 2019.
Data collection and analysis
Selection of studies
To be included, studies had to report on the consumption of green
tea, non-fermented tea or 'matsu-cha'. Two review authors checked
studies identified by the searches and included articles on initial
screen only if they could determine from the abstract that the
article was a report of either an experimental intervention or a
nonexperimental study. When we could not reject with certainty a
title or abstract, we assessed the full text.
Two review authors independently analysed the full text of all
potentially relevant eligible studies. Reasons for excluding any
study are stated in Criteria for considering studies for this review.
All disagreements were resolved by discussion between the two
review authors. If any data were missing from the study reports, we
attempted to obtain the data by contacting the study authors.
Data extraction and management
Two review authors independently performed data extraction
using pre-defined and pre-tested data extraction forms. We
resolved discrepancies by discussion. We categorised studies into
experimental (RCTs) and nonexperimental studies (i.e. cohort
studies, including cohort-nested studies, and case-control studies).
We also grouped data according to study design and cancer
type. We entered the extracted data into Review Manager 5
(Review Manager 2014), and two review authors double-checked
the entries.
Assessment of risk of bias in included studies
Four review authors independently assessed the risk of bias of the
included studies.
Experimental studies
We used the Cochrane 'Risk of bias' tool to assess risk of bias in
the included RCTs (Higgins 2017). The criteria relate to the following
domains:
• Selection bias: random sequence generation and allocation
concealment• Performance bias: blinding of participants and personnel (i.e.
treatment providers)• Detection bias: blinding of outcome assessment• Attrition bias: incomplete outcome data• Reporting bias: selective reporting of outcomes• other possible sources of bias (please specify)
We considered studies that we assessed as 'adequate' in all main
domains to be at low risk of bias. Studies in which there was no clear
judgement concerning the procedures in one or more key domains
we considered to be at least of medium risk of bias. Studies with
clearly inadequate procedures in one or more of the key domains
we considered to be at high risk of bias.
Nonexperimental studies
We used the Newcastle-Ottawa Scale (NOS) to assess the
methodological quality of epidemiologic studies (Wells 2001). The
NOS is based on a 'star' system in which a study is assessed on three
broad perspectives:
• selection of study groups;• comparability of the groups;• ascertainment of outcome or exposure of interest for cohort or
case-control studies, respectively.
High-quality answers to each NOS question are identified with a
star/asterisk. Details used during the evaluation are reported in two
templates, one for cohort (Appendix 4), and one for case-control
studies (Appendix 5). Both cohort and case-control studies can
receive a maximum of nine stars or points. We considered studies
with six or fewer points as low quality, with seven to eight points as
medium quality, and with nine points as high quality.
Measures of treatment e:ect
We used the following measures of the eGect of treatment or
exposure.
• For dichotomous outcomes (i.e. cancer risk), we used the risk
ratio (RR) for both experimental and nonexperimental studies.• For continuous outcomes (evaluation of scores for quality of
life), we used the mean diGerence between treatment arms in
experimental studies.
Unit of analysis issues
We did not note any unit of analysis issues.
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Dealing with missing data
When a study had missing data in the level of exposure assessment,
risk estimates or confidence intervals, we attempted to obtain the
data by contacting the study authors. Nevertheless, we reported
the available data in Characteristics of included studies. We did not
impute missing data for any of the outcomes for data analysis.
Assessment of heterogeneity
We used the Chi2 test for heterogeneity and the I2 statistic (Higgins
2003), to quantify heterogeneity of study results. We interpreted
the I2 statistic as per guidance provided in the Cochrane Handbook
for Systematic Reviews of Interventions (Deeks 2017): 0% to 40%
might not be important; 30% to 60% represented moderate
heterogeneity; 50% to 90% represented substantial heterogeneity;
and 75% to 100% represented considerable heterogeneity.
Assessment of reporting biases
We followed the recommendations for testing for funnel plot
asymmetry as described in the Cochrane Handbook for Systematic
Reviews of Interventions (Sterne 2017). Funnel plot asymmetry may
be due to reporting bias. We produced funnel plots to assess the
potential for small-study eGects when at least five studies reported
results for the same type of cancer (Egger 1997).
Data synthesis
We carried out a meta-analysis of the included studies when the
study results reported estimate for cancer risk or we could compute
it from raw data. When studies reported more than one estimated
risk, we used the results generated by the most adjusted model. We
used a random-eGects model for all analyses. We carried out and
reported overall analyses and analyses stratified by study design.
Subgroup analysis and investigation of heterogeneity
We performed subgroup analysis for any cancer incidence and
mortality and, whenever possible, for all diGerent types of cancer
site according to categories identified in Primary outcomes.
In order to investigate possible sources of heterogeneity, we
also performed stratified analyses according to study design
of nonexperimental studies (hospital-based case-control design,
population-based case-control design, cohort design).
Sensitivity analysis
We performed the following sensitivity analyses:
• study design of nonexperimental studies (hospital-based case-
control design, population-based case-control design, cohort
design).
Summary of findings and assessment of the certainty of the
evidence
We presented the overall certainty of evidence of all outcomes
investigated in the experimental studies, namely prostate cancer,
gynaecological cancer and non-melanoma skin cancer. We also
presented the certainty of evidence for the primary outcomes of
nonexperimental studies and for which it was possible to evaluate
publication bias, that is, when at least five studies reported results
for the same type of cancer (Egger 1997).
We evaluated the overall certainty of evidence according to the
GRADE approach (Atkins 2004), which takes into account issues
related not only to internal validity (risk of bias, inconsistency,
imprecision, publication bias) but also to external validity, such
as directness of results (Langendam 2013). We created three
'Summary of findings' tables (Summary of findings for the main
comparison; Summary of findings 2; Summary of findings 3),
adhering to the methods described in the Cochrane Handbook for
Systematic Reviews of Interventions (Schünemann 2017), and using
GRADEpro GDT. We used the GRADE checklist and GRADE Working
Group certainty of evidence definitions (Meader 2014), as follows.
• High-certainty: we are very confident that the true eGect lies
close to that of the estimate of the eGect.• Moderate-certainty: we are moderately confident in the eGect
estimate. The true eGect is likely to be close to the estimate of the
eGect, but there is a possibility that it is substantially diGerent.• Low-certainty: our confidence in the eGect estimate is limited,
and the true eGect may be substantially diGerent from the
estimate of the eGect.• Very low-certainty: we have very little confidence in the eGect
estimate, and the true eGect is likely to be substantially diGerent
from the estimate of eGect.
R E S U L T S
Description of studies
Results of the search
For the initial version of this review (Boehm 2009), we identified
a total of 675 hits from the literature searches from database
inception to January 2009. However, 586 clearly did not match
inclusion criteria and were excluded by title and abstract screening.
The main reasons for exclusion were that the paper did not
investigate people or cancer. Of the remaining 89 papers, we
retrieved the full-text articles and assessed them according to the
inclusion criteria provided in the protocol. Thirty-eight of them did
not fulfil the inclusion criteria. The main reasons for exclusion were
as follows: no distinction between green and black tea, endpoints
other than cancer, frequency of green tea consumption was not
specified, or they were duplicate publications. Of the remaining
records we identified 51 studies for inclusion (1 RCT, 23 prospective
cohort studies and 27 retrospective case-control studies).
In this update of the original review, we conducted the literature
search from January 2009 to January 2019, and we retrieved an
additional 2399 hits from database searching. We included a further
21 articles of potential relevance from trials registries and citation
chasing (Booth 2008; EUnetHTA 2017). AKer de-duplication, we
screened a total of 1932 references. Of these, we excluded 1742
references as clearly irrelevant on the basis of the title and abstract
review. We then retrieved the full-text articles for the remaining
190 publications and assessed them for possible relevance. We
considered 130 of these publication as eligible for inclusion. For
the 60 studies that we excluded, 30 studies reported exposure not
including green tea separately, 13 had an ineligible study design
(e.g. cross-sectional studies or pharmacokinetic studies), 11 did
not include cancer among the outcomes, four were undertaken in
non-healthy individuals all with cancer, and two studies were from
paediatric populations (Figure 1).
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Figure 1.   PRISMA flow-chart
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Figure 1.   (Continued)
 
In total we identified 181 references (51 from the original review
and 130 from the update searches) referring to 144 studies (22
references for 11 experimental studies, 157 references for 131
nonexperimental studies and two ongoing studies) for inclusion
in this review (Figure 1; Characteristics of included studies;
Characteristics of ongoing studies). Only the number of studies,
not the number of references, was subsequently mentioned in the
review.
Included studies
Overall, the 142 epidemiological studies of experimental and
nonexperimental design considered in this review included over
1,100,000 participants. A total number of 1795 participants
were included in experimental studies (Table 1), over 957,000
participants in cohort studies (Table 2), and 47,973 cases and
130,306 referents in case-control studies (Table 3). Studies were
carried out in 10 diGerent countries.
In the experimental group, six studies were carried out in the USA,
two in Italy, and one each in the UK, Egypt, and Japan. The ongoing
experimental studies are being carried out in the USA and China.
In the nonexperimental group, 63 studies (9 cohort and 54 case-
control) were carried out in China, 50 (34 cohort and 16 case-
control) in Japan, 11 (3 cohort and 8 case-control) in the USA,
two (case-control) each in Algeria and Australia, and one (case-
control) each in Czech Republic, Iran and Romania. The studies
were published between 1985 and 2018. The majority of references
(N = 165) were published in English, while 15 were published in
Chinese and one in Japanese (Characteristics of included studies).
Outcomes
Of the 46 cohort studies, 37 measured cancer incidence and
9 measured cancer mortality (Iwai 2002; Khan 2004; Kuriyama
2006; Lin 2008; Liu 2016; Naganuma 2009; Odegaard 2015; Saito
2015; Suzuki 2009). All of the 85 case-control studies assessed
any association between green tea consumption and cancer
risk. Details of individual study results are reported in Table
4; Table 5. The 11 included RCTs (Bettuzzi 2006; Dostal 2015;
Dryden 2013; Garcia 2014; Garland 2006; Kumar 2015; Lane
2018; Micali 2017; Roshdy 2013; Sinicrope 2017; Tsao 2009), and
two ongoing studies (Shannon 2010; NCT01496521), investigated,
amongst other outcomes, cancer incidence (namely prostate
cancer, gynaecological cancers and non-melanoma skin cancer),
quality of life (Bettuzzi 2006; Dryden 2013; Micali 2017; Roshdy
2013), and safety data (Bettuzzi 2006; Dostal 2015; Dryden 2013;
Garcia 2014; Garland 2006; Kumar 2015; Lane 2018; Micali 2017;
Roshdy 2013; Sinicrope 2017; Tsao 2009). Details of individual study
results are reported in Table 6.
Diagnoses
Any cancer type
Two cohort studies (Nagano 2001; Nakachi 2000), and one case-
control study (Li 2011a), reported incidence of any cancer. Eight
cohort studies (Iwai 2002; Khan 2004; Kuriyama 2006; Liu 2016;
Odegaard 2015; Saito 2015; Suzuki 2009; Zhao 2017) reported any
cancer mortality.
Gastrointestinal tract cancer
Two experimental studies reported data on gastrointestinal cancer:
one study assessed the clinical and histologic response of high-
risk oral lesions aKer green tea as ministration (Tsao 2009), and
one study assessed the histological presence of rectal aberrant
crypt foci of colon cancer (Sinicrope 2017). One experimental
study assessing incidence of oesophageal cancer is ongoing
(NCT01496521).
Seventy-one nonexperimental studies reported data on the risk
of cancer of the gastrointestinal tract and provided data on nine
diGerent types of cancer.
• Oral cancer: one cohort study (Ide 2007), four case-control
studies (Chen 2017a; Fu 2013; Yan 2016; Zheng 1993)• Overall oral, pharyngeal and laryngeal cancer: one cohort study
(Oze 2014)• Pharyngeal cancer: one case-control study (Takezaki 2000)• Oesophageal cancer: three cohort studies (Ishikawa 2006,
Nagano 2001; Nechuta 2012), 12 case-control studies (Chen
2011; Gao 1994; Inoue 1998; Islami 2009; Mu 2003; Oze 2014;
Peng 2015; Takezaki 2000;Wang 1999; Wang 2006; Wang 2007;
Wu 2009b)• Stomach cancer: seven cohort studies (Galanis 1998; Inoue
2009a; Khan 2004; Kuriyama 2006; Nagano 2001; Nechuta 2012;
Suzuki 2009), 13 case-control studies (Hoshiyama 1992; Huang
1999; Ji 1996; Kono 1988; Liu 2010; Mao 2011; Mu 2003; Setiawan
2001; Tajima 1985; Wang 1999; Wang 2015; Ye 1998; Yu 1995).• Liver cancer: five cohort studies (Inoue 2009b; Nagano 2001;
Nechuta 2012; Tamura 2018; Ui 2009), one case-control study
(Mu 2003)• Pancreatic cancer: six cohort studies (Khan 2004; Lin 2008; Luo
2007; Nagano 2001; Nakamura 2011; Nechuta 2012), four case-
control studies (Goto 1990; Ji 1997; Mizuno 1992; Wang 2012c)• Biliary tract cancer: three cohort studies (Makiuchi 2016; Nagano
2001; Nechuta 2012)• Colorectal cancer: nine cohort studies (Khan 2004; Kuriyama
2006; Lee 2007; Nagano 2001; Nechuta 2012; Sun 2007; Suzuki
2005; Suzuki 2009; Yang 2011a), eight case-control studies
(Gavrilas 2018; Green 2014; Inoue 1998; Ji 1997; Kato 1990; Li
2011a; Peng 2013; Tajima 1985)• Colon cancer only: six cohort studies (Lee 2007; Nagano 2001;
Nechuta 2012; Oba 2006; Suzuki 2005; Yang 2011a), four case-
control studies (Green 2014; Inoue 1998; Ji 1997; Kato 1990)• Rectal cancer only: six cohort studies (Lee 2007; Nagano 2001;
Nechuta 2012; Oba 2006; Suzuki 2005; Yang 2011a), four case-
control studies (Green 2014; Inoue 1998; Ji 1997; Kato 1990).
Respiratory tract cancer
One experimental study assessing lung cancer risk reported data on
quality of life only (Garland 2006).
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Twenty-one nonexperimental studies reported data on the risk of
cancer of the respiratory tract and provided data on three diGerent
types of cancer.
• Nasopharyngeal cancer: two case-control studies (Hsu 2012;
Ruan 2010)• Lung cancer: six cohort studies (Khan 2004; Kuriyama 2006; Li
2008; Li 2018; Nagano 2001; Suzuki 2009), and 11 case-control
studies (Bonner 2005; Han 2008; Jin 2013; Kubik 2008; Lei 1994;
Le Marchand 2000; Lin 2012; Takezaki 2001; Tewes 1990; Xu 2013;
Zhong 2001)• Lung cancer and mesothelioma: one case-control study (Jia
2016).
Breast cancer
One experimental study carried out for prevention of breast cancer
(Dostal 2015) did not report results on this primary outcome, but
data on secondary outcomes (other types of cancer, quality of life)
are available.
FiKeen nonexperimental studies reported data on the risk of breast
cancer: five cohort studies (Dai 2010; Iwasaki 2010a; Key 1999;
Nagano 2001; Suzuki 2004), and nine case-control studies (Inoue
2008; Iwasaki 2014; Li 2011a; Li 2016; Mizoo 2013; Shrubsole 2009;
Wang 2013a; Wu 2003; Zhang 2007)
Urogenital tract cancer
Eight experimental studies reported data on cancer of the
urogenital tract and provided data on three diGerent types of
cancer.
• Cervical cancer: one study reported data on cervical cancer
incidence (Garcia 2014)• Endometrial cancer: one study reported data on endometrial
cancer incidence (Dostal 2015) and one study carried out in
women with uterine fibroids reported data on quality of life only
(Roshdy 2013)• Prostate cancer: three studies reported data on incidence of
prostate cancer (Bettuzzi 2006; Kumar 2015; Micali 2017), one
study assessing prostate cancer incidence is ongoing (Shannon
2010), and one study assessing prostate cancer incidence
reported data on PSA levels and clinical outcomes only (Lane
2018)
Thirty-one nonexperimental studies reported data on the risk of
cancer of the urogenital tract and provided data on five diGerent
types of cancer.
• Prostate cancer: five cohort studies (Allen 2004; Kikuchi 2006;
Kurahashi 2007; Montague 2012; Severson 1989), eight case-
control studies (Berroukche 2012; Jian 2004; Lassed 2016; Lee
2017; Li 2014; Sonoda 2004; Tse 2017; Wu 2009a)• Endometrial cancer: one cohort study (Shimazu 2008), and four
case-control studies (Bandera 2010: Gao 2005; Kakuta 2009; Xu
2007)• Ovarian cancer: five case-control studies (Goodman 2003; Leung
2016; Nagle 2010; Song 2008; Zhang 2002)• Renal cancer: one case-control study (Wang 2012a)• Urinary tract cancer: three cohort studies (Chyou 1993;
Kurahashi 2009; Nagano 2001), four case-control studies
(Hemelt 2010; Wakai 2004; Wang 2013b; Wilkens 1996)
Haematopoietic cancer
Nine nonexperimental studies reported data on the risk of cancer
of the haematopoietic system and reported data on four diGerent
types of cancer.
• Hematopoetic cancer: two cohort studies (Nagano 2001;
Naganuma 2009).• Leukaemia: one cohort study (Ugai 2018) assessed acute
myeloid leukaemia, and four case-control studies (Kuo 2009; Li
2011a; Liu 2017; Zhang 2008) assessed overall leukaemia.• Lymphoma: one cohort study (Ugai 2017).• Multiple myeloma: one cohort study (Ugai 2017) and one case-
control study (Wang 2012b).
Other types of cancer
One experimental study reported also data on incidence of non-
melanoma skin cancer (Dostal 2015). One case-control study
assessed the association between green tea consumption and non-
melanoma skin cancer (Hakim 2000), while two cohort studies
investigated the risk of thyroid cancer (Michikawa 2011) and brain
cancer (Ogawa 2016).
Exposure
In experimental studies, amount of supplemented green tea
extracts or total green tea polyphenols ranged from 400 mg/day up
to 1315 mg/day, corresponding to EGCG intakes ranging from 200
up to 843 mg/day (Table 1).
Nonexperimental studies assessed green tea exposure through
administration of either food-frequency questionnaires, structured
interviews by trained personnel, or self-administrated surveys in
which participants had to declare the frequency and amount of
certain food and beverage intakes.
Amounts of green tea consumption were rated either per day, per
week, per month or per year and ranged from 0 cups to 10 cups
or more per day or week. Some studies specified the amount in
grams of green tea leaves consumed over a defined period of time
(e.g. month or year). Drinking green tea has oKen been defined as
consumption of one or more cups per week for at least six months.
Finally, some studies estimated lifetime consumption of green tea
in grams per month per year of drinking.
Sponsorship
All but two experimental studies reported funding sources, mainly
grants of National Institutes of Health or National Cancer Institute
for studies in the USA, and a Cancer Research UK grant in one
Italian study. Three studies reported funding from pharmaceutical
companies, two in Italy (Bettuzzi 2006; Micali 2017), and one in
Japan (Tsao 2009), while one ongoing trial carried out in the USA
mentioned that no significant financial relationships to disclose
were present (Shannon 2010), and conversely, the other ongoing
RCT did not report any financial source (NCT01496521). Of the
131 nonexperimental studies, only 27 did not declare any type
of sponsorship or founding source. For the remaining studies,
National Institutes of Health or National Cancer Institute generally
sponsored the USA studies. In Japan, mainly the Ministry of
Health, Labour and Welfare or the Ministry of Education, Science
and Culture sponsored the investigations. In China, the Natural
Science Foundation sponsored some of the studies. Finally, the
'Ministry of Health' and 'National Health and Medical Research
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Council' supported with grants the studies from Czech Republic and
Australia, respectively.
Risk of bias in included studies
Experimental studies
We used the Cochrane tool for assessing risk of bias for
the experimental studies (Deeks 2017). Detailed 'Risk of bias'
assessments of included experimental studies are reported in
study-specific tables (Characteristics of included studies) and are
summarised in Table 7.
Allocation
All studies were randomised. Four studies did not clearly specify
their method of allocation concealment (Bettuzzi 2006; Garland
2006; Micali 2017; Sinicrope 2017) so we judged them to be at
unclear risk of bias for this domain. We judged the remaining
studies at a low risk of bias.
Blinding
All studies were double-blinded and, specifically, we judged all
studies at low risk of bias regarding blinding of participants and
personnel involved in the recruitment. Conversely, we judged
blinding during outcome assessment at unclear risk for some but
not all outcomes in three studies (Bettuzzi 2006; Sinicrope 2017;
Tsao 2009).
Incomplete outcome data
All but two studies (Garland 2006; Lane 2018), reported summary
results for all outcomes. However, in three studies incomplete
reporting for some outcomes can be noted. In particular, two
studies reported results for lower urinary tract symptoms (Bettuzzi
2006; Kumar 2015), and one study assessed uterine leiomyoma
burden (Roshdy 2013) but none of these studies stated the number
of participants included in the analysis.
Selective reporting
The study protocol was not available for four studies so we judged
them at unclear (Bettuzzi 2006; Micali 2017; Tsao 2009), or high
(Lane 2018), risk of selective reporting bias.
Other potential sources of bias
Four RCTs reported a high number of withdrawals (Dostal 2015;
Kumar 2015; Micali 2017; Roshdy 2013). In two RCTs other
concomitant interventions were reported. In particular, some
participants were taken lycopene capsules during the study (Lane
2018), while the other RCTs some participants in the treatment
group, but not in the placebo arm, took immunomodulatory drugs,
possible aGecting response rates (Dryden 2013).
Nonexperimental studies
We assessed the methodological quality of the nonexperimental
studies by using the Newcastle Ottawa Scale (NOS), for both cohort
(Appendix 4) and case-control studies (Appendix 5).
Cohort studies
All but one of the cohort studies were of high methodological
quality and reached 8 or 9 stars on the NOS (Wells 2001), while one
study was of medium methodological quality reaching 7 stars (Key
1999). The median score was 9 (out of 9) for the 46 cohort studies
with a range of 7 to 9 stars (Table 5; Figure 2). Detailed results of
single NOS items are shown in Table 8. Regarding 'selection' items,
we judged study participants as being truly representative of the
average general population in almost all studies, while two studies
restricted participants to those of Japanese ancestry (Chyou 1993;
Galanis 1998), some participants in three studies were survivors
from the atomic bomb in Hiroshima and Nagasaki (Allen 2004; Key
1999; Nagano 2001), and one study was carried out in working
people (Li 2018). All studies described the modality of exposure
assessment of green tea consumption, generally relying on the use
of structured interviews or food-frequency questionnaires, and all
studies excluded participants with previous history of cancer. For
'comparability' items, all studies controlled the analysis for age,
and all but six adjusted for smoking habit in the multivariate model
(Allen 2004; Galanis 1998; Inoue 2008; Iwai 2002; Key 1999; Severson
1989). Concerning 'outcome' items, all studies used a record linkage
based on a cancer registry for outcome assessment, with a follow-
up at least of five years in all but two studies (Dai 2010; Galanis
1998). Finally, while we considered the follow-up rate inadequate
(i.e. less than 90% of participants and no description of those lost)
in three studies studies (Hoshiyama 2002 and Hoshiyama 2004 in:
Inoue 2009a; Ishikawa 2006).
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Figure 2.   Newcastle-Ottawa scale for nonexperimental studies
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Figure 2.   (Continued)
 
Case-control studies
The median score was 7 (out of 9) for the 85 case-control studies
with an overall range from 3 to 9 stars (Table 6; Figure 2). Detailed
results of single NOS items (see Table 9) showed that, regarding
'selection' items almost all studies adequately identified cases
by accessing medical records in hospitals or cancer registries, or
both. Two studies (Lei 1994; Xu 2013), did not describe the source
of cases, and only one study (Tewes 1990), was based on self-
reports. All but six studies (Kato 1990; Lei 1994; Mu 2003; Wu
2009a; Wu 2009b; Xu 2013), selected consecutive or obviously
representative series of cases during a clear, identified period.
Regarding selection of controls, they were recruited from the same
community of the corresponding paired case in 42 studies, while
they were recruited from hospital attenders in 39 studies. Three
studies recruited and presented results using two sets of controls in
the analyses: population or hospital controls (Kono 1988; Li 2011a;
Zhang 2002). Two studies (Gavrilas 2018; Xu 2013) did not provide a
clear description of selection of controls. Regarding 'comparability'
items, all but three studies (Kuo 2009; Lassed 2016; Wang 2006),
controlled for age and approximately one-third (N = 28) of the
studies did not include smoking habits in the statistical model.
Regarding exposure-related items, four studies implemented a
food-frequency questionnaire or a structured interview to assess
green tea exposure (Bonner 2005; Inoue 1998; Jia 2016; Kato 1990),
while two studies did not provide a description (Lei 1994; Wang
1999). The same method of exposure assessment for both cases
and controls was clearly used in all but one study (Kono 1988).
Finally, in relation to the response rate, it was largely comparable
for both cases and controls in 30 studies or, if rates were diGerent,
non-respondents were described in 24 studies, while 31 studies did
not provide a description of non-respondents.
Publication bias
There were too few studies to yield reliable funnel plots for
experimental studies, but we were able to assess the reporting
bias for most outcomes from the nonexperimental studies. For the
latter studies, the funnel plot for any cancer mortality (Figure 3),
showed a symmetrical distribution, as did the funnel plots for oral
cancer (Figure 4) and any gut cancer (Figure 5). Conversely, analysis
for oesophageal cancer showed an asymmetrical distribution
(Figure 6), mainly from results of case-control studies. In other
gastrointestinal cancers we did not detect evidence of publication
bias (Figure 7; Figure 8; Figure 9; Figure 10; Figure 11; Figure 12),
as was the case for lung cancer (Figure 13), breast cancer (Figure
14), and other gynaecological cancer (Figure 15; Figure 16; Figure
17). For prostate cancer, an indication of publication bias toward
a decreased risk of cancer emerged (Figure 18), while we found
symmetry from the studies assessing urinary tract cancer (Figure
19).
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Figure 3.   Funnel plot of comparison 2. Nonexperimental studies: highest versus lowest green tea exposure,
outcome 2.2, any cancer mortality
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Figure 4.   Funnel plot of comparison 2. Nonexperimental studies: highest versus lowest green tea exposure,
outcome 2.3, oral cancer
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Figure 5.   Funnel plot of comparison 2. Nonexperimental studies: highest versus lowest green tea exposure,
outcome 2.6, any gut cancer
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Figure 6.   Funnel plot of comparison 2. Nonexperimental studies: highest versus lowest green tea exposure,
outcome 2.7, oesophageal cancer
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Figure 7.   Funnel plot of comparison 2. Nonexperimental studies: highest versus lowest green tea exposure,
outcome 2.21, prostate cancer
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Figure 8.   Funnel plot of comparison 2. Nonexperimental studies: highest versus lowest green tea exposure,
outcome 2.23, urinary tract cancer
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Figure 9.   Funnel plot of comparison 2. Nonexperimental studies: highest versus lowest green tea exposure,
outcome 2.8, stomach cancer
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Figure 10.   Funnel plot of comparison 2. Nonexperimental studies: highest versus lowest green tea exposure,
outcome 2.9, liver cancer
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Figure 11.   Funnel plot of comparison 2. Nonexperimental studies: highest versus lowest green tea exposure,
outcome 2.10, pancreatic cancer
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Figure 12.   Funnel plot of comparison 2. Nonexperimental studies: highest versus lowest green tea exposure,
outcome 2.12, colorectal cancer
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Figure 13.   Funnel plot of comparison 2. Nonexperimental studies: highest versus lowest green tea exposure,
outcome 2.13, colon cancer
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Figure 14.   Funnel plot of comparison 2. Nonexperimental studies: highest versus lowest green tea exposure,
outcome 2.14, rectal cancer
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Figure 15.   Funnel plot of comparison 2. Nonexperimental studies: highest versus lowest green tea exposure,
outcome 2.16, lung cancer
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Figure 16.   Funnel plot of comparison 2. Nonexperimental studies: highest versus lowest green tea exposure,
outcome 2.17, breast cancer
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Figure 17.   Funnel plot of comparison 2. Nonexperimental studies: highest versus lowest green tea exposure,
outcome 2.18, gynaecological cancer
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Figure 18.   Funnel plot of comparison 2. Nonexperimental studies: highest versus lowest green tea exposure,
outcome 2.19, endometrial cancer
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Figure 19.   Funnel plot of comparison 2. Nonexperimental studies: highest versus lowest green tea exposure,
outcome 2.20, ovarian cancer
 
E:ects of interventions
See: Summary of findings for the main comparison Green tea
extract supplementation compared with placebo for preventing
cancer: experimental studies; Summary of findings 2 Highest
compared with lowest green tea exposure for preventing cancer:
primary outcomes in nonexperimental studies; Summary of
findings 3 Highest compared with lowest green tea exposure for
preventing cancer: individual cancer types in nonexperimental
studies
Experimental studies
Primary outcome
We included 11 RCTs with administration of green tea extracts
(Table 1; Summary of findings for the main comparison).
Prostate cancer
Low-certainty evidence from three studies reporting data on
prostate cancer incidence in 201 men (101 in the intervention
group and 100 in the control group) with high-grade prostatic
intraepithelial neoplasia, thus at high risk of prostate cancer,
yielded a summary RR of 0.50 (95% CI 0.18 to 1.36; Analysis 1.1;
Bettuzzi 2006; Kumar 2015; Micali 2017) in the intervention arms.
Gynaecological cancer
Low-certainty evidence from two studies reporting data on
gynaecological cancer, showed that green tea moderately
increased the incidence of gynaecological cancer (summary RR
1.50, 95% CI 0.41 to 5.48), but findings for the two studies
individually yielded contradictory results (Analysis 1.2). One study
favoured experimental group and reported a decreased risk of
endometrial cancer (RR 0.33, 95% CI 0.01 to 8.15) (Dostal 2015).
Conversely, the other study favoured control group and reported
increased risk of cervical cancer (RR 2.00, 95% CI 0.54 to 7.46)
(Garcia 2014). Overall, all the RRs generated by these RCTs were
statistically imprecise.
Non-melanoma skin cancer
Low-certainty evidence from one study assessing non-melanoma
skin cancer showed no diGerence in eGect due to green tea extract
supplementation (RR 1.00, 95% CI 0.06 to 15.92; Analysis 1.3; Dostal
2015).
Secondary outcomes
Quality of life
Three studies assessed quality of life in relation to administration
of green tea extracts, where quality of life was slightly improved in
the intervention group compared to the placebo group (Bettuzzi
2006; Micali 2017; Roshdy 2013). Bettuzzi 2006 assessed quality of
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life (Grumann 2001), in relation to lower urinary tract symptoms
aKer three months of treatment and found that it decreased in the
intervention group (from 2.06 to 1.76), while it slightly increased
in the placebo group (from 1.30 to 1.47). Similarly, Micali 2017
reported lower urinary tract symptoms (Denis 1994), and quality-
of-life scores (Grumann 2001), to be improved aKer one year but
did not present detailed results. Roshdy 2013 used two diGerent
questionnaires to evaluate severity of fibroid-specific symptoms
and health-related quality of life (Spies 2002; Wyatt 2001), and
reported that green tea extract administration improved quality of
life. The first scale showed a decrease in symptom severity with
a mean change in the intervention group of −25.28 (SD ± 17.38)
compared to a mean change of +7.1 (SD ± 15.5) in the placebo group
(Spies 2002). Similarly, in the percentile scores for health-related
quality of life there was an overall increase of 20.7 (SD ± 21.0) in the
treatment group and 2.19 (SD ± 17.4) in the placebo group (Wyatt
2001).
Conversely, Kumar 2015 observed no significant diGerences
between the treatment and placebo arms in lower urinary tract
symptoms (Marberger 2013), and quality-of-life scores (McHorney
1993), from baseline to the end of the study.
Finally, two studies reported only baseline evaluation of quality
of life: Dostal 2015 used the Menopause-Specific Quality of
Life questionnaire (Lewis 2005), and Dryden 2013 used the
Inflammatory Bowel Disease Questionnaire (Guyatt 1989).
Safety data
All the experimental studies assessed the safety of green tea
supplementation (see Characteristics of included studies), and only
two studies reported no diGerence in adverse eGects between
groups (Bettuzzi 2006; Roshdy 2013). Conversely, the most common
adverse eGects related to green tea extracts were gastrointestinal
disorders, including generally mild-to-moderate or grade 1 to 2
disorders, particularly nausea, but also diarrhoea and other mild
gastrointestinal disorders, for example, indigestion, constipation or
gastroesophageal reflux (green tea versus placebo: 28.6% versus
24.6% (Dostal 2015); 32.0% versus 18.8% (Garcia 2014); 6.35%
versus 5.48% (Garland 2006); 35% versus 25% (Kumar 2015);
percentage not reported in Micali 2017; 30.0% versus 18.2% (Tsao
2009)). Three studies reported the elevation of liver enzymes (ALT
and/or AST), generally of grade 2+ or 3, more frequently in the
treatment group compared with placebo (green tea versus placebo:
6.7% versus 0.7% (Dostal 2015); 10% versus 2.1% (Garcia 2014);
5.26% versus 0% (Sinicrope 2017)). Similarly, three studies reported
insomnia more frequently in the treatment group (green tea versus
placebo: 21% versus 8% (Lane 2018); percentage not reported
in Micali 2017; 36.7% versus 18.2% (Tsao 2009)), although it was
generally of low grade, except for Tsao 2009. Two studies reported
hypertension to be slightly more frequent in the treatment arm
(green tea versus placebo: 21.8% versus 19.7% (Dostal 2015); 21%
versus 15% (Lane 2018)). Also, two studies reported slightly higher
frequencies of skin and subcutaneous tissue disorders (mainly
rash or allergic skin reactions) in the treatment group (green
tea versus placebo: 3.4% versus 1.5% (Dostal 2015); 14% versus
6% (Kumar 2015)), and two studies reported higher incidence of
dizziness (green tea versus placebo: 14.0% versus 6.3% (Garcia
2014); 6.7% versus 0% (Tsao 2009)). Finally, Dryden 2013 reported
higher incidence of heartburn and increased thirst (27% versus 0%).
Nonexperimental studies
We compared the risk of cancer in the highest category of green
tea intake with the bottom category of exposure, by computing a
summary risk ratio (RR) along with its 95% CI (Table 2; Table 3;
Summary of findings 2).
Any cancer
We meta-analysed results of two cohort studies on any cancer
incidence (Nagano 2001; Nakachi 2000), and one population-
based case-control study (Li 2011a), along with data from eight
cohort studies evaluating any cancer mortality (Iwai 2002; Khan
2004; Kuriyama 2006; Liu 2016; Odegaard 2015; Saito 2015; Suzuki
2009; Zhao 2017), and a total of over 530,000 participants. For
participants in the highest category of green tea intake compared
with those in the lowest exposure category, the summary RR for any
cancer incidence was 0.83 (95% CI 0.65 to 1.07; 3 studies, 52,479
participants; low-certainty evidence; (Analysis 2.1; Summary of
findings 2), and for any cancer mortality 0.99 (95% CI 0.91 to
1.07; low-certainty evidence; Analysis 2.2). We observed moderate
heterogeneity for both incidence (I2 = 66%) and mortality (I2 = 58%)
studies.
Gastrointestinal cancers
Oral, laryngeal and pharyngeal cancer
One cohort study (Ide 2007), found that increased green tea
consumption was associated with a lower risk of oral cancer
(RR 0.44, 95% CI 0.19 to 1.04). Results from case-control studies
generally showed a decreased RR of oral cancer associated with
the highest green tea consumption in either the one population-
based study (RR 0.58, 95% CI 0.42 to 0.79; Yan 2016), and the three
hospital-based studies with summary RR of 0.77 (95% CI 0.65 to
0.90; Analysis 2.3; Chen 2017a; Fu 2013; Zheng 1993). Conversely,
one cohort study evaluating risk of oral, pharyngeal and laryngeal
cancer found an increased risk in the highest category of green tea
intake, with RR of 1.47 (95% CI 1.12 to 1.93; Analysis 2.4; Oze 2014).
The one hospital-based case-control study showed a decreased but
statistically imprecise risk of pharyngeal cancer (OR 0.83, 95% CI
0.30 to 2.30; Analysis 2.5; Takezaki 2000). The analysis of any gut
cancer by combining all these nonexperimental studies showed a
decreased risk in the highest category of green tea exposure, with
a summary RR of 0.78 (95% CI 0.59 to 1.02),high heterogeneity (I2
= 73%) and low-certainty evidence between study results (Analysis
2.6).
Oesophageal cancer
Overall results showed that the highest green tea intake category
was associated with lower oesophageal cancer risk (summary RR
0.81, 95% CI 0.64 to 1.04), with high heterogeneity (I2 = 69%) and
very low-certainty evidence between study results (Analysis 2.7;
Summary of findings 3). Two cohort studies reported only the total
number of cases, thus we could not include them in the meta-
analysis (Nagano 2001; Nechuta 2012), while Ishikawa 2006 found
an increased risk of oesophageal cancer in participants consuming
the highest amounts of green tea (summary RR 1.67, 95% CI 0.88
to 3.16; Analysis 2.7). Conversely, overall risk estimate of the 12
case-control studies found a decreased risk of oesophageal cancer
in participants in the highest category of green tea intake, with
summary RR of 0.74 (95% CI 0.55 to 1.00) for the nine population-
based case-control studies, and 0.86 (95% CI 0.57 to 1.27) for the
three hospital-based case-control studies (Analysis 2.7; Summary
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of findings 3; Chen 2011; Gao 1994; Inoue 1998; Islami 2009; Mu
2003; Oze 2014; Peng 2015; Takezaki 2000; Wang 1999; Wang 2006;
Wang 2007; Wu 2009b).
Stomach cancer
Of the 20 nonexperimental studies assessing stomach cancer risk,
two did not report confidence intervals of risk estimates, thus
we could not include them in the meta-analysis (Tajima 1985;
Wang 1999). Overall results from available studies suggest an
association between green tea intake and decreased stomach
cancer risk, with summary RR of 0.86 (95% CI 0.74 to 1.01) and high
heterogeneity (I2 = 75%) and very-low certainty evidence between
study results (Analysis 2.8; Summary of findings 3). In the overall
estimate from seven cohort studies (Galanis 1998; Inoue 2009a;
Khan 2004; Kuriyama 2006; Nagano 2001; Nechuta 2012; Suzuki
2009), there was no association between green tea consumption
and decreased risk of stomach cancer (summary RR 0.99, 95% CI
0.85 to 1.14; Analysis 2.8). Conversely, summary findings from case-
control studies showed a lower stomach cancer risk in participants
in the highest category of green tea intake with summary RR of
0.74 (95% CI 0.53 to 1.02) from eight population-based case-control
studies (Hoshiyama 1992; Ji 1996; Kono 1988; Liu 2010; Mu 2003;
Setiawan 2001; Ye 1998; Yu 1995), and summary RR of 0.90 (95%
CI 0.74 to 1.09) from the three hospital-based case-control studies
(Huang 1999; Mao 2011; Wang 2015) see Analysis 2.8 and Summary
of findings 3. We observed moderate heterogeneity (I2 = 39%)
between results of cohort studies, and high (I2 = 85%) and no
heterogeneity (I2 = 0%) between population-based and hospital-
based case-control studies, respectively.
Liver cancer
Overall study results showed a slightly but imprecise decreased risk
with a higher intake of green tea (summary RR 0.88, 95% CI 0.68
to 1.14), with moderate heterogeneity (I2 = 46%) and low-certainty
evidence (Analysis 2.9; Summary of findings 3). Summary findings
from five cohort studies found a slightly lower liver cancer risk in
association with the highest green tea intake (summary RR 0.93,
95% 0.71 to 1.20; Analysis 2.9; Summary of findings 3; Inoue 2009b;
Nagano 2001; Nechuta 2012; Tamura 2018; Ui 2009). In the only
population-based case-control study, an indication of decreased
liver cancer risk with increasing green tea intake emerged (RR 0.55,
95% 0.28 to 1.09; Analysis 2.9; Mu 2003).
Pancreatic cancer
Overall, an inverse but imprecise association emerged for
pancreatic cancer (summary RR of 0.88, 95% CI 0.70 to 1.10) in
subjects with the highest green tea intake, high heterogeneity (I2
= 63%) and low-certainty evidence (Analysis 2.10; Summary of
findings 3). Null association was found from six cohort studies
(Khan 2004; Lin 2008; Luo 2007; Nagano 2001; Nakamura 2011;
Nechuta 2012), assessing pancreatic cancer risk (summary RR 1.04,
95% CI 0.84 to 1.30; Analysis 2.10). Conversely, overall findings from
three population-based case-control studies (Goto 1990; Ji 1997;
Wang 2012c), and one hospital-based case-control study (Mizuno
1992), showed contradictory findings with summary RR of 0.67
(95% CI 0.48 to 0.96) and 1.94 (95% CI 1.06 to 3.55), respectively
(Analysis 2.10). We observed low heterogeneity in cohort studies (I2
= 8%), whereas there was high heterogeneity in population-based
case-control studies (I2 = 73%).
Biliary tract cancer
Summary results from the three cohort studies (Makiuchi 2016;
Nagano 2001; Nechuta 2012), assessing biliary tract cancer risk and
consumption of green tea showed an indication of lower risk with
higher green tea intake (summary RR 0.79, 95% CI 0.57 to 1.11;
Analysis 2.11), with low heterogeneity (I2 = 25%).
Colorectal cancer
One study did not report confidence intervals of risk estimates,
thus we could not include it in the meta-analysis (Tajima
1985). Findings of 16 nonexperimental studies investigating the
association between green tea intake and risk of colorectal cancer
are contrasting. Overall results suggested a decreased risk of
colorectal cancer in subjects with the highest green tea intake, with
a summary RR of 0.84 (95% CI 0.74 to 0.96), with high heterogeneity
(I2 = 65%) and low-certainty evidence (Analysis 2.12; Summary of
findings 3). However, nine cohort studies (Khan 2004; Kuriyama
2006; Lee 2007; Nagano 2001; Nechuta 2012; Sun 2007; Suzuki
2005; Suzuki 2009; Yang 2011a), found no association, with a
summary RR of 1.00 (95% CI 0.92 to 1.08) and no heterogeneity.
Conversely, case control studies reported an inverse association:
in population-based case-control studies we found a summary RR
of 0.74 (95% CI 0.61 to 0.90; Green 2014; Ji 1997; Kato 1990; Li
2011a; Peng 2013), and in hospital-based case-control studies a
summary RR of 0.53 (95% CI 0.17 to 1.60; Gavrilas 2018; Inoue
1998), with high heterogeneity (I2 = 62% and I2 = 88%, respectively;
Analysis 2.12). Stratified analysis by dividing colon and rectal cancer
showed comparable results (Analysis 2.13; Analysis 2.14; Summary
of findings 3).
Respiratory tract cancers
Nasopharyngeal cancer
The two case-control studies on nasopharyngeal cancer, one
population-based (Hsu 2012), and one hospital-based (Ruan 2010),
reported a negative association between green tea intake and risk,
with a summary RR of 0.49 (95% CI 0.36 to 0.67; Analysis 2.15). We
observed moderate heterogeneity (I2 = 51%) between studies.
Lung cancer
Overall, a negative association was found between green tea
consumption and lung cancer risk, with a summary RR of 0.88
(95% CI 0.76 to 1.02) and moderate heterogeneity (I2 = 55%), with
very low-certainty evidence (Analysis 2.16; Summary of findings
3). However, the five cohort studies found no association between
green tea intake and lung cancer risk (summary RR 1.02, 95% CI 0.79
to 1.31), with low-to-moderate heterogeneity (I2 = 38%) (Analysis
2.16; Summary of findings 3 Khan 2004; Kuriyama 2006; Li 2008;
Li 2018; Nagano 2001; Suzuki 2009). Conversely, results from the
five population-based case-control studies (Han 2008; Jin 2013; Le
Marchand 2000; Xu 2013; Zhong 2001), and the six hospital-based
case-control studies (Bonner 2005; Kubik 2008; Lei 1994; Lin 2012;
Takezaki 2001; Tewes 1990), suggested a lower risk in association
with higher green tea intake, with summary RR of 0.73 (95% CI 0.61
to 0.87) and 0.90 (95% CI 0.69 to 1.17), respectively. Heterogeneity
for these study categories was low (I2 = 13%) and high (I2 = 63%),
respectively (Analysis 2.16).
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Breast cancer
Summary findings from nonexperimental studies on breast cancer
risk suggested a lower risk following higher green tea intake, with
summary RR of 0.88 (95% CI 0.75 to 1.02), with high heterogeneity
(I2 = 67%) and very low-certainty evidence (Analysis 2.17; Summary
of findings 3). The five cohort studies investigating the association
between green tea intake and risk of breast cancer in women found
no association (summary RR 1.01, 95% CI 0.86 to 1.19; Analysis
2.17; Dai 2010; Iwasaki 2010a; Key 1999; Nagano 2001; Suzuki
2004). However, four population-based (Inoue 2008; Li 2011a;
Shrubsole 2009; Wu 2003), and five hospital-based (Iwasaki 2014; Li
2016; Mizoo 2013; Wang 2013a; Zhang 2007), case-control studies,
showed a slight inverse association (summary RR 0.87, 95% 0.70
to 1.08, and 0.81, 95% CI 0.58 to 1.13, respectively). We observed
no heterogeneity in the cohort studies, while it was moderate (I2
= 51%) and high (I2 = 76%) in the population-based and hospital-
based control studies, respectively (Analysis 2.17).
Gynaecological cancer
In general, the nonexperimental studies evaluating the association
between green tea intake and gynaecological cancer showed a
negative association for both endometrial and ovarian cancer risk,
with a summary RR of 0.69 (95% CI 0.57 to 0.83), with moderate
heterogeneity (I2 = 42%) and low-certainty evidence (Analysis
2.18; Summary of findings 3). In particular, studies assessing
endometrial cancer risk showed a summary RR of 0.77 (95% CI 0.65
to 0.91), based on RR of 0.75 (95% CI 0.43 to 1.30) of one cohort
study (Shimazu 2008), and on summary RR of 0.75 (95% CI 0.61 to
0.94) from the four population-based case-control studies (Analysis
2.19; Bandera 2010; Gao 2005; Kakuta 2009; Xu 2007), with low
heterogeneity between study results. Regarding ovarian cancer, the
RR from the five population-based case-control studies suggested
an inverse association for participants in the highest category of
green tea intake with a summary RR of 0.64 (95% CI 0.45 to 0.90) and
moderate (I2 = 52%) heterogeneity (Analysis 2.20; Goodman 2003;
Leung 2016; Nagle 2010; Song 2008; Zhang 2002).
Urogenital tract cancer
Prostate cancer
Results from nonexperimental studies comparing highest versus
lowest intake of green tea and prostate cancer risk showed a lower
risk in overall analysis (summary RR 0.73, 95% CI 0.56 to 0.94;
I2 = 72%; very low-certainty evidence; Analysis 2.21; Summary of
findings 3), but there were conflicting results in stratified analysis
according to the study design. Indeed, a slightly increased risk was
found overall in five cohort studies with a summary RR of 1.09
(95% CI 0.89 to 1.32), with low heterogeneity (I2 = 25%; Analysis
2.21; Allen 2004; Kikuchi 2006; Kurahashi 2007; Montague 2012;
Severson 1989), and a decreased for case-control studies. In the
latter eight studies , a negative association for participants in the
highest category of green intake emerged for population-based
studies (summary RR 0.59, 95% CI 0.40 to 0.87) and for hospital-
based studies (summary RR 0.50, 95% CI 0.39 to 0.63; Analysis 2.21;
Berroukche 2012; Jian 2004; Lassed 2016; Lee 2017; Li 2014; Sonoda
2004; Tse 2017; Wu 2009a).
Renal cancer
The one hospital-based case-control study investigating kidney
cancer found a strong negative association between green tea
consumption and risk (OR 0.34, 95% CI 0.21 to 0.55; Analysis 2.22;
Wang 2012a).
Urinary tract cancer
Nonexperimental studies investigating green tea consumption and
risk of urinary tract (mainly urinary bladder) cancer showed no
association (summary RR 1.04, 95% CI 0.79 to 1.37), with moderate
heterogeneity (I2 = 56%) and very low-certainty evidence (Analysis
2.23; Summary of findings 3). However, the summary estimate
from the three cohort studies showed a positive association with a
summary RR of 1.24 (95% CI 0.87 to 1.76) and low heterogeneity (I2
= 31%; Analysis 2.23; Chyou 1993; Kurahashi 2009; Nagano 2001).
Conversely, one population-based case-control study (Wilkens
1996), and three hospital-based case-control studies (Hemelt 2010;
Wakai 2004; Wang 2013b), found little to no association between
green tea consumption and urinary tract cancer risk, with summary
RR of 1.08 (95% CI 0.61 to 1.92) and 0.84 (95% CI 0.53 to 1.32),
respectively.
Haematological cancer
Findings from overall haematological cancers showed a lower,
though imprecise risk in the highest category of green tea
consumption (summary RR 0.75, 95% CI 0.45 to 1.27), with
moderate heterogeneity (I2 = 60%; Analysis 2.24). Indeed, results
of studies assessing leukaemia risk were highly variable (Analysis
2.25), with high risk in one cohort study (Ugai 2018), assessing acute
myeloid leukaemia risk (RR 1.20, 95% CI 0.62 to 2.32), null risk
from the two population-based case-control studies assessing all
leukaemia (summary RR 1.03, 95% CI 0.50 to 2.14; Kuo 2009; Li
2011a), and lower risk from the two hospital-based case-control
studies assessing all leukaemias (summary RR 0.64, 95% 0.45 to
0.91; Analysis 2.25; Liu 2017; Zhang 2008). Similarly, a slightly lower
risk (RR 0.89, 95% CI 0.61 to 1.30) was reported in one cohort study
evaluating risk of lymphoma (Analysis 2.26; Ugai 2017), as well as
from studies assessing risk of multiple myeloma (summary RR 0.50,
95% CI 0.26 to 0.95; Analysis 2.27).
Other types of cancers
The one case-control study assessing non-melanoma skin cancer
risk showed an indication of lower risk in the highest category
of green tea consumption (OR 0.82, 95% CI 0.35 to 1.90; Analysis
2.28; Hakim 2000). Similarly, a lower risk was reported for thyroid
cancer (RR 0.88, 95% CI 0.56 to 1.37) by one cohort study (Analysis
2.29; Michikawa 2011). Conversely, slightly increased and highly
imprecise risk was reported by one cohort study (RR 1.07, 95% CI
0.71 to 1.62) assessing brain cancer risk (Analysis 2.30; Ogawa 2016).
D I S C U S S I O N
Summary of main results
The aims of this review were to examine the possible association
between green tea consumption and the risk of cancer incidence
and mortality, as well as quality of life. This updated review includes
data from 11 experimental studies (all RCTs), 10 more than in
the previous version of this review (Boehm 2009), and 160 (106
additional) nonexperimental studies, which were cohort and case-
control studies.
Experimental studies have reported contrasting results. For
instance, a decreased risk was suggested for prostate cancer
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incidence, in men at high risk of prostate cancer, but with RRs
ranging from highly beneficial eGect to no eGect in the three
RCTs for this outcome, whilst an increased risk in the green tea-
supplemented participants was reported for gynaecological cancer
incidence, and no eGect emerged for non-melanoma skin cancer.
Conversely, results from most nonexperimental studies showed
a decreased risk for any cancer incidence, but not for mortality.
Also, either decreased or increased results were reported for site-
specific cancers. Though a general decreased risk emerged when
we considered all studies, stratified analyses according to study
design, that is, case-control versus cohort studies, showed a null
or even increased risk estimates in the upper category of green tea
consumption for the latter, while results for the case-control studies
were generally contradictory. This was true for any gut cancer,
stomach, liver, colorectal, lung cancer, and even more for prostate,
pancreatic, urinary tract cancer, and leukaemia.
Overall completeness and applicability of evidence
We aimed to extend the previous assessment of the relationship
between green tea exposure and cancer risk by including all
experimental and nonexperimental studies in adult populations
published up until January 2019, without any limitation of time
and language. During the past few decades, a large number of
epidemiological studies have examined the association between
green tea consumption and risk of various cancers. We included 16
non-English papers (15 in Chinese and 1 in Japanese).
We included all publications assessing the association between
green tea intake and cancer risk independently from the source of
exposure, that is, including supplementation with green extracts
in experimental studies, and any green tea consumption in
nonexperimental studies, in liquid and solid form. We excluded
all studies in which green tea exposure could not be precisely
or independently identified, including those assessing intake of
tea without allowing the selective measurement of consumption
of green tea. Besides the database search, we screened previous
reviews on this topic published up to May 2019 (Booth 2008;
EUnetHTA 2017). This allowed us to assess the most up-to-
date evidence compared with several previous systematic reviews
carried out on single specific outcomes (Borrelli 2004; Butler
2011; Chang 2014; Chen 2014; Chen 2017b; Fang 2015; Gao 2013;
Gianfredi 2018; Guo 2017; Jacob 2017; Huang 2016; Huang 2017;
Hou 2013; Lin 2014; Najaf 2018; Ni 2017; Qin 2012; Sang 2013; Tang
2015; Vieira 2017; Wang 2014b; Weng 2017 Wu 2013b; Xiong 2017;
Yang 2019; Yiannakopoulou 2014; Yu 2014; Zeng 2014; Zhang 2015b;
Zheng 2011; Zheng 2012; Zheng 2013; Zhong 2014; Zhou 2016).
In contrast to the previous version of this review (Boehm 2009), we
included a quantitative assessment of cancer risk related to green
tea intake, adding a meta-analysis of all cancer outcomes whenever
there were suGicient data available to perform the analysis.
The inconsistency and high heterogeneity of results from
epidemiological studies might have various possible explanations.
One is exposure misclassification, since exposure to green tea
polyphenols may vary greatly across study population in terms of
either quantity (e.g. cups per day) of green tea consumption and
amount and type of catechins, depending on the type of green tea,
brewing time and temperature (Astill 2001; Sharpe 2016).
In addition, exposure to green tea catechins between experimental
studies and nonexperimental studies may be very diGerent. One
capsule containing 200 mg of EGCG corresponds to two or three
cups of brewed tea, therefore the tested doses up to 800 mg of
EGCG or more per day in experimental studies are equivalent to the
consumption of at least eight cups of green tea per day (Coppock
2016; Crew 2015), a high level of exposure. Such a high quantity is
diGicult to reach when consuming only brewed tea. Moreover some
experimental studies have shown that green tea supplementation
is not free from adverse eGects, such as gastrointestinal adverse
eGects, elevation of liver enzymes, and insomnia, probably due to
the caGeine residues during extraction of catechins or polyphenols
(Coppock 2016), hypertension, and skin or subcutaneous tissue
reactions.
Also, in nonexperimental studies, we cannot rule out residual,
unmeasured confounding eGects, due to smoking and alcohol
consumption (Chen 2017a), but also to other possible beneficial
and adverse factors of dietary and non-dietary origin, possibly a
major source of heterogeneity (Bhagwat 2014; Khan 2017; Malir
2014; Manach 2005; Podwika 2018; Rothwell 2017).
Quality of the evidence
Overall, both the experimental and nonexperimental studies that
we included in this review were generally of high quality, based on
the assessment of risk of bias. In the latter, a higher quality was
seen in the cohort studies, with all NOS scores above 7 stars (Figure
1), thus indicating a medium and high methodological quality.
Conversely, case-control studies, particularly those with a hospital-
based design, showed lower scores, and those with an NOS score
equal to or below 6 stars should be considered at high risk of
bias (Figure 1). We found little evidence of publication bias for all
outcomes except for oesophageal cancer and prostate cancer, thus
for these latter outcomes the risk of low reporting/publication for
studies with unfavourable or no cancer risk cannot be ruled out.
The certainty of the evidence presented in the Summary of findings
for the main comparison, Summary of findings 2 and Summary
of findings 3 showed low- or very low-certainty evidence from
both experimental and nonexperimental studies, independently
from the detection of either decreased or increased cancer risk.
In experimental studies, we downgraded the certainty mainly
due to the high imprecision of the estimates, based on small
sample sizes and few observed cases with the outcome of
interest. Also, moderate to high inconsistency was generally
detected across study results, such as the results being reversed
for risk of gynaecological cancers. Similarly in non-experimental
studies, despite some generally decreased RR in the most exposed
categories, we could not exclude a serious risk of bias due to the
case-control design of most studies, since null or increased risk was
reported in cohort studies for several outcomes such as stomach,
pancreatic, colorectal, lung, breast and prostate cancer.
Potential biases in the review process
We attempted to minimise bias at every step of the review
process. We performed a comprehensive search of the literature
by accessing leading electronic databases (e.g. CENTRAL, MEDLINE,
Embase), indexing relevant research and by implementing citation-
chasing methods for identification of all other additional relevant
research. Regarding experimental studies in particular, it is unlikely
that we have not identified any RCTs. However, unpublished trials
or ongoing trials not registered in clinical trials registries could have
been missed. Should such trials be identified, we will include them
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in future updates of the review. For study selection and assessment,
at least two review authors independently assessed studies,
performed data extraction, assessed risk of bias and GRADE, with
the additional contribution of a third review author in order to solve
conflicts. Regarding publication bias, in experimental studies, we
were unable to assess its presence due to the few studies available
to generate reliable funnel plots. In nonexperimental studies,
we found symmetrical distribution for most of the outcomes
considered, except oesophageal and prostate cancer, mainly due
to results from case-control studies. However, we systematically
performed stratified analysis according to study design.
Agreements and disagreements with other studies or
reviews
A previous meta-analysis showed that black tea but not green
tea consumption was related to a lower risk of cancer mortality
(Zhang 2015a), in line with the results of this review. Other reviews
that stratified analyses according to study design, also reported
results consistent with our findings; they generally showed inverse
associations in case-control studies and much weaker or no
diGerence in cohort studies. For example, for prostate cancer,
a recent meta-analysis concluded that there is a dose-response
relationship between green tea consumption and prevention of
prostate cancer (Guo 2017). However, when only cohort studies
were considered, no diGerence in risk was found. Similarly,
nonexperimental (observational) studies also reported an inverse
association between green tea and risk of both endometrial and
ovarian cancer when only case-control studies were considered
(Butler 2011). Conversely, in cohort studies no diGerence in
risk emerged. Consistent with this finding, contradictory results
according to study design were found for risk of lung cancer
(Guo 2019). In addition, the preventive role of green tea on
gastrointestinal cancer was not confirmed when tea temperature
was also evaluated. For instance, with reference to oesophageal
and gastric cancer, high-doses and long-term consumption seemed
to reduce the risk, whereas very high-temperature green tea
appeared to increase the risk of cancer (Huang 2017; Yi 2019).
A U T H O R S '   C O N C L U S I O N S
Implications for practice
Overall, findings from epidemiological studies yielded inconsistent
results for the eGect of green tea consumption on cancer risk,
despite some indications of a beneficial eGect of green tea on
a few site-specific cancers. In addition, the majority of included
studies were carried out in Asian populations characterised by
high intakes of green tea, thus limiting the generalisability of
the findings to other populations. Therefore, the epidemiological
evidence appears to be still inadequate to support a beneficial
eGect of green tea on cancer risk. In addition, the possibility that
high consumption of green tea extracts may have adverse eGects
should be taken into careful consideration.
Implications for research
Recommendations for future research arise from the observation
that evidence for green tea preventing cancer risk is still highly
inconsistent. Some evidence of a beneficial eGect of green tea
on prostate cancer risk emerged from the randomised controlled
trials (RCTs), but their methodological limitations, such as the low
number and size of the studies, and the inconsistencies of the
results limit the interpretability of their results. The other cancer
outcomes investigated in RCTs, gynaecological cancer and non-
melanoma skin cancer, were not clearly associated with either
beneficial or adverse eGects, and also suggested the possible
occurrence of side eGects associated with high intake of green tea
extracts. Well conducted and adequately powered RCTs, together
with nonexperimental cohort design studies, are therefore clearly
needed to elucidate the possible eGects of green tea consumption
on cancer risk in humans. RCTs should be carried out using low
to moderate doses of green tea to avoid side eGects and to reflect
more closely the exposure patterns in most populations. They
should also have an adequate sample size and allow a long period
of follow-up in order to detect long-term and even small decreases
in cancer risk.
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Characteristics of included studies [ordered by study ID]
 
Methods Cohort study in Japan
Participants Participants: more than 119,500 men from Hiroshima and Nagasaki. 18,115 men included in the
present study
Inclusion criteria: resident in Hiroshima and Nagasaki included in the Adult Health Study (a subcohort
of the Life Span study cohort) carried out among atomic-bomb survivors and in residents in the cities in
either city in the period between 1950 and 1953 and who completed the questionnaire surveys (in 1963,
1965 and 1979 to 1981), free from prostate cancer before the survey
Parent cohort: Adult Health Study, a subcohort of the Life Span Study
Recruitment: from 1963-1996
Interventions N/A
Outcomes Number of cases prostate cancer: 193 cases (out of total 196 identified)
Green tea in exposure cat-
egories
Exposure assessment: intake of green tea
Lowest exposure: < 1 time/d
Intermediate exposure: 2-4 times/d
Highest exposure: > 5 times/d
Allen 2004 
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Notes Funding: RERF Research Protocols (RP) no. 26-63 and 14-78
Statistical methods: Poisson regression
Variables controlled in analysis: age, calendar period, city of residence, radiation dose and education
level
Variables controlled by matching: -
Allen 2004  (Continued)
 
 
Methods PCC in USA
Participants Participants: 397 cases and 373 controls (all women)
Inclusion criteria: women aged ≥ 21 years, newly diagnosed and histologically confirmed from the Es-
trogen, Diet, Genetic and Endometrial Cancer study, from 6 counties, New Jersey, USA
Recruitment: from 1 July 2001-30 June 2005
Interventions N/A
Outcomes Number of cases
Endometrial cancer: 397 cases from the 469 eligible (all women)
Green tea in exposure cat-
egories
Exposure assessment: green tea intake
Lowest exposure: 0 cup/week
Intermediate exposure: < 1 cup/week
Highest exposure: ≥ 1 cups/week
Notes Funding: NIH-K07 CA095666 and R01CA83918
Statistical methods: unconditional logistic regression
Variables controlled in analysis: age, education, race, age at menarche, menopausal status and age at
menopause for postmenopausal women, parity, oral contraceptive use, HRT use, BMI, smoking (pack-
years), smoking status, added sugar/honey, milk, cream, or nondairy creamer in tea
Variables controlled by matching -
Bandera 2010 
 
 
Methods HCC in Algeria
Participants Participants: 160 cases and 160 controls (all men)
Inclusion criteria: free from other prostatic diseases or malignant tumours, not being under dietary re-
strictions or patients in critical conditions from Department of Urology of Sidibel-Abbes UHC and of
Saida Hospital, Algeria
Recruitment: from January 2007-March 2011
Interventions N/A
Outcomes Number of cases
Berroukche 2012 
Green tea (Camellia sinensis) for the prevention of cancer (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
60
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Prostate cancer: 160 cases (all men)
Green tea in exposure cat-
egories
Exposure assessment: intake of green tea
Lowest exposure: ≤ 1 cup/d
Intermediate exposure 1: 2-3 cups/d
Intermediate exposure 2: 4-5 cups/d
Highest exposure: > 6 cups/d
Notes Funding: not declared
Statistical methods: conditional logistic regression
Variables controlled in analysis: tobacco smoking, total energy intake and family history of prostate
cancer
Variables controlled by matching: age (± 5 years)
Berroukche 2012  (Continued)
 
 
Methods RCT, parallel, double-blind in Italy
Participants Participants: 60 men with HG-PIN, 30 in each group
Inclusion criteria: age 45-75 years, with HG-PIN diagnosed needle biopsies collection, not consuming
green tea or taking antioxidants, not vegetarians and not under antiandrogenic therapy
Recruitment: NR
Interventions Treatment group: 3 capsules of GTEs, containing green tea catechins (200 mg each) capsules/d = total
600 mg/d, corresponding to approximately 300 mg/d of EGCG
Control group: placebo
Duration: 1 year
Outcomes Primary outcome
Prostate cancer incidence
Secondary outcomes
LUTS using IPSS
PSA levels
QoL data
Safety data
Green tea in exposure cat-
egories
N/A
Notes Grant support: PRIN 2004 (MIUR, Italy). Dr. Rizzi was supported by Genprofiler Srl (Bolzano, Italy).
Risk of bias
Bias Authors' judgement Support for judgement
Bettuzzi 2006 
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Random sequence genera-
tion (selection bias)
Low risk Quote: "Volunteers were randomly assessed to a placebo- or GTCs [green tea
catechins]-arm by simple randomisation"
Comment: it is unclear how sequence was generated, however the baseline
characteristics reported in Table 1 are mainly equally distributed.
Allocation concealment
(selection bias)
Unclear risk Quote: "That same day [when they signed the informed consent, NDR], they
were alternatively assigned to the placebo- or GTCs [green tea catechins]-arm
and given the appropriate treatment. To all subjects, capsules were given by
the urologist according to the double blind method"
Comment: insufficient information to answer
Blinding of participants
and personnel (perfor-
mance bias) 
Prostate cancer incidence
Low risk Quote: "capsules were given by the urologist according to the double blind
method"
Comment: probably done
Blinding of participants
and personnel (perfor-
mance bias) 
Lower urinary tract symp-
toms
Low risk Quote: "In the second arm, men received placebo (three identical capsules
per day). To all subjects, capsules were given by the urologist according to the
double blind method".
Comment: probably done
Blinding of participants
and personnel (perfor-
mance bias) 
PSA levels
Low risk Review authors do not believe this will introduce bias since this measurement
is independent from individual evaluation
Blinding of outcome as-
sessment (detection bias) 
Prostate cancer incidence
Unclear risk No explicit statement on blinded outcome assessment
Blinding of outcome as-
sessment (detection bias) 
Lower urinary tract symp-
toms
Unclear risk No explicit statement on blinded outcome assessment
Blinding of outcome as-
sessment (detection bias) 
PSA levels
Low risk Review authors do not believe this will introduce bias since this measurement
is independent from individual evaluation
Incomplete outcome data
(attrition bias) 
Prostate cancer incidence
Low risk All randomised participants were included in the analysis
Incomplete outcome data
(attrition bias) 
Lower urinary tract symp-
toms
Unclear risk Quote: "patients, diagnosed with prostate cancer at the 6 months biopsy
check, leK the study"
Comment: number of participants included in analysis not stated
Incomplete outcome data
(attrition bias) 
PSA levels
Low risk All randomised participants were included in the analysis
Selective reporting (re-
porting bias)
Unclear risk The study protocol is not available and it is not clear if the published reports
include all expected outcomes. Insufficient information to answer
Bettuzzi 2006  (Continued)
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Other bias Low risk Study controlled for total serum PSA at the time of enrolment, prostate vol-
ume at the time of enrolment, prostate volume at the end of study, total num-
ber of HG-PIN scores vs total scores taken at the time of enrolment, total num-
ber of HG-PIN scores taken at the end of study; total number of mono-focal or
plurifocal HG-PIN lesions by means of a multivariate analysis
Bettuzzi 2006  (Continued)
 
 
Methods PCC in China
Participants Participants: 122 (male/female: 79/43) cases and 121 (male/female: 78/43) controls
Inclusion criteria: newly diagnosed lung cancer, mean age 54.71 (SD 11.45) in cases and 54.44 (SD
11.97) in controls from residents of Xuan Weu, China
Recruitment: from March 1995-March 1996
Interventions N/A
Outcomes Number of cases
Lung cancer: 122 (male/female: 79/43) cases
Green tea in exposure cat-
egories
Exposure assessment: intake of green tea
Lowest exposure: never
Intermediate exposure: 2-3 times/week
Highest exposure: ≥ 1 time/d
Notes Funding: not declared
Statistical methods: unconditional logistic regression
Variables controlled in analysis: smoking (pack-years)
Variables controlled by matching: age, sex, village of residence, type of heating and cooking fuel
Bonner 2005 
 
 
Methods HCC in China
Participants Participants: 150 (male/female: 102/48) cases and 300 (male/female: 204/96) controls
Inclusion criteria: histologically confirmed squamous cell oesophageal carcinoma, mean age 54.5 (SD
6) in cases and 54.0 (SD 7) in control from First Affiliated Hospital of Ji'nan University, China
Recruitment: from June 2004-May 2010
Interventions N/A
Outcomes Number of cases
Oesophageal cancer: 150 (male/female: 102/48) cases
Green tea in exposure cat-
egories
Exposure assessment: green tea intake
Chen 2011 
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Lowest exposure: never
Intermediate exposure 1: < 100 g/month
Intermediate exposure 2: 100-250 g/month
Highest exposure: > 250 g/month
Notes Funding: Medical Science fund of Guangong Province (B2008094)
Statistical methods: conditional logistic regression
Variables controlled in analysis: age, sex, education level, annual income, cancer family history, smok-
ing status and alcohol drinking status
Variables controlled by matching: age (± 3 years) and sex
Chen 2011  (Continued)
 
 
Methods HCC in China
Participants Chen 2015
Participants: 203 (male/female: 153/50) cases and 572 (male/female: 416/156) controls
Inclusion criteria: newly diagnosed cases of oral cancer, living in Fujian, China for > 10 years, with no
pathological diagnosis of oral inflammation, benign lesions, or secondary tumours and without critical
illness
Recruitment: from September 2010-January 2015
Chen 2016
Participants: 207 cases and 480 controls (all women)
Inclusion criteria: newly diagnosed cases of oral cancer, consecutively recruited from the First Affiliated
Hospital of Fujian Medical University, China
Recruitment: from September 2010-January 2015
Chen 2017a and Chen 2017c with duplicate results)
Participants: 586 (male/female: 379/207) cases and 1024 (male/female: 630/394) controls
Inclusion criteria: newly diagnosed cases of oral cancer, consecutively recruited from the First Affiliated
Hospital of Fujian Medical University, China
Recruitment: from September 2010-January 2015
Interventions N/A
Outcomes Number of cases
In Chen 2015
Oral cancer: 188 cases out of 203 recruited (15 cases excluded because drinkers of other types of tea)
In Chen 2016
Oral cancer: 196 cases out of 207 recruited (11 cases excluded because drinkers of other types of tea)
In Chen 2017a
Chen 2017a 
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Oral cancer: 586 (male/female: 379/207) cases, including squamous cell carcinoma (N = 507), adenocar-
cinoma (N = 59), others (N = 20)
Green tea in exposure cat-
egories
Exposure assessment: green tea drinking habit (same for Chen 2015, Chen 2016 and Chen 2017a)
Lowest exposure: not drinking tea
Highest exposure: drinking green tea (≥ 1 cup/week for ≥ 6 months)
Notes Chen 2015
Article in Chinese
Funding: Research Project of Science and Technology Department of Fujian Province (2015J01304); Re-
search Project of Fujian Provincial Department of Education (JA13141); Research and Application of
New Technology of Key Laboratory of Environment and Health, School of Public Health, Fujian Medical
University (201201).
Statistical methods: unconditional logistic regression
Variables controlled in analysis: sex, age, occupation, ethnicity, marital status, education level, BMI and
place of residence
Variables controlled by matching: -
Chen 2016
Funding: grants from the Natural Science Foundation of China (Nos. 30771845 and 81172766), Natural
Science Foundation of Fujian Province (No. 2015J01304) and the Scientific Research Program of Educa-
tion Department of Fujian Province (No. JA13141)
Statistical methods: unconditional logistic regression
Variables controlled in analysis: age, family history of cancer, occupation, education, BMI, residence,
marital status, tobacco smoking, alcohol drinking, cooking oil fumes and passive smoking
Variables controlled by matching: -
Chen 2017a
Funding: grants from Natural Science Foundation of Fujian Province (N. 2015J01304) and from Universi-
ty Development Foundation of National Financial Support (N. 1003-03900130)
Statistical methods: unconditional logistic regression
Variables controlled in analysis: age, sex, occupation, education, BMI, marital status, residence, family
cancer history, vegetables and fruits, alcohol drinking and tobacco smoking
Variables controlled by matching: -
Data also available stratified according to milk consumption in non-smoking and non-drinking par-
ticipants. Previous report on the same population also reported in Chen 2015 and Chen 2016 in: Chen
2017a.
Chen 2017a  (Continued)
 
 
Methods Cohort study in USA
Participants Participants: 7991 male participants out of 8006 recruited
Inclusion criteria: American men of Japanese ancestry, born from 1990-1919 and residing on the
Hawaiian island of Oahu, Hawaii, USA
Parent cohort: Honolulu Hearth Program
Recruitment: from 1965-1968
Chyou 1993 
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Interventions N/A
Outcomes Number of cases
Outcome assessment: May 1991
Urinary tract cancer: 96 cases, including urinary bladder (N = 83), pelvis (N = 8) and ureter (N = 5)
Green tea in exposure cat-
egories
Exposure assessment: green tea intake
Lowest exposure: almost never
Highest exposure: not specified, probably merging 4 categories: < 2 times/week, 2-4 times/week, al-
most daily, ≥ 1 time/d
Notes Funding: grants provided by National Cancer Institute (R01 CA33644)
Statistical methods: proportional hazard regression
Variables controlled in analysis: age and smoking
Variables controlled by matching: -
Chyou 1993  (Continued)
 
 
Methods Cohort study in China
Participants Participants: 72,861 Chinese women
Inclusion criteria: women aged 40-70 years, no history of cancer at baseline. 381 women regularly
drinking only black or oolong tea excluded
Parent cohort: Shangai Women's Health Study
Recruitment: from March 1997-May 2000
Data on the same cohort also reported in Nechuta 2012
Interventions N/A
Outcomes Number of cases
Outcome assessment: 31 December 2005
Breast cancer: 614 cases (all female)
Green tea in exposure cat-
egories
Exposure assessment: intake of green tea
Lowest exposure: no
Highest exposure: yes
Exposure assessment: dosage of green tea
Lowest exposure: no drinking
Intermediate exposure 1: 0-1.67 g/d
Intermediate exposure 2: 1.68-3.33 g/d
Intermediate exposure 3: 3.34-5.00 g/d
Dai 2010 
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Highest exposure: > 5.00 g/d
Notes Funding: grants provided by National Institutes of Health (R01CA70867, R01CA106591, N02 CP1101066)
Statistical methods: Cox proportional hazard regression
Variables controlled in analysis: age, educational achievement, income, family history of breast cancer,
history of fibroadenoma, BMI, waist-to-hip ratio, physically active, smoking status, alcohol consump-
tion status, passive smoking status, ginseng intake, age at menarche, age at first live birth, menopausal
status, age at menopause, use of HRT and dietary intake of total energy, fruits, vegetables, red meat,
fish and isoflavones
Variables controlled by matching: -
Dai 2010  (Continued)
 
 
Methods RCT, parallel, double-blind in USA - Minnesota Green Tea Trial (MGTT)
Participants Participants: 1075 post-menopausal women (538 in the treatment group and 537 in the control group)
Inclusion criteria: age 50-70 years, classified as having high mammography density attending annual
screening mammogram at 8 clinical centres in the Minneapolis-St. Paul metropolitan area (Minnesota
Green Tea Trial (MGTT), planning to reside in or near Minnesota for study duration.
Exclusion criteria: tested positive for serological status of hepatitis B surface antigen or antibodies to
hepatitis C virus; baseline ALT > 1.5 times the upper limit of 60 U/L; any history of cancer; any history of
proliferative breast disease; history of breast augmentation; BMI < 18.5 or > 40 kg/m2; weight change >
4.6 kg during the previous 12 months; current or recent (within 6 months) use of HRT; current use of an-
ti-inflammatory agents including methotrexate or etanercept; current smoker; regular consumption of
≥ 7 alcoholic beverages/week; and regular consumption of ≥ 1 cups of green tea/week. Full details re-
ported in Samavat et al. 2015.
Recruitment: from August 2009-April 2013
Interventions Treatment group: 4 oral GTE capsules, i.e. 1315 (± 116) mg of total catechins/d, including 843 (± 44) mg
of EGCG
Control group: placebo
Duration: 1 year
Outcomes Primary outcome
Effects on biomarkers of breast cancer risk: mammographic density, circulating reproductive hor-
mones and circulating insulin-like growth factor axis proteins
Secondary outcome
Circulating F2-isoprostanes, urinary oestrogen metabolites, anthropometric variables and obesity-as-
sociated hormone concentrations
QoL
Safety data
Green tea in exposure cat-
egories
N/A
Notes Funding: from National Institutes of Health/National Cancer Institute grant R01 CA127236, Award Num-
ber T32CA132670 from the National Cancer Institute, the Department of Defense/US Army Medical Re-
search and Materiel Command Award Number W81XWH-11-1-0013, the University of Minnesota Agricul-
Dostal 2015 
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tural Experiment Station Project Number MIN-18-103 and the National Center for Advancing Transla-
tional Sciences of the National Institutes of Health Award Number UL1TR000114
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "A detailed description of the Minnesota Green Tea Trial (MGTT) design,
eligibility criteria, study conduct and patient flow through the trial will be pub-
lished separately (Samavat et al., Cancer Causes and Control)." reporting that
"Investigational Drug Services (IDS) pharmacy utilized a computer generated
randomisation scheme using the permuted block method"
Comment: probably low risk
Allocation concealment
(selection bias)
Low risk Quote: "A detailed description of the Minnesota Green Tea Trial (MGTT) de-
sign, eligibility criteria, study conduct and patient flow through the trial will be
published separately (Samavat et al., Cancer Causes and Control)." reporting
that "Randomization was performed by the Investigational Drug Services (IDS)
pharmacy at University of Minnesota Medical Center - Fairview". Central allo-
cation.
Comment: probably done
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: from Samavat 2015 “In this double-blinded study, study staG, partici-
pants, laboratory personnel and all parties involved with assessment of the
study endpoints were blinded to treatment assignment. The treatment codes
were only available to the IDS [Investigational Drug Services] pharmacy staG
in charge of randomisation and a study biostatistician.” From Dostal 2015 :
“Participants, investigators, laboratory staG and those monitoring clinical out-
comes and adverse events were blinded to treatment assignment” and “Place-
bo capsules were identical in appearance to GTE". Study investigators were
kept blinded to the assigned treatment of all participants experiencing an ad-
verse effects
Comment: probably done
Blinding of participants
and personnel (perfor-
mance bias) 
Non-melanoma skin can-
cer incidence
Low risk Quote: from Samavat 2015 “In this double-blinded study, study staG, partici-
pants, laboratory personnel and all parties involved with assessment of the
study endpoints were blinded to treatment assignment. The treatment codes
were only available to the IDS [Investigational Drug Services] pharmacy staG
in charge of randomisation and a study biostatistician.” From Dostal 2015 :
“Participants, investigators, laboratory staG and those monitoring clinical out-
comes and adverse events were blinded to treatment assignment” and “Place-
bo capsules were identical in appearance to GTE". Study investigators were
kept blinded to the assigned treatment of all participants experiencing an ad-
verse effects
Comment: probably done
Blinding of participants
and personnel (perfor-
mance bias) 
Gynaecological cancer in-
cidence
Low risk Quote: from Samavat 2015 “In this double-blinded study, study staG, partici-
pants, laboratory personnel and all parties involved with assessment of the
study endpoints were blinded to treatment assignment. The treatment codes
were only available to the IDS pharmacy staG in charge of randomisation and
a study biostatistician.” From Dostal 2015 : “Participants, investigators, labo-
ratory staG and those monitoring clinical outcomes and adverse events were
blinded to treatment assignment” and “Placebo capsules were identical in ap-
pearance to GTE". Study investigators were kept blinded to the assigned treat-
ment of all participants experiencing an adverse effects
Dostal 2015  (Continued)
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Comment: probably done
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk From Dostal 2015 "Participants, investigators, laboratory staG and those moni-
toring clinical outcomes and adverse events were blinded to treatment assign-
ment" and "Placebo capsules were identical in appearance to GTE". Study in-
vestigators were kept blinded to the assigned treatment of all participants ex-
periencing an adverse effects
Comment: probably done
Blinding of outcome as-
sessment (detection bias) 
Non-melanoma skin can-
cer incidence
Low risk From Dostal 2015 "Participants, investigators, laboratory staG and those moni-
toring clinical outcomes and adverse events were blinded to treatment assign-
ment" and "Placebo capsules were identical in appearance to GTE". Study in-
vestigators were kept blinded to the assigned treatment of all participants ex-
periencing an adverse effects
Comment: probably done
Blinding of outcome as-
sessment (detection bias) 
Gynaecological cancer in-
cidence
Low risk From Dostal 2015 "Participants, investigators, laboratory staG and those moni-
toring clinical outcomes and adverse events were blinded to treatment assign-
ment" and "Placebo capsules were identical in appearance to GTE". Study in-
vestigators were kept blinded to the assigned treatment of all participants ex-
periencing an adverse effects
Comment: probably done
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Number and reason of participants' withdrawal from the study reported.
Study authors performed an ITT analysis.
Incomplete outcome data
(attrition bias) 
Non-melanoma skin can-
cer incidence
Low risk Number and reason of participants' withdrawal from the study reported.
Study authors performed an ITT analysis.
Incomplete outcome data
(attrition bias) 
Gynaecological cancer in-
cidence
Low risk Number and reason of participants withdrawal from the study reported. Au-
thors performed an ITT analysis.
Selective reporting (re-
porting bias)
Low risk Results to the Minnesota Green Tea Trial RCT (ClinicalTrials.gov identifier (NCT
number): NCT00917735) reported in several publications all included in this re-
view.
Other bias Unclear risk Elevated number of withdrawals
Dostal 2015  (Continued)
 
 
Methods RCT, parallel, double-blind in USA
Participants Participants: 20 people with ulcerative colitis. Ratio 4:1 randomisation treatment/placebo
Inclusion criteria: age ≥ 18 years, with mildly to moderately active disease
Recruitment: NR
Interventions Treatment groups: green tea catechins (using Polyphenon E, Mitsu-Norin, Fujieda) in low dose of cate-
chins containing 200 mg of EGCG and high dose of catechins containing 400 mg of EGCG
Dryden 2013 
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Control group: placebo
Duration: 56 d
Outcomes Primary outcome
Safety data
Secondary outcome:
QoL
Green tea in exposure cat-
egories
N/A
Notes Funding: National Institutes of Health grant (5K23DK073750), University of Louisville Research Foun-
dation Project Initiation Grant, Polyphenon E supplied by Mitsui-Norin (Fujieda, Japan) through the
Chemoprevention Agent Development Group of the National Cancer Institute. Baseline characteris-
tics were not equally distributed: both men and women included in the treatment groups, while on-
ly women were included in the placebo group. Treated participants were also slightly older and with
higher mean weight and all used azathioprine. Tobacco use prevalence was 7% and 50% in treatment
and control group, respectively.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Patients...were randomized in a double-blinded fashion according
to a random number generator compiled by a statistician not involved in the
study"
Comment: probably done
Allocation concealment
(selection bias)
Low risk Quote: "Patients...were randomized in a double-blinded fashion according
to a random number generator compiled by a statistician not involved in the
study"
Comment: probably done
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "Patients ….. were randomized in a double-blinded fashion": Also UC-
DAI was assessed at day 0 and 56, while for other laboratory analyses at day 1,
14, 28, 56 and 70.
Response: review authors do not believe this will introduce bias
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "Patients ….. were randomized in a double-blinded fashion": Also UC-
DAI was assessed at day 0 and 56, while for other laboratory analyses at day 1,
14, 28, 56 and 70.
Response: review authors do not believe this will introduce bias
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Number of participants included in analysis stated and reported
Selective reporting (re-
porting bias)
Low risk The study protocol is available (ClinicalTrials.gov identifier (NCT number):
NCT00718094) and the published reports include all expected outcomes
Other bias High risk Results from Inflammatory Bowel Disease Questionnaire, a validated, IBD-spe-
cific indicator of QoL, was significantly different between groups at baseline.
Dryden 2013  (Continued)
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Some participants in the treatment group, but not in the placebo arm, took
immunomodulatory drugs
Dryden 2013  (Continued)
 
 
Methods HCC in China
Participants Participants: 723 (male/female: 485/238) cases and 857 (male/female: 576/281) controls
Inclusion criteria: aged 30-80 years, with incident and histologically confirmed oral squamous cell can-
cer from 8 cities in different parts of China
Recruitment: from 2007-2010
Interventions N/A
Outcomes Number of cases
Oral cancer: 723 (male/female: 485/238) cases of squamous cell cancer
Green tea in exposure cat-
egories
Exposure assessment: intake of green tea
Lowest exposure: < 4 g/d
Intermediate exposure: 4-7 g/d
Highest exposure: ≥ 8 g/d
Notes Funding: Grant (N. 06dz22026) from the Science and Technology Commission of Shanghai Municipality.
Statistical methods: unconditional logistic regression
Variables controlled in analysis: age, sex, long-term residency area, years of education, tobacco smok-
ing and alcohol drinking
Variables controlled by matching: sex, age (± 5 years) and long-term residency area.
Fu 2013 
 
 
Methods Cohort study of Japanese population living in Hawaii, USA
Participants Participants: 40,575 eligible participants (of whom 12,789 were Japanese). Final population 11,907
(male/female: 5610/6297), 882 excluded for missing information on covariates
Inclusion criteria: Japanese participants, complete information on covariates
Parent cohort: Hawaii Health Surveillance Program Cohort (HHSPC)
Recruitment: from 1975-1980
Interventions N/A
Outcomes Number of cases
Oucome assessment: 31 December 1994
Stomach cancer: 108 (male/female: 64/44) cases
Galanis 1998 
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Green tea in exposure cat-
egories
Exposure assessment: intake of green tea
Lowest exposure: none
Intermediate exposure: 1 cup/d
Highest exposure: ≥ 2 cups/d
Notes Funding: not declared
Statistical methods: Cox proportional hazard regression
Variables controlled in analysis: age, years of education, Japanese place of birth and sex (in combined
analyses). Analyses among men were also adjusted for cigarette smoking and alcohol intake status.
Variables controlled by matching: -
Galanis 1997 is a letter reporting preliminary findings subsequently published in Galanis 1998.
Galanis 1998  (Continued)
 
 
Methods PCC in China
Participants Participants: 902 (66% male) cases and 1552 (55% male) controls. 1312 (male/female: 654/658) controls
considered in the present analysis
Inclusion criteria: aged 30-74 years, permanent residents in Shangai, China
Recruitment: from 1 October 1990-31 January 1993
Interventions N/A
Outcomes Number of cases
Oesophageal cancer: 659 (male/female: 417/242) out of 902 eligible cases excluding participants drink-
ing other types of tea, including squamous cell carcinoma (N = 605), adenocarcinoma (N = 51), other
specified types (N = 25) and unspecified types (N = 53)
Green tea in exposure cat-
egories
Exposure assessment: intake of green tea
Lowest exposure: nondrinker
Highest exposure: drinkers (≥ 1 cup/week for ≥ 6 months)
Exposure assessment: consumption of green tea
Lowest exposure: nondrinker
Intermediate exposure: 1-199 g/month in men and 1-149 g/month in women
Highest exposure: ≥ 200 g/month in men and ≥ 150 g/month in women
Notes Funding: Dr J Schneider funded by "Consejeria de Sanidad del Gobierno Vasco" and by "Fondo de In-
vestigationed Sanitaria"; Dr MP Rubio funded by "Gobierno de Navarra".
Statistical methods: unconditional logistic regression
Variables controlled in analysis: age, education, birthplace, cigarette smoking and alcohol intake (only
men)
Variables controlled by matching: age (± 5 years) and sex
Gao 1994 
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Methods PCC in China
Participants Participants: 995 cases and 1087 controls (all women)
Inclusion criteria: aged 30-69 years, living in Shangai, China
Recruitment: from January 1997-December 2002
Interventions N/A
Outcomes Number of cases
Endometrial cancer: 965 cases (out of total 995 identified)
Green tea in exposure cat-
egories
Exposure assessment: intake of green tea
Lowest exposure: non drinkers
Highest exposure: drinker (2 cups/week for ≥ 3 months)
Notes Article in Chinese
Funding: National Cancer Institute funded project (R01CA92585)
Statistical methods: unconditional logistic regression
Variables controlled in analysis: age, education level, age at menarche, number of pregnancies,
whether to take oral contraceptives, first-degree relatives, malignant tumours, history of the genus and
BMI
Variables controlled by matching: age
Gao 2005 
 
 
Methods RCT, parallel, double-blind in USA
Participants Participants: 98 women with persistent high-risk HPV infection and low-grade CIN (grade 1), 50 in the
intervention group and 48 in the control group
Inclusion criteria: aged ≥ 18 years, normal liver and kidney function and good performance status.
Exclusion criteria: pregnant or breast feeding, consumed tea regularly within 1 month of enrolment,
had a history of allergic reaction to tea or related dietary products, had been treated for genital condy-
loma within 30 days of enrolment, were receiving other investigational agents, had prior pelvic irradia-
tion, were HIV-positive, had uncontrolled inter-current illness, had invasive or high-grade intraepithe-
lial neoplasia, or had a history of cancer except nonmelanoma skin cancer
Recruitment: at the University of Arizona (Tucson, Arizona), with additional accrual at Maricopa Inte-
grated Health System (Phoenix, Arizona) and Southern Pines Women's Health Center (Southern Pines,
North Carolina), period NR.
Interventions Treatment group: green tea catechins (using Polyphenon E capsules), corresponding to 800 mg of
EGCG/d
Control group: placebo
Duration: 4 months
Outcomes Primary outcome
Garcia 2014 
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Oncogenic HPV clearance and clearance of CIN1
Secondary outcome:
Safety data
Green tea in exposure cat-
egories
N/A
Notes Funding: Contract (N01-CN35158) from the National Cancer Institute and the Arizona Cancer Center
Support Grant (P30CA023074). The paper was partially written using funding provided by the National
Cancer Institute of the National Institutes of Health under Award Number R25CA078447.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "participants were randomized to receive Polyphenon E or placebo. An
adaptive allocation randomization procedure was implemented to balance
the two groups on the basis of age."
Comment: probably done
Allocation concealment
(selection bias)
Low risk Quote: "participants were randomized to receive Polyphenon E or placebo. An
adaptive allocation randomization procedure was implemented to balance
the two groups on the basis of age."
Comment: probably done
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "All histopathology specimens were reviewed in a blinded fashion by
an experienced gynaecologic pathologist and were subjected to a second
quality control review."
Comment: done
Blinding of participants
and personnel (perfor-
mance bias) 
Gynaecological cancer in-
cidence
Low risk Quote: "All histopathology specimens were reviewed in a blinded fashion by
an experienced gynaecologic pathologist and were subjected to a second
quality control review."
Comment: done
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "All histopathology specimens were reviewed in a blinded fashion by
an experienced gynaecologic pathologist and were subjected to a second
quality control review."
Comment: done
Blinding of outcome as-
sessment (detection bias) 
Gynaecological cancer in-
cidence
Low risk Quote: "All histopathology specimens were reviewed in a blinded fashion by
an experienced gynaecologic pathologist and were subjected to a second
quality control review."
Comment: done
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Number of participants included in analysis stated. ITT analysis implemented
Incomplete outcome data
(attrition bias) 
Low risk Number of participants included in analysis stated. ITT analysis implemented
Garcia 2014  (Continued)
Green tea (Camellia sinensis) for the prevention of cancer (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
74
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Gynaecological cancer in-
cidence
Selective reporting (re-
porting bias)
Low risk The study protocol is available (ClinicalTrials.gov identifier (NCT number):
NCT00303823) and the published report includes all expected outcomes
Other bias Low risk No reported withdrawals
Garcia 2014  (Continued)
 
 
Methods RCT, quadruple-blind in USA
Participants 178 (male/female: 89/89) participants: 42 (male/female: 21/21) in group A, 63 (male/female: 31/32) in
group B and 73 (male/female: 37/36) in group C, 89 men
Interventions Group A: green tea beverage and placebo capsules
Group B: placebo beverage and Polyphenon E capsules (Mitsui-Norin Co, Ltd, Shizuoka, Japan), corre-
sponding to 800 mg/d of ECGC
Group C: placebo beverage and placebo capsules
Duration: 6 months
Outcomes Primary outcome
Change in levels of biomarkers of oxidative stress
Secondary outcome
Safety data
Green tea in exposure cat-
egories
N/A
Notes No results on lung cancer prevention published or reported on ClinicalTrials.gov (NCT00363805)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "We are conducting a 6-month randomized, controlled, double-blind
trial..."
Comment: probably done
Allocation concealment
(selection bias)
Unclear risk No statement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Review authors do not believe this would introduce bias since all biological
analyses were performed
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Review authors do not believe this would introduce bias since all biological
analyses were performed
Garland 2006 
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Incomplete outcome data
(attrition bias) 
All outcomes
High risk Data on lung cancer NR, only on biomarkers
Selective reporting (re-
porting bias)
Low risk All outcomes reported on ClinicalTrials.gov (NCT00363805)
Other bias Unclear risk The number of withdrawals is low, however since no full publication is avail-
able, only an abstract and report on ClinicalTrials.gov, it is difficult to judge if
other biases are present.
Garland 2006  (Continued)
 
 
Methods HCC in Romania
Participants Participants: 151 (male/female: 92/59) cases and 151 (male/female: 90/61) controls
Inclusion criteria: recently diagnosed cases undergoing conventional treatment recruited from
MEDISPROF Oncology Hospital, Cluj-Napoca, Romania
Recruitment: from April 2015-October 2017
Interventions N/A
Outcomes Colorectal cancer: 151 (male/female: 92/59) cases
Green tea in exposure cat-
egories
Exposure assessment: drinking of green tea
Lowest exposure: < 1 serving/week
Intermediate exposure 1: 1-2 servings/week
Intermediate exposure 2: 3-5 servings/week
Highest exposure: > 5 servings/week
Notes Funding: not declared
Statistical methods: crude analysis with raw data
Variables controlled in analysis: crude analysis
Variables controlled by matching: age (± 5 years)
Gavrilas 2018 (Bulletin UASVM Food Science and Technology) reports same results subsequently pub-
lished in Gavrilas 2018
Gavrilas 2018 
 
 
Methods PCC in USA
Participants Participants: 164 cases and 194 controls (all women)
Inclusion criteria: aged 18-84 years, diagnosed with epithelial ovarian cancer. Controls Oahu residents
from Hawai Health Survey Program and from women aged ≥ 65 years, in the Health Care Financing Ad-
ministration on Oahu, Hawaii, USA
Recruitment: from 1 July 1993-30 June 1999
Goodman 2003 
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Interventions N/A
Outcomes Number of cases
Ovarian cancer: 164 cases of epithelial ovarian cancer
Green tea in exposure cat-
egories
Exposure assessment: drinking of green tea (yes/no)
Lowest exposure: no drinking
Highest exposure: drinking green tea further divided in:
Highest exposure 1: < 1 cup/week
Highest exposure 2: ≥ 1 cups/week
Notes Funding: by the Anneliese Lermann Fund for Cancer Research, US Public Health Service grants R01-
CA-58598 and P30-CA-71789 and contracts N01-CN-55424 and N01-PC-67001 from the National Cancer
Institute.
Statistical methods: unconditional logistic regression
Variables controlled in analysis: age, ethnicity, oral contraceptive pill use and tubal ligation.
Variables controlled by matching: -
Goodman 2003  (Continued)
 
 
Methods PCC in Japan
Participants Participants: 71 (male/female: NR) cases and 142 (male/female: NR) controls
Inclusion criteria: permanent residents in Hokkaido Prefecture, Japan
Recruitment: NR
Interventions N/A
Outcomes Number of cases
Pancreatic cancer: 71 (male/female: NR) cases
Green tea in exposure cat-
egories
Exposure assessment: drinking of green tea
Lowest exposure: no drinking
Highest exposure: drinking green tea almost every day
Notes Article in Japanese
Funding: not declared
Statistical methods: unconditional logistic regression
Variables controlled in analysis: sex, age and area of residence
Variables controlled by matching: sex and age (± 3 years)
Goto 1990 
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Methods PCC in Australia
Participants Participants: 854 (male/female: 525/329) and 948 (male/female: 556/392) controls
Inclusion criteria: histologically confirmed incident cases aged 40-79 years, from the Western Australian
Bowel Health Study (WABOHS)
Recruitment: 1 June 2005-31 August 2007
Interventions N/A
Outcomes Number of cases
Colorectal cancer: 854 (male/female: 525/329) cases
Proximal colon cancer: 281 cases
Distal colon cancer: 260 cases
Rectal cancer: 323 cases
Green tea in exposure cat-
egories
Exposure assessment: intake of green tea
Lowest exposure: no drinking
Intermediate exposure 1: < 1 cup/month
Intermediate exposure 2: < 1 cup/week
Highest exposure: ≥ 1 cup/week
Notes Funding: Australian National Health and Medical Research Council (Project Grant #353568 and Fellow-
ship #37614900) and Dutch Cancer Society
Statistical methods: conditional logistic regression
Variables controlled in analysis: age group, sex, energy intake from food, alcohol intake, smoking sta-
tus, use of multivitamins, diabetes, physical activity during the age period 19–34 years, BMI at age 40
years, socioeconomic status and country of birth
Variables controlled by matching: sex and age
Green 2014 
 
 
Methods PCC in USA
Participants Participants: 234 (male/female: 138/96) cases and 216 (male/female: 125/91) controls
Inclusion criteria: aged ≥ 30 years, histopathologically confirmed squamous cell carcinoma of the skin
diagnosed within 4 months before the 1st interview and had no prior history of a skin cancer, non-His-
panic and Hispanic white cases' ethnicity from Southeastern Arizona Skin Cancer Study, Arizona, USA.
Recruitment: from January 1993-December 1996
Interventions N/A
Outcomes Number of cases
Skin cancer: 234 (138/96) cases of squamous cell carcinoma
Green tea in exposure cat-
egories
Exposure assessment: intake of hot green tea
Hakim 2000 
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Lowest exposure: nondrinker
Highest exposure: drinker, merging all categories (1–3 cups/month, 1–6 cups/week and ≥ 1 cup/d)
Notes Funding: grant from Unilever Health Institute Vlaardingen, the Netherlands and by Public Health Ser-
vice Grant P01 CA27502
Statistical methods: unconditional logistic regression
Variables controlled in analysis: age, sex, energy intake, inability to tan after prolonged sun exposure
and history of diagnosed and treated actinic keratosis
Variables controlled by matching: sex and age (± 10 years)
Hakim 2000  (Continued)
 
 
Methods PCC in China
Participants Participants: 523 cases (male/female: 365/158) and 1924 (male/female: 1367/557) controls
Inclusion criteria: newly diagnosed cases 35-79 years of age; residence in Dafeng City, China
Recruitment: from January 2003 from Dafeng City Center for Disease Control and Prevention
Interventions N/A
Outcomes Number of cases
Lung cancer: 523 (male/female: 365/158) cases
Green tea in exposure cat-
egories
Exposure assessment 1: green tea intake
Lowest exposure: never drinking
Highest exposure: drinking
Exposure assessment 2: green tea consumption
Lowest exposure: 0 g/month
Intermediate exposure 1: 0-49 g/month
Intermediate exposure 2: 50-99 g/month
Highest exposure: ≥ 100 g/month
Notes Article in Chinese
Funding: Jiangsu Provincial Medical Engineering Key Talent Research Fund (RC2003090)
Statistical methods: unconditional logistic regression
Variables controlled in analysis: sex, age, education, income per capita, frequent exposure to cooking
fumes, smoking habits, alcohol intake, family history of lung cancer, daily fruit and vegetable intake
Variables controlled by matching: sex, age (± 2 years) and living in the same area.
Han 2008 
 
 
Methods HCC in China
Participants Participants: 432 (male/female: 358/74) and 392 (male/female: 299/93) controls
Hemelt 2010 
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Inclusion criteria: all incident bladder cancer cases (ICD-10 C67), aged ≥ 40 years, admitted to 4 hos-
pitals (First Affliated Hospital in Hangzhou, First Municipal Hospital in Guangzhou, Tongji Hospital in
Wuhan and Second Xiangya Hospital in Changsha), China
Recruitment: from October 2005-June 2008
Interventions N/A
Outcomes Number of cases
Bladder cancer: 419 out of 432 eligible cases, mainly urothelial carcinoma (N = 323), followed by adeno-
carcinoma (N = 11) and squamous cell carcinoma (N = 7)
Green tea in exposure cat-
egories
Exposure assessment 1: green tea drinking
Lowest exposure: no
Highest exposure: yes
Exposure assessment 2: green tea drinking
Lowest exposure: no
Intermediate exposure: < daily
Highest exposure: daily, further divided in < 4 cups/d and ≥ 4 cups/d
Notes Funding: not declared
Statistical methods: unconditional logistic regression
Variables controlled in analysis: age, sex, smoking status, smoking frequency and smoking duration.
Hospital was modelled as a random effect
Variables controlled by matching: sex and age (± 5 years)
Hemelt 2010  (Continued)
 
 
Methods PCC in Japan
Participants Participants: 251 cases and 483 controls (all men)
Inclusion criteria: histologically confirmed single and multiple stomach cancer cases admitted to the
Saitama Cancer Center Hospital, living in the Saitama Prefecture for at least 10 years, Japan
Recruitment: from August 1984-July 1990
Interventions N/A
Outcomes Number of cases
Stomach cancer: 419 out of 432 eligible cases: 216 single stomach cancer and 35 multiple stomach can-
cer (all men)
Green tea in exposure cat-
egories
Exposure assessment: green tea drinking
Lowest exposure: ≤ 4 cups/d
Intermediate exposure: 5-7 cups/d
Highest exposure: ≥ 8 cups/d
Notes Funding: not declared
Hoshiyama 1992 
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Statistical methods: unconditional logistic regression
Variables controlled in analysis: age and smoking status
Variables controlled by matching: -
Hoshiyama 1992  (Continued)
 
 
Methods PCC in China
Participants Participants: 371 (69.5% male) cases and 321 (69.2% male) controls. Only 317 of the 321 eligible con-
trols) included in the analysis
Inclusion criteria: aged ≤ 75 years, no previous diagnosis for nasopharyngeal carcinoma and residence
in Taipei city/county, Taiwan (China) for > 6 months
Recruitment: from 15 July 1991-31 December 1994
Interventions N/A
Outcomes Number of cases
Nasopharyngeal carcinoma: 368 cases out of 371 eligible cases
Green tea in exposure cat-
egories
Exposure assessment: intake of green tea
Lowest exposure: 0 times/week
Intermediate exposure: < 1 time/week
Highest exposure: ≥ 1 time/week
Notes Funding: National Institutes of Health, USAA
Statistical methods: unconditional logistic regression
Variables controlled in analysis: age, sex, ethnicity, educational level, nasopharyngeal carcinoma fam-
ily history, total calories intake, years of cigarette smoking and exposure to formaldehyde and wood
dust
Variables controlled by matching: -
Hsu 2012 
 
 
Methods HCCs in Japan
Participants Huang 1999:
Participants: 887 (male/female: 595/292) cases and 28,619 (male/female: 7892/20,727) controls
Inclusion criteria: aged 20-79 years, from the Aichi Cancer Center Hospital (ACCH) in Aichi Prefecture,
Japan
Recruitment: from 1988-1995
Inoue 1994
Participants: 127,477 inhabitants of 45 areas of Japan, data retrieved from 26,426 participants: 668
(male/female: 420/248) cases and 668 (male/female: 420/248) controls
Inclusion criteria: aged 20-79 years, from the Aichi Cancer Center Hospital (ACCH) in Aichi Prefecture,
Japan
Huang 1999 
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Recruitment: from January 1988-June 1991
Kato 1990a
Participants: 427 (male/female: 289/138) cases and 3014 (male/female: 1247/1767) controls
Inclusion criteria: aged ≥ 18 years, who underwent endoscopic examination and with no other types of
cancer attending at Aichi Cancer Center Hospital, Japan. Controls considered in the present analysis
are those with normal gastric mucosa
Recruitment: from April 1985-March 1989
Interventions N/A
Outcomes Huang 1999
Number of cases
Stomach cancer: 887 (male/female: 595/292) cases
Inoue 1994:
Number of cases
Stomach cancer: 668 cases, 123 of cardia, 218 of middle stomach and 256 of antrum
Kato 1990a
Number of cases
Stomach cancer: 427 (male/female: 289/138) cases
Green tea in exposure cat-
egories
Exposure assessment: intake of green tea
Lowest exposure: never
Intermediate exposure 1: 1-2 cups/d
Intermediate exposure 2: 3-5 cups/d
Highest exposure: > 6 cups/d
Inoue 1994
Exposure assessment: green tea drinking
Lowest exposure: < every day
Highest exposure: every day
Kato 1990a
Exposure assessment: consumption of green tea
Lowest exposure: nondrinker
Intermediate exposure: 1-4 cups/d
Highest exposure: ≥ 5 cups/d
Notes Huang 1999
Funding: National Institutes of Health, USAA
Statistical methods: unconditional logistic regression
Variables controlled in analysis: sex and age
Huang 1999  (Continued)
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Variables controlled by matching: -
Inoue 1994
Funding: Grant-in-Aid for Cancer Research (4-2) and for a comprehensive 10-year Strategy for Cancer
Control from the Ministry of Health and Welfare, Japan
Statistical methods: conditional logistic regression
Variables controlled in analysis: age and intake of fresh vegetables
Variables controlled by matching: sex, age (± 2 years) and first time of hospital visit (± 2 months)
Kato 1990a
Funding: Grant-in-Aid for a Comprehensive 10-year Strategy for Cancer Control. Japan, from the Min-
istry of Health and Welfare
Statistical methods: Walker-Duncan logistic regression
Variables controlled in analysis: age and residence
Variables controlled by matching: -
Huang 1999  (Continued)
 
 
Methods Cohort study in Japan
Participants Participants: 127,477 inhabitants of 45 areas of Japan, data retrieved from 20,550 men and 29,671
women
Inclusion criteria: aged 40-79 (≥ 18 years in 1949). Details reported in Ohno 2001.
Parent cohort: Japan Collaborative Cohort Study of Evaluation of Cancer Risk (JACC Study)
Recruitment: from 1988-1990
Interventions N/A
Outcomes Number of cases
Outcome assessment: 2001
Oral cancer: 37 (male/female: 20/17) cases, including cancers of the tongue (N = 22, male/female: 13/9)
and other oral cavity (N = 15, male/female: 7/8)
Green tea in exposure cat-
egories
Exposure assessment: intake of green tea
Lowest exposure: < 1 cup/d
Intermediate exposure 1: 1-2 cups/d
Intermediate exposure 2: 3-4 cups/d
Highest exposure: ≥ 5 cups/d
Notes Funding: Grants-in-Aid for Scientific Research from the Ministry of Education, Science, Sports and Cul-
ture of Japan (Monbusho) (N. 61010076, 62010074, 63010074, 1010068, 2151065, 3151064, 4151063,
5151069, 6279102, 11181101 and 12218237)
Statistical methods: Cox hazard proportional regression
Variables controlled in analysis: sex, age, smoking status, alcohol consumption, consumption of coffee,
consumption of green/yellow vegetables, salty foods and fruits
Variables controlled by matching: -
Ide 2007 
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Methods HCC in Japan
Participants Participants: 127,477 inhabitants of 45 areas of Japan, data retrieved from 21,128 participants
Inclusion criteria: aged 40-79 years, from the Aichi Cancer Center Hospital (ACCH) in Aichi Prefecture,
Japan
Recruitment: from January 1988-June 1991
Interventions N/A
Outcomes Number of cases
Oesophageal cancer: 185 (male/female: 161/24) cases
Stomach cancer: 893 (male/female: 613/280) cases
Colon cancer: 362 (male/female: 213/149) cases
Rectal cancer: 266 (male/female: 173/93) cases
Green tea in exposure cat-
egories
Exposure assessment: intake of green tea
Lowest exposure: rarely
Intermediate exposure 1: occasional
Intermediate exposure 2: 1-2 cups/d
Intermediate exposure 3: 4-6 cups/d
Highest exposure: ≥ 7 cups/d
Notes Funding: Grant-in-Aid for Cancer Research (9-4) from the Ministry of Health and Welfare, Japan and a
grant from the Foundation of All Japan Coffee Association
Statistical methods: unconditional logistic regression
Variables controlled in analysis: coffee intake, black tea intake, sex, age, year and season at 1st hospital
visit, habitual smoking, habitual alcohol drinking, regular physical exercise, fruit intake, rice intake and
beef intake
Variables controlled by matching: -
Data on Aichi also reported in Inoue 2009a for stomach cancer
Inoue 1998 
 
 
Methods PCC in China
Participants Participants: 63,257 (male/female: 27,959/35,298) participants, 380 cases and 662 controls (all female)
Inclusion criteria: aged 40-74 years, belonging to the Hokkien or Cantonese dialect group in Singapore,
China
Parent cohort: Singapore Chinese Health Study (SCHS)
Recruitment: from April 1993-December 1998
Interventions N/A
Inoue 2008 
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Outcomes Number of cases
Outcome assessment: 31 July 2007
Breast cancer: 380 female breast cancer out of 736 eligible cases
Green tea in exposure cat-
egories
Exposure assessment: green tea intake
Lowest exposure: none or < weekly
Intermediate exposure: weekly to < daily
Highest exposure: daily
Notes Funding: National Cancer Institute, Bethesda, MD (R01-CA55069, R35-CA53890 and R01-CA80205)
Statistical methods: unconditional logistic regression
Variables controlled in analysis: age, year of enrolment, education, dialect, BMI, age when period be-
came regular, number of live births and black tea intake
Variables controlled by matching: -
Inoue 2008  (Continued)
 
 
Methods Cohort studies in Japan
Participants Participants: 219,080 (male/female: 100,479/118,601) participants
Inclusion criteria: all studies were carried out on Japanese populations starting from mid-1980s to
mid-1990s with information on diet (including green tea)
Parent cohorts
Japan Public Health Center-based Prospective Study (JPHC)-I
Japan Public Health Center-based Prospective Study (JPHC)-II
Japan Collaborative Cohort Study (JACC) (only from 24 of the 45 investigated areas)
Miyagi Cohort Study (MIYAGI)
Three Prefecture Study - Miyagi portion (3-pref MIYAGI)
Three Prefecture Study - Aichi portion (3-pref AICHI)
Recruitment
JPHC-I: 1990
JPHC-II: from 1993-1994
JACC: from 1988-1990
MIYAGI: 1990
3-pref MIYAGI: 1984
3-pref AICHI: 1985
Previous reports
Fujino 2002
Inoue 2009a 
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Participants: 127,477 inhabitants of 45 areas of Japan, data retrieved from 18,746 men and 26,184
women
Inclusion criteria: aged 40-79 (≥ 18 years in 1949). Details reported in Ohno 2001
Parent cohort: Japan Collaborative Cohort Study of Evaluation of Cancer Risk (JACC Study)
Recruitment: from 1988-1990
Hoshiyama 2002
Participants: 127,477 inhabitants of 45 areas of Japan, data retrieved from 18,746 men and 26,184
women
Inclusion criteria: aged 40-79 (≥ 18 years in 1949). Details reported in Ohno 2001
Parent cohort: Japan Collaborative Cohort Study of Evaluation of Cancer Risk (JACC Study)
Recruitment: from 1988-1990
Hoshiyama 2004: (nested case-cohort study due to availability of serum samples)
Participants: 127,477 inhabitants of 45 areas of Japan, data retrieved from 30,370 men and 42,281
women including 151 cases and 265 controls
Inclusion criteria: aged 40-79 (≥ 18 years in 1949). Details reported in Ohno 2001
Parent cohort: Japan Collaborative Cohort Study of Evaluation of Cancer Risk (JACC Study)
Recruitment: from 1988-1990
Koizumi 2003
Participants: 31,345 (male/female: 13,992/17,353) from cohort 1 and 47,605 (male/female:
22,836/24,769). Final included subjects 26,311 (male/female: 11,902/14,409) from cohort 1 and 39,604
(male/female: NR) from cohort 2
Inclusion criteria: aged ≥ 40 years, residents in three municipalities of the Miyagi Prefecture, Northern
Japan (cohort 1); aged 40-64 years (cohort 2) in residents of Miyagi Prefecture, Japan
Parent cohorts
Cohort 1: Three Prefecture Study - Miyagi portion (3-pref MIYAGI)
Cohort 2: Miyagi Cohort Study (MIYAGI)
Recruitment: from 1984 for cohort 2 and from 1990 for cohort 2
Tsubono 2001
Participants: 31,345 (male/female: 13,992/17,353) with final included participants 26,311 (male/female:
11,902/14,409)
Inclusion criteria: aged ≥ 40 years, residents in 3 municipalities of the Miyagi Prefecture, Northern
Japan
Parent cohort: Three Prefecture Study - Miyagi portion (3-pref MIYAGI)
Recruitment: from 1984
Sasazuki 2004
Participants: 140,420 (male/female: 68,722/71,698), with 61,595 from cohort 1 and 78,825 from cohort 2
and 72,943 (male/female: 34,832/38,111) participants with complete data
Inclusion criteria: aged 40-59 years, from 5 Public Health Centre areas (Iwate, Akita, Nagano, Okinawa
and Tokyo) for cohort 1 and aged 40-69 years for cohort 2, from 6 public health centre areas (Ibaraki, Ni-
Inoue 2009a  (Continued)
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igata, Kochi, Nagasaki, Okinawa and Osaka), respondent at 5-year follow-up. Katsushika Public Health
Center was excluded due to missing cancer data.
Parent cohorts
Cohort 1: Japan Public Health Center-based Prospective Study (JPHC)-I
Cohort 2: Japan Public Health Center-based Prospective Study (JPHC)-II
Recruitment: from 1990 for cohort 1 and 1993/1994 for cohort 2
Interventions N/A
Outcomes Number of cases
Inoue 2009b
Outcome assessment
JPHC-I: 2001
JPHC-II: 2003-2004
JACC: 2001
MIYAGI: 2001
3-pref MIYAGI: 1992
3-pref AICHI: 2000
Stomach cancer: 3577 (male/female: 2495/1082) cases
Previous reports
Fujino 2002
Outcome assessment: 31 December 1997
Stomach cancer mortality: 379 (male/female: 261/118) cases
Hoshiyama 2002
Outcome assessment: 31 December 1997
Stomach cancer mortality: 359 (male/female: 240/119) cases
Hoshiyama 2004
Outcome assessment: 31 December 1997
Stomach cancer: 151 cases of the 804 eligible cases due to availability of serum samples
Koizumi 2003
Outcome assessment: December 1992 for 3-pref MIYAGI, NR for MIYAGI (probably 1997)
Stomach cancer: 733 (male/female: NR) cases; 419 (male/female: 296/123) cases in 3-pref-MIYAGI I and
314 (male/female: NR) cases in MIYAGI-
Tsubono 2001
Outcome assessment: 31 December 1992 for 3-pref MIYAGI only
Stomach cancer: 419 (male/female: 296/123) cases from 3-pref MIYAGI only
Sasazuki 2004
Inoue 2009a  (Continued)
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Outcome assessment: 31 December 2001
Stomach cancer: 892 (male/female: 665/227) cases, including 109 (male/female: 88/21) including up-
per-third gastric cancers and 631 (male/female: 461/170) distal cancers and as histological categorisa-
tion, 471 (male/female: 386/85) cases of differentiated type and 312 (male/female: 197/115) cases of
undifferentiated type
Green tea in exposure cat-
egories
Exposure assessment: green tea intake (same for Inoue 2009a, Koizumi 2003, Tsubono 2001 and
Sasazuki 2004)
Lowest exposure: < 1 cup/d
Intermediate exposure 1: 1-2 cups/d
Intermediate exposure 2: 3-4 cups/d
Highest exposure: ≥ 5 cups/d
Exposure assessment: intake of green tea (in Fujino 2002)
Lowest exposure: ≤ 3 times/week
Intermediate exposure: > 3 times/week
Highest exposure: every day
Exposure assessment: intake of green tea (In Hoshiyama 2002 and Hoshiyama 2004)
Intermediate exposure 1: 1-2 cups/d
Intermediate exposure 2: 3-4 cups/d
Intermediate exposure 3: 5-9 cups/d
Highest exposure: ≥ 10 cups/d
Notes Funding: in Tsubono: grants from the Japanese Ministry of Health and Welfare and the Japanese Min-
istry of Education, Science and Culture. In Koisumi 2003 not declared and this study was supported
by a Grant for the Third Term Comprehensive Control Research for Cancer from the Ministry of Health,
Labour and Welfare of Japan.
Statistical methods: Cox proportional hazard regression
Inoue 2009b
Variables controlled in analysis: age, area (JPHC-I, JPHC-II and JACC only), smoking, ethanol intake, rice
intake, soy bean paste soup, coffee intake, pickled vegetable intake and green–yellow vegetable intake
Fujino 2002
Funding: Grants-in-Aid for Scientific Research from the Ministry of Education, Science, Sports and Cul-
ture of Japan (Monbusho) (N. 61010076, 63010074, 1010068, 2151065, 3151064, 4151063, 5151069,
6279102, 11181101, 12218237 and 12218216).
Statistical methods: Cox proportional hazard regression
Variables controlled in analysis: age
Hoshiyama 2002
Funding: Ministry of Education, Science, Sports and Culture of Japan grants: 61010076, 62010074,
63010074, 1010068, 2151065, 3151064, 4151063, 5151069, 6279102, 11181101, 12218237
Statistical methods: Cox hazard proportional regression
Variables controlled in analysis: age, smoking status, history of peptic ulcer, family history of stomach
cancer, consumption of rice, miso soup, green-yellow vegetables, white vegetables, fruits and prefer-
ence for salty foods
Hoshiyama 2004
Inoue 2009a  (Continued)
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Funding: Ministry of Education, Science, Sports and Culture of Japan grants: 61010076, 62010074,
63010074, 1010068, 2151065, 3151064, 4151063, 5151069, 6279102, 11181101, 12218237
Statistical methods: Cox hazard proportional regression
Variables controlled in analysis: age, smoking status, HP infection, history of peptic ulcer, family history
of stomach cancer, educational level, consumption of rice, miso soup, green-yellow vegetables, white
vegetables, fruits and preference for salty foods
Koizumi 2003
Variables controlled in analysis: sex, age, type of health insurance, parental history of gastric cancer,
history of peptic ulcer, cigarette smoking, alcohol consumption, consumption of rice, black tea, coffee,
pickled vegetables, bean-paste soup. Plus consumption of meat, green or yellow vegetables, other veg-
etables and fruits for cohort 1 and consumption of pork, ham, spinach, carrot, cabbage, Chinese cab-
bage, orange and other fruits for cohort 2
Tsubono 2001
Variables controlled in analysis: sex, age, type of health insurance, history of peptic ulcer, smoking sta-
tus, alcohol consumption, daily consumption of rice, consumption of black tea and consumption of
coffee, and consumption of meat, green or yellow vegetables, pickled vegetables, other vegetables,
fruits and bean-paste soup.
Sasazuki 2004
Funding: Grant-in-Aid for Cancer Research and for the Second Term Comprehensive 10-year Strategy
for Cancer Control from the Ministry of Health, Labour and Welfare of Japan
Statistical methods: Cox proportional hazard regression
Variables controlled in analysis: age, area and cigarette smoking (stratified by sex)
Variables controlled by matching: -
Note: Ohno 2001 study report rationale for initiating the Japan Collaborative Cohort (JACC) Study
Inoue 2009a  (Continued)
 
 
Methods Cohort study in Japan
Participants Participants: 68,975 participants, results of 18,815 (male/female: 6414/12,401) participants
Inclusion criteria: aged 40-69 years, from 6 Public Health Centre areas across Japan
Parent cohort: Japan Public Health Center-based Prospective Study (JPHC)-II
Recruitment: from 1993-1994
Interventions N/A
Outcomes Number of cases
Liver cancer: 110 (male/female: 73/37) cases
Outcome assessment: 31 December 2006
Green tea in exposure cat-
egories
Exposure assessment: green tea intake
Lowest exposure: < 3 cups/d
Intermediate exposure: 3-4 cups/d
Inoue 2009b 
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Highest exposure: ≥ 5 cups/d
Notes Funding: Grant-in-Aid for Cancer Research, for Research on Hepatitis and for the Third-Term Compre-
hensive Control Research for Cancer from the Ministry of Health, Labour and Welfare of Japan
Statistical methods: Cox proportional hazard regression
Variables controlled in analysis: sex, age, area, smoking status, weekly ethanol intake, BMI, history of
diabetes mellitus, coffee consumption, serum ALT level, hepatitis C infection status and hepatitis B in-
fection status
Variables controlled by matching: -
Inoue 2009b  (Continued)
 
 
Methods Cohort study in Japan
Participants Participants: 31,345 (male/female: 13,991/17,354) participants in cohort 1 and 47,605 (male/female:
22,836/24,769) participants in cohort 2. Final participants are 26,723 (male/female: 9008/17,715) partic-
ipants with covariate information
Inclusion criteria: aged ≥ 40 years, in 3 municipalities of Miyagi Prefecture in cohort 1 and aged 40-64
years, in the 14 municipalities of Miyagi Prefecture, Japan
Parent cohorts
Cohort 1: Three Prefecture Study - Miyagi portion (3-pref MIYAGI)
Cohort 2: Miyagi Cohort Study (MIYAGI)
Recruitment: from January 1994 (cohort 1) and from June-August 1990 (cohort 2)
Interventions N/A
Outcomes Number of cases
Outcome assessment: 31 December 1992 (cohort 1) and 31 December 1997 (cohort 2)
Oesophageal cancer: 38 + 40 in cohort 1 and cohort 2 respectively
Green tea in exposure cat-
egories
Exposure assessment: green tea consumption
Lowest exposure: never or occasionally
Intermediate exposure 1: 1-2 cups/d
Intermediate exposure 2: 3-4 cups/d
Highest exposure: ≥ 5 cups/d
Notes Funding: not declared
Statistical methods: Cox proportional hazard regression
Variables controlled in analysis: age, cigarette smoking, alcohol drinking and coffee consumption
Variables controlled by matching: -
Ishikawa 2006 
 
 
Methods PCC in Iran
Islami 2009 
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Participants Participants: 300 cases (male/female: 150/150) and 571 (male/female: 278/293) controls
Inclusion criteria: newly diagnosed histologically confirmed oesophageal cancer in residents in the
eastern part of Golestan Province, Iran, attending the Atrak Clinic.
Recruitment: from December 2003 to March 2007
Interventions N/A
Outcomes Number of cases
Oesophageal cancer: 266/300 eligible cases
Green tea in exposure cat-
egories
Exposure assessment: frequency of green tea consumption
Lowest exposure: never, < weekly
Highest exposure: daily, weekly
Notes Funding: not declared
Statistical methods: conditional logistic regression
Variables controlled in analysis: ethnicity, daily vegetable intake, alcohol consumption, tobacco or opi-
um ever used, duration of residence in rural areas, education level, car ownership, tea temperature and
black tea intake
Variables controlled by matching: place of residence, age (± 2 years) and sex
Islami 2009  (Continued)
 
 
Methods Cohort study in Japan
Participants Participants: 4411 participants from the Tottori Prefecture, Japan. Data from 2855 (male/female:
1404/1451) participants, only men for cancer mortality
Inclusion criteria: aged 40-79 years
Parent cohort: Japan Collaborative Cohort Study of Evaluation of Cancer Risk (JACC Study)
Recruitment: from April-May 1989
Interventions N/A
Outcomes Number of cases
Outcome assessment: 31 December 1999
Total cancer mortality: 31 cases (all men)
Green tea in exposure cat-
egories
Exposure assessment: frequency of green tea consumption
Lowest exposure: < 0.5 cups/d
Intermediate exposure: 0.5-3 cups/d
Highest exposure: ≥ 4 cups/d
Notes Funding: Grant-in-Aid for Scientific Research from Monbusho, the Japanese Ministry of Education,
Science and Culture (N.11181101)
Statistical methods: Cox proportional hazard regression
Iwai 2002 
Green tea (Camellia sinensis) for the prevention of cancer (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
91
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Variables controlled in analysis: coffee consumption, age, history of cancer and apoplexy, educational
status and smoking status
Variables controlled by matching: -
Iwai 2002  (Continued)
 
 
Methods Cohort studies in Japan (Iwasaki 2010a) and case-cohort nested study (Iwasaki 2010b)
Participants Participants: 140,420 (male/female: 68,722/71,698) from cohort 1 and cohort 2. From the available
67,422 women
Inclusion criteria: incident breast cancer cases in women at baseline aged 40-59 years in cohort 1 and
40-69 years in cohort 2, with no history of breast cancer, respondent to baseline questionnaire, not
moved out of study area
In Iwasaki 2010b: included data with available plasma tea polyphenol levels. Final population of 144
cases and 288 controls
Parent cohorts
Japan Public Health Center-based Prospective Study (JPHC)-I
Japan Public Health Center-based Prospective Study (JPHC)-II
Recruitment
JPHC-I: 1990
JPHC-II: from 1993-1994
Interventions N/A
Outcomes Number of cases
Outcome assessment: 31 December 2006 in Iwasaki 2010a and 31 December 2002 in Iwasaki 2010b
Breast cancer: 581 cases, based on baseline questionnaire data
Green tea in exposure cat-
egories
Exposure assessment: green tea intake at baseline
Iwasaki 2010a
Lowest exposure: < 1 cup/week
Intermediate exposure 1: 1-2 cups/week
Intermediate exposure 2: 3-4 cups/week
Intermediate exposure 3: 1-2 cups/d
Intermediate exposure 4: 3-4 cups/d
Highest exposure: ≥ 5 cups/d
Iwasaki 2010b
Lowest exposure: < 1 cup/week
Highest exposure: ≥ 5 cups/d
Notes Iwasaki 2010a
Iwasaki 2010a 
Green tea (Camellia sinensis) for the prevention of cancer (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
92
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Funding: Grant-in-Aid for Scientific Research from Monbusho, the Japanese Ministry of Education,
Science and Culture (N.11181101)
Statistical methods: Cox proportional hazard regression
Variables controlled in analysis: age, area (10 Public Health Centres), age at menarche, menopausal sta-
tus at baseline, number of births, age at first birth, height, BMI, alcohol intake, smoking status, leisure
time physical activity, exogenous hormone use, family history of breast cancer, oolong tea intake, black
tea intake and coffee intake
Variables controlled by matching: -
Iwasaki 2010b
Funding: Grants-in-Aid for Cancer Research and for the Third Term Comprehensive Ten-Year Strategy
for Cancer Control from the Ministry of Health, Labour and Welfare of Japan and Grants-in-Aid for Sci-
entific Research on Priority Areas (17015049) from the Ministry of Education, Culture, Sports, Science
and Technology of Japan.
Statistical methods: crude data analysis
Variables controlled in analysis: crude data
Variables controlled by matching: -
Data of parent study Iwasaki 2010a were used for breast cancer analysis including a larger population.
Iwasaki 2010a  (Continued)
 
 
Methods HCC in Japan
Participants Participants: 405 cases and 405 controls (all women)
Inclusion criteria: female, newly diagnosed and histologically confirmed breast cancer cases at 4 hospi-
tals of Nagano prefecture, Japan
Recruitment: from May 2001-September 2005
Interventions N/A
Outcomes Number of cases
Breast cancer: 369/405 eligible cases due to missing information on green tea, SNP genotype informa-
tion, or DNA sample. Major histologic types were invasive ductal carcinoma (85.6%), invasive lobular
carcinoma (4.1%) and mucinous carcinoma (3.8%).
Green tea in exposure cat-
egories
Exposure assessment: green tea intake
Lowest exposure: 1-119 mL/d
Intermediate exposure: 120-599 mL/d
Highest exposure: ≥ 600 mL/d
Notes Funding: Grants-in-Aid for Research on Risk of Chemical Substances and the Third-Term Comprehen-
sive Ten-Year Strategy for Cancer Control from the Ministry of Health, Labour and Welfare of Japan
and Grants-in-Aid for Scientific Research on Innovative Areas (221S0001) and for Young Scientists (B)
(22700934) from the Ministry of Education, Culture, Sports, Science and Technology of Japan and
the Japan Society for the Promotion of Science and Foundation for Promotion of Cancer Research in
Japan.
Statistical methods: conditional logistic regression
Iwasaki 2014 
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Variables controlled in analysis: menopausal status, number of births, family history of breast cancer,
smoking status, moderate physical activity in the past 5 years, vitamin supplement use, oolong tea con-
sumption, black tea consumption, coffee consumption and canned coffee consumption
Variables controlled by matching: sex, age (± 3 years) and residential area
Iwasaki 2014  (Continued)
 
 
Methods PCC in China
Participants Participants: 1124 (male/female: 770/354) cases and 1451 (male/female: 819/632) controls. 1347 (male/
female: 753/594) of the eligible controls included in the analysis.
Inclusion criteria: aged 20-69 years, permanent resident of the 10 urban districts of Shanghai, China
Recruitment: from 1 December 1988-30 November 1989
Interventions N/A
Outcomes Number of cases
Stomach cancer: 1029 (male/female: 684/345) of the eligible cases, including cancers of cardia (N = 145,
18.8% in men and N = 40, 11.3% in women), distal stomach (N = 530, 68.9% in men and N = 257, 72.6%
in women) and unclassified (N = 95, 12.3% in men N = 57, 16.1% in women)
Green tea in exposure cat-
egories
Exposure assessment A: green tea drinking status
Lowest exposure: nondrinker
Highest exposure: regular drinker
Exposure assessment B: consumption of green tea leaves
Lowest exposure: nondrinker
Men
Intermediate exposure 1: ≤ 1200 g/year
Intermediate exposure 2: 1200-≤ 2000 g/year
Intermediate exposure 3: 2000-≤ 3000 g/year
Highest exposure: > 3000 g/year
Women
Intermediate exposure: ≤ 1200 g/year
Highest exposure: > 1200 g/year
Notes Funding: not declared
Statistical methods: logistic regression
Variables controlled in analysis: age, income and educational level among women; further adjusted for
smoking and alcohol drinking among men
Variables controlled by matching: sex and age (± 5 years)
Ji 1996 
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Methods PCC in China
Participants Participants: 2266 (male/female: NR) cases and 1552 (male/female: NR) controls
Inclusion criteria: aged 30/74 years, permanent resident of the 10 urban districts of Shanghai, China
Recruitment: from October 1990-June 1993
Interventions N/A
Outcomes Number of cases
Colon cancer: 885 (male/female: 426/459) out of the 931 eligible cases
Rectal cancer: 843 (male/female: 441/402) out of the 884 eligible cases
Pancreatic cancer: 428 (male/female: 246/182) out of the 451 eligible cases
Green tea in exposure cat-
egories
Exposure assessment A: green tea drinking habit
Lowest exposure: nondrinker
Highest exposure: regular drinker
Exposure assessment B: green tea consumption
Men
Lowest exposure: nondrinker
Intermediate exposure 1: 1-199 g/month
Intermediate exposure 2: 200-299 g/month
Highest exposure: ≥ 300 g/month
Women
Lowest exposure: nondrinker
Intermediate exposure: 1-199 g/month
Highest exposure: ≥ 200 g/month
Exposure assessment C: lifetime green tea consumption
Men
Lowest exposure: nondrinker
Intermediate exposure 1: 1-3499 g/month per years of drinking
Intermediate exposure 2: 3500-8499 g/month per years of drinking
Highest exposure: ≥ 8500 g/month per years of drinking
Women
Lowest exposure: nondrinker
Intermediate exposure: 1-3499 g/month per years of drinking
Highest exposure: ≥ 3500 g/month per years of drinking
Notes Funding: not declared
Ji 1997 
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Statistical methods: logistic regression
Variables controlled in analysis: age, income, education and cigarette smoking
Variables controlled by matching: sex and age (± 5 years)
Ji 1997  (Continued)
 
 
Methods Case-control study in China
Participants Participants: 53 (male/female: 19/34) cases and 106 (male/female: 48/58) controls
Inclusion criteria: participants of the cohort of Dayao in Yunnan, a rural area with naturally occurring
asbestos, China
Recruitment: NR
Interventions N/A
Outcomes Number of cases
Lung cancer: 23 cases
Pleural mesothelioma: 26 cases
Green tea in exposure cat-
egories
Exposure assessment: green tea intake
Lowest exposure: never
Intermediate exposure 1: 1-3 times/week
Intermediate exposure 2: 4-6 times/week
Highest exposure: ≥ 7 times/week
Notes Article in Chinese
Funding: National Natural Research Fundation of China (no. 41071064)
Statistical methods: conditional logistic regression
Variables controlled in analysis: sex, age, ethnicity, cultural level, BMI, alcohol consumption, history of
lung cancer, family history of cancer
Variables controlled by matching: sex and age (± 3 years)
Jia 2016 
 
 
Methods HCC in China
Participants Participants: 130 cases and 274 controls (all men)
Inclusion criteria: aged ≥ 45 years, incident and histopathologically confirmed cases of adenocarcino-
ma of the prostate from 8 hospitals of Hangzhou, southeast China, residents in the Zhejiang Province,
China for at least 10 years
Recruitment: from July 2001-June 2002
Interventions N/A
Outcomes Number of cases
Jian 2004 
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Prostate cancer: 130 cases (all men) of prostatic adenocarcinoma
Green tea in exposure cat-
egories
Exposure assessment A: green tea drinking habits
Lowest exposure: no
Highest exposure: yes
Exposure assessment B: intake of green tea
Lowest exposure: < 1 cup/d
Intermediate exposure: 1-3 cups/d
Highest exposure: > 3 cups/d
Notes Funding: not declared
Statistical methods: conditional logistic regression
Variables controlled in analysis: age at interview, locality, education, family income, BMI, physical ac-
tivity, alcohol consumption, tobacco smoking, total fat intake, marital status, age at marriage, number
of children, vasectomy, family history of prostate cancer
Variables controlled by matching: age and geographical area
Jian 2007
Subsequent report on the exact same population, controlling for lycopene intake
Jian 2004  (Continued)
 
 
Methods PCC in China
Participants Participants: 799 (male/female: 553/246) cases and 2010 (male/female: 1600/410) controls
Inclusion criteria: aged 20-90 years, residents in the Ganyu county, Jiangsu Province, China
Recruitment: 2010
Interventions N/A
Outcomes Number of cases
Lung cancer: 799 (male/female:553/246) cases
Green tea in exposure cat-
egories
Exposure assessment A: intake of green tea
Lowest exposure: nondrinker
Highest exposure: drinker
Exposure assessment B: consumption of green tea
Lowest exposure: 0 cup/d
Intermediate exposure 1: 1 cup/d
Intermediate exposure 2: 2 cups/d
Highest exposure: > 2 cups/d
Notes Article in Chinese
Jin 2013 
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Funding: grant from Jiangsu Provincial Health Department (RC 2003090)
Statistical methods: unconditional logistic regression
Variables controlled in analysis: sex, age, education, income, BMI, family history of cancer, cigarette
smoking, alcohol intake and garlic consumption
Variables controlled by matching: sex and age (± 5 years)
Jin 2013  (Continued)
 
 
Methods PCC in Japan
Participants Participants: 152 cases and 285 controls (all women)
Inclusion criteria: aged < 80 years, having endometrial cancer and underwent total hysterectomy at ei-
ther Tohoku University Hospital (centre 1) or at the Miyagi Cancer Center (centre 2), histologically con-
firmed and with no history of cancer at any other organ or site, Miyagi prefecture, Japan
Recruitment: from November 2002-March 2007 (centre 1) or from June 2005-June 2006 (centre 2)
Interventions N/A
Outcomes Number of cases
Endometrial cancer: 152 cases of endometrioid adenocarcinoma
Green tea in exposure cat-
egories
Exposure assessment: consumption of green tea
Lowest exposure: < 4 cups/week
Intermediate exposure 1: 5-6 cups/week-1 cup/d
Intermediate exposure 2: 2-3 cups/d
Highest exposure: > 4 cups/d
Notes Funding: Grant-in-Aid for Scientific Research on Priority Areas, a Grant-in-Aid for Scientific Research, a
Grant-in-Aid for Young Scientists, a Grant-in-Aid for Exploratory Research, from the Ministry of Educa-
tion, Science, Sports and Culture, Japan; Grant-in-Aid from the Ministry of Health, Labour and Welfare,
Japan; the 21st Century COE Program Special Research Grant (Tohoku University) from the Ministry of
Education Science, Sports and Culture, Japan; Grant-in-aid from the Kurokawa Cancer Research Foun-
dation, the Uehara Memorial Foundation, All Japan Coffee Association and the Third Term Comprehen-
sive 10-year Strategy for Cancer Control from the Ministry of Health, Labour and Welfare, Japan
Statistical methods: conditional logistic regression
Variables controlled in analysis: BMI, education, number of pregnancies, menopausal status, smoking
status, diabetes mellitus, total calorie intake, miso soup consumption, tofu consumption and coffee
consumption
Variables controlled by matching: age (± 5 years) and area of residence
Kakuta 2009 
 
 
Methods PCC in Japan
Participants Participants: 221 (male/female: 138/83) cases and 578 (male/female: 377/201) controls
Inclusion criteria: aged ≥ 18 years, receiving a coloscopic examination at Aichi Cancer Center Hospital,
Japan
Kato 1990 
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Recruitment: from June 1986-March 1990
Interventions N/A
Outcomes Number of cases
Colorectal cancer: 221 (male/female: 138/83) cases (2 cases have both colon and rectal cancer)
Colon cancer: 132 (male/female: 79/53) cases
Rectal cancer: 91 (male/female: 60/31) cases
Green tea in exposure cat-
egories
Exposure assessment: hot green tea
Lowest exposure: < daily drinker
Highest exposure: daily drinker
Notes Funding: Grants-in-Aid for Cancer Research from the Ministry of Health and Welfare of Japan (61-6 and
1-6)
Statistical methods: unconditional logistic regression
Variables controlled in analysis: age, sex and residence
Variables controlled by matching: age (± 5 years), sex and municipality
Kato 1990  (Continued)
 
 
Methods Cohort study in Japan
Participants Participants: 34,759 women from Hiroshima and Nagasaki
Inclusion criteria: women (93,741) present in Hiroshima and Nagasaki at the time of the bombings and
city residents on 1 October 1950 and residents (23,580) not present at the time of the bombings but
present between 1950 and 1953. Data of women recruited in the 1st and 2nd mail surveys, alive on 1
September 1969 (survey 1) and alive in September 1979 (Hiroshima) and July 1979 (Nagasaki)
Parental cohort: Radiation Effects Research Fundation's Life Span Study: final population of 34,765
women
Recruitment: 1969-1970 (survey 1) and 1979 (survey 2)
Interventions N/A
Outcomes Number of cases
Outcome assessment: 31 December 1993
Breast cancer: 405/427 eligible cases (22 cases excluded due to missing data on green tea intake)
Green tea in exposure cat-
egories
Exposure assessment: hot green tea intake
Lowest exposure: ≤ 1 time/d
Intermediate exposure: 2-4 times/d
Highest exposure: ≥ 5 times/d
Notes Funding: research performed at the Radiation Effects Research Foundation (RERF), Hiroshima and Na-
gasaki, Japan. RERF is funded equally by the Japanese Ministry of Health and Welfare and the USA De-
partment of Energy (DOE) Department of Energy through the National Academy of Sciences, Japan
Key 1999 
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Statistical methods: Poisson regression
Variables controlled in analysis: age, calendar period, city, age at the time of the bombing and radiation
dose
Variables controlled by matching: -
Key 1999  (Continued)
 
 
Methods Cohort study in Japan
Participants Participants: 3158 (male/female: 1524/1634) participants
Inclusion criteria: aged ≥ 40 years, attending the 45 Public Health Centres located in the Hokkaido Pre-
fecture, Japan
Recruitment: 2002
Interventions N/A
Outcomes Number of cases
Outcome assessment: 31 December 1993
Total cancer mortality: 243 (male/female: 154/89) cases
Lung cancer mortality: 51 (male/female: 40/10) cases
Stomach cancer mortality: 51 (male/female: 36/15) cases
Colorectal cancer mortality: 29 (male/female: 15/14) cases
Pancreatic cancer mortality: 25 (male/female: 12/13) cases
Other cancers mortality: 88 (male/female: 51/37) cases
Green tea in exposure cat-
egories
Exposure assessment: green tea intake
Lowest exposure: never drink or drink several times per year or per month
Highest exposure: drink several times/week or every day
Notes Funding: Department of Health and Welfare of Hokkaido Government, Japan
Statistical methods: Cox proportional hazard regression
Variables controlled in analysis: age and smoking
Variables controlled by matching: -
Khan 2004 
 
 
Methods Cohort study in Japan
Participants Participants: 26,481 participants (all men). Data on green tea consumption available for 18,961 men
Inclusion criteria: aged 40-79 years, living in 14 municipalities of Miyagi Prefecture in Japan
Parent cohort: Ohsaki Cohort Study
Recruitment: from 1994
Kikuchi 2006 
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Interventions N/A
Outcomes Number of cases
Otucome assessment: 2002
Prostate cancer: 110 cases
Green tea in exposure cat-
egories
Exposure assessment: green tea intake
Lowest exposure: < 1 cup/d
Intermediate exposure 1: 1-2 cups/d
Intermediate exposure 2: 3-4 cups/d
Highest exposure: ≥ 5 cups/d
Notes Funding: Grant-in-aid of Third Term Comprehensive Control Research for Cancer from the Ministry of
Health, Labour and Welfare, Japan (H16-3ji-gan-010)
Statistical methods: Cox proportional hazard regression
Variables controlled in analysis: age, BMI, alcohol consumption, smoking status, marital status, daily
calorie intake, daily calcium intake, walking duration, consumption frequencies of black tea and coffee
and consumption frequencies of meat and fish
Variables controlled by matching: -
Kikuchi 2006  (Continued)
 
 
Methods PCC and HCC in Japan
Participants Participants: 139 (male/female: 74/65) cases, 278 (male/female: 148/130) population controls and 2575
(male/female: 1171/1404) hospital controls
Inclusion criteria: aged 20-75 years, newly diagnosed cases from Karatsu city and 9 neighbouring vil-
lages in Saga Prefecture, Japan. Hospital controls were aged 25-75 years, free from cancer at clini-
cal/radiological examination. Population controls were residents of Saga Prefecture, Japan
Recruitment: from 1979-1982
Interventions N/A
Outcomes Number of cases
Stomach cancer: 139 (male/female: 74/65) cases
Green tea in exposure cat-
egories
Exposure assessment: green tea intake
Lowest exposure: none or 1-4 cups/d
Intermediate exposure: 5-9 cups/d
Highest exposure: ≥ 10 cups/d
Notes Funding: Grant-in-Aid, Ministry of Education, Science and Culture, Japan
Statistical methods: unconditional logistic regression for hospital controls and conditional logistic re-
gression for population controls
Variables controlled in analysis: sex, age, class, smoking, consumption of mandarin oranges, fruits and
others
Kono 1988 
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Variables controlled by matching: sex, age, class
Kono 1988  (Continued)
 
 
Methods HCC in Czech Republic
Participants Kubik 2008
Participants: 1096 (male/female: 509/587) cases and 2966 (male/female: 788/2178) controls
Inclusion criteria: aged 25-89 years, with microscopically confirmed lung cancer attending Prague Uni-
versity Hospital Na Bulovce, Departments of pneumology, thoracic surgery and internal medicine
Recruitment: from April 2002-August 2006 (men) and from April 1998-November 2006 (women)
Kubik 2004
Participants: 435 cases and 1710 controls (all women)
Inclusion criteria: women aged 25-89 years, with microscopically confirmed lung cancer attending
Prague University Hospital Na Bulovce, Departments of pneumology, thoracic surgery and internal
medicine
Recruitment: from April 1998-November 2002
Interventions N/A
Outcomes Kubik 2008
Number of cases
Lung cancer: 1096 (male/female: 509/587) cases: 308 (male/female: 101/207) cases of adenocarcinoma,
398 (male/female: 249/149) squamous cell cancers and 213 (male/female: 81/132) small-cell cancers
Kubik 2004
Number of cases
Lung cancer: 435 cases (all women)
Green tea in exposure cat-
egories
Kubik 2008
Exposure assessment: green tea intake
Lowest exposure: never
Highest exposure: monthly or less, weekly or less, daily or several times/week
Kubik 2004
Exposure assessment: green tea intake
Lowest exposure: never
Intermediate exposure: monthly (≤ 1 month ) or weekly (≤ 1 week but > 1 monthly)
Highest exposure: daily (daily or several times/week)
Notes Kubik 2008
Kubik 2008 
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Funding: grant (N. NR/8411-3) from the Internal Grant Agency of the Ministry of Health of the Czech Re-
public and by an institutional research project (N. MZO 00064211) from the Ministry of Health, Czech
Republic
Statistical methods: unconditional logistic regression
Variables controlled in analysis: age, residence, education and pack-years of smoking
Variables controlled by matching: -
Kubik 2004
Funding: Internal Grant Agency of the Ministry of Health of the Czech Republic (NJ/6732–3)
Statistical methods: unconditional logistic regression
Variables controlled in analysis: age, residence, education and pack-years of smoking
Variables controlled by matching: -
Kubik 2008  (Continued)
 
 
Methods RCT, parallel, double-blind in USA
Participants Participants: originally 97 men with HG-PIN and/or ASAP (49 in the intervention group and 48 in the
control group)
Inclusion criteria: age 30-80 years, with HG-PIN and/or ASAP biopsy diagnosed < 3 months before ran-
domisation, with no history of cancer, hepatic or renal disease, restricted from taking steroid or other
supplements, or > 6-12 cups of green tea/d
Recruitment: from September 2008-March 2013 (> 95%) at the Moffitt Cancer Center, James A. Haley VA
Hospital, Tampa and University of Florida, Jacksonville, Florida
Interventions Treatment group: Polyphenon E (Poly E) by Mitsui Norin Co (containing 200 mg of catechins/capsule),
two capsules/d = total 400 mg/d of EGCG
Control group: placebo
Duration: 1 year
Outcomes Primary outcome
Prostate cancer incidence
Secondary outcome
Prostate cancer incidence + ASAP in men with HG-PIN
LUTS using the LUTS Symptoms Scale and QoL, using the Rand Short-form (SF)-36
Adverse effects (safety data)
Green tea in exposure cat-
egories
N/A
Notes Funding: NIH–National Cancer Institute R01 CA12060-01A1
Risk of bias
Bias Authors' judgement Support for judgement
Kumar 2015 
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Random sequence genera-
tion (selection bias)
Low risk Quote: "participants were assigned to the intervention or placebo arm (1:1) us-
ing the SRAR system, a web-delivered subject registration application."
Comment: probably done
Allocation concealment
(selection bias)
Low risk Quote: "a web-delivered subject registration application"
Comment: central allocation, probably done
Blinding of participants
and personnel (perfor-
mance bias) 
Prostate cancer incidence
Low risk Quote: "All study staG and participants, with the exception of the clinical phar-
macist and biostatistician, were blinded to the assignments until the comple-
tion of the trial. Both PolyE and the matching placebo used in the trial were
hard gelatin capsules with no difference in appearance, taste, or smell"
Comment: probably done
Blinding of participants
and personnel (perfor-
mance bias) 
Lower urinary tract symp-
toms
Low risk Quote: "All study staG and participants, with the exception of the clinical phar-
macist and biostatistician, were blinded to the assignments until the comple-
tion of the trial. PolyE and matching placebo capsules were manufactured un-
der contract to NCI"
Comment: probably done
Blinding of participants
and personnel (perfor-
mance bias) 
PSA levels
Low risk Review authors do not believe this would introduce bias
Blinding of outcome as-
sessment (detection bias) 
Prostate cancer incidence
Low risk Quote: "All study staG and participants, with the exception of the clinical phar-
macist and biostatistician, were blinded to the assignments until the comple-
tion of the trial"
Comment: probably done
Blinding of outcome as-
sessment (detection bias) 
Lower urinary tract symp-
toms
Low risk Quote: "All study staG and participants, with the exception of the clinical phar-
macist and biostatistician, were blinded to the assignments until the comple-
tion of the trial. PolyE and matching placebo capsules were manufactured un-
der contract to NCI"
Comment: probably done
Blinding of outcome as-
sessment (detection bias) 
PSA levels
Low risk Review authors do not believe this would introduce bias
Incomplete outcome data
(attrition bias) 
Prostate cancer incidence
Low risk Comment: number of participants included in analysis stated
Incomplete outcome data
(attrition bias) 
Lower urinary tract symp-
toms
Unclear risk Comment: number of participants included in analysis NR
Incomplete outcome data
(attrition bias) 
PSA levels
Low risk Comment: number of participants included in analysis stated
Kumar 2015  (Continued)
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Selective reporting (re-
porting bias)
Low risk The study protocol is available (ClinicalTrials.gov identifier (NCT number):
NCT00596011) and the published reports include all expected outcomes
Other bias Unclear risk Elevated number of withdrawal
Kumar 2015  (Continued)
 
 
Methods PCC in China
Participants Participants: 252 (male/female: NR) cases and 637 (male/female: NR) controls
Inclusion criteria: aged > 30 years, and residents in Kaohsiung metropolitan area (Kaohsiung City and
its suburbs including 4 complexes of Tsoying, Tasheh, Jenwu and Linyuan are in south-western Taiwan)
at the time of the diagnosis. Data on adults (16-29 years) are included
Recruitment: from November 1997-December 2006
Interventions N/A
Outcomes Number of cases
Leukaemia: 93 (male/female: 42%/58%) adult cases and 223 (male/female: 39%/61%) controls
Green tea in exposure cat-
egories
Exposure assessment: green tea intake with the questionnaire and with catechin urinary levels. Only
crude data of intake used.
Notes Funding: National Institutes of Health (ES09723, ES00002)
Statistical methods: crude analysis
Variables controlled in analysis: crude analysis
Variables controlled by matching: -
Kuo 2009 
 
 
Methods Cohort studies in Japan
Participants Participants: 65,659 men, with final data on 49,920 men with complete data
Inclusion criteria: aged 40-59 years, from 5 Public Health Centre areas (Iwate, Akita, Nagano, Okinawa
and Tokyo) for cohort 1 and aged 40-69 years for cohort 2, from 6 Public Health Centre areas (Ibaraki,
Niigata, Kochi, Nagasaki, Okinawa and Osaka), Japan
Parent cohorts
Cohort 1: Japan Public Health Center-based Prospective Study (JPHC)-I
Cohort 2: Japan Public Health Center-based Prospective Study (JPHC)-II
Recruitment: from 1990 for cohort 1 and 1993 for cohort 2
Interventions N/A
Outcomes Number of cases
Outcome assessment: 31 December 2004
Kurahashi 2007 
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Prostate cancer: 404 cases, including 114 advanced, 271 localised and 19 of undetermined stage
Green tea in exposure cat-
egories
Exposure assessment: green tea consumption
Lowest exposure: < 1 cup/d
Intermediate exposure 1: 1-2 cups/d
Intermediate exposure 2: 3-4 cups/d
Highest exposure: ≥ 5 cups/d
Notes Funding: Grants-in-Aid for cancer research from the Ministry of Health, Labour and Welfare of Japan for
the Third Term Comprehensive 10-Year Strategy for Cancer Control and by Grants-in-Aid for scientific
research on priority areas from the Ministry of Education, Culture, Sports, Science and Technology for
research on the risk of chemical substances
Statistical methods: Cox proportional hazard regression
Variables controlled in analysis: age, area, smoking status, alcohol consumption, BMI, marital status
and coffee, black tea, miso soup consumption, fruits, green or yellow vegetables, dairy food, soy food
and genistein consumption
Variables controlled by matching: -
Kurahashi 2007  (Continued)
 
 
Methods Cohort studies in Japan
Participants Participants: 133,084 (male/female: 65,660/67,424) and 104,440 (male/female: 49,566/54,874) people
with complete data
Inclusion criteria: aged 40-59 years, from 5 Public Health Centre areas (Iwate, Akita, Nagano, Okinawa
and Tokyo) for cohort 1 and aged 40-69 years for cohort 2, from 6 Public Health Centre areas (Ibaraki,
Niigata, Kochi, Nagasaki, Okinawa and Osaka), Japan
Parent cohorts
Cohort 1: Japan Public Health Center-based Prospective Study (JPHC)-I
Cohort 2: Japan Public Health Center-based Prospective Study (JPHC)-II
Recruitment: from 1990 for cohort 1 and 1993 for cohort 2
Interventions N/A
Outcomes Number of cases
Outcome assessment: 31 December 2005
Bladder cancer: 206 (male/female: 164/42) cases
Green tea in exposure cat-
egories
Exposure assessment: green tea consumption
Men
Lowest exposure: < 1 cup/d
Intermediate exposure 1: 1-2 cups/d
Intermediate exposure 2: 3-4 cups/d
Highest exposure: ≥ 5 cups/d
Kurahashi 2009 
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Women
Lowest exposure: < 3 cups/d
Intermediate exposure 1: 3-4 cups/d
Highest exposure: ≥ 5 cups/d
Notes Funding: Grant-in-Aid for Cancer Research (19shi-2)
Statistical methods: Cox proportional hazard regression
Variables controlled in analysis: age, area, smoking status, alcohol drinking and coffee
Variables controlled by matching: -
Kurahashi 2009  (Continued)
 
 
Methods Cohort study in Japan
Participants Participants: 52,029 participants. Final data on 40,530 participants included
Inclusion criteria: aged 40-79 years living in 14 municipalities of Miyagi Prefecture in the catchment
area of the Ohsaki Public Health Centre, Miyagi, Japan.
Parent cohort: Ohsaki Cohort Study
Recruitment: from October-December 1994
Data on the same cohort also reported in Naganuma 2009 and Ui 2009
Interventions N/A
Outcomes Number of cases
Total cancer mortality: 1134 (male/female: 734/395) cases
Stomach cancer mortality: 193 (male/female: 138/55) cases
Lung cancer mortality: 218 (male/female: 166/52) cases
Colorectal cancer mortality: 132 (male/female: 84/48) cases
Outcome assessment: 31 December 2001
Green tea in exposure cat-
egories
Exposure assessment: green tea consumption
Lowest exposure: < 1 cup/d
Intermediate exposure 1: 1-2 cups/d
Intermediate exposure 2: 3-4 cups/d
Highest exposure: ≥ 5 cups/d
Notes Funding: Health Sciences Research Grant for Health Services (H18-Choju-Ippan-014, H16-Seisaku-Ip-
pan-023, H18- Junkankitou [Seisyu]-Ippan-012), Ministry of Health, Labour and Welfare, Japan
Statistical methods: Cox proportional hazard regression
Variables controlled in analysis: age, sex, job status, years of education, BMI, engaging in sports or ex-
ercise, walking duration, history of hypertension, diabetes mellitus and gastric ulcer, smoking status,
alcohol drinking, total energy intake/d, daily consumption of rice, daily consumption of miso (soybean
Kuriyama 2006 
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paste) soup, daily consumption of soybean products, total meat, total fish, dairy products, total fruits
and total vegetables and consumption of oolong tea, black tea and coffee
Variables controlled by matching: -
For stomach cancer, data from Inoue 2009a were used
Kuriyama 2006  (Continued)
 
 
Methods RCT, parallel, double-blind in UK
Participants Participants: 133 men at high risk of prostate cancer randomised
Inclusion criteria: participants previously enrolled in the Prostate testing for cancer and Treatment
(ProtecT) trial. Men aged 50-69 years, with localised prostate cancer with no history of allergies to ly-
copene-containing foods or green tea, current or prior prostate cancer, major co-morbidities or 5-ARI
medication
Recruitment: from December 2009-May 2011
Interventions 3 lycopene (dietary advice, capsules, placebo) and 3 green tea (drink, capsules, placebo) interventions:
9 different interventions for 6 months, particularly regarding green tea:
45 participants in the green tea drink: at least 3 cups/d, around 600 mL/d of tea made with green tea
bag, PG Tips, Unilever Ltd
45 participants in the green tea capsules: 2 capsules with 300 mg/d green tea leaf-derived extracted =
600 mg/d EGCG (Frutarom Ltd.)
43 participants in the green tea placebo
Duration: 6 months
Outcomes Primary outcome
Prostate cancer incidence
Secondary outcomes
PSA levels
Safety data
Green tea in exposure cat-
egories
N/A
Notes Funding: Cancer Research UK (C11046/A10052)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "randomly allocated to one of three lycopene interventions and to one
of three green tea interventions using a blocked random allocation [1:1:1 ratio;
generated by the trial statistician (C. Metcalfe) using the Stata uniform () "func-
tion]"
Comment: probably done
Lane 2018 
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Allocation concealment
(selection bias)
Low risk Quote: "opaque envelopes for allocation. The allocation was concealed from
the study nurse recruiting individuals"
Comment: probably done
Blinding of participants
and personnel (perfor-
mance bias) 
PSA levels
Low risk Review authors do not believe this would introduce bias
Blinding of outcome as-
sessment (detection bias) 
PSA levels
Low risk Review authors do not believe this would introduce bias
Incomplete outcome data
(attrition bias) 
PSA levels
Unclear risk Missing outcome data without explanation
Selective reporting (re-
porting bias)
High risk In the study protocol other outcomes are reported (ClinicalTrials.gov identifier
(NCT number): NCT01105338)
Other bias Unclear risk Some men also took lycopene capsules
Lane 2018  (Continued)
 
 
Methods HCC in Algeria
Participants Participants: 90 cases and 190 controls (all men)
Inclusion criteria: aged 50-88 years, histologically confirmed prostate cancer followed at the service of
urology and at the emergency department in Clinic of Urology-Nephrology and Kidney Transplant Das-
ki, Constantine, Algeria
Recruitment: from 2011-2013
Interventions N/A
Outcomes Number of cases
Prostate cancer: 90 cases (all men)
Green tea in exposure cat-
egories
Exposure assessment: green tea consumption
Lowest exposure: < 1 cup/d
Intermediate exposure: 1-3 cups/d
Highest exposure: > 3 cups/d
Notes Funding: Individual Project (F0092012009) and research unit programmatic funding (VARENBIOMOL) at
Constantine University, Algeria
Statistical methods: Chi2 test (Woolf logit method)
Variables controlled in analysis: -
Variables controlled by matching: -
Lassed 2016 
 
Green tea (Camellia sinensis) for the prevention of cancer (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
109
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
 
Methods PCC in USA
Participants Participants: 582 (male/female: 375/207) cases and 582 (male/female: 375/207) controls
Inclusion criteria: aged 26-79 years, histologically confirmed primary lung cancer, no history of lung
cancer, appropriate ethnicity, Oahu residents, Hawaii State, USA
Recruitment: from 1 January 1992-31 March 1997
Interventions N/A
Outcomes Number of cases
Lung cancer: 582 (male/female: 375/27) cases
Green tea in exposure cat-
egories
Exposure assessment: green tea intake
Lowest exposure: lowest quartile < 0.0 g/d
Intermediate exposure 1: between 0.0 to median value g/d
Intermediate exposure 2: between median value to 171.1 g/d
Highest exposure: highest quartile > 171.1 g/d
Notes Funding: Public Health Service R01CA55874 and contract N01CP67001 from National Cancer Institute
and EDT-78 grant from the American Cancer Society
Statistical methods: Poisson regression
Variables controlled in analysis: matching variables, smoking status, duration, duration^2, number of
cigarettes smoked/d and beta-carotene and saturated fat intake
Variables controlled by matching: age, sex and ethnicity
Le Marchand 2000 
 
 
Methods Cohort study in Japan
Participants Participants: 96,162 (male/female: 46,023/50,139) people with complete data.
Inclusion criteria: aged 40-59 years, from 11 Prefectures, Japan (See also Kurahashi 2007)
Parent cohort: Japan Public Health Centre-based Prospective Study (JPHC)
Recruitment: from 1990-1994
Interventions N/A
Outcomes Number of cases
Outcome assessment: 31 December 2002
Colorectal cancer: 1158 (male/female: 724/434) cases out of 1163 eligible cases
Colon cancer: 760 (male/female: 476/284) cases out of 763 eligible cases
Rectal cancer: 398 (male/female: 248/150) cases out of 400 eligible cases
Green tea in exposure cat-
egories
Exposure assessment: green tea consumption
Lee 2007 
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Lowest exposure: almost never
Intermediate exposure 1: < 1 cup/d
Intermediate exposure 2: 1-2 cups/d
Intermediate exposure 3: 3-4 cups/d
Highest exposure: ≥ 5 cups/d
Notes Funding: Cancer Research, Third-Term Comprehensive Control Research for Cancer from the Ministry of
Health, Labour and Welfare, Japan
Statistical methods: Cox proportional hazard regression
Variables controlled in analysis: age, study area, BMI, smoking status, alcohol drinking, family history of
colorectal cancer, physical activity and intake of green vegetables, beef, pork, coffee, Chinese tea and
black tea
Variables controlled by matching: -
Lee 2007  (Continued)
 
 
Methods HCC in China
Participants Participants: 404 cases and 395 controls (all men)
Inclusion criteria: aged < 85 years, newly diagnosed primary prostate cancer cases referring at hospital
of New Territories East Cluster of Hong Kong, China
Recruitment: from August 2011-June 2016
Interventions N/A
Outcomes Number of cases
Prostate cancer: 404 cases
Green tea in exposure cat-
egories
Exposure assessment A: green tea intake
Lowest exposure: nondrinkers
Highest exposure: green tea drinker
Exposure assessment B: green tea concentration in 250 mL of tea
Lowest exposure: < 2.5 g
Intermediate exposure 1: 2.5-5.0 g
Intermediate exposure 2: 5.0-7.5 g
Highest exposure: ≥ 7.5 g
Notes Funding: Grant from the Health and Medical Research Fund of the Hong Kong Special Administrative
Region, China; Project N. 11121091 and 12131081
Statistical methods: unconditional logistic regression
Variables controlled in analysis: age at interview, deep fried food consumption, green vegetable con-
sumption, alcohol consumption, coffee consumption, tobacco consumption, education attainment
and family prostate cancer history
Variables controlled by matching: age (± 5 years)
Lee 2017 
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Methods HCC in China
Participants Participants: 792 cases (male/female: NR) and 792 (male/female: NR) controls
Inclusion criteria: people referred to hospitals of Guangzhou and residents in Guangzhou province, Chi-
na
Recruitment: 1986
Interventions N/A
Outcomes Number of cases
Lung cancer: 792 (male/female: NR) cases
Green tea in exposure cat-
egories
Exposure assessment: green tea drinking
Lowest exposure: nondrinkers
Highest exposure: drinkers
Notes Article in Chinese
Funding: not declared
Statistical methods: conditional logistic regression
Variables controlled in analysis: NR
Variables controlled by matching: sex and age
Lei 1994 
 
 
Methods PCC in China
Participants Participants: 524 cases and 1587 controls (all women) from the Ovarian Cancer in Alberta and British
Columbia (OVAL-BC) Study
Inclusion criteria: aged 20-79 years, incident cases in residents in Alberta (AB) and aged 40-79 years, in-
cident cases in residents in British Columbia (BC), Canada
Recruitment: from 2002-2012
Interventions N/A
Outcomes Number of cases
Epithelian ovarian cancer: 104 cases out of 524 eligible cases with information on green tea and 471 out
of 1587 eligible controls
Green tea in exposure cat-
egories
Exposure assessment A: green tea intake
Lowest exposure: nondrinkers
Highest exposure: green tea drinker
Exposure assessment B: green tea consumption
Lowest exposure: nondrinkers
Leung 2016 
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Intermediate exposure 1: ≤ 1 lifetime cups-years
Intermediate exposure 2: 1-5 lifetime cups-years
Highest exposure: > 5 lifetime cups-years
Notes Funding: grants from the Canadian Institutes for Health Research and by a grant from WorkSafe BC (for-
merly the Workers’ Compensation Board of British Columbia)
Statistical methods: unconditional logistic regression
Variables controlled in analysis: study site, reference or diagnosis age, race, educational level, BMI,
smoking, lifetime average alcohol drinking, first-degree female relative history of ovarian/breast can-
cer, years of oral contraceptive use, parity, menopausal status and hormone therapy use
Variables controlled by matching: age (± 5 years)
Leung 2016  (Continued)
 
 
Methods Cohort study in Japan
Participants Participants: 52,029 participants. Final data on 41,440 participants included
Inclusion criteria: aged 40-79 years, living in 14 municipalities of Miyagi Prefecture in the catchment
area of the Ohsaki Public Health Centre, Miyagi, Japan
Parent cohort: Ohsaki Cohort Study
Recruitment: from October-December 1994
Interventions N/A
Outcomes Number of cases
Outcome assessment: 31 December 2001
Lung cancer: 302 (male/female: 227/75) cases
Green tea in exposure cat-
egories
Exposure assessment: green tea consumption
Lowest exposure: < 1 cup/d
Intermediate exposure 1: 1-2 cups/d
Intermediate exposure 2: 3-4 cups/d
Highest exposure: ≥ 5 cups/d
Notes Funding: Grant-in-Aid for Cancer Research and for the Third Term Comprehensive Ten-Year Strategy for
Cancer Control (H18-3jigan-ippan-001), Ministry of Health, Labour and Welfare, Japan
Statistical methods: Cox proportional hazard regression
Variables controlled in analysis: age, sex, education level, marital status, passive smoking, BMI, walk-
ing duration, family history of cancer, smoking status, number of cigarettes smoked/d, years of smok-
ing, alcohol drinking, total energy intake/d and daily consumption of soybean products, total meat, to-
tal fish, dairy products, total fruits and total vegetables and consumption of coffee
Variables controlled by matching: -
Li 2008 
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Methods PCC and HCC in China
Participants Participants: 540 (male/female: NR) cases, 540 (male/female: NR) population controls and 540 (male/
female: NR) hospital controls
Inclusion criteria: aged 18-85 years, participants with histopathology and haematology cancer diag-
nosed at the First Hospital of China Medical University from permanent residents of urban Shenyang,
China
Recruitment: from August 2009-July 2010
Interventions N/A
Outcomes Number of cases
Total (any) cancer: 425 (male/female: NR) cases
Breast cancer: 224 (male/female: NR) cases
Colorectal cancer: 175 (male/female: NR) cases
Leukaemia: 26 (male/female: NR) cases
Green tea in exposure cat-
egories
Exposure assessment A: green tea intake
Lowest exposure: never or seldom
Highest exposure: ≥ 1 time/d
Exposure assessment B: dried green tea leaves
Lowest exposure: 0 g/year
Intermediate exposure: 500-< 1000 g/year
Highest exposure: ≥ 1000 g/year
Notes Funding: National Health and Medical Research Council of Australia project grant (APP ID 572542)
Statistical methods: (un)conditional logistic regression
Variables controlled in analysis: education, BMI 5 years ago, smoking, passive smoking, alcohol con-
sumption, physical activity, energy intake, cancer in first-degree relative
Variables controlled by matching: sex and age (± 5 years)
Li 2011a 
 
 
Methods PCC in China
Participants Participants: 250 cases and 500 controls (all men)
Inclusion criteria: newly diagnosed and histopathologically confirmed prostate cancer and with PSA
value < 4.0 ng/mL from Changhai and Changzheng Hospitals of the Second Military Medical University
and Zhongshan Hospital of the Fudan University located respectively in Yangpu, Huangpu and Xuhui
District in Shangai city, China
Recruitment: from 1 January 2007-1 July 2013
Interventions N/A
Outcomes Number of cases
Li 2014 
Green tea (Camellia sinensis) for the prevention of cancer (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
114
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Prostate cancer: 250 cases (all men)
Green tea in exposure cat-
egories
Exposure assessment: green tea consumption
Lowest exposure: never
Highest exposure: consumption
Notes Funding: National Natural Science Foundation of China (N. 81072377)
Statistical methods: conditional logistic regression
Variables controlled in analysis: multivariate model but not clear all factors included in the model
Variables controlled by matching: race and age (± 5 years)
Li 2014  (Continued)
 
 
Methods HCC in China
Participants Participants: 756 cases and 789 controls (all women)
Inclusion criteria: aged 20-84 years, Chinese women, newly diagnosed primary breast cancer in Hong
Kong, China
Recruitment: November 2011-May 2014
Interventions N/A
Outcomes Number of cases
Breast cancer: 756 cases (all women)
Green tea in exposure cat-
egories
Exposure assessment: green tea consumption
Lowest exposure: non-tea drinkers
Highest exposure: green tea drinker (any)
Notes Funding: Research Grants Council of Hong Kong (N. 474811)
Statistical methods: unconditional logistic regression
Variables controlled in analysis: age at interview, age at menarche, age at first birth, parity, HRT, first-
degree family history and BMI
Variables controlled by matching: age (± 5 years)
Li 2016 
 
 
Methods Cohort study in China
Participants Participants: 103,010 participants
Inclusion criteria: aged ≥ 18 years, men, including employed and retired workers of Kailuan group, with
no previous diagnosis of cancer, China
Parent cohort: Kailuan Cohort
Recruitment: from May 2006-May 2014
Li 2018 
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Interventions N/A
Outcomes Number of cases
Outcome assessment : 31 December 2015
Lung cancer: 964 cases (all men)
Green tea in exposure cat-
egories
Exposure assessment: green tea consumption
Lowest exposure: < 4 times/week
Highest exposure: ≥ 4 times/week
Notes Article in Chinese
Funding: National Key R&D Plan (2016YFC0905400, 2016YFC1302500, 2017YFC0907900); Beijing Excel-
lent Talent Cultivation Funding (2017000021223TD05), Central Health Special Fund (W2017BJ39), Con-
cord Youth Fund (2017320013, 3332016131), National Natural Science Foundation of China (81673265).
Statistical methods: Cox proportional hazard regression
Variables controlled in analysis: age, education, economic income, smoking status, drinking status,
dust exposure, BMI, drinking tea type and family history of cancer
Variables controlled by matching: -
Li 2018  (Continued)
 
 
Methods Cohort study in Japan
Participants Participants: 110,792 inhabitants of 45 areas of Japan. Data retrieved for 77,850 (male/female:
32,774/45,076)
Inclusion criteria: aged 40-79 (≥ 18 years in 1949). Details reported in Ohno 2001
Parent cohort: Japan Collaborative Cohort Study of Evaluation of Cancer Risk (JACC Study)
Recruitment: from 1988-1990
Same population of Fujino 2002 and Hoshiyama 2002
Interventions N/A
Outcomes Number of cases
Outcome assessment: 31 December 2003
Pancreatic cancer mortality: 292 (male/female: 140/152) cases
Green tea in exposure cat-
egories
Exposure assessment: green tea drinking
Lowest exposure: < 1 cup/d
Intermediate exposure 1: 1-2 cups/d
Intermediate exposure 2: 3-4 cups/d
Intermediate exposure 3: 5-6 cups/d
Highest exposure: ≥ 7 cups/d
Notes Funding: Grant-in-Aid for Scientific Research on Priority Areas 2 (No. 13220019) from the Ministry of Ed-
ucation, Culture, Sports, Science and Technology of Japan. The JACC Study has also been supported
Lin 2008 
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by Grants-in-Aid for Scientific Research from the same ministry (Nos. 61010076, 62010074, 63010074,
1010068, 2151065, 3151064, 4151063, 5151069, 6279102 and 11181101).
Statistical methods: Cox hazard proportional regression
Variables controlled in analysis: age, sex , BMI, cigarette smoking, alcohol drinking, history of diabetes
and history of gallbladder diseases
Variables controlled by matching: -
Lin 2008  (Continued)
 
 
Methods HCC in China
Participants Participants: 170 (male/female: 102/68) cases and 340 (male/female: 204/136) controls
Inclusion criteria: incident cancer aged < 80 years, diagnosed in Changhwa Christian Hospital (Changh-
wa County, Taiwan, China)
Recruitment: from August 2004-October 2008
Interventions N/A
Outcomes Number of cases
Lung cancer: 170 (male/female: 102/68) cases, including adenocarcinoma (N = 93), squamous cell car-
cinoma (N = 46) and others (N = 31, including small-cell carcinoma, neuroendocrine carcinoma, mixed
cell carcinoma and unspecific malignant cell)
Green tea in exposure cat-
egories
Exposure assessment: green tea drinking
Lowest exposure: 0 cup/d
Intermediate exposure: < 1 cup/d
Highest exposure: ≥ 1 cup/d
Notes Funding: National Science Council, Taiwan (NSC-98-2815-C-040-028-B; NSC 95-2815-C-040-019-B; NSC
93-2815-C-040-008-B)
Statistical methods: conditional logistic regression
Variables controlled in analysis: sex and age
Variables controlled by matching: sex and age (± 5 years)
Lin 2012 
 
 
Methods PCC in China
Participants Participants: 641 (male/female: NR) cases and 1847 (male/female: NR) controls
Inclusion criteria: mean age 63.5 years in both cases and controls, residents in Dafeng City, Jiangsu
Province, China
Recruitment: from January 2005-December 2007
Interventions N/A
Outcomes Number of cases
Liu 2010 
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Stomach cancer: 641 (male/female: NR) cases
Green tea in exposure cat-
egories
Exposure assessment: green tea drinking
Lowest exposure: nondrinkers
Highest exposure: > 21 cups/week
Notes Article in Chinese
Funding: not declared
Statistical methods: unconditional logistic regression
Variables controlled in analysis: age, sex, education level, income, smoking status, alcohol drinking and
family history of stomach cancer
Variables controlled by matching: -
Liu 2010  (Continued)
 
 
Methods Cohort study in China
Participants Participants: 222,279 men, including a total of 164,681 men who remained in the main analyses
Inclusion criteria: aged > 40 years, men randomly selected from residential units within 45 national-
ly representative Disease Surveillance Points with no prior diagnosis of cancer, stroke, heart disease,
chronic obstructive pulmonary disease, asthma, tuberculosis, peptic ulcer, diabetes, hypertension, kid-
ney cirrhosis, chronic hepatitis
Parent cohort: Chinese Prospective Smoking Study (CPSS)
Recruitment: from 1990-1991
Interventions N/A
Outcomes Number of cases
Outcome assessment: 31 December 2006
Total cancer mortality: 7002 cancer deaths (all men)
Green tea in exposure cat-
egories
Exposure assessment: green tea drinking
Lowest exposure: nondrinkers
Intermediate exposure 1: ≤ 5 g/month
Intermediate exposure 2: 5-10 g/month
Highest exposure: ≥ 10 g/month
Notes Funding: Chinese Ministry of Health, the UK Medical Research Council, British Heart Foundation and
Cancer Research UK, the World Bank loan to China and the Canadian International Development Re-
search Centre.
Statistical methods: Cox proportional hazard regression
Variables controlled in analysis: age, BMI, marital status, urban locality, job status, smoking status,
times of weekly fish consumption, times of weekly meat consumption, times of weekly poultry con-
sumption, times of weekly egg consumption, times of weekly milk consumption, black tea drinker, jas-
mine tea drinker and other tea drinker
Variables controlled by matching: -
Liu 2016 
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Methods HCC in China
Participants Participants: 442 (male/female: 256/186) cases and 442 (male/female: 256/186) controls
Inclusion criteria: aged ≥ 16 years, with incident first-time haematologically confirmed diagnosis of
leukaemia residing in the respective provinces for at least 1 year and presenting as an inpatient to the
participating hospitals, namely the First and the Second Affiliated Hospitals of Zhejiang University in
Hangzhou, Zhejiang province and the First Hospital of China Medical University in Shenyang, Liaoning
Province, China
Recruitment: from August 2008-August 2013
Interventions N/A
Outcomes Number of cases
Leukaemia: 442 (male/female: 256/186) cases
Green tea in exposure cat-
egories
Exposure assessment: green tea drinking
Lowest exposure: nondrinker (< 1 time/month)
Highest exposure: drinker
Notes Funding: National Health and Medical Research Council (Australia) Project Grant (N. 572542)
Statistical methods: conditional logistic regression
Variables controlled in analysis: matching variable and resident locality, education, cigarette smoking
and alcohol consumption
Variables controlled by matching: sex, age (± 5 years) and study site
Liu 2017 
 
 
Methods Cohort study in Japan
Participants Participants: 133,084 (male/female: 65,660/67,424) and 102,137 (male/female: 48,783/53,354) partici-
pants with complete data
Inclusion criteria: aged 40-59 years, from 5 Public Health Centre areas (Iwate, Akita, Nagano, Okinawa
and Tokyo) for cohort 1, and aged 40-69 years cohort 2, from 6 Public Health Centre areas (Ibaraki, Ni-
igata, Kochi, Nagasaki, Okinawa and Osaka) for cohort 2, Japan
Parent cohorts:
Cohort 1: Japan Public Health Centre-based Prospective Study (JPHC)-I
Cohort 2: Japan Public Health Centre-based Prospective Study (JPHC)-II
Recruitment: from 1990 for cohort 1 and 1993/1994 for cohort 2
Interventions N/A
Outcomes Number of cases
Outcome assessment: 31 December 2003
Pancreatic cancer: 233 (male/female: 135/98 ) cases
Luo 2007 
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Green tea in exposure cat-
egories
Exposure assessment: green tea drinking
Lowest exposure: rarely
Intermediate exposure 1: < 1 cup/d
Intermediate exposure 2: 1-2 cups/d
Intermediate exposure 3: 3-4 cups/d
Highest exposure: ≥ 5 cups/d
Notes Funding: Grant-in-Aid from the Cancer Research and Third-Term Comprehensive Control Research for
Cancer from the Ministry of Labour, Health and Welfare of Japan.
Statistical methods: Cox proportional hazard regression
Variables controlled in analysis: sex, age, BMI, leisure-time physical activity in terms of frequency of
sports, smoking status, alcohol intake, history of diabetes, history of cholelithiasis, study area and cof-
fee intake
Variables controlled by matching: -
Luo 2007  (Continued)
 
 
Methods Cohort study in Japan
Participants Participants: 140,420 (male/female: 68,722/71,698), with 61,595 from cohort 1 and 78,825 from cohort 2
and 89,555 (male 51.6%) participants with complete data
Inclusion criteria: aged 40-59 years, from 5 Public Health Centre areas (Iwate, Akita, Nagano, Okinawa
and Tokyo) for cohort 1 and aged 40-69 years for cohort 2, from 6 Public Health Centre areas (Ibaraki,
Niigata, Kochi, Nagasaki, Okinawa and Osaka), respondent at 5-year follow-up
Parent cohorts
Cohort 1: Japan Public Health Centre-based Prospective Study (JPHC)-I
Cohort 2: Japan Public Health Centre-based Prospective Study (JPHC)-II
Recruitment: from 1990 for cohort 1 and 1993/1994 for cohort 2
Interventions N/A
Outcomes Number of cases
Outcome assessment: 31 December 2009 in Osaka Public Health Centre and 31 December 2010 in all
other areas
Biliary tract cancer: 271 (male/female: 160/111) cases out of 284 eligible cases, including cancers of
gallbladder cancer (N = 116) and of extrahepatic bile duct (N =145)
Green tea in exposure cat-
egories
Exposure assessment: green tea consumption
Lowest exposure: ≤ 120 mL/d
Intermediate exposure 1: 120-360 mL/d
Intermediate exposure 2: 360-720 mL/d
Highest exposure: ≥ 720 mL/d
Notes Funding: Grant-in-Aid from the Cancer Research and Third-Term Comprehensive Control Research for
Cancer from the Ministry of Labour, Health and Welfare of Japan
Makiuchi 2016 
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Statistical methods: Cox proportional hazard regression
Variables controlled in analysis: sex, age, BMI, leisure-time physical activity in terms of frequency of
sports, smoking status, alcohol intake, history of diabetes, history of cholelithiasis, study area and cof-
fee intake
Variables controlled by matching: -
Makiuchi 2016  (Continued)
 
 
Methods HCC in China
Participants Participants: 200 (male/female: 139/61) cases and 200 (male/female: 139/61) controls
Inclusion criteria: mean age 51.5 (SD = 7) years, with histologically confirmed cancer, referring at the
Kunming General Hospital of Chinese PLA and the First People’s Hospital of Yunnan Province, China
Recruitment: from May 2010-February 2011
Interventions N/A
Outcomes Number of cases
Stomach cancer: 200 (male/female: 139/61) cases
Green tea in exposure cat-
egories
Exposure assessment A: green-tea drinking status
Lowest exposure: nondrinkers
Intermediate exposure: former drinkers
Highest exposure: current drinkers
Exposure assessment B: green tea consumption
Lowest exposure: never
Intermediate exposure 1: < 150 g/month
Intermediate exposure 2: 150-250 g/month
Highest exposure: > 250 g/month
Notes Funding: not declared
Statistical methods: conditional logistic regression
Variables controlled in analysis: age, sex, education level, BMI, annual income, cancer family history,
smoking and drinking status
Variables controlled by matching: sex and age (± 5 years)
Mao 2011 
 
 
Methods RCT, parallel, double-blind in Italy
Participants Participants: 60 men at high risk of prostate cancer (30 in the treatment group and 30 in the control
group)
Inclusion criteria: age 55-65 years, with HG-PIN assessed using prostate biopsy with no previous cancer,
not anti-androgenic or chemoprevention therapies, non-obese, without diabetes or other endocrino-
logical diseases
Micali 2017 
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Recruitment: from May 2007-February 2011
Interventions Treatment group: 2 oral GTE capsules total 300 mg of Categ Plus, Sofar SPA, Milan, Italy = total 600 mg/
d
Control group: placebo
Duration: 1 year
Outcomes Primary outcome
Prostate cancer incidence
Secondaty outcomes
Safety data: side effects
PSA levels
LUTS score
QoL score
Green tea in exposure cat-
egories
N/A
Notes Funding: no specific funding reported. Sofar SPA, Milan provided free samples of Categ Plus employed
in the trial
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "The random allocation sequence was obtained by means of 'Easy Ran-
dom Picker' software (TrustFm© 1998-2016)"
Comment: probably done
Allocation concealment
(selection bias)
Unclear risk Comment: insufficient information
Blinding of participants
and personnel (perfor-
mance bias) 
Prostate cancer incidence
Low risk Quote: "Both participants and care providers were blinded after assignment to
interventions, in order to avoid any bias. Two capsules of Categ Plus® or place-
bo per day were given to all subjects by the clinical trial investigators, accord-
ing to the double-blind method"
Comment: probably done
Blinding of participants
and personnel (perfor-
mance bias) 
Lower urinary tract symp-
toms
Low risk Quote: " Both participants and care providers were blinded after assignment
to interventions, in order to avoid any bias. Two capsules of Categ Plus® or
placebo per day were given to all subjects by the clinical trial investigators, ac-
cording to the double-blind method.”
Comment: Probably done
Blinding of participants
and personnel (perfor-
mance bias) 
PSA levels
Low risk Review authors do not believe this would introduce bias
Blinding of outcome as-
sessment (detection bias) 
Low risk Quote: "Both participants and care providers were blinded after assignment to
interventions, in order to avoid any bias"
Micali 2017  (Continued)
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Prostate cancer incidence Comment: probably done
Blinding of outcome as-
sessment (detection bias) 
Lower urinary tract symp-
toms
Low risk Quote: "Both participants and care providers were blinded after assignment to
interventions, in order to avoid any bias"
Comment: probably done
Blinding of outcome as-
sessment (detection bias) 
PSA levels
Low risk Review authors do not believe this would introduce bias
Incomplete outcome data
(attrition bias) 
Prostate cancer incidence
Low risk Comment: number of participants included in analysis stated
Incomplete outcome data
(attrition bias) 
Lower urinary tract symp-
toms
Low risk Comment: number of participants included in analysis not clearly stated but
probably the same as prostate cancer risk
Incomplete outcome data
(attrition bias) 
PSA levels
Low risk Comment: number of participants included in analysis not clearly stated but
probably the same as prostate cancer risk
Selective reporting (re-
porting bias)
Unclear risk The study protocol is not available and it is not clear if the published reports
include all expected outcomes
Other bias High risk High dropout in both groups (26.7%)
Micali 2017  (Continued)
 
 
Methods Cohort study in Japan
Participants Participants: 140,420 (male/female: 68,722/71,698), with 61,595 from cohort 1 and 78,825 from cohort 2
and 100,507 (male/female: 48,802/51,705) participants with complete data.
Inclusion criteria: aged 40-59 years, from 5 Public Health Centre areas (Iwate, Akita, Nagano, Okinawa
and Tokyo) for cohort 1, and aged 40-69 years for cohort 2 from 6 Public Health Centre areas (Ibara-
ki, Niigata, Kochi, Nagasaki, Okinawa and Osaka), respondent at 5-year follow-up. Katsushika Public
Health Centre was excluded due to missing cancer data.
Parent cohorts
Cohort 1: Japan Public Health Centre-based Prospective Study (JPHC)-I
Cohort 2: Japan Public Health Centre-based Prospective Study (JPHC)-II
Recruitment: from 1990 for cohort 1 and 1993/1994 for cohort 2
Interventions N/A
Outcomes Number of cases
Outcome assessment: 31 December 2007
Thyroid cancer: 159 (male/female: 26/133) cases, including 133 cases of papillary carcinoma, 7 cases of
follicular carcinoma, 1 case of anaplastic carcinoma and 18 cases of other or unknown histologic types
Michikawa 2011 
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Green tea in exposure cat-
egories
Exposure assessment: green tea drinking
Lowest exposure: < 1 cup/d
Intermediate exposure 1: 1-2 cups/d
Intermediate exposure 2: 3-4 cups/d
Highest exposure: ≥ 5 cups/d
Notes Funding: Grant-in-Aid for Cancer Research from the Ministry of Health, Labour and Welfare, Japan (until
2009) and by Management Expenses Grants from the Government to the National Cancer Center (since
2010). It has also supported by a Grant-in-Aid for the Third-Term Comprehensive Control Research for
Cancer from the Ministry of Health, Labour and Welfare, Japan and by a Grant-in-Aid from Keio Medical
Association.
Statistical methods: Cox proportional hazard regression
Variables controlled in analysis: age, area, smoking history, passive smoking in the workplace, alco-
hol consumption, BMI, consumption of green vegetable and seaweed, health screening in the previous
year and coffee consumption. For women, additionally adjusted for menopausal status and use of ex-
ogenous female hormones.
Variables controlled by matching: -
Michikawa 2011  (Continued)
 
 
Methods HCC in Japan
Participants Participants: 472 cases and 464 controls (all women)
Inclusion criteria: aged ≥ 20 years, consecutive patients treated at the Okayama University Hospital,
Okayama Rousai Hospital and Mizushima Kyodo Hospital in Okayama and at Kagawa Prefecture Cen-
tral Hospital in Kagawa, Japan. Controls from women under breast cancer screening.
Recruitment: from December 2010-November 2011
Interventions N/A
Outcomes Number of cases
Breast cancer: 472 cases
Green tea in exposure cat-
egories
Exposure assessment: green tea consumption
Lowest exposure: < 1 time/week
Intermediate exposure 1: 1 time/week
Intermediate exposure 2: 2-3 times/week
Highest exposure: ≥ 4 times/week
Notes Funding: Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science
and Technology of Japan
Statistical methods: unconditional logistic regression
Variables controlled in analysis: age.
Variables controlled by matching: -
Mizoo 2013 
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Methods HCC in Japan
Participants Participants: 124 (male/female: 68/56) cases, 124 (male/female: 68/56) controls
Inclusion criteria: aged 40-79 years, pathologically, radiographically and/or serodiagnostically con-
firmed diagnosis at the 7 co-operating institutes, i.e. the National Cancer Center Hospital, Chiba Uni-
versity Hospital, Shinshu University Hospital, the Cancer Institute Hospital, Kobe University Hospital,
Saitama Cancer Center Hospital and Nagasaki University Hospital, Japan
Recruitment: from January 1989-December 1990
Interventions N/A
Outcomes Number of cases
Pancreatic cancer: 124 (male/female: 68/57) cases
Green tea in exposure cat-
egories
Exposure assessment: green tea intake
Lowest exposure: nondrinkers
Intermediate exposure NR
Highest exposure: ≥ 5 cups/d
Notes Funding: Grant- in-Aid for Cancer Research from the Ministry of Health and Welfare of Japan.
Statistical methods: unconditional logistic regression
Variables controlled in analysis: sex and age
Variables controlled by matching: sex and age
Mizuno 1992 
 
 
Methods Cohort study in China
Participants Participants: 63,257 (male/female: 27,959/35,298) participants. Data on 27,293 men with no history of
cancer
Inclusion criteria: aged 45-74 years, belonging to the Hokkien or Cantonese dialect group in Singapore,
China
Parent cohort: Singapore Chinese Health Study (SCHS)
Recruitment: from April 1993 to December 1998
Interventions N/A
Outcomes Number of cases
Outcome assessment: 31 December 2007
Prostate cancer: 298 cases
Green tea in exposure cat-
egories
Exposure assessment: green tea intake
Lowest exposure: none
Intermediate exposure 1: monthly
Montague 2012 
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Intermediate exposure 2: weekly
Highest exposure: daily, further divided in 1 cup/d and ≥ 2 cups/d
Notes Funding: National Institute of Health grant R01CA144034.
Statistical methods: Cox proportional hazard regression
Variables controlled in analysis: age, dialect group, interview year, education, BMI, smoking history and
black tea intake.
Variables controlled by matching: -
Montague 2012  (Continued)
 
 
Methods PCC in China
Participants Participants: 628 (male/female: 438/190) cases, 415 (male/female 287/128) controls
Inclusion criteria: aged ≥ 20 years, newly diagnosed hospital-based case-control (HCC) cases included
in the Taixing Tumor Registry and living for at least 10 years in Taixing, China
Recruitment: from 1 June-31 December 2000 for stomach cancer, from 1 January-30 June 2000 for liver
cancer and 2000 for oesophageal cancer
In Mu 2005
Participants: 206 (male/female: 137/68) cases and 415 (male/female 287/128) controls
Inclusion criteria: aged ≥ 20 years, newly diagnosed HCC cases included in the Taixing Tumor Registry
and living for at least 10 years in Taixing, China.
Recruitment: from 1 June-31 December 2000 for stomach cancer
In Li 2011b
Participants: 204 (male/female: 159/45) cases and 415 (male/female: 287/128) controls
Inclusion criteria: aged ≥ 20 years, newly diagnosed HCC cases included in the Taixing Tumor Registry
and living for at least 10 years in Taixing, China.
Recruitment: from 1 January-30 June 2000
Data on liver cancer also reported in Mu 2003
Interventions N/A
Outcomes Number of cases
Mu 2003
Stomach cancer: 206 (male/female: 138/68) cases
Liver cancer: 204 (male/female: 159/45) cases, HCC
Oesophageal cancer: 218 (male/female: 141/77) cases
Mu 2005
Stomach cancer: 206 (male/female: 137/68) cases, the majority (> 90%) with adenocarcinoma of the
distal stomach
Li 2011b
Mu 2003 
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Liver cancer: 204 (male/female: 159/45) cases of HCC
Green tea in exposure cat-
egories
Exposure assessment: green tea consumption
Lowest exposure: never
Intermediate exposure 1: < 125 g/month
Intermediate exposure 2: 125-250 g/month
Highest exposure: ≥ 250 g/month
Exposure assessment B: green tea intake (only for stomach cancer - Mu 2005)
Lowest exposure: never
Highest exposure: ever
Notes Mu 2003:
Article in Chinese
Funding: not declared
Statistical methods: unconditional logistic regression
Variables controlled in analysis: age, education, smoking, alcohol drinking (for oesophageal cancer,
other outcome reported in subsequent reports)
Variables controlled by matching: -
Mu 2005
Funding: National Institute of Health, National Cancer Institute (ES06718, CA77954, CA09142, CA16042,
CA42710, AT00151), UCLA Jonsson Comprehensive Cancer Center, UICC Technology Transfer Fellow-
ship of the Foundation for the Author of National Excellent Doctoral Dissertation of P.R. China (200157)
Statistical methods: unconditional logistic regression
Variables controlled in analysis: age, sex, education, income, BMI, pack-years of smoking, alcohol drink-
ing, very hot food eating habit, H. pylori infection, stomach disease history and family history of stom-
ach cancer
Variables controlled by matching: -
Li 2011b
Funding: International Union against Cancer Technology Transfer fellowship awarded to Dr. Li-Na
Mu and by the Foundation for the Author of National Excellent Doctoral Dissertation of PR China (N.
200157) awarded to Dr Lin Cai. The study was also partially supported by the NIH National Institute of
Environmental Health Sciences, National Cancer Institute, Department of Health and Human Services,
Grants CA09142, ES 011667 as well as the Alper Research Program for Environmental Genomics of the
UCLA Jonsson Comprehensive Cancer Center.
Statistical methods: unconditional logistic regression
Variables controlled in analysis: age, sex, education, income, BMI, family history of cancer, smoking, al-
cohol drinking and HBSAg
Variables controlled by matching: -
Mu 2003a, in reports same results as Mu 2003
Mu 2003  (Continued)
 
 
Methods Cohort study in Japan
Nagano 2001 
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Participants Participants: 38,540 (male/female: 14,873/23,667) participants
Inclusion criteria: aged 45-74 years, carried out among atomic-bomb survivors alive as of 1 September
1979, mean age at beginning of follow-up of 52.8 years in men and 56.8 years in women
Parent cohort: Life Span study cohort
Recruitment: from 1979-1981
Sauvaget 2005
Participants: people from Hiroshima and Kahasaki
Inclusion criteria: participants (93,741) present in Hiroshima and Nagasaki at the time of the bombings
and city residents on 1 October 1950 and residents (23,580) not present at the time of the bombings but
present between 1950 and 1953. Data of 38,576 (male/female: 14,885/23,691) participants included are
carried out in participants aged 34-98 years, respondents to second mail surveys, alive on 1 September
1978.
Parental cohort: Radiation Effects Research Fundation's Life Span Study
Recruitment: 1979, completed on 1 January 1980 for men and 1 February 1981 for women
Interventions N/A
Outcomes Number of cases
Outcome assessment: 31 December 1994
Total cancer: 4049 (male/female: 1982/2087) cases
Total solid cancer: 3881 (male/female: 1890/1991) cases
Oesophageal cancer: 59 (male/female: 46/13) cases (risk not assessed)
Stomach cancer: 901 (male/female: 518/383) cases
Colon cancer: 432 (male/female: 221/211) cases
Rectal cancer: 193 (male/female:100/93) cases
Liver cancer: 418 (male/female: 260/158) cases
Gallbladder cancer: 122 (male/female: 40/82) cases
Pancreatic cancer: 122 (male/female: 43/79) cases
Lung cancer: 436 (male/female: 265/171) cases
Skin cancer: 89 (male/female: 36/53) cases (risk not assessed)
Breast cancer: 281 (male/female: 276/5) cases
Cervical cancer: 100 female cases (risk not assessed)
Corpus uteri: 53 female cases (risk not assessed)
Ovarian cancer: 49 female cases (risk not assessed)
Prostate cancer: 92 male cases (risk not assessed)
Bladder cancer: 122 (male/female: 88/34) cases
Kidney cancer: 76 (male/female: 39/37) cases (risk not assessed)
Thyroid cancer: 99 (male/female: 18/81) cases (risk not assessed)
Nagano 2001  (Continued)
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Other solid cancers: 237 (male/female: 119/118) cases (risk not assessed)
Haematopoietic cancer: 188 (male/female: 92/96) cases
Lymphoma: 94 (male/female: 45/ 51) cases (risk not assessed)
Multiple myeloma: 40 (male/female: 20/20) cases (risk not assessed)
Leukaemia: 52 (male/female: 27/25) cases (risk not assessed)
In Sauvaget 2005
Outcome assessment: 31 December 1999
Stomach cancer: 1270 (male/female: 719/551) out of 1280 (male/female: NR) eligible cases, including
27% in the gastric body, 6% in the cardia, 5% in the lesser curve, 2% in the fundus and 27% were not
specified. Regarding the histology type, 99% of the cases were classified as carcinoma and 1% as sarco-
ma (10 cases who were excluded from subsequent analyses)
Green tea in exposure cat-
egories
Nagano 2001
Exposure assessment: green tea intake
Lowest exposure: 0-1 times/d
Intermediate exposure: 2-4 times/d
Highest exposure: ≥ 5 times/d
Sauvaget 2005
Exposure assessment: hot green tea
Lowest exposure: < 2 times/d
Intermediate exposure: 2-4 times/d
Highest exposure: ≥ 5 times/d
Notes Nagano 2001
Funding: RERF foundation, Hiroshima and Nagasaki, Japan equally funded by the Japanese Ministry of
Health and Welfare and the US Department of Energy through the National Academy of Sciences
Statistical methods: Poisson regression
Variables controlled in analysis: city, age, sex, radiation dose, smoking status, alcohol drinking history,
BMI, education level and calendar time
Variables controlled by matching: -
Sauvaget 2005
Funding: Research performed at the Radiation Effects Research Foundation (RERF), Hiroshima and Na-
gasaki, Japan. RERF is funded equally by the Japanese Ministry of Health and Welfare and the US De-
partment of Energy (DOE). RERF Research Protocols RP # 18–61 and 14–78
Statistical methods: Poisson regression
Variables controlled in analysis: sex, sex-specific age, city, radiation dose, sex-specific smoking habits
and education level
Nagano 2001  (Continued)
 
 
Methods Cohort study in Japan
Naganuma 2009 
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Participants Participants: 52,029 participants. Final data on 41,761 (male/female: 19,749/22,012) participants in-
cluded
Inclusion criteria: aged 40-79 years, living in 14 municipalities of Miyagi Prefecture in the catchment
area of the Ohsaki Public Health Centre, Miyagi, Japan
Parent cohort: Ohsaki Cohort Study
Recruitment: from October-December 1994
Data on the same cohort also reported in Kuriyama 2006 and Ui 2009.
Interventions N/A
Outcomes Number of cases
Outcome assessment: 31 December 2003
Haematopoietic cancer: 157 (male/female: 88/69) cases
Lymphoid cancer: 119 (male/female: 66/53) cases
Myeloid cancer: 36 (male/female: 20/16) cases
Green tea in exposure cat-
egories
Exposure assessment: green tea consumption
Lowest exposure: < 1 cup/d
Intermediate exposure 1: 1-2 cups/d
Intermediate exposure 2: 3-4 cups/d
Highest exposure: ≥ 5 cups/d
Notes Funding: Health Sciences Research Grant for Health Services, Ministry of Health, Labour and Welfare of
Japan (H19-Seisaku-Ippan-026, H20-Junkankitou(Seisyu)-Ippan-013, H21-3jigan-Ippan-003).
Statistical methods: Cox proportional hazard regression
Variables controlled in analysis: age, sex, educational level, cigarette smoking, alcohol drinking, fish
consumption and soybean products consumption
Variables controlled by matching: -
Naganuma 2009  (Continued)
 
 
Methods PCC in Australia
Participants Participants: 1459 cases and 1462 controls with complete data on diet, but 24 and 113 omitted due to
> 10% of missing items and with implausible total energy intake respectively. Final population of 1368
cases and 1416 controls (all women).
Inclusion criteria: women aged 18-79 years, from the Australian Ovarian Cancer Study diagnosed with
epithelial ovarian cancer
Recruitment: from January 2002-June 2005
Interventions N/A
Outcomes Number of cases
Nagle 2010 
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Ovarian cancer: 1368 cases out of 1459 eligible cases of epithelial ovarian cancer
Green tea in exposure cat-
egories
Exposure assessment: green tea intake
Lowest exposure: never
Intermediate exposure 1: < 1 time/week
Intermediate exposure 2: < 1 time/d
Intermediate exposure 3: 1 time/d
Intermediate exposure 4: 2-3 times/d
Highest exposure: ≥ 4 times/d
Notes Funding: US Army Medical Research and Materiel Command under award DAMD17-01-1-0729, the Can-
cer Council Tasmania and Cancer Foundation of Western Australia; the Australian Cancer Study was
funded by the National Health and Medical Research Council of Australia (199600).
Statistical methods: unconditional logistic regression
Variables controlled in analysis: age, education, parity, hormonal contraceptive use, smoking status,
fruit consumption, vegetable consumption, coffee consumption and other types of tea
Variables controlled by matching: age (± 5 years) and state of residence
Nagle 2010  (Continued)
 
 
Methods Cohort study in Japan
Participants Participants: 8552 (male/female: NR) participants
Inclusion criteria: aged > 40 years, residents in a town in Saitama Prefecture, Japan
Recruitment: from 1986
Interventions N/A
Outcomes Number of cases
Outcome assessment: 1997
Total cancer incidence: 488 (male/female: NR) cases, including stomach (N = 140), lung (N = 69), col-
orectal (N = 60) and liver (N = 35) cancer, not individually evaluated
Green tea in exposure cat-
egories
Exposure assessment: green tea drinking
Lowest exposure: ≤ 3 cups/d
Intermediate exposure: 4-9 cups/d
Highest exposure: ≥ 10 cups/d
Notes Funding: Grants-in-Aid for Cancer Research from the Ministry of Education, Science, Sports and Culture
of Japan, from the Ministry of Health and Welfare of Japan and from the Ministry of Health and Welfare
for a 2nd-Term Comprehensive 10-Year Strategy for Cancer Control and by a grant from the Smoking
Research Foundation of Japan
Statistical methods: Cox proportional hazard regression
Variables controlled in analysis: age, cigarette smoking, alcohol consumption, intake of green and yel-
low vegetables and intake of rice
Variables controlled by matching: -
Nakachi 2000 
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Imai 1997 reports same results as Nakachi 2000
Nakachi 2000  (Continued)
 
 
Methods Cohort study in Japan
Participants Participants: 30,826 (male/female: 14,241/16,585) participants
Inclusion criteria: aged ≥ 35 years, non-hospitalised inhabitants in Takayama, Gifu Prefecture, Japan
Recruitment: from September 1992
Data on the same cohort also reported in Oba 2006.
Interventions N/A
Outcomes Number of cases
Outcome assessment: 31 December 1999
Pancreatic cancer mortality: 52 (male/female: 33/19) cases
Green tea in exposure cat-
egories
Exposure assessment: green tea drinking
Lowest exposure: never
Intermediate exposure: ≤ 1 cup/month to ≤ 4–6 cups/week
Highest exposure: ≥ 1 cup/d
Notes Funding: Grant from the Ministry of Education, Culture, Sports, Science and Technology, Japan. It was
also funded by Grant-in-Aid for Cancer Research (21Shi-11-1) from the Ministry of Health, Labour and
Welfare, Japan.
Statistical methods: Cox proportional hazard regression
Variables controlled in analysis: age, smoking, BMI and history of diabetes mellitus
Variables controlled by matching: -
Nakamura 2011 
 
 
Methods Cohort study in China
Participants Participants: 74,941 Chinese women. Final data on 67,230 women witch complete and reliable data on
dietary information and reporting consumption of green tea alone or in combination with other types
of tea.
In Yang 2007: final population of 69,710 participants
Inclusion criteria: women aged 40-70 years, no history of cancer at baseline recruited in seven urban ar-
eas in Shanghai, China
Parent cohort: Shangai Women's Health Study
Recruitment: from December 1996-May 2000
Data on the same cohort also reported in Dai 2010
Interventions N/A
Nechuta 2012 
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Outcomes Number of cases
Nechuta 2012
Outcome assessment: 31 December 2005
Digestive system cancer: 1239 cases
Stomach cancer: 287 cases
Stomach and oesophageal cancer: 314 cases
Colorectal cancer: 579 cases
Colon cancer: 355 cases
Rectal cancer: 224 cases
Liver cancer: 133 cases
Pancreatic cancer: 131 cases
Gallbladder and bile duct cancer: 82 cases
Yang 2007
Outcome assessment: 2004
Colorectal cancer: 256 cases (all female)
Green tea in exposure cat-
egories
Exposure assessment: green tea consumption
Lowest exposure: never drinking
Highest exposure: ≥ 3 times/week for > 6 months
In Yang 2007
Exposure assessment: intake of green tea
Lowest exposure: nondrinker
Highest exposure: drinker, further divided in amount of green tea consumption:
Highest exposure A: 1-4 g/d
Highest exposure B: ≥ 5 g/d
Notes Nechuta 2012
Funding: National Cancer Institute (R37 CA70867)
Statistical methods: Cox proportional hazard regression
Variables controlled in analysis: age, marital status, education, occupation, BMI, exercise, fruit and veg-
etable intake, meat intake, diabetes and family history of digestive system cancer
Variables controlled by matching: -
Yang 2007
Funding: USPHS grant R01CA70867 and National Institue of Health intramural programme, Division of
Cancer Epidemiology and Genetics (N02 CP1101066)
Statistical methods: Cox proportional hazard regression
Variables controlled in analysis: age, education, household income, cigarette smoking, alcohol drink-
ing, physical activity, BMI, menopausal status, nonsteroidal anti-inflammatory drug use, vitamin sup-
Nechuta 2012  (Continued)
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plement use, prior histories of colorectal polyps and chronic ulcerative colitis, family history of colorec-
tal cancer and intakes of total energy, vegetables, fruits and red meat
Variables controlled by matching: -
Nechuta 2012  (Continued)
 
 
Methods Cohort study in Japan
Participants Participants: 30,826 (male/female: 14,241/16,585) participants
Inclusion criteria: aged ≥ 35 years, non-hospitalised inhabitants in Takayama, Gifu Prefecture, Japan
Recruitment: from September 1992
Data on the same cohort also reported in Nakamura 2011
Interventions N/A
Outcomes Number of cases
Outcome assessment: 31 December 2000
Colon cancer: 213 (male/female: 111/102) cases
Green tea in exposure cat-
egories
Exposure assessment: green tea drinking
Lowest exposure: never to < 1 cup/month
Intermediate exposure: from 1 cup/month to < 1 cup/d
Highest exposure: ≥ 1 cup/d
Notes Funding: grants from the Ministry of Education, Culture, Science and Technology, the Ministry of
Health, Labour and Welfare and the Japan Coffee Association
Statistical methods: Cox proportional hazard regression
Variables controlled in analysis: age, height, BMI, total pack-years of cigarette smoking, alcohol intake,
physical activity, black tea intake and coffee intake
Variables controlled by matching: -
Oba 2006 
 
 
Methods Cohort study in China
Participants Participants: 63,257 (male/female: 27,959/35,298) participants. Data on 52,584, free from diabetes, car-
diovascular disease and cancer at baseline
Inclusion criteria: aged 45-74 years, belonging to the Hokkien or Cantonese dialect group in Singapore,
China
Parent cohort: Singapore Chinese Health Study (SCHS)
Recruitment: from April 1993-December 1998
Interventions N/A
Outcomes Number of cases
Odegaard 2015 
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Outcome assessment: 31 December 2011
Total cancer mortality: 4092 cases (deaths)
Green tea in exposure cat-
egories
Exposure assessment: green tea intake
Lowest exposure: none
Intermediate exposure 1: any to < 1 cup/d
Intermediate exposure 2: 1 cup/d
Highest exposure: ≥ 2 cups/d
Notes Funding: NIH grants NCI RO1 CA055069, R35 CA053890, R01 CA080205, R01 CA098497, R01 CA144034
and R01 DK080720.
Statistical methods: Cox proportional hazard regression
Variables controlled in analysis: age, sex, dialect, education, year of interview, smoking, moderate and
vigorous activity, sleep, BMI, nonbeverage vegetable-fruit-soy–rich dietary pattern score, energy in-
take, intake of coffee, black tea, alcohol, soK drinks and juice
Variables controlled by matching: -
Odegaard 2015  (Continued)
 
 
Methods Cohort study in Japan
Participants Participants: 140,420 (male/female: 68,722/71,698), with 61,595 from cohort 1 and 78,825 from cohort 2
and 106,324 (male/female: 50,438/55,886) participants with complete data in the present study
Inclusion criteria: aged 40-59 years, from 5 Public Health Centre areas (Iwate, Akita, Nagano, Okinawa
and Tokyo) for cohort 1, and aged 40-69 years for cohort 2 from 6 Public Health Centre areas (Ibaraki,
Niigata, Kochi, Nagasaki, Okinawa and Osaka), respondent at 5-year follow-up
Parent cohorts
Cohort 1: Japan Public Health Centre-based Prospective Study (JPHC)-I
cohort 2: Japan Public Health Centre-based Prospective Study (JPHC)-II
Recruitment: from 1990 for cohort 1 and 1993/1994 for cohort 2
Interventions N/A
Outcomes Number of cases
Outcome assessment: 31 December 2012
Brain cancer: 155 (male/female: 70/85) cases out of 157 eligible, including glioma (N = 60), meningioma
(N = 51), lymphoma (N = 9), schwannoma (N = 3), pituitary adenoma (N = 2) and unspecified brain tu-
mour (N = 32)
Green tea in exposure cat-
egories
Exposure assessment: intake of green tea
Lowest exposure: ≤ 4 d/week
Intermediate exposure: 1-2 cups/d
Highest exposure: ≥ 3 cups/d
Ogawa 2016 
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Notes Funding: National Cancer Center Research and Development Fund (23-A-31[toku] and 26-A-2) (since
2011) and a Grant-in-Aid for Cancer Research from the Ministry of Health, Labour and Welfare of Japan
(from 1989-2010)
Statistical methods: Cox proportional hazard regression
Variables controlled in analysis: age, sex, BMI, pack years of cigarettes, alcohol intake, coffee, past his-
tory of allergy and past history of diabetes mellitus
Variables controlled by matching: -
Ogawa 2016  (Continued)
 
 
Methods PCC in Japan
Participants Participants: 961 (male/female: 775/186) cases and 2883 (male/female: 2325/558) controls
Inclusion criteria: aged 20-79 years, from the Aichi Cancer Center Hospital (ACCH) in Aichi Prefecture,
Japan
Recruitment: from January 2001-December 2005
Interventions N/A
Outcomes Number of cases
Upper aerodigestive tract cancer: 922 (male/female: NR) cases of the 961 (male/female: 775/186) eligi-
ble cases, including 420 (male/female: NR) cases of oesophageal cancer and 502 (male/female: NR) cas-
es of oral, pharyngeal and laryngeal cancer
Green tea in exposure cat-
egories
Exposure assessment: green tea drinking
Lowest exposure: < daily
Intermediate exposure 1: 1 cup/d
Intermediate exposure 2: 2 cups/d
Highest exposure: ≥ 3 cups/d
Notes Funding: Ministry of Education, Science, Sports, Culture and Technology of Japan (Grants-in-Aid for Sci-
entific Research); Ministry of Health, Labour and Welfare of Japan [Third-Term Comprehensive 10-Year
Strategy for Cancer Control and Health and Labor Sciences Research Grant for Clinical Cancer Research
(H24-Gannorinshou-Ippan-006)]; National Cancer Center Research and Development Fund (24- A-3);
Foundation for Promotion of Cancer Research in Japan and Japan Society for the promotion of Science
A3 Foresight Program
Statistical methods: conditional logistic regression
Variables controlled in analysis: age, sex, coffee and green tea intake, alcohol consumption, cumulative
smoking, fruit and vegetable intake, BMI, occupation and frequency of rice intake
Variables controlled by matching: sex and age (10-year categories)
Oze 2014 
 
 
Methods PCC in China
Participants Participants: 672 (male/female: 446/226) cases and 672 (male/female: 446/226) controls of unrelated
ethnic Han Chinese from Fuzhou in Fujian Province and surrounding regions
Peng 2013 
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Inclusion criteria: histopathologically confirmed colorectal cancer cases from 3 hospitals (the Union
Hospital of Medical University, the First Affiliated Hospital of Fujian Medical University and the National
Fujian Hospital) in Fuzhou, in the Fujian Province of China. Controls recruited from local residents who
underwent a routine health check and were free from any known major diseases
Recruitment: from June 2006-May 2010
Interventions N/A
Outcomes Number of cases
Colorectal cancer: 672 (male/female: 446/226) cases
Green tea in exposure cat-
egories
Exposure assessment: green tea drinking
Lowest exposure: no
Highest exposure: yes
Notes Funding: National Natural Science Foundation of China (N. 81001279), the Fujian Science and Tech-
nology Innovation Foundation for Young Scientists (N. 2010J05067), the Key Program of Scientific Re-
search of Fujian Medical University (N. 09ZD004) and the Foundation of Fujian Educational Committee
(N. JA10138 and JA11106).
Statistical methods: conditional logistic regression
Variables controlled in analysis: age, sex, education, income, marriage, job, a family history of cancer in
first-degree relatives and intake of fruits, vegetables and meat, smoking status and alcohol drinking
Variables controlled by matching: sex and age (± 5 years), ethnicity and area of residence
Peng 2013  (Continued)
 
 
Methods PCC in China
Participants Participants: 285 (male/female: 168/117) cases and 570 (male/female: 336/234) controls of unrelated
ethnic Han Chinese from AnXi or the surrounding regions
Inclusion criteria: histologically confirmed oesophageal squamous cell carcinoma, at AnXi Hospital in
the Fujian Province of China
Recruitment: from June 2010-May 2011
Interventions N/A
Outcomes Number of cases
Oesophageal cancer: 285 (male/female: 168/117) cases of oesophageal squamous cell carcinoma
Green tea in exposure cat-
egories
Exposure assessment: green tea drinking
Lowest exposure: no
Highest exposure: yes, defined as drinking at least 1 cup of green tea/week for > 6 months
Notes Funding: grants from the Program for Outstanding Young Talents of Scientific Research in University of
Fujian Province, China (No. JA11106), the National Natural Science Foundation of China (No. 81473047),
the Key Program of Scientific Research of Fujian Medical University (09ZD004) and the Foundation of
Fujian Province Key Laboratory of Environment and Health (201405)
Statistical methods: conditional logistic regression
Peng 2015 
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Variables controlled in analysis: age, sex, education, income, marital status, alcohol drinking, smoking,
pickled vegetables, fresh vegetables and fruits, meat, family history of oesophageal squamous cell car-
cinoma, history of reflux oesophagitis and hot beverage/food intake
Variables controlled by matching: sex and age (± 5 years), ethnicity and area of residence
Peng 2015  (Continued)
 
 
Methods RCT, parallel, double-blind in Egypt
Participants Participants: 39 Egyptian women, 22 in the intervention group and 17 in the control group
Inclusion criteria: age ≥18 years, women in pre-menopause with follicle-stimulating hormone level <
10 mIU/L, had reported at least moderately severe leiomyoma-related symptoms (a score of ≥ 25 on
the UF quality-of-life symptom severity subscale), had a total uterine volume of ≥ 160 mL by vaginal
and abdominal ultrasound and at least 1 UF/leiomyoma that was ≥ 2 cm3, not pregnant or breastfeed-
ing, with untreated abnormal pap smear, with no major morbidity of severe anaemia, elevated liver
enzymes > 1.5 times the upper limit of normal, or active substance abuse and no use of such medica-
tion (oral or systemic corticosteroids, hormones i.e. oestrogen, progestin, oral contraceptives, herbal
or botanical supplements with possible hormonal or GTE effects, or GnRH analogues or Depo-Provera)
in the previous 6 months
Recruitment: from November 2010-August 2011
Interventions Treatment group: 2 capsules (400 mg each)/d with 95% polyphenols and 45% GTE = total 800 mg/d
Control group: placebo (brown rice)
Duration: 4 months
Outcomes Primary outcome
Mean change in uterine leiomyoma burden
Secondary outcomes
Health-related QoL assessed with 2 different questionnaires. Scale 1: the fibroid-specific symptom
severity (SS) scale ranges from 5-40, where high values are indicative of greater symptom severity.
Scale 2: the HRQoL questionnaire, which measures perceived impact of leiomyoma on activities of dai-
ly living, general concern and worry, energy, mood, sense of self-control, self-consciousness and sexual
functioning of the participants. The scale ranges from 29-145 where higher scores indicate better QoL.
Safety monitoring: monthly haemoglobin levels, liver- and kidney-function tests and pregnancy testing
Green tea in exposure cat-
egories
N/A
Notes Funding: Grant support: grant 1 - R01 HD04 228-01 from the National Institute of Child Health and Hu-
man Development, National Institutes of Health; RCMI grant 2 - G12 RR003032
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "The study pharmacist at Sohag Faculty of Medicine carried out the
randomization process (by sequential digital assignment coding) and dis-
pensed green tea extract or placebo capsules to participants, based on the as-
signment code randomly picked by each participant prior to treatment."
Roshdy 2013 
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Comment: probably done
Allocation concealment
(selection bias)
Low risk Quote: "based on the assignment code randomly picked by each participant
prior to treatment"
Comment: probably done
Blinding of participants
and personnel (perfor-
mance bias) 
Uterine leiomyoma bur-
den
Low risk Quote: "The study staG and the participants were blinded to the treatment as-
signment throughout the whole study. The placebo capsules were identical to
the EGCG capsules in appearance and weight"
Comment: probably done
Blinding of outcome as-
sessment (detection bias) 
Uterine leiomyoma bur-
den
Low risk Quote: "The study staG and the participants were blinded to the treatment as-
signment throughout the whole study. The placebo capsules were identical to
the EGCG capsules in appearance and weight"
Comment: probably done
Incomplete outcome data
(attrition bias) 
Uterine leiomyoma bur-
den
Unclear risk Comment: number of participants included in analysis not stated
Selective reporting (re-
porting bias)
Low risk The study protocol is available (ClinicalTrials.gov identifier (NCT number):
NCT01311869) and the published reports include all expected outcomes
Other bias Unclear risk High rate of dropout in the placebo group (35%). In the protocol, treatment
duration was reported to be 6 months. In the study, treatment duration was 4
months.
Roshdy 2013  (Continued)
 
 
Methods HCC in China
Participants Participants: 1387 (male/female: 1025/362) cases and 1459 (male/female: 1038/421) controls
Inclusion criteria: aged < 80 years, histologically confirmed cases with no previous diagnosis of or treat-
ment for nasopharyngeal cancer, residents in Guangdong province and referring at the Sun Yat-sen Uni-
versity Cancer Center in Guangzhou, Guangdong province, southern China
Recruitment: from October 2005-October 2007
Interventions N/A
Outcomes Number of cases
Nasopharyngeal cancer: 1355 (male/female: NR) cases out of 1387 (male/female: 1025/362) eligible cas-
es (green tea drinkers and non tea drinkers)
Green tea in exposure cat-
egories
Exposure assessment: intake of green tea
Lowest exposure: nondrinker
Highest exposure: drinkers (≥ 1 cup/week for ≥ 6 months)
Ruan 2010 
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Notes Funding: National Natural Science Foundation of China (grant nos. 30671798 and 30471487), the Na-
tional Science and Technology Support Program of China (N. 2006BAI02A11) and the National Major
Basic Research Program of China (863 Program) (N. 2006AA02A404).
Statistical methods: unconditional logistic regression
Variables controlled in analysis: sex, age, education, dialect, household type and family history of na-
sopharyngeal cancer
Variables controlled by matching: sex and age (± 5 years), education, dialect and household type (rural
or urban)
Ruan 2010  (Continued)
 
 
Methods Cohort study in Japan
Participants Participants: 140,420 (male/female: 68,722/71,698), with 61,595 from cohort 1 and 78,825 from cohort 2
and 90,914 (male/female: 42,836/48,078) participants with complete data
Inclusion criteria: aged 40-59 years, from 5 Public Health Centre areas (Iwate, Akita, Nagano, Okinawa
and Tokyo) for cohort 1, and aged 40-69 years for cohort 2 from 6 Public Health Centre areas (Ibaraki,
Niigata, Kochi, Nagasaki, Okinawa and Osaka), respondent at 5-year follow-up
Parent cohorts
Cohort 1: Japan Public Health Centre-based Prospective Study (JPHC)-I
cohort 2: Japan Public Health Centre-based Prospective Study (JPHC)-II
Recruitment: from 1990 for cohort 1 and 1993/1994 for cohort 2
Interventions N/A
Outcomes Number of cases
Outcome assessment: 31 December 2011
Total cancer mortality: 5327 (male/female: 3468/1859) cases
Green tea in exposure cat-
egories
Exposure assessment: green tea drinking
Lowest exposure: < 1 cup/d
Intermediate exposure 1: 1-2 cups/d
Intermediate exposure 2: 3-4 cups/d
Highest exposure: ≥ 5 cups/d
Notes Funding: by the National Cancer Center Research and Development Fund (23-A-31[toku] and 26-A-2;
since 2011), by a Grant-in-Aid for Cancer Research from the Ministry of Health, Labour and Welfare of
Japan (from 1989 to 2010) and by Health and Labour Sciences Research Expenses for Commission
(Comprehensive Research on Life-Style Related Diseases including Cardiovascular Diseases and Dia-
betes Mellitus H26-005)
Statistical methods: Cox proportional hazard regression
Variables controlled in analysis: age, Public Health Centre area, BMI, history of hypertension, history of
diabetes, leisure-time sports or physical exercise, intake of coffee, Chinese tea, black tea and soda or
juice, energy intake and intakes of fruits, vegetables, fish, meat, dairy products, rice and miso soup and
job status (stratified by sex)
Variables controlled by matching: -
Saito 2015 
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Methods PCC in China
Participants Participants: 133 (male/female: 93/40) cases and 433 (male/female: 214/219) controls
Inclusion criteria: randomly selected patients, newly-diagnosed at Yangzhong Central Hospital En-
doscopy Unit, who had lived for at least 1 year in Yangzhong, China
Recruitment: from 1 January 1995-30 June 1995
Interventions N/A
Outcomes Number of cases
Stomach cancer: 133 (male/female: 93/40) cases
Green tea in exposure cat-
egories
Exposure assessment A: green tea intake
Lowest exposure: no
Highest exposure: yes
Exposure assessment B: green tea consumption
Lowest exposure: nondrinkers
Intermediate exposure: 1-21 cups/week
Highest exposure: ≥ 21 cups/week
Notes Funding: National Institute of Health National Cancer Institute, Department of Health and Human Ser-
vices (CA77954, CA09142 and CA16042) and grants from the University of California-Los Angeles Jons-
son Comprehensive Cancer Center Foundation and the Weissman Fund.
Statistical methods: unconditional logistic regression
Variables controlled in analysis: age, sex, education, BMI, pack-years of smoking and alcohol drinking.
Variables controlled by matching: -
Setiawan 2001 
 
 
Methods Cohort study in USA
Participants Participants: 7821 male participants out of 8006 recruited
Inclusion criteria: American men of Japanese ancestry, born from 1990-1919 and residing on the
Hawaiian island of Oahu, Hawaii, USA
Parent cohort: Honolulu Hearth Program
Recruitment: from 1965-1968
Interventions N/A
Outcomes Number of cases
Outcome assessment: 30 September 1986
Prostate cancer: 174 cases (all men)
Severson 1989 
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Green tea in exposure cat-
egories
Exposure assessment: green tea drinking habit
Lowest exposure: never
Highest exposure: ever
Notes Funding: USPHS Grant ROI CA 33644, awarded by the National Cancer Institute, Mil. Bethesda, MD
Statistical methods: Cox proportional hazard regression
Variables controlled in analysis: age at examination
Variables controlled by matching: -
Severson 1989  (Continued)
 
 
Methods Cohort study in Japan
Participants Participants: 53,724 women from the Japan Public Health Centre study
Inclusion criteria: aged 40-59 years, from 5 Public Health Centre areas (Iwate, Akita, Nagano, Okinawa
and Tokyo) for cohort 1, and aged 40-69 years for cohort 2 from 6 Public Health Centre areas (Ibaraki,
Niigata, Kochi, Nagasaki, Okinawa and Osaka), respondent at 5-year follow-up
Parent cohorts
Cohort 1: Japan Public Health Centre-based Prospective Study (JPHC)-I
Cohort 2: Japan Public Health Centre-based Prospective Study (JPHC)-II
Recruitment: 1990 (cohort 1) and 1993 (cohort 2)
Interventions N/A
Outcomes Number of cases
Outcome assessment: 31 December 2005
Endometrial cancer: 117 cases
Green tea in exposure cat-
egories
Exposure assessment: green tea drinking habit
Lowest exposure: ≤ 4 cups/week
Intermediate exposure 1: 1-2 cups/d
Intermediate exposure 2: 3-4 cups/d
Highest exposure: ≥ 5 cups/d
Notes Funding: not declared
Statistical methods: Cox proportional hazard regression model
Variables controlled in analysis: age, study area, BMI, menopausal status, age at menopause for
menopausal women, parity, use of exogenous female hormones, smoking status, green vegetable con-
sumption, beef consumption and pork consumption
Variables controlled by matching: -
Shimazu 2008 
 
 
Green tea (Camellia sinensis) for the prevention of cancer (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
142
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Methods PCC in China
Participants Participants: 3371 cases and 3380 controls (all female)
Inclusion criteria: Shanghai Breast Cancer Study, with newly diagnosed cases aged 25–70 years, resi-
dent of urban Shanghai and with no previous history of any cancer
Recruitment: from August 1996-March 1998 (phase 1) and from April 2002 to February 2005 (phase 2)
Interventions N/A
Outcomes Number of cases
Breast cancer: 3371 cases
Green tea in exposure cat-
egories
Exposure assessment A: green tea intake
Lowest exposure: never
Highest exposure: ever
Exposure assessment B: green tea consumption in tea leaves/month
Lowest exposure: never regular
Intermediate exposure 1: ≤ 50 g/month
Intermediate exposure 2: 50-< 100 g/month
Intermediate exposure 3: 100-< 225 g/month
Highest exposure: ≥ 225 g/month
Notes Funding: National Institute of Health National Cancer Institute (R01CA64277)
Statistical methods: unconditional logistic regression
Variables controlled in analysis: age, study phase, education, family history of breast cancer, personal
history of fibroadenoma, age at menarche, parity, age at first live birth, age at menopause, physical ac-
tivity, waist:hip ratio, total energy intake, total fruit and vegetable intake and fat intake
Variables controlled by matching: age (± 5 years)
Shrubsole 2009 
 
 
Methods RCT, parallel, double-blind in USA
Participants 39 (male/female: 14/25) participants: participants with prior advanced adenoma (N = 37), or colon can-
cer (N = 2)
Inclusion criteria: at least 5 rectal ACF at baseline. 19 (male/female: 6/13) participants in the treatment
group and 20 (male/female: 8/12) in the control group
Interventions Group A: GTE (Polyphenon E, 2 capsules of 200 mg twice/d = 800 mg) containing 400 mg of EGCG
Group B: placebo
Duration: 6 months
Outcomes Change in rectal ACF
Safety data
Sinicrope 2017 
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Green tea in exposure cat-
egories
N/A
Notes ClinicalTrial.gov identifier: NCT01606124
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Described as randomised in the abstract and in ClinicalTrials.gov
Allocation concealment
(selection bias)
Unclear risk No information about concealment process
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Probably done as it is described as double-blind and placebo capsules were
implemented
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Probably done as it is described as double-blind and placebo capsules were
implemented, but no explicit statement
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk All results reported for all included participants
Selective reporting (re-
porting bias)
Low risk Results for the trial reported on (ClinicalTrials.gov identifier (NCT number):
NCT01606124)
Other bias Low risk No withdrawals reported
Sinicrope 2017  (Continued)
 
 
Methods PCC in USA
Participants Participants: 781 cases and 1263 controls (all women)
Inclusion criteria: aged 35-74 years, diagnosed with a primary invasive or borderline epithelial ovarian
cancer in English-speaking women who had residential telephones at the time of cancer diagnosis and
were residents of a 13-county area of western Washington State, USA
Recruitment: from 2002-2005
Interventions N/A
Outcomes Number of cases
Ovarian cancer: 781 cases
Green tea in exposure cat-
egories
Exposure assessment: green tea intake
Lowest exposure: nondrinker
Intermediate exposure: < 1 cup/d
Highest exposure: ≥ 2 cups/d
Song 2008 
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Notes Funding: National Institute of Health grant RO1 CA87538
Statistical methods: unconditional logistic regression
Variables controlled in analysis: age, county, year of diagnosis/reference date, race/ethnicity, num-
ber of full-term pregnancies, duration of hormonal contraception, education, BMI, smoking, tubal liga-
tion/hysterectomy and family history of breast/ovarian cancer
Variables controlled by matching: age, county of residence and year of diagnosis/reference date
Song 2008  (Continued)
 
 
Methods HCC in Japan
Participants Participants: 140 cases and 140 controls (all male)
Inclusion criteria: aged 59-73 years, cases with confirmed histological diagnosis of prostatic adenocar-
cinoma from the Department of Urology of Tsukuba University Hospital in Ibaraki and from the Depart-
ment of Urology of Sapporo Medical University Hospital in Hokkaido, Japan. Controls were recruited
from Department of Oral Surgery, Ophthalmology, or Dermatology of the same hospitals
Recruitment: from January 1996-September 2002
Interventions N/A
Outcomes Number of cases
Prostate cancer: 140 cases, including 2 cases of stage I, 86 cases of stage II, 36 cases of stage III and 16
cases of stage IV of adenocarcinoma
Green tea in exposure cat-
egories
Exposure assessment: green tea intake
Lowest exposure: ≤ 1 cup/d
Intermediate exposure 1: 2-4 cups/d
Intermediate exposure 2: 5-9 cups/d
Highest exposure:≥ 10 cups/d
Notes Funding: not declared
Statistical methods: conditional logistic regression
Variables controlled in analysis: age, cigarette smoking and energy intake
Variables controlled by matching: age (± 5 years)
Sonoda 2004 
 
 
Methods Cohort study in China
Participants Participants: 63,257 (male/female: 27,959/35,298) participants. Data on 61,320 (male/female: NR) with
no history of invasive cancer other than non-melanoma skin cancer.
Inclusion criteria: aged 45-74 years, belonging to the Hokkien or Cantonese dialect group in Singapore,
China
Parent cohort: Singapore Chinese Health Study (SCHS)
Recruitment: from April 1993-December 1998
Sun 2007 
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Interventions N/A
Outcomes Number of cases
Outcome assessment: 31 December 2004
Colorectal cancer: 845 (male/female: 470/375) cases, mainly adenocarcinoma
Colon cancer: 516 (male/female: 241/275) cases
Rectal cancer: 329 (male/female: 204/125) cases
Green tea in exposure cat-
egories
Exposure assessment A: green tea intake
Lowest exposure: nondrinker
Highest exposure: drinker
Exposure assessment B: green tea intake
Lowest exposure: nondrinker
Intermediate exposure 1: monthly drinker
Intermediate exposure 2: weekly drinker
Highest exposure: daily drinker
Notes Funding: National Cancer Institute, Bethesda, MD (R01 CA55069, R35 CA53890, R01 CA80205 and R01
CA98497)
Statistical methods: Cox proportional hazard regression
Variables controlled in analysis: sex, age at baseline interview, year of interview, dialect , education,
family history of colorectal cancer, history of diabetes, cigarette smoking, alcohol drinking, coffee
drinking, weekly moderate physical activity, BMI, total energy, total fat, dietary fibre, calcium, vitamin
C and black tea intake
Variables controlled by matching: -
Sun 2007  (Continued)
 
 
Methods Cohort study in Japan
Participants Participants: 31,345 (male/female: 13,992/17,353) from cohort 1 and 47,605 (male/female:
22,836/24,769) from cohort 2. Final included participants were 35,004 women, 14,409 from cohort 1 and
20,595 from cohort 2.
Inclusion criteria: aged ≥ 40 years, residents in 3 municipalities of the Miyagi Prefecture, Northern
Japan (cohort 1); aged 40-64 years, (cohort 2)
Parent cohorts
Cohort 1: Three Prefecture Study - Miyagi portion (3-pref MIYAGI)
Cohort 2: Miyagi Cohort Study (MIYAGI)
Recruitment: from 1984 for cohort 1 and from 1990 for cohort 2
Same population and outcome of Tsubono 2001 in: Inoue 2009a for cohort 1 Characteristics of cohort 2
reported in Fukao 1995 in: Suzuki 2004. Same population also reported in Koizumi 2003 in: Inoue 2009a
and Suzuki 2005
Suzuki 2004 
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Interventions N/A
Outcomes Number of cases
Outcome assessment: not clearly stated, 9 and 7 years of follow-up for cohort 1 and cohort 2 respec-
tively (probably 1992 and 1997)
Breast cancer: 222 cases (all women), 103 in cohort 1 and 119 in cohort 2
Green tea in exposure cat-
egories
Exposure assessment: green tea intake
Lowest exposure: < 1 cup/d
Intermediate exposure 1: 1-2 cups/d
Intermediate exposure 2: 3-4 cups/d
Highest exposure: ≥ 5 cups/d
Notes Funding: not declared
Statistical methods: Cox proportional hazard regression
Variables controlled in analysis: age, types of health insurance, age at menarche, menopausal status,
age at first birth, parity, mother’s history of breast cancer, smoking, alcohol drinking, BMI, and con-
sumption frequencies of black tea and coffee.
Variables controlled by matching: -
Suzuki 2004  (Continued)
 
 
Methods Cohort study in Japan
Participants Participants: 31,345 (male/female: 13,992/17,353) from cohort 1 and 47,605 (male/female:
22,836/24,769) from cohort 2.
Final included participants were 26,311 (male/female: NR) from cohort 1 and 39,604 (male/female: NR)
from cohort 2
Inclusion criteria: aged ≥ 40 years, residents in 3 municipalities of the Miyagi Prefecture, Northern
Japan (cohort 1); aged 40-64 years (cohort 2)
Parent cohorts
Cohort 1: Three Prefecture Study - Miyagi portion (3-pref MIYAGI)
Cohort 2: Miyagi Cohort Study (MIYAGI)
Recruitment: from 1984 for cohort 1 and from 1990 for cohort 2
Same population and outcome of Tsubono 2001 in: Inoue 2009a for cohort 1 Characteristics of cohort
2 reported in Fukao 1995 in: Suzuki 2004. Same population also reported in Koizumi 2003 in:Koizumi
2003Inoue 2009a and Suzuki 2004
Interventions N/A
Outcomes Number of cases
Outcome assessment: 31 December 1992 for cohort 1 and 31 March 1997 for cohort 2
Colon cancer: 305 (male/female: 185/120) cases, 158 (male/female: NR) in cohort 1 and 147 (male/fe-
male: NR) in cohort 2
Suzuki 2005 
Green tea (Camellia sinensis) for the prevention of cancer (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
147
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Rectal cancer: 211 (male/female: 119/92) cases 111 (male/female: NR) in cohort 1 and 100 (male/fe-
male: NR) in cohort 2
Green tea in exposure cat-
egories
Exposure assessment: green tea intake
Lowest exposure: < 1 cup/d
Intermediate exposure 1: 1-2 cups/d
Intermediate exposure 2: 3-4 cups/d
Highest exposure: ≥ 5 cups/d
Notes Funding: not declared
Statistical methods: Cox proportional hazard regression
Variables controlled in analysis: age, family history of colorectal cancer, cigarette smoking, alcohol
consumption, BMI and consumption of black tea and coffee
Variables controlled by matching: -
Subsequent report on stomach cancer in Inoue 2009a, from which we used data in the analysis.
Suzuki 2005  (Continued)
 
 
Methods Cohort study in Japan
Participants Participants: 13,636 (male/female: 6,916/6,720) eligible participants and 12,251 (male/female:
6231/6020) participants included in the present analysis
Inclusion criteria: aged 65-84 years, residents from 74 municipalities in Shizuoka, Japan, with reported
information on green tea intake.
Parent cohort: Prospective Shizuoka Elderly Cohort
Recruitment: from December 1999
Interventions N/A
Outcomes Number of cases
Outcome assessment: March 2006
Total cancer mortality: 400 (male/female: 304/96) cases (deaths)
Stomach cancer mortality: 68 (male/female: NR) cases (deaths)
Lung cancer mortality: 88 (male/female: NR) cases (deaths)
Colorectal cancer mortality: 43 (male/female: NR) cases (deaths), including 28 colon cancer deaths and
15 rectal cancer deaths
Green tea in exposure cat-
egories
Exposure assessment: green tea intake
Lowest exposure: < 1 cup/d
Intermediate exposure 1: 1-3 cups/d
Intermediate exposure 2: 4-6 cups/d
Highest exposure: ≥ 7 cups/d
Suzuki 2009 
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Notes Funding: grant from Health and Labour Sciences Research Grants, Comprehensive Research on Aging
and Health
Statistical methods: Cox proportional hazard regression
Variables controlled in analysis: smoking status, alcohol consumption, BMI and the frequency of physi-
cal activity
Variables controlled by matching: -
Suzuki 2009  (Continued)
 
 
Methods HCC in Japan
Participants Participants: 186 (male/female: NR) cases and 186 controls (male/female: NR) controls
Inclusion criteria: aged 40-70 years, newly diagnosed cases from the Aichi Cancer Center Hospital
(ACCH) in Aichi Prefecture, Japan
Recruitment: from April 1981-March 1983
Interventions N/A
Outcomes Number of cases
Stomach cancer: 93 (male/female: NR) cases
Colorectal cancer: 93 (male/female: NR) cases, including 42 colon cancer and 51 rectal cancer
Green tea in exposure cat-
egories
Exposure assessment: green tea drinking
Lowest exposure: < 4 cups/d
Highest exposure: ≥ 4 cups/d
Notes Funding: Grant-in-Aid for Cancer Research from the Ministry of Health and Welfare
Statistical methods: Mantel-Haenszel method
Variables controlled in analysis: sex and age
Variables controlled by matching: -
The estimates cannot be included due to missing CIs
Tajima 1985 
 
 
Methods HCC in Japan
Participants Participants: 127,477 inhabitants of 45 areas of Japan, data retrieved from 66,885 participants: 346 cas-
es and 11,936 controls (all male) included in the present study
Inclusion criteria: aged 40-79 years, from the Aichi Cancer Center Hospital (ACCH) in Aichi Prefecture,
Japan.
Recruitment: from January 1988-1997
Interventions N/A
Outcomes Number of cases
Takezaki 2000 
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Pharynx (hypopharynx) cancer: 62 (male/female: NR) cases
Oesophageal cancer: 284 cases, including 53, 159 and 72 cases in upper, middle and lower third of the
oesophagus
Green tea in exposure cat-
egories
Exposure assessment: green tea drinking
Lowest exposure: occasionally or less
Intermediate exposure: 1-6 cups/d
Highest exposure: ≥ 7 cups/d
Notes Funding: Grant-in-Aid for Cancer Research and the Comprehensive 10-year Strategy for Cancer Control
from the Ministry of Health and Welfare of Japan
Statistical methods: unconditional logistic regression
Variables controlled in analysis: age, year and season of visit, smoking and alcohol drinking
Variables controlled by matching: -
Takezaki 2000  (Continued)
 
 
Methods HCC in Japan
Participants Participants: 945 cases (male/female: 748/297) and 4153 (male/female: 2964/1189) controls
Inclusion criteria: newly diagnosed cases, 40-79 years of age from the Aichi Cancer Center Hospital
(ACCH) in Aichi Prefecture, Japan
Recruitment: from 1988-1997 referring to Aichi Cancer Center Hospital
Interventions N/A
Outcomes Number of lung cases:
Lung cancer:
Adenocarcinoma: 507 (male/female: 367/240) cases
Squamous cell and small-cell carcinomas 438 (male/female: 381/57) cases
Green tea in exposure cat-
egories
Exposure assessment: green tea intake
Lowest exposure: < 1 cup/d
Intermediate exposure 1: 1 cup/d
Intermediate exposure 2: 2 cups/d
Highest exposure: ≥ 3 cups/d
Notes Funding: Grant-in-Aid for Cancer Research and the Comprehensive 10-year Strategy for Cancer Control
from the Ministry of Health and Welfare of Japan
Statistical methods: unconditional logistic regression
Variables controlled in analysis: age, season and year of visit, occupation, prior lung diseases, smoking
and consumption of green vegetables and meat
Variables controlled by matching: sex and age (± 5 years)
Takezaki 2001 
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Methods Cohort study in Japan
Participants Participants: 30,824 (14,240/16,584) participants
Inclusion criteria: aged ≥ 35 years, in residents in Takayama, Gifu Prefecture, Japan
Recruitment: from 1 September 1992
Interventions N/A
Outcomes Number of cases
Outcome assessment: 31 March 2008
Liver cancer: 172 (male/female: 106/66) cases
Green tea in exposure cat-
egories
Exposure assessment: intake of green tea
Lowest exposure: nondrinkers
Intermediate exposure 1: < 1 time/d
Intermediate exposure 2: 1 time/d
Intermediate exposure 3: 2-3 times/d
Highest exposure: ≥ 4 times/d
Notes Funding: grants from the Ministry of Education, Culture, Sports, Science and Technology and the Minis-
ter of Health, Labour and Welfare of Japan
Statistical methods: Cox proportional hazard regression
Variables controlled in analysis: age, sex, ethanol intake, smoking status, BMI, education, total energy
intake, physical activity and medical history of diabetes mellitus.
Variables controlled by matching: -
Tamura 2018 
 
 
Methods HCC in China
Participants Participants: 200 cases and 200 controls (all women)
Inclusion criteria: female Chinese participants living in Hong Kong, mean age 61.8 (SD 10.0) for cases
and 60.6 (SD 9.6) for controls.
Recruitment: from 1981-1983
Interventions N/A
Outcomes Number of cases
Lung cancer: 200 cases (all women)
Green tea in exposure cat-
egories
Exposure assessment: drinking habit
Lowest exposure: no drinking
Highest exposure: usually drinking
Notes Funding: not declared
Tewes 1990 
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Statistical methods: conditional logistic regression
Variables controlled in analysis: age, number of live births, schooling, smoking habits, alcohol drinking,
frequency of consumption/month of fresh vegetables and fruits.
Variables controlled by matching: age and district of residence.
Tewes 1990  (Continued)
 
 
Methods RCT, parallel, double-blind in Japan
Participants Participants: 41 (male/female: 19/22) participants aged 18-75 years, with ≥ 1 histologically confirmed,
bidimensionally measurable oral premalignant lesions, with Zubrod performance status < 2, adequate
hematologic, liver, renal and cardiac function, with one of the following: harbouring at least mild dys-
plasia, located in a high-risk area (i.e. floor of mouth, ventrolateral tongue and soK palate), significant
extent of lesion tissue involvement and presence of symptoms. 11, 9 and 10 participants were ran-
domised in intervention group A, B and C respectively and 11 participants in control group
Recruitment: from August 2002-March 2008
Interventions Treatment groups: GTE contains high amounts of polyphenols, including EGCG:
Group A: 500 mg/m2 GTE, N = 11 (male/female: 5/6)
Group B: 750 mg/m2 GTE, N = 9 (male/female: 4/5)
Group C: 1,000 mg/m2 GTE, N = 10 (male/female: 4/6)
Control group: placebo, N = 11 (male/female: 6/5)
Duration: 12 weeks
Outcomes Primary outcome
Clinical and histologic response of high-risk oral lesions
Secondary outcome
Safety data: qualitative and quantitative toxicities of GTE
Green tea in exposure cat-
egories
NA
Notes Funding: support to En Ltd., including YM Sagesaka as employee of Ito En Ltd
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "The randomization was done with the Pocock-Simon dynamic alloca-
tion scheme"
Comment: done
Allocation concealment
(selection bias)
Low risk Quote: "The randomization was done with the Pocock-Simon dynamic alloca-
tion scheme"
Comment: probably concealed
Tsao 2009 
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Blinding of participants
and personnel (perfor-
mance bias) 
Oral premalignant-lesions
Low risk Quote: "GTE and placebo capsules were supplied to the pharmacy in blister
packs containing 10 capsules each"
Comment: participants and personnel probably blinded
Blinding of outcome as-
sessment (detection bias) 
Oral premalignant-lesions
Unclear risk No explicit statement on blinded outcome assessment, only for immunohisto-
chemical staining
Incomplete outcome data
(attrition bias) 
Oral premalignant-lesions
Low risk Data reported for all participants who completed the study. ITT analysis imple-
mented
Selective reporting (re-
porting bias)
Unclear risk The study protocol is not available and it is not clear if the published reports
include all expected outcomes
Other bias Low risk No other bias
Tsao 2009  (Continued)
 
 
Methods HCC in China
Participants Participants: 431 cases and 402 controls (all male)
Inclusion criteria: aged 35-84 years, newly diagnosed at Department of Surgery and Clinical Oncology
from the Prince of Wales Hospital of New Territories East Cluster in Hong Kong, China
Recruitment: from August 2011-November 2016
Interventions N/A
Outcomes Number of cases
Prostate cancer: 431 cases (all male)
Green tea in exposure cat-
egories
Exposure assessment: drinking habit
Lowest exposure: non habitual users
Highest exposure: habitual users
Notes Funding: grant from the Health and Medical Research Fund (N. 11121091), Hong Kong Special Adminis-
trative Region, China
Statistical methods: unconditional logistic regression
Variables controlled in analysis: age at interview, marital status, unemployment status, family prostate
cancer history, consumption of deep fried food, consumption of pickled vegetables, nightshift work
and cumulative bisphenol A exposure index
Variables controlled by matching: age (± 5 years)
Tse 2017 
 
 
Methods Cohort study in Japan
Ugai 2017 
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Participants Participants: 140,420 (male/female: 68,722/71,698), with 61,595 from cohort 1 and 78,825 from cohort 2
and 95,807 (male/female: 45,937/49,870) participants with complete data in the present study.
Inclusion criteria: aged 40-59 years, from 5 Public Health Centre areas (Iwate, Akita, Nagano, Okinawa
and Tokyo) for cohort 1, and aged 40-69 years for cohort 2 from 6 Public Health Centre areas (Ibaraki,
Niigata, Kochi, Nagasaki, Okinawa and Osaka), respondent at 5-year follow-up.
Parent cohorts
Cohort 1: Japan Public Health Centre-based Prospective Study (JPHC)-I
cohort 2: Japan Public Health Centre-based Prospective Study (JPHC)-II
Recruitment: from 1990 for cohort 1 and 1993/1994 for cohort 2
Interventions N/A
Outcomes Number of cases
Outcome assessment: 31 December 2012
Malignant lymphoma: 411 (male/female: 237/174) cases
Multiple myeloma: 138 (male/female: 66/72) cases
Green tea in exposure cat-
egories
Exposure assessment: green tea drinking
Lowest exposure: almost none
Intermediate exposure 1: 1-4 times/week
Intermediate exposure 2: 1-2 cups/d
Intermediate exposure 3: 3-4 cups/d
Highest exposure: ≥ 5 cups/d
Notes Funding: National Cancer Center Research and Development Fund (23-A-31(toku) and 26-A-2; since
2011) and a Grant-in-Aid for Cancer Research from the Ministry of Health, Labour and Welfare of Japan
(from 1989-2010).
Statistical methods: Cox proportional hazard regression
Variables controlled in analysis: age at baseline, sex, smoking status, alcohol consumption, BMI, occu-
pation and study area
Variables controlled by matching: -
Ugai 2017  (Continued)
 
 
Methods Cohort study in Japan
Participants Participants: 140,420 (male/female: 68,722/71,698), with 61,595 from cohort 1 and 78,825 from cohort 2
and 95,807 (male/female: 45,937/49,870) participants with complete data in the present study.
Inclusion criteria: aged 40-59 years, from 5 Public Health Centre areas (Iwate, Akita, Nagano, Okinawa
and Tokyo) for cohort 1 and aged 40-69 years in cohort 2, from 6 Public Health Centre areas (Ibaraki, Ni-
igata, Kochi, Nagasaki, Okinawa and Osaka), respondent at 5-year follow-up
Parent cohorts
Cohort 1: Japan Public Health Centre-based Prospective Study (JPHC)-I
Cohort 2: Japan Public Health Centre-based Prospective Study (JPHC)-II
Ugai 2018 
Green tea (Camellia sinensis) for the prevention of cancer (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
154
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Recruitment: from 1990 for cohort 1 and 1993/1994 for cohort 2
Interventions N/A
Outcomes Number of cases
Outcome assessment: 31 December 2012
Acute myeloid leukaemia: 85 (male/female: 50/85) cases
(Also reported 70 (male/female: 50/20) cases of myelodysplastic syndromes, not cancer)
Green tea in exposure cat-
egories
Exposure assessment: green tea drinking
Lowest exposure: < 1 cup/d
Intermediate exposure 1 : 1-2 cups/d
Intermediate exposure 2: 3-4 cups/d
Highest exposure: ≥ 5 cups/d
Notes Funding: National Cancer Center Research and Development Fund (23-A-31(toku) and 26-A-2; since
2011) and Ministry of Health, Labour and Welfare of Japan (from 1989-2010; a Grant-in-Aid for Cancer
Research)
Statistical methods: Cox proportional hazard regression
Variables controlled in analysis: age at baseline, sex, smoking status, alcohol consumption, BMI, occu-
pation and study area
Variables controlled by matching: -
Ugai 2018  (Continued)
 
 
Methods Cohort study in Japan
Participants Participants: 52,029 participants. Final data on 41,761 (male/female: 19,749/22,012) participants in-
cluded
Inclusion criteria: aged 40-79 years, living in 14 municipalities of Miyagi Prefecture in the catchment
area of the Ohsaki Public Health Centre, Miyagi, Japan
Parent cohort: Ohsaki Cohort Study
Recruitment: from October-December 1994
Data on the same cohort also reported in Kuriyama 2006 and Naganuma 2009.
Interventions N/A
Outcomes Number of cases
Outcome assessment: 31 December 2002
Liver cancer: 247 (male/female: 164/83) cases
Green tea in exposure cat-
egories
Exposure assessment: green tea consumption
Lowest exposure: < 1 cup/d
Intermediate exposure 1: 1-2 cups/d
Intermediate exposure 2: 3-4 cups/d
Ui 2009 
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Highest exposure: ≥ 5 cups/d
Notes Funding: Grant-in-Aid for Cancer Research and for the Third Term Comprehensive Ten-Year Strategy for
Cancer Control (H18-3jigan-ippan-001), Ministry of Health, Labour and Welfare, in Japan
Statistical methods: Cox proportional hazard regression
Variables controlled in analysis: age, sex, alcohol consumption, smoking status, coffee consumption,
vegetable consumption, dairy products consumption, fruit consumption, fish consumption and soy-
bean consumption
Variables controlled by matching: -
Ui 2009  (Continued)
 
 
Methods HCC in Japan
Participants Participants: 124 (male/female: 100/24) cases and 620 (male/female: 500/120) controls
Inclusion criteria: aged 40-79 years, from the Aichi Cancer Center Hospital (ACCH) in Aichi Prefecture,
Japan
Recruitment: from January 1988-December 2000
Interventions N/A
Outcomes Number of cases
Bladder cancer: 124 (male/female: 100/24) cases, including cancers of renal pelvis (N = 5), ureter (N = 6)
or bladder (N = 113)
Green tea in exposure cat-
egories
Exposure assessment: green tea drinking
Lowest exposure: < 1 cup/d
Intermediate exposure 1: 1-4 cups/d
Intermediate exposure 2: 5-9 cups/d
Highest exposure: ≥ 10 cups/d
Notes Funding: Grant-in-Aid for Cancer Research and the Comprehensive 10-year Strategy for Cancer Control
from the Ministry of Health, Labour and Welfare of Japan
Statistical methods: unconditional logistic regression
Variables controlled in analysis: age, sex, year of first visit, cumulative consumption of cigarettes, in-
take of green vegetables and intake frequency of eggs
Variables controlled by matching: age (5 years, strata), sex and year of first visit
Wakai 2004 
 
 
Methods PCC in China
Participants Participants: 209 cases (male/female: 129/80) and 209 (male/female: 129/80) controls
Inclusion criteria: 35-79 years of age; residence in Yangzhong, Jiangsu Province, China
Recruitment: 2000
Wang 1999 
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Interventions N/A
Outcomes Number of cases
Oesophageal cancer: 68 cases
Cardia (stomach) cancer: 69 cases
Other stomach cancer: 72 cases
Green tea in exposure cat-
egories
Exposure assessment: drinking habit
Lowest exposure: never drinking
Highest exposure: drinking
Notes Article in Chinese
Sponsor: not declared
Statistical methods: logistic regression
Variables controlled in analysis: age, education, cigarette smoking and alcohol intake
Variables controlled by matching: sex
Wang 1999  (Continued)
 
 
Methods PCC in China
Participants Participants: 107 cases (male/female: 60/47) and 107 (male/female: 60/47) controls
Inclusion criteria: newly diagnosed unrelated ethnic Han Chinese and residents in 5 townships of
Chuzhou District, which were located at the north side of the General Irrigation Canal, Huaian City,
Jiangsu Province, China
Recruitment: from 2002-2003
Interventions N/A
Outcomes Number of cases
Oesophageal cancer: 107 (male/female: 60/47) cases of oesophageal squamous cell carcinoma
Green tea in exposure cat-
egories
Exposure assessment: green tea intake
Lowest exposure: nondrinkers
Highest exposure: drinking at least 1 cup/d for at least 6 months
Notes Funding: grants CA94683 and CA90997 from NCI/NIH
Statistical methods: conditional logistic regression
Variables controlled in analysis: sex, age (± 5 years), residence, oesophageal lesion, eating fast, a family
history of cancer, HP infection, clean up of storage utensils
Variables controlled by matching: sex, age (± 5 years) and residence
Wang 2006 
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Methods PCC in China
Participants Participants: 355 cases (male/female: 223/132) and 209 (male/female: 252/156) controls
Inclusion criteria: aged ≥ 30 years, referring to Yangzhong Cancer Research Institute and Yangzhong
People's Hospital and living in Yangzhong, China
Recruitment: from 1 January 2004-28 February 2006
Interventions N/A
Outcomes Number of cases
Oesophageal cancer: 355 (male/female: 223/132) cases of squamous cell carcinoma
Green tea in exposure cat-
egories
Exposure assessment: drinking habit
Lowest exposure: no drinking
Highest exposure: drinking
Notes Funding: National Nature Science Foundation of China
Statistical methods: unconditional logistic regression
Variables controlled in analysis: age, marital status and education years
Variables controlled by matching: sex and age (± 5 years)
Wang 2007 
 
 
Methods HCC in China
Participants Participants: 250 cases (male/female: 150/100) and 299 (male/female: 178/121) controls
Inclusion criteria: participants of Han Chinese ancestry newly diagnosed, pathologically confirmed spo-
radic cases of clear cell renal cell carcinoma at the Departments of Urology, the 1st and 2nd Affiliated
Hospitals of Second Military Medical University, Shanghai, China
Recruitment: from May 2007-December 2009
Interventions N/A
Outcomes Number of cases
Renal cancer: 250 (male/female: 150/100) cases of clear cell renal cell carcinoma
Green tea in exposure cat-
egories
Exposure assessment: drinking habit
Lowest exposure: < 500 mL/d
Highest exposure: ≥ 500 mL/d
Notes Sponsor: National Natural Science Foundation of China (30873041, 81025015)
Statistical methods: unconditional logistic regression
Variables controlled in analysis: age, BMI, hypertension, diabetes, urolithiasis, smoking, alcohol con-
sumption and the polymorphisms
Variables controlled by matching: sex and age (± 3 years)
Wang 2012a 
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Methods HCC in China
Participants Participants: 220 cases (male/female: 135/85) and 220 (male/female: 135/85) controls
Inclusion criteria: participants with pathologically confirmed diagnosis and interviewed within 6
months of diagnosis referring at 5 hospitals (Xijing Hospital, Tangdu Hospital, Northwest Hospital, Xi'an
Centre Hospital and Shaanxi Province People’s Hospital) in Xi'an, China.
Recruitment: from August 2009-December 2011
Interventions N/A
Outcomes Number of cases
Multiple myeloma: 220 (male/female: 135/85) cases
Green tea in exposure cat-
egories
Exposure assessment: drinking habit
Lowest exposure: never
Intermediate exposure 1: 1-3 times/month
Intermediate exposure 2: 1-2 times/ week
Highest exposure: ≥ 3 times/week
Notes Sponsor: China Special Grant for the Prevention and Control of Infectious Diseases (2009ZX10002-027).
Statistical methods: conditional logistic regression
Variables controlled in analysis: age, sex, education, family history of cancer in first-degree relatives
and dietary risk factors (shallot and garlic, soy food, fried food, cured/smoked food, black tea, fish and
brined vegetables, pickle or sauerkraut)
Variables controlled by matching: sex, age (± 5 years) and inpatient hospital
Wang 2012b 
 
 
Methods PCC in China
Participants Participants: 908 cases (male/female: 526/382) and 1067 (male/female: 605/462) controls
Inclusion criteria: aged 35–79 years, residents in urban Shanghai through an 'instant case reporting'
system in 37 major hospitals newly diagnosed with pancreatic cancer and living in Shanghai, China.
Participants reported to drink other type of tea than green tea were excluded.
Recruitment: from December 2006-January 2011
Interventions N/A
Outcomes Number of cases
Pancreatic cancer: 908 (male/female: 526/382) cases
Green tea in exposure cat-
egories
Exposure assessment A: green tea intake
Lowest exposure: never
Highest exposure: ever
Exposure assessment B: green tea consumption
Lowest exposure: 0 g/month
Wang 2012c 
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Intermediate exposure 1: 1-99 g/month
Intermediate exposure 2: 100-149 g/month
Highest exposure: ≥ 150 g/month
Notes Sponsor: grant of US National Cancer Institute (5R01CA114421), by the Science and Technology
Commission of the Shanghai Municipality (08411954100), by the Shanghai Municipal Health Bureau
(20114080) and by the Shanghai Cancer Institute (SB10-06).
Statistical methods: conditional logistic regression
Variables controlled in analysis: age, BMI, education level, family history of cancer, smoking, history of
type 2 diabetes, menopausal status, oral contraceptive use and menopausal hormone therapy.
Variables controlled by matching: sex, age (± 5 years) and inpatient hospital
Wang 2012c  (Continued)
 
 
Methods HCC in China
Participants Participants: 157 cases and 314 controls (all women)
Inclusion criteria: newly diagnosed and histologically confirmed cases in participants referring to
Chung-Shan Medical University Hospital
Recruitment: from June 2009-June 2011
Interventions N/A
Outcomes Number of cases
Breast cancer: 157 cases (all women)
Green tea in exposure cat-
egories
Exposure assessment: green tea intake
Lowest exposure: no (< 1 cup/d)
Highest exposure: yes (≥ 1 cup/d)
Notes Sponsor: grant CSH-2010-A-03 from Chung-Shan Medical University Hospital, Taiwan
Statistical methods: conditional logistic regression
Variables controlled in analysis: education level, age at menarche and past hormone therapy
Variables controlled by matching: age (± 2 years)
Wang 2013a 
 
 
Methods HCC in USA
Participants Participants: 1007 (male/female: 784/223) cases and 1299 (male/female: 1013/286) controls
Inclusion criteria: histologically confirmed bladder cancer with no prior treatment of chemotherapy or
radiotherapy at the time of recruitment at the University of Texas MD Anderson Cancer Center and Bay-
lor College of Medicine, Texas, USA.
Recruitment: from 1999, still ongoing in 2013
Interventions N/A
Wang 2013b 
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Outcomes Number of cases
Bladder cancer: 1007 (male/female: 784/223) cases, all types, but generally transitional cell carcinoma
Green tea in exposure cat-
egories
Exposure assessment: green tea intake
Lowest exposure: never
Intermediate exposure: 0.1-0.13 serving/d
Highest exposure: ≥ 0.14 serving/d
(one serving = cup 8 fl oz/240 mL)
Notes Sponsor: National Cancer Institute grants K07 CA134831 and R01 CA74880
Statistical methods: unconditional logistic regression
Variables controlled in analysis: age, sex, ethnicity, energy intake and smoking
Variables controlled by matching: sex, age (± 5 years) and ethnicity
Wang 2013b  (Continued)
 
 
Methods HCC in China
Participants Participants: 160 (male/female: 74/86) cases and 320 (male/female: 154/166) controls
Inclusion criteria: histological or cytological confirmed cases in participants referring to Zhengzhou
University and Liaoning Cancer Hospital, Zhengzhou, China
Recruitment: from February 2005-February 2010
Interventions N/A
Outcomes Number of cases
Stomach cancer: 160 (male/female: 74/86) cases
Green tea in exposure cat-
egories
Exposure assessment A: green tea intake
Lowest exposure: never
Highest exposure: current
Exposure assessment B: green tea consumption
Lowest exposure: never
Intermediate exposure 1: 1-24 g/week
Intermediate exposure 2: 25-35 g/week
Highest exposure: ≥ 35 g/week
Notes Funding: not declared
Statistical methods: conditional logistic regression
Variables controlled in analysis: not clearly reported
Variables controlled by matching: sex and age (± 3 years)
Wang 2015 
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Methods PCC in USA
Participants Participants: 261 (male/female: 195/66) cases and 522 (male/female: 390/132) controls
Inclusion criteria: white or Japanese ancestry with newly diagnosed cancer referring to the 7 largest
civilian hospitals on the island of Oahu, Hawaii, USA
Recruitment: from 1977-1986
Interventions N/A
Outcomes Number of cases
Urinary tract cancer: 261 (male/female: 195/66) cases, mainly transitional cell cancer (95%), including
urinary bladder (90%), renal pelvis (7%) and ureter (3%)
Green tea in exposure cat-
egories
Exposure assessment: green tea drinking habit
Lowest exposure: first tertile
Intermediate exposure: second tertile
Highest exposure: third tertile
Values of tertiles NR
Notes Funding: National Cancer Institute grants R26 CA 25903 and NOl CA 15655
Statistical methods: conditional logistic regression
Variables controlled in analysis: age, smoking status, pack-years, employment in a high-risk occupa-
tion, consumption of dark green vegetables in men and total vitamin C consumption in women.
Variables controlled by matching: sex, age (± 5 years) and ethnic group
Wilkens 1996 
 
 
Methods PCC in USA
Participants Participants: 501 cases and 594 controls (all women)
Inclusion criteria: aged 25-74 years, in Asian Americans (Chinese, Japanese or Filipino), newly diag-
nosed cases identified through the Los Angeles County Cancer Surveillance Program, Los Angeles, USA
Recruitment: from 1 January 1995-31 December 1998
Interventions N/A
Outcomes Number of cases
Breast cancer: 501 cases (all women)
Green tea in exposure cat-
egories
Exposure assessment: green tea drinking habit
Lowest exposure: nondrinkers
Intermediate exposure: > 0-85.7 mL/d
Highest exposure: ≥ 85.7 mL/d
Wu 2003 
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Notes Funding: grants of California Breast Cancer Research Program (1RB-0287, 3PB-0102) and of USC/Norris
Comprehensive Cancer Center (2 P30 CA14089-26)
Statistical methods: conditional logistic regression
Variables controlled in analysis: age, Asian ethnicity, birthplace, education, age at menarche, pregnan-
cy, current BMI, total caloric intake, menopausal status, use of menopausal hormones, intake of soy,
dark green vegetables, smoking history, alcohol intake, physical activity and family history of breast
cancer, coffee intake and black tea intake
Variables controlled by matching: Asian ethnicity, age (5-year groups) and birthplace
Wu 2003  (Continued)
 
 
Methods HCC in China
Participants Participants: 142 cases and 142 control (all men)
Inclusion criteria: aged ≥ 18 years, referring to the First, Second and Third affiliated hospitals of Shan-
shan University and the Sun Yat-Sen University, Department of Urology, Cancer Center in Guangdong,
China
Recruitment: from May 2005-March 2008
Interventions N/A
Outcomes Number of cases
Prostate cancer: 142 cases (all men)
Green tea in exposure cat-
egories
Exposure assessment: green tea drinking habit
Lowest exposure: occasionally or never
Intermediate exposure 1: 3-4 time/month
Intermediate exposure 2: 1-6 times/week
Highest exposure: every d
Notes Article in Chinese
Funding: not declared
Statistical methods: conditional logistic regression
Variables controlled in analysis: age group (± 4-5 years), ethnic group and type of residence
Variables controlled by matching: age group (± 4-5 years), ethnic group and type of residence
Wu 2009a 
 
 
Methods PCC in China
Participants Participants: 1502 (male/female: 1191/329) cases and 3879 (male/female: 2916/963) controls, includ-
ing 637 (male/female: 426/211) cases and 1938 (male/female: 1368/570) controls in the Dafeng area and
883 (male/female: 765/118) cases and 1941 (male/female: 1548/393) controls in Ganyu.
Inclusion criteria: participants resident in 2 counties, Dafeng and Ganyu, with high and low mortality
for oesophageal cancer in Jiangsu province, China
Wu 2009b 
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Recruitment: from 2003-2007
Interventions N/A
Outcomes Number of cases
Oesophageal cancer: 1502 (male/female: 1191/329) cases
Green tea in exposure cat-
egories
Exposure assessment: green-tea drinking habit
Lowest exposure: never drinking
Highest exposure: has ever drunk (≥ 1 cup/week for ≥ 6 months), further divided into former and cur-
rent drinkers
Notes Funding: Jiangsu Provincial Health Department (RC 2003090)
Statistical methods: unconditional logistic regression
Variables controlled in analysis: sex, age, education level, 10 years' income, cancer family history, BMI,
pack-year of smoking, alcohol drinking and tea temperature
Variables controlled by matching: sex and age (± 5 years)
Wu 2009b  (Continued)
 
 
Methods PCC in China
Participants Participants: 1204 cases and 1212 controls (all women)
Inclusion criteria: aged 30-69 years, medical confirmed cases from Shanghai Cancer Registry with no
history of cancer or hysterectomy, within the Shanghai
Endometrial Cancer Study
Recruitment: from 1997-2003
Interventions N/A
Outcomes Number of cases
Endometrial cancer: 1204 cases (all women)
Green tea in exposure cat-
egories
Exposure assessment: green-tea drinking habit
Lowest exposure: never
Highest exposure: primarily green tea drinking (≥ 3 times/week for ≥ 6 months)
Notes Funding: USA Public Health Service grant R01CA92585 from the National Cancer Institute
Statistical methods: unconditional logistic regression
Variables controlled in analysis: age, education, menopausal status, years of menstruation, number of
pregnancies, diagnosis of diabetes, alcohol consumption, BMI, physical activity, energy intake and to-
tal fruit and vegetable intake and soy protein intake
Variables controlled by matching: age (± 5 years)
Xu 2007 
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Methods PCC in China
Participants Participants: 1225 cases (male/female: NR) and 1234 (male/female: NR) controls
Inclusion criteria: newly diagnosed cases in China
Recruitment: from 2006-2012
Interventions N/A
Outcomes Number of cases
Lung cancer: 1225 cases (male/female: NR)
Green tea in exposure cat-
egories
Exposure assessment: drinking habit
Lowest exposure: no drinking
Highest exposure: drinking
Notes Article in Chinese
Sponsor: not declared
Statistical methods: unconditional logistic regression
Variables controlled in analysis: NR
Variables controlled by matching: sex and age (± 3 years)
Xu 2013 
 
 
Methods PCC in China
Participants Participants: 593 (male/female: 392/201) cases and 1128 (male/female: 695/433) controls
Inclusion criteria: aged 20-80 years, newly diagnosed at the First Hospital of the University of Medical
Sciences in residents for at least 10 years in Fujian Province, China
Recruitment: from September 2010-March 2006
Interventions N/A
Outcomes Number of cases
Oral cancer: 593 (male/female: 392/201) cases of oral squamous cell carcinoma
Green tea in exposure cat-
egories
Exposure assessment: green tea drinking habit
Lowest exposure: nondrinkers
Highest exposure: green tea drinker (≥ 1 cup/week for ≥ 6 consecutive months)
Notes Article in Chinese
Funding: grants of California Breast Cancer Research Program (1RB-0287, 3PB-0102) and of USC/Norris
Comprehensive Cancer Center (2 P30 CA14089-26)
Statistical methods: unconditional logistic regression
Variables controlled in analysis: sex, age, residence, smoking, drinking and eating vegetables and fruits
Variables controlled by matching: sex and age
Yan 2016 
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Methods Cohort study in China
Participants Participants: 61,500 Chinese men, included in the present study 60,567 participants
Inclusion criteria: men aged 40-74 years, no history of cancer at baseline from 8 communities of Shang-
hai, China
Parent cohort: Shangai Men's Health Study
Recruitment: from 2002-2006
Interventions N/A
Outcomes Number of cases
Outcome assessment: 31 December 2008
Colorectal cancer: 243 cases (all male), including colon cancer (N = 133) and rectal cancer (N = 130)
Green tea in exposure cat-
egories
Exposure assessment A: intake of green tea
Lowest exposure: nondrinker
Highest exposure: drinker
Exposure assessment B: consumption of green tea
Lowest exposure: never
Intermediate exposure: < 250 g/month
Highest exposure: ≥ 250 g/month
Notes Funding: US Public Health Service grants (R01 CA082729, in part by R01 CA122364).
Statistical methods: Cox proportional hazard regression
Variables controlled in analysis: age, education, cigarette smoking, pack-years of cigarette smoking, al-
cohol consumption, regular exercise, BMI, history of diabetes, family history of colorectal cancer and
intakes of vegetables, fruits and red meat.
Variables controlled by matching: -
Yang 2011a 
 
 
Methods PCC in China
Participants Participants: 272 (male/female: 233/39) cases, 544 (male/female: 466/78) controls
Inclusion criteria: age 30-78 years, histologically confirmed or diagnosed by operation cases in resi-
dents in Changle City and Fuqing City for at least 20 years, Fujian Province, China
Recruitment: from January 1993-July 1995
Interventions N/A
Outcomes Number of cases
Stomach cancer: 272 (male/female: 233/39) cases
Ye 1998 
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Green tea in exposure cat-
egories
Exposure assessment: intake of green tea
Lowest exposure: < 0.75 kg/year
Highest exposure: ≥ 75 kg/year
Notes Funding: 8.5 National Major Project, No. 95-914-01-10, China
Statistical methods: conditional logistic regression
Variables controlled in analysis: matching variables
Variables controlled by matching: sex, age (± 3 years) and village
Ye 1998  (Continued)
 
 
Methods PCC in China
Participants Participants: 711 (male/female: 453/258) cases and 711 (male/female: 453/258) controls
Inclusion criteria: aged < 80 years, newly diagnosed cases among residents of Hongkou district of Sh-
naghai and Nanhui county in suburb area of Shangai, China
Recruitment: from October 1991-December 1993
Interventions N/A
Outcomes Number of cases
Stomach cancer: 711 (male/female: 453/258) cases, including cancers of cardia (N = 128), pylori (N =
216), antrum (N = 153), other sites (N = 124) and site unknown (N = 90)
Green tea in exposure cat-
egories
Exposure assessment: intake of green tea
Lowest exposure: nondrinkers
Highest exposure: drinkers further divided in:
Highest exposure A: 1-3 new batches
Highest exposure B: ≥ 4 new batches
Notes Funding: USA Public Health Service grant CA52560 from the National Cancer Institute, National Insti-
tutes of Health, Department of Health and Human Service
Statistical methods: conditional logistic regression
Variables controlled in analysis: sex, age education, birthplace, alcohol drinking and cigarette smoking
Variables controlled by matching: sex and age (± 3 years)
Yu 1995 
 
 
Methods PCC and HCC in China
Participants Participants: 254 cases and 652 controls, including 340 hospital and 261 population controls (all
women)
Inclusion criteria: aged < 75 years, newly diagnosed cases at Women’s Hospital, School of Medicine,
Zhejiang University, Zhejiang Cancer Hospital and other general hospitals in residents for at least 10
years living in Zhejiang province, China
Zhang 2002 
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Recruitment: from July 1999-June 2000
Interventions N/A
Outcomes Number of cases
Ovarian cancer: 254 cases of epithelial ovarian cancer
Green tea in exposure cat-
egories
Exposure assessment: intake of green tea
Lowest exposure: never or seldom
Intermediate exposure 1: ≤1 time/week
Intermediate exposure 2: 2-6 times/week
Highest exposure: ≥ 1 time/d
Notes Funding: US Public Health Service grant CA52560 from the National Cancer Institute, National Institutes
of Health, Department of Health and Human Service
Statistical methods: conditional logistic regression
Variables controlled in analysis: age at interview, education, living area, BMI, tobacco smoking, alcohol
consumption, coffee drinking, family income, marital status, menopause status, parity, tubal ligation,
oral contraceptive use, physical activity and family history of ovarian cancer
Variables controlled by matching: age and geographical area
Zhang 2002  (Continued)
 
 
Methods HCC in China
Participants Participants: 1009 cases and 1009 controls (all women)
Inclusion criteria: aged 20-87 years, newly diagnosed with invasive ductal carcinomas or in situ carcino-
ma of the breast, residents in Hangzhou, Zhejiang Province, China
Recruitment: from July 2004-September 2005
Interventions N/A
Outcomes Number of cases
Breast cancer: 1009 cases (all female)
Green tea in exposure cat-
egories
Exposure assessment: intake of green tea
Lowest exposure: never or seldom
Intermediate exposure 1: ≤ 1 cup/week
Intermediate exposure 2: 2–6 times/week
Intermediate exposure 3: 1 cup/d
Highest exposure: ≥ 2 cups/d
Notes Funding: not declared
Statistical methods: conditional logistic regression
Zhang 2007 
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Variables controlled in analysis: resident area, education, BMI, age at menarche, number of children
breastfed, menopausal status, oral contraceptive use, HRT, biopsy-confirmed benign breast diseases,
breast cancer in first-degree relatives, total energy intake, passive smoking, alcohol consumption, cof-
fee consumption, physical activity, soy intake, vegetable intake and fruit intake
Variables controlled by matching: age (± 5 years)
Zhang 2009 reports same data as Zhang 2007 but stratified by intake of mushrooms.
Zhang 2007  (Continued)
 
 
Methods HCC in China
Participants Participants: 107 (male/female: 66/41) cases and 110 (male/female: 70/40) controls
Inclusion criteria: aged 16/81 years, histopathologically confirmed cases Zhejiang University residents
in Hangzhou, Zhejiang Province, China
Recruitment: from 2005-2006
Interventions N/A
Outcomes Number of cases
Leukaemia: 107 (male/female: 66/41) cases, including acute myeloid leukaemia (N = 72), acute lympho-
cytic leukaemia (N = 22), chronic myeloid leukaemia (N = 10), chronic lymphocytic leukaemia (N = 3)
Green tea in exposure cat-
egories
Exposure assessment A: intake of green tea
Lowest exposure: no
Highest exposure: yes
Exposure assessment B: consumption of green tea
Lowest exposure: nondrinkers or ≤ 1 time/week
Intermediate exposure: 2-6 times/week
Highest exposure: ≥ 1 time/d
Notes Funding: not declared
Statistical methods: unconditional logistic regression
Variables controlled in analysis: age, sex, residence, education, smoking, medication use of
chloromycetin, occupational exposure to benzene and organophosphorous
Variables controlled by matching: age and hospital
Zhang 2008b reports same data as Zhang 2008 but paper in Chinese
Zhang 2008 
 
 
Methods Cohort studies in China
Participants Participants: 61,491 men in Shanghai Men's Health Study and 74,941 women in Shanghai Women's
Health Study. Total of 115,954 (male/female: 51,920/64,034) included in the present study
Inclusion criteria: aged 40-74 years, in men's study and 40-70 years, in women's study with no prevalent
cancer, coronary heart disease, stroke, or diabetes at the baseline survey and living in Shnaghai, China
Zhao 2017 
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Parent cohorts: Shanghai Men's Health Study and Shanghai Women's Health Study
Recruitment: from 2002-2006 (for men's study) and from 1997-2000 (for women's study)
Interventions N/A
Outcomes Number of cases
Outcome assessment: 2006 for men's study and 2000 for women's study
Total cancer mortality: 3210 (male/female: 1378/1832) deaths
Green tea in exposure cat-
egories
Exposure assessment A: intake of green tea
Lowest exposure: nondrinker
Highest exposure: drinker
Exposure assessment B: consumption of green tea
Lowest exposure: 0 g/d
Intermediate exposure: 0-< median g/d
Highest exposure: ≥ median g/d
Median value = 8.22 g/d in men's study and 3.29 g/d in women's study
Notes Funding: funds of State Key Laboratory of Oncogene and Related Genes (No. 91-15-10) and Shanghai
Health Bureau Key Disciplines and Specialties Foundation and grants from the US National Institutes of
Health (R37 CA070867 and UM1 CA182910, R01 CA082729 and UM1 CA173640)
Statistical methods: Cox proportional hazard regression
Variables controlled in analysis: age, education, income, smoking status, alcohol intake, energy intake,
BMI, physical activity, history of hypertension, gastritis, menopause status for women
Variables controlled by matching: -
Zhao 2017  (Continued)
 
 
Methods HCC in China
Participants Participants: 404 (male/female: NR) cases and 404 (male/female: NR) controls
Inclusion criteria: aged 18-80 years, newly diagnosed oral cancer in residents in Beijing, China.
Recruitment: from 1 May 1989-24 December 1989
Interventions N/A
Outcomes Number of cases
Oral cancer: 404 (male/female: NR) cases
Green tea in exposure cat-
egories
Exposure assessment: intake of green tea
Lowest exposure: < 1 cup/month
Highest exposure: ≥ 1 cup/month
Notes Funding: not declared
Zheng 1993 
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Statistical methods: conditional logistic regression
Variables controlled in analysis: sex, age, tobacco smoking, alcohol drinking, inadequate dentition,
years of education and Quetelet Index
Variables controlled by matching: sex and age (± 5 years)
Zheng 1993  (Continued)
 
 
Methods PCC in China
Participants Participants: 649 cases and 675 controls (all women)
Inclusion criteria: aged 35–69 years, newly diagnosed primary lung carcinoma through Shanghai Can-
cer Registry in residents in Shanghai, China
Recruitment: from 1 February 1992-31 January 1994
Interventions N/A
Outcomes Number of cases
Lung cancer: 649 cases (all women), including 473 histologically confirmed: adenocarcinoma (N = 331,
70.0%), squamous cell carcinomas (N = 83, 17.5%), small-cell carcinomas (N = 13, 2.7%), large-cell carci-
noma (N = 1, 0.2%) and mixed-cell carcinomas (N = 45, 9.5%)
Green tea in exposure cat-
egories
Exposure assessment: intake of green tea
Lowest exposure: on regular drinkers
Highest exposure: regular drinkers
Notes Funding: not declared
Statistical methods: conditional logistic regression
Variables controlled in analysis: age, income, number of years of exposure to environmental tobacco
smoke at work, high-risk occupation, family history of lung cancer, Vitamin C intake, cooking food at
high temperature, and respondent status
Variables controlled by matching: age (± 5 years)
Zhong 2001 
ACF: aberrant crypt foci; AKP: alkaline phosphatase; ALT: alanine aminotransferase; ASAP: atypical small acinar proliferation;
AST: aspartate aminotransferase; BMI: body mass index; CIN: cervical intraepithelial neoplasia; CI: confidence interval; EGCG: (-)-
epigallocatechin-3-gallate; GnRH: gonadotropin releasing hormone; GTE: green tea extract; HBSAg: hepatitis B surface antigen;
HCC: hospital-based case-control study; HG-PIN: high-grade prostate intraepithelial neoplasia; HP: Helicobacter pylori; HPV: human
papillomavirus; HR: hazard ratio; HRQoL: health-related quality of life; HRT: hormone replacement therapy; IBD: inflammatory bowel
disease; IPSS: International Prostate Symptom Score; ITT: intention-to-treat; LUTS: lower urinary tract symptoms; MENQOL: Menopause-
specific Quality of life; N/A: not applicable; NR: not reported; OR: odds ratio; PCC: population-based case-control study; PSA: prostate-
specific antigen; QoL: quality of life; RERF: Radiation EGects Research Foundation; RCT: randomised controlled trial; RR: risk ratio; SD:
standard deviation; SNP: single nucleotide polymorphisms; UF: uterine fibroid
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Ahmad 2012 Wrong exposure (not green tea)
Allen 2011 Wrong exposure (not green tea)
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Study Reason for exclusion
Alsanad 2016 Wrong patient population
Amarasinghe 2013 Wrong outcomes
Arts 2001 No distinction between green and black tea
Asgari 2011 Wrong exposure (not green tea)
Askari 2014 Wrong exposure (not green tea)
Azeem 2013 Wrong exposure (not green tea)
Bailey 2017 Paediatric population
Bamia 2015 Wrong exposure (not green tea)
Bao 2015 Wrong patient population
Baroudi 2014 Wrong exposure (not green tea)
Bates 2007 Wrong exposure (not green tea)
Bianchi 2000 No distinction between green and black tea
Bonaventure 2013 Paediatric population
Butler 2015 Wrong exposure (not green tea)
Chen 2009 Wrong exposure (not green tea)
Chyou 1995 No green tea
DArena 2013 Wrong patient population
Deandrea 2010 Wrong exposure (not only green tea)
Emami 2014 Wrong study design
Ettrich 2012 Wrong outcomes
Ferrucci 2014 Wrong exposure (not green tea)
Gao 2002 Wrong exposure (not green tea)
Gao 2009 Wrong exposure (not green tea)
Hara 1984 Participants all people with cancer
He 2017 Wrong exposure (not green tea)
Henning 2012 Wrong outcomes
Ide 2008 Wrong exposure (not green tea)
Il'yasova 2003 No distinction between green and black tea
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Study Reason for exclusion
Inoue 1997 Participants all people with cancer
Inoue 2001 Study does not address cancer
Ishizuka 2003 Measured gallstones
Jatoi 2003 Participants all people with cancer
Jia 2012 Cases not only people with cancer but included also participants with pre-cancerous lesions
Johnson 2011 Wrong exposure (not green tea)
Kono 1991 Measured polyps of the colon
Kuwahara 2000 Measured atrophic gastritis
Lee 1990 Mixed reporting of results for oolong, black and green tea
No distinction between at least 2 amounts of frequency of green tea consumption
Lee 2013 Wrong exposure (not green tea)
Liu 2013a Wrong exposure (not green tea)
Liu 2014 Wrong exposure (not green tea)
Liu 2015 Wrong outcomes
Luo 2010 Wrong exposure (not green tea)
Menzler 2015 Wrong outcomes
Mineharu 2011 Wrong outcomes
Montella 2007 No distinction between green and black tea
Montella 2009 No distinction between green and black tea
Nagano 2000 Summarised and added new data in Nagano 2001
Nakachi 1998 Participants all people with cancer
Nakachi 2003 Paper reviews Nakachi and colleague's 1998 study, participants all people with cancer
Oguni 1992 Abstract only, insufficient data
Ohno 1985 No amount of frequency of green tea consumption specified
Ohno 1995 "Okinawa tea" consumption, which is half-fermented oolong tea
Parodi 2017 Wrong exposure (not green tea)
Pisters 2001 Participants all people with cancer
Ren 1991 Type of tea not specified
Green tea (Camellia sinensis) for the prevention of cancer (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
173
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Study Reason for exclusion
Sasazuki 2008 Wrong exposure (not green tea)
Sasazuki 2012 Wrong study design
Sawada 2017 Wrong study design
Seo 2013 Wrong outcomes
Shibata 2000 Measured atrophic gastritis
Shim 1995 Study does not address cancer
Shimizu 2008 Wrong outcomes
Shin 2018 Wrong outcomes
Stingl 2011 Wrong outcomes
Suganuma 1999 Wrong study design
Sun 2002 Not clear green tea exposure, but urinary oesophagogastroduodenoscopy
Tong 2014 Wrong study design
Tsubono 1997 Not related to cancer risk factors
Tsugane 2014 Wrong study design
Wakai 1993 Participants all people with cancer
Wang 2002 No cancer (precancerous lesions)
Wang 2008 Wrong exposure (not green tea)
Wang 2010 Wrong study design
Wang 2012d Wrong patient population
Wang 2012e Wrong study design
Wang 2014a Wrong study design
Wu 2003a Amount of frequency of green tea consumption not specified
Wu 2013a Wrong study design
Yu 1991 Amount of frequency of green tea consumption not specified, not green tea only
YuanJ M 2007 Wrong exposure (not green tea)
Zeegers 2001a Wrong exposure (not green tea)
Zeegers 2001b Wrong study design
Zhang 2004 Follow-up study to Zhang 2002, participants all people with cancer
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Study Reason for exclusion
Zhang 2006 Results did not differentiate between black and green tea drinkers
Zhang 2009 Wrong exposure (not green tea)
Zhang 2013 Wrong exposure (not green tea)
Zhang 2016 Wrong outcomes
Zhu 2016 Wrong exposure (not green tea)
 
Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title Chemoprevention of esophageal squamous cell carcinoma (ESCC) with aspirin and tea polyphenols
(CREAT)
Methods RCT, quadruple-blind
Participants Adults aged 40-60 years
Interventions Intervention group A: aspirin 100 mg/d
Intervention group B: tea polyphenols 100 mg/d
Control group: placebo
Outcomes Primary outcomes
Occurrence of high-grade dysplasia and invasive ESCC (at six months)
Secondary outcomes
Mortality of the participants (at 6 months and at 3 or 5 years later)
Number of participants with adverse events (at 6 months and at 3 or 5 years later)
Occurrence of high-grade dysplasia and invasive ESCC (at 3 or 5 years later)
Starting date January 2012
Contact information Shu-Tian Zhang, MD, Beijing Friendship Hospital Capital Medical University
Notes Estimated study completion date: January 2013. No information on ClinicalTrials.gov
NCT01496521 
 
 
Trial name or title Fish oil and green tea extract in preventing prostate cancer in patients who are at risk for develop-
ing prostate cancer
ClinicalTrial ID: Shannon 2010
Methods Randomised, double-blind, placebo-controlled study
Shannon 2010 
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Participants Men at high risk of prostate cancer
Participants are stratified according to age (< 65 vs ≥ 65)
Interventions Intervention group A: GTE polyphenols (75%) and EGCG (at least 30% = 300 mg) per 1000 mg cap-
sule (2 capsules/d)
Intervention group B: fish oil capsule per 1000 mg with ethyl esters of eicosapentaenoic acid
(20:5n-3) and docosahexanoic acid (3 capsules/d)
Intervention group C: A+B
Control group: placebo, olive oil capsule 2/3 times/d
Duration: 12 weeks
Outcomes Primary outcomes
Fatty acid synthase expression by immunohistochemistry at pre- and post-intervention (FAS Sum-
mary Score)
Cell proliferation by Ki67-immunohistochemistry at pre- and post-intervention
Incidence of prostate cancer
Starting date July 2005
Contact information Jackie Shannon, Principal Investigator, OHSU Knight Cancer Institute
Notes According to 2010 abstract 67 men completed the study, 4 were enrolled. Anticipated sample size
120 men, or 30 men/group
Shannon 2010  (Continued)
EGCG: epigallocatechin-3-gallate; ESCC: (o)esophageal squamous cell carcinoma; FAS: fatty acid synthase; GTE: green tea extract; RCT:
randomised controlled trial
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Experimental studies: highest versus lowest green tea exposure
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Prostate cancer incidence 3 201 Risk Ratio (IV, Random, 95% CI) 0.50 [0.18, 1.36]
2 Gynaecological cancer incidence 2 1157 Risk Ratio (M-H, Random, 95% CI) 1.50 [0.41, 5.48]
2.1 Endometrial cancer 1 1075 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.01, 8.15]
2.2 Cervical cancer 1 82 Risk Ratio (M-H, Random, 95% CI) 2.0 [0.54, 7.46]
3 Non-melanoma skin cancer incidence 1 1075 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.06, 15.92]
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Analysis 1.1.   Comparison 1 Experimental studies: highest versus
lowest green tea exposure, Outcome 1 Prostate cancer incidence.
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
  n/N n/N IV, Random, 95% CI   IV, Random, 95% CI
Bettuzzi 2006 1/30 9/30 19.21% 0.11[0.01,0.82]
Kumar 2015 5/49 9/48 44.69% 0.54[0.2,1.51]
Micali 2017 4/22 4/22 36.09% 1[0.29,3.5]
   
Total (95% CI) 101 100 100% 0.5[0.18,1.36]
Total events: 10 (Experimental), 22 (Control)  
Heterogeneity: Tau2=0.31; Chi2=3.32, df=2(P=0.19); I2=39.79%  
Test for overall effect: Z=1.36(P=0.17)  
Favours experimental 1000.01 100.1 1 Favours control
 
 
Analysis 1.2.   Comparison 1 Experimental studies: highest versus
lowest green tea exposure, Outcome 2 Gynaecological cancer incidence.
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.2.1 Endometrial cancer  
Dostal 2015 0/538 1/537 16% 0.33[0.01,8.15]
Subtotal (95% CI) 538 537 16% 0.33[0.01,8.15]
Total events: 0 (Experimental), 1 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.67(P=0.5)  
   
1.2.2 Cervical cancer  
Garcia 2014 6/41 3/41 84% 2[0.54,7.46]
Subtotal (95% CI) 41 41 84% 2[0.54,7.46]
Total events: 6 (Experimental), 3 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.03(P=0.3)  
   
Total (95% CI) 579 578 100% 1.5[0.41,5.48]
Total events: 6 (Experimental), 4 (Control)  
Heterogeneity: Tau2=0.07; Chi2=1.04, df=1(P=0.31); I2=4.24%  
Test for overall effect: Z=0.61(P=0.54)  
Test for subgroup differences: Chi2=1.03, df=1 (P=0.31), I2=3.2%  
Favours experimental 1000.01 100.1 1 Favours control
 
 
Analysis 1.3.   Comparison 1 Experimental studies: highest versus lowest
green tea exposure, Outcome 3 Non-melanoma skin cancer incidence.
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Dostal 2015 1/538 1/537 100% 1[0.06,15.92]
   
Total (95% CI) 538 537 100% 1[0.06,15.92]
Favours experimental 1000.01 100.1 1 Favours control
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Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 1 (Experimental), 1 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0(P=1)  
Favours experimental 1000.01 100.1 1 Favours control
 
 
Comparison 2.   Nonexperimental studies: highest versus lowest green tea exposure
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Any cancer incidence 3 52479 Risk Ratio (Random, 95% CI) 0.83 [0.65, 1.07]
1.1 Cohort studies 2 51629 Risk Ratio (Random, 95% CI) 0.81 [0.50, 1.32]
1.2 Population-based case-
control studies
1 850 Risk Ratio (Random, 95% CI) 0.78 [0.60, 1.01]
2 Any cancer mortality 8 504366 Risk Ratio (Random, 95% CI) 0.99 [0.91, 1.07]
3 Oral cancer 5 55977 Risk Ratio (Fixed, 95% CI) 0.71 [0.62, 0.82]
3.1 Cohort studies 1 50258 Risk Ratio (Fixed, 95% CI) 0.44 [0.19, 1.04]
3.2 Population-based case-
control studies
1 1721 Risk Ratio (Fixed, 95% CI) 0.58 [0.42, 0.79]
3.3 Hospital-based case-con-
trol studies
3 3998 Risk Ratio (Fixed, 95% CI) 0.77 [0.65, 0.90]
4 Oral, pharyngeal and laryn-
geal cancer
1 2040 Risk Ratio (Random, 95% CI) 1.47 [1.12, 1.93]
4.1 Cohort studies 1 2040 Risk Ratio (Random, 95% CI) 1.47 [1.12, 1.93]
5 Pharyngeal cancer 1 12282 Risk Ratio (Random, 95% CI) 0.83 [0.30, 2.30]
5.1 Hospital-based case-con-
trol study
1 12282 Risk Ratio (Random, 95% CI) 0.83 [0.30, 2.30]
6 Any gut cancer 7 70299 Risk Ratio (Random, 95% CI) 0.78 [0.59, 1.02]
6.1 Cohort studies 2 52298 Risk Ratio (Random, 95% CI) 0.86 [0.27, 2.79]
6.2 Population-based case-
control studies
1 1721 Risk Ratio (Random, 95% CI) 0.58 [0.42, 0.79]
6.3 Hospital-based case-con-
trol studies
4 16280 Risk Ratio (Random, 95% CI) 0.77 [0.65, 0.90]
7 Oesophageal cancer 13 74895 Risk Ratio (Random, 95% CI) 0.81 [0.64, 1.04]
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studies
No. of
partici-
pants
Statistical method Effect size
7.1 Cohort studies 1 26801 Risk Ratio (Random, 95% CI) 1.67 [0.88, 3.16]
7.2 Population-based case-
control studies
9 14111 Risk Ratio (Random, 95% CI) 0.74 [0.55, 1.00]
7.3 Hospital-based case-con-
trol studies
3 33983 Risk Ratio (Random, 95% CI) 0.86 [0.57, 1.27]
8 Stomach cancer 18 438595 Risk Ratio (Random, 95% CI) 0.86 [0.74, 1.01]
8.1 Cohort studies 7 398286 Risk Ratio (Random, 95% CI) 0.99 [0.85, 1.14]
8.2 Population-based case-
control studies
8 9923 Risk Ratio (Random, 95% CI) 0.74 [0.53, 1.02]
8.3 Hospital-based case-con-
trol studies
3 30386 Risk Ratio (Random, 95% CI) 0.90 [0.74, 1.09]
9 Liver cancer 6 198885 Risk Ratio (Random, 95% CI) 0.88 [0.68, 1.14]
9.1 Cohort studies 5 198266 Risk Ratio (Random, 95% CI) 0.93 [0.71, 1.20]
9.2 Population-based case-
control studies
1 619 Risk Ratio (Random, 95% CI) 0.55 [0.28, 1.09]
10 Pancreatic cancer 10 326564 Risk Ratio (Random, 95% CI) 0.88 [0.70, 1.10]
10.1 Cohort studies 6 320596 Risk Ratio (Random, 95% CI) 1.04 [0.84, 1.30]
10.2 Population-based case-
control studies
3 5720 Risk Ratio (Random, 95% CI) 0.67 [0.48, 0.96]
10.3 Hospital-based case-
control studies
1 248 Risk Ratio (Random, 95% CI) 1.94 [1.06, 3.55]
11 Biliary tract cancer 3 195800 Risk Ratio (Random, 95% CI) 0.79 [0.57, 1.11]
11.1 Cohort studies 3 195800 Risk Ratio (Random, 95% CI) 0.79 [0.57, 1.11]
12 Colorectal cancer 16 610295 Risk Ratio (Random, 95% CI) 0.84 [0.74, 0.96]
12.1 Cohort studies 9 554298 Risk Ratio (Random, 95% CI) 1.00 [0.92, 1.08]
12.2 Population-based case-
control studies
5 12811 Risk Ratio (Random, 95% CI) 0.74 [0.61, 0.90]
12.3 Hospital-based case-
control studies
2 43186 Risk Ratio (Random, 95% CI) 0.53 [0.17, 1.60]
13 Colon cancer 10 389974 Risk Ratio (Random, 95% CI) 0.89 [0.80, 0.98]
13.1 Cohort studies 6 361348 Risk Ratio (Random, 95% CI) 0.93 [0.82, 1.05]
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studies
No. of
partici-
pants
Statistical method Effect size
13.2 Population-based case-
control studies
3 7136 Risk Ratio (Random, 95% CI) 0.83 [0.69, 1.00]
13.3 Hospital-based case-
control studies
1 21490 Risk Ratio (Random, 95% CI) 0.77 [0.47, 1.26]
14 Rectal cancer 9 356851 Risk Ratio (Random, 95% CI) 0.89 [0.75, 1.05]
14.1 Cohort studies 5 329570 Risk Ratio (Random, 95% CI) 0.92 [0.77, 1.09]
14.2 Population-based case-
control studies
3 5887 Risk Ratio (Random, 95% CI) 0.83 [0.56, 1.24]
14.3 Hospital-based case-
control studies
1 21394 Risk Ratio (Random, 95% CI) 1.25 [0.62, 2.51]
15 Nasopharyngeal carcino-
ma
2 2290 Risk Ratio (Random, 95% CI) 0.49 [0.36, 0.67]
15.1 Population-based case-
control studies
1 685 Risk Ratio (Random, 95% CI) 0.61 [0.41, 0.91]
15.2 Hospital-based case-
control studiesCohort studies
1 1605 Risk Ratio (Random, 95% CI) 0.44 [0.36, 0.54]
16 Lung cancer 17 269565 Risk Ratio (Random, 95% CI) 0.88 [0.76, 1.02]
16.1 Cohort studies 6 240987 Risk Ratio (Random, 95% CI) 1.02 [0.79, 1.31]
16.2 Population-based case-
control studies
5 9703 Risk Ratio (Random, 95% CI) 0.73 [0.61, 0.87]
16.3 Hospital-based case-
control studies
6 18875 Risk Ratio (Random, 95% CI) 0.90 [0.69, 1.17]
17 Breast cancer 14 250822 Risk Ratio (Random, 95% CI) 0.88 [0.75, 1.02]
17.1 Cohort studies 5 235706 Risk Ratio (Random, 95% CI) 1.01 [0.86, 1.19]
17.2 Population-based case-
control studies
4 9336 Risk Ratio (Random, 95% CI) 0.87 [0.70, 1.08]
17.3 Hospital-based case-
control studies
5 5780 Risk Ratio (Random, 95% CI) 0.81 [0.58, 1.13]
18 Gynaecological cancer 10 66738 Risk Ratio (Random, 95% CI) 0.69 [0.57, 0.83]
18.1 Cohort studies 1 53841 Risk Ratio (Random, 95% CI) 0.75 [0.43, 1.30]
18.2 Population-based case-
control studies
9 12897 Risk Ratio (Random, 95% CI) 0.68 [0.56, 0.84]
19 Endometrial cancer 5 60416 Risk Ratio (Random, 95% CI) 0.77 [0.65, 0.91]
Green tea (Camellia sinensis) for the prevention of cancer (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
180
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Outcome or subgroup title No. of
studies
No. of
partici-
pants
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19.1 Cohort studies 1 53841 Risk Ratio (Random, 95% CI) 0.75 [0.43, 1.30]
19.2 Population-based case-
control studies
4 6575 Risk Ratio (Random, 95% CI) 0.75 [0.61, 0.94]
20 Ovarian cancer 5 6322 Risk Ratio (Random, 95% CI) 0.64 [0.45, 0.90]
20.1 Population-based case-
control studies
5 6322 Risk Ratio (Random, 95% CI) 0.64 [0.45, 0.90]
21 Prostate cancer 13 127239 Risk Ratio (Random, 95% CI) 0.73 [0.56, 0.94]
21.1 Cohort studies 5 123289 Risk Ratio (Random, 95% CI) 1.09 [0.89, 1.32]
21.2 Population-based case-
control studies
1 750 Risk Ratio (Random, 95% CI) 0.59 [0.40, 0.87]
21.3 Hospital-based case-
control studies
7 3200 Risk Ratio (Random, 95% CI) 0.50 [0.39, 0.63]
22 Renal cancer 1 549 Risk Ratio (Random, 95% CI) 0.34 [0.21, 0.55]
22.1 Hospital-based case-
control studies
1 549 Risk Ratio (Random, 95% CI) 0.34 [0.21, 0.55]
23 Urinary tract cancer 7 156039 Risk Ratio (Random, 95% CI) 1.04 [0.79, 1.37]
23.1 Cohort studies 3 151395 Risk Ratio (Random, 95% CI) 1.24 [0.87, 1.76]
23.2 Population-based case-
control studies
1 783 Risk Ratio (Random, 95% CI) 1.08 [0.61, 1.92]
23.3 Hospital-based case-
control studies
3 3861 Risk Ratio (Random, 95% CI) 0.84 [0.53, 1.32]
24 Hematopoietic cancer 2 80646 Risk Ratio (Random, 95% CI) 0.75 [0.45, 1.27]
24.1 Cohort studies 2 80646 Risk Ratio (Random, 95% CI) 0.75 [0.45, 1.27]
25 Leukaemia 5 97778 Risk Ratio (Random, 95% CI) 0.81 [0.57, 1.15]
25.1 Cohort studies - acute
myeloid leukaemia
1 95892 Risk Ratio (Random, 95% CI) 1.20 [0.62, 2.32]
25.2 Population-based
case-control studies - all
leukaemia
2 785 Risk Ratio (Random, 95% CI) 1.03 [0.50, 2.14]
25.3 Hospital-based
case-control studies - all
leukaemia
2 1101 Risk Ratio (Random, 95% CI) 0.64 [0.45, 0.91]
26 Lymphoma 1 96218 Risk Ratio (Random, 95% CI) 0.89 [0.61, 1.30]
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26.1 Cohort studies 1 96218 Risk Ratio (Random, 95% CI) 0.89 [0.61, 1.30]
27 Multiple myeloma 2 96385 Risk Ratio (Random, 95% CI) 0.50 [0.26, 0.95]
27.1 Cohort studies 1 95945 Risk Ratio (Random, 95% CI) 0.74 [0.39, 1.41]
27.2 Hospital-based case-
control studies
1 440 Risk Ratio (Random, 95% CI) 0.38 [0.27, 0.53]
28 Non-melanoma skin can-
cer
1 450 Risk Ratio (Random, 95% CI) 0.82 [0.35, 1.90]
28.1 Population-based case-
control studies
1 450 Risk Ratio (Random, 95% CI) 0.82 [0.35, 1.90]
29 Thyroid cancer 1 100666 Risk Ratio (Random, 95% CI) 0.88 [0.56, 1.37]
29.1 Cohort studies 1 100666 Risk Ratio (Random, 95% CI) 0.88 [0.56, 1.37]
30 Brain cancer 1 106479 Risk Ratio (Random, 95% CI) 1.07 [0.71, 1.62]
30.1 Cohort studies 1 106479 Risk Ratio (Random, 95% CI) 1.07 [0.71, 1.62]
 
 
Analysis 2.1.   Comparison 2 Nonexperimental studies: highest
versus lowest green tea exposure, Outcome 1 Any cancer incidence.
Study or subgroup Cases Con-
trols/Non
cases
log[Risk
Ratio]
Risk Ratio Weight Risk Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
2.1.1 Cohort studies  
Nagano 2001 4049 38540 -0 (0.049) 49.38% 0.98[0.89,1.08]
Nakachi 2000 488 8552 -0.5 (0.263) 16.7% 0.59[0.35,0.98]
Subtotal (95% CI)       66.08% 0.81[0.5,1.32]
Heterogeneity: Tau2=0.1; Chi2=3.71, df=1(P=0.05); I2=73.05%  
Test for overall effect: Z=0.85(P=0.39)  
   
2.1.2 Population-based case-control studies  
Li 2011a 425 425 -0.2 (0.134) 33.92% 0.78[0.6,1.01]
Subtotal (95% CI)       33.92% 0.78[0.6,1.01]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.86(P=0.06)  
   
Total (95% CI)       100% 0.83[0.65,1.07]
Heterogeneity: Tau2=0.03; Chi2=5.91, df=2(P=0.05); I2=66.14%  
Test for overall effect: Z=1.42(P=0.16)  
Test for subgroup differences: Chi2=0.02, df=1 (P=0.9), I2=0%  
  50.2 20.5 1  
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Analysis 2.2.   Comparison 2 Nonexperimental studies: highest
versus lowest green tea exposure, Outcome 2 Any cancer mortality.
Study or subgroup Cases Con-
trols/Non
cases
log[Risk
Ratio]
Risk Ratio Weight Risk Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
Iwai 2002 31 2855 -0.1 (0.321) 1.59% 0.92[0.49,1.73]
Khan 2004 89 1634 0 (0.24) 2.71% 1[0.63,1.6]
Khan 2004 154 1524 0 (0.24) 2.71% 1[0.63,1.6]
Kuriyama 2006 1134 40530 0.1 (0.085) 11.75% 1.11[0.94,1.31]
Liu 2016 7002 164681 -0.2 (0.042) 18.41% 0.86[0.79,0.93]
Odegaard 2015 4092 52584 0.1 (0.064) 14.75% 1.1[0.97,1.25]
Saito 2015 3468 42836 0 (0.059) 15.65% 1.04[0.93,1.17]
Saito 2015 1859 48078 -0.1 (0.076) 13.01% 0.87[0.75,1.01]
Suzuki 2009 400 12251 -0.2 (0.307) 1.73% 0.82[0.45,1.5]
Zhao 2017 3210 115954 0 (0.046) 17.67% 1.04[0.95,1.14]
   
Total (95% CI)       100% 0.99[0.91,1.07]
Heterogeneity: Tau2=0.01; Chi2=21.36, df=9(P=0.01); I2=57.87%  
Test for overall effect: Z=0.27(P=0.79)  
  50.2 20.5 1  
 
 
Analysis 2.3.   Comparison 2 Nonexperimental studies: highest
versus lowest green tea exposure, Outcome 3 Oral cancer.
Study or subgroup Cases Con-
trols/Non
cases
log[Risk
Ratio]
Risk Ratio Weight Risk Ratio
  N N (SE) IV, Fixed, 95% CI   IV, Fixed, 95% CI
2.3.1 Cohort studies  
Ide 2007 37 50221 -0.8 (0.439) 2.78% 0.44[0.19,1.04]
Subtotal (95% CI)       2.78% 0.44[0.19,1.04]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.87(P=0.06)  
   
2.3.2 Population-based case-control studies  
Yan 2016 593 1128 -0.6 (0.161) 20.59% 0.58[0.42,0.79]
Subtotal (95% CI)       20.59% 0.58[0.42,0.79]
Heterogeneity: Not applicable  
Test for overall effect: Z=3.42(P=0)  
   
2.3.3 Hospital-based case-control studies  
Chen 2017a 286 690 -0.7 (0.238) 9.44% 0.51[0.32,0.82]
Chen 2017a 300 334 -0.2 (0.216) 11.47% 0.85[0.56,1.3]
Fu 2013 238 281 -0.1 (0.155) 22.26% 0.93[0.69,1.26]
Fu 2013 485 576 -0.3 (0.131) 31.36% 0.72[0.56,0.93]
Zheng 1993 404 404 -0.2 (0.504) 2.1% 0.86[0.32,2.31]
Subtotal (95% CI)       76.64% 0.77[0.65,0.9]
Heterogeneity: Tau2=0; Chi2=4.85, df=4(P=0.3); I2=17.58%  
Test for overall effect: Z=3.18(P=0)  
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Study or subgroup Cases Con-
trols/Non
cases
log[Risk
Ratio]
Risk Ratio Weight Risk Ratio
  N N (SE) IV, Fixed, 95% CI   IV, Fixed, 95% CI
Total (95% CI)       100% 0.71[0.62,0.82]
Heterogeneity: Tau2=0; Chi2=8.56, df=6(P=0.2); I2=29.93%  
Test for overall effect: Z=4.65(P<0.0001)  
Test for subgroup differences: Chi2=3.71, df=1 (P=0.16), I2=46.1%  
  100.1 50.2 20.5 1  
 
 
Analysis 2.4.   Comparison 2 Nonexperimental studies: highest versus lowest
green tea exposure, Outcome 4 Oral, pharyngeal and laryngeal cancer.
Study or subgroup Cases Con-
trols/Non
cases
log[Risk
Ratio]
Risk Ratio Weight Risk Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
2.4.1 Cohort studies  
Oze 2014 502 1538 0.4 (0.139) 100% 1.47[1.12,1.93]
Subtotal (95% CI)       100% 1.47[1.12,1.93]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.78(P=0.01)  
   
Total (95% CI)       100% 1.47[1.12,1.93]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.78(P=0.01)  
  100.1 50.2 20.5 1  
 
 
Analysis 2.5.   Comparison 2 Nonexperimental studies: highest
versus lowest green tea exposure, Outcome 5 Pharyngeal cancer.
Study or subgroup Cases Con-
trols/Non
cases
log[Risk
Ratio]
Risk Ratio Weight Risk Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
2.5.1 Hospital-based case-control study  
Takezaki 2000 346 11936 -0.2 (0.52) 100% 0.83[0.3,2.3]
Subtotal (95% CI)       100% 0.83[0.3,2.3]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.36(P=0.72)  
   
Total (95% CI)       100% 0.83[0.3,2.3]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.36(P=0.72)  
  100.1 50.2 20.5 1  
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Analysis 2.6.   Comparison 2 Nonexperimental studies: highest
versus lowest green tea exposure, Outcome 6 Any gut cancer.
Study or subgroup Cases Con-
trols/Non
cases
log[Risk
Ratio]
Risk Ratio Weight Risk Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
2.6.1 Cohort studies  
Ide 2007 37 50221 -0.8 (0.439) 6.41% 0.44[0.19,1.04]
Oze 2014 502 1538 0.4 (0.139) 15.04% 1.47[1.12,1.93]
Subtotal (95% CI)       21.44% 0.86[0.27,2.79]
Heterogeneity: Tau2=0.62; Chi2=6.87, df=1(P=0.01); I2=85.44%  
Test for overall effect: Z=0.24(P=0.81)  
   
2.6.2 Population-based case-control studies  
Yan 2016 593 1128 -0.6 (0.161) 14.29% 0.58[0.42,0.79]
Subtotal (95% CI)       14.29% 0.58[0.42,0.79]
Heterogeneity: Not applicable  
Test for overall effect: Z=3.42(P=0)  
   
2.6.3 Hospital-based case-control studies  
Chen 2017a 286 690 -0.7 (0.238) 11.65% 0.51[0.32,0.82]
Chen 2017a 300 334 -0.2 (0.216) 12.4% 0.85[0.56,1.3]
Fu 2013 238 281 -0.1 (0.155) 14.5% 0.93[0.69,1.26]
Fu 2013 485 576 -0.3 (0.131) 15.3% 0.72[0.56,0.93]
Takezaki 2000 346 11936 -0.2 (0.52) 5.1% 0.83[0.3,2.3]
Zheng 1993 404 404 -0.2 (0.504) 5.32% 0.86[0.32,2.31]
Subtotal (95% CI)       64.27% 0.77[0.65,0.9]
Heterogeneity: Tau2=0; Chi2=4.88, df=5(P=0.43); I2=0%  
Test for overall effect: Z=3.2(P=0)  
   
Total (95% CI)       100% 0.78[0.59,1.02]
Heterogeneity: Tau2=0.11; Chi2=29.97, df=8(P=0); I2=73.3%  
Test for overall effect: Z=1.79(P=0.07)  
Test for subgroup differences: Chi2=2.61, df=1 (P=0.27), I2=23.4%  
  1000.01 100.1 1  
 
 
Analysis 2.7.   Comparison 2 Nonexperimental studies: highest
versus lowest green tea exposure, Outcome 7 Oesophageal cancer.
Study or subgroup Cases Con-
trols/Non
cases
log[Risk
Ratio]
Risk Ratio Weight Risk Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
2.7.1 Cohort studies  
Ishikawa 2006 78 26723 0.5 (0.325) 6.17% 1.67[0.88,3.16]
Subtotal (95% CI)       6.17% 1.67[0.88,3.16]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.58(P=0.12)  
   
2.7.2 Population-based case-control studies  
Gao 1994 242 658 -1.1 (0.361) 5.63% 0.34[0.17,0.69]
Gao 1994 417 654 -0.2 (0.183) 8.64% 0.79[0.55,1.13]
  20.5 1.50.7 1  
Green tea (Camellia sinensis) for the prevention of cancer (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
185
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Study or subgroup Cases Con-
trols/Non
cases
log[Risk
Ratio]
Risk Ratio Weight Risk Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
Islami 2009 266 571 -0.1 (0.436) 4.64% 0.89[0.38,2.09]
Mu 2003 218 415 -0.5 (0.262) 7.23% 0.58[0.35,0.97]
Oze 2014 420 2883 0.3 (0.164) 8.96% 1.31[0.95,1.81]
Peng 2015 285 570 -0.4 (0.18) 8.69% 0.64[0.45,0.91]
Wang 1999 68 68 -1.6 (0.614) 2.98% 0.2[0.06,0.67]
Wang 2006 107 107 -2 (0.797) 2% 0.13[0.03,0.62]
Wang 2007 132 156 -1.4 (0.664) 2.67% 0.26[0.07,0.94]
Wang 2007 223 252 0.3 (0.187) 8.56% 1.37[0.95,1.97]
Wu 2009b 883 1941 0.3 (0.188) 8.55% 1.3[0.9,1.88]
Wu 2009b 637 1938 0 (0.182) 8.65% 1[0.7,1.43]
Subtotal (95% CI)       77.22% 0.74[0.55,1]
Heterogeneity: Tau2=0.17; Chi2=44.06, df=11(P<0.0001); I2=75.04%  
Test for overall effect: Z=1.96(P=0.05)  
   
2.7.3 Hospital-based case-control studies  
Chen 2011 150 300 -0.1 (0.472) 4.23% 0.92[0.36,2.32]
Inoue 1998 185 21128 0.1 (0.367) 5.55% 1.14[0.56,2.34]
Takezaki 2000 284 11936 -0.4 (0.286) 6.83% 0.7[0.4,1.22]
Subtotal (95% CI)       16.61% 0.86[0.57,1.27]
Heterogeneity: Tau2=0; Chi2=1.13, df=2(P=0.57); I2=0%  
Test for overall effect: Z=0.77(P=0.44)  
   
Total (95% CI)       100% 0.81[0.64,1.04]
Heterogeneity: Tau2=0.15; Chi2=48.73, df=15(P<0.0001); I2=69.22%  
Test for overall effect: Z=1.64(P=0.1)  
Test for subgroup differences: Chi2=5.07, df=1 (P=0.08), I2=60.57%  
  20.5 1.50.7 1  
 
 
Analysis 2.8.   Comparison 2 Nonexperimental studies: highest
versus lowest green tea exposure, Outcome 8 Stomach cancer.
Study or subgroup Cases Con-
trols/Non
cases
log[Risk
Ratio]
Risk Ratio Weight Risk Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
2.8.1 Cohort studies  
Galanis 1998 108 11907 0.4 (0.218) 4.93% 1.5[0.98,2.3]
Inoue 2009a 2495 100479 0.1 (0.107) 6.83% 1.06[0.86,1.31]
Inoue 2009a 1082 118601 -0.2 (0.1) 6.94% 0.79[0.65,0.96]
Khan 2004 15 1634 -0.4 (0.509) 1.87% 0.7[0.26,1.9]
Khan 2004 36 1524 0.1 (0.516) 1.84% 1.1[0.4,3.02]
Kuriyama 2006 193 40530 0.2 (0.207) 5.12% 1.17[0.78,1.76]
Nagano 2001 1270 38576 0.1 (0.084) 7.16% 1.06[0.9,1.25]
Nechuta 2012 287 67230 -0.2 (0.155) 6.02% 0.79[0.58,1.07]
Suzuki 2009 68 12251 -0.2 (0.753) 0.99% 0.81[0.19,3.54]
Subtotal (95% CI)       41.7% 0.99[0.85,1.14]
Heterogeneity: Tau2=0.02; Chi2=13.13, df=8(P=0.11); I2=39.09%  
Test for overall effect: Z=0.2(P=0.84)  
  100.1 50.2 20.5 1  
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Study or subgroup Cases Con-
trols/Non
cases
log[Risk
Ratio]
Risk Ratio Weight Risk Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
   
2.8.2 Population-based case-control studies  
Hoshiyama 1992 216 483 -0.1 (0.188) 5.45% 0.9[0.62,1.3]
Hoshiyama 1992 35 483 0.5 (0.455) 2.22% 1.6[0.66,3.9]
Ji 1996 345 594 -0.3 (0.196) 5.31% 0.77[0.52,1.13]
Ji 1996 684 753 -0 (0.118) 6.65% 0.96[0.76,1.21]
Kono 1988 139 278 -1.2 (0.432) 2.38% 0.3[0.13,0.7]
Liu 2010 641 1847 -0.9 (0.139) 6.3% 0.42[0.32,0.55]
Mu 2003 206 415 -0.9 (0.432) 2.38% 0.39[0.17,0.91]
Setiawan 2001 133 433 -0.6 (0.3) 3.71% 0.52[0.29,0.94]
Ye 1998 272 544 0.5 (0.16) 5.93% 1.72[1.26,2.36]
Yu 1995 711 711 -0.3 (0.14) 6.29% 0.71[0.54,0.93]
Subtotal (95% CI)       46.61% 0.74[0.53,1.02]
Heterogeneity: Tau2=0.21; Chi2=60.33, df=9(P<0.0001); I2=85.08%  
Test for overall effect: Z=1.85(P=0.06)  
   
2.8.3 Hospital-based case-control studies  
Huang 1999 887 28619 -0.1 (0.107) 6.83% 0.9[0.73,1.11]
Mao 2011 200 200 0.1 (0.439) 2.33% 1.13[0.48,2.67]
Wang 2015 160 320 -0.3 (0.414) 2.53% 0.72[0.32,1.62]
Subtotal (95% CI)       11.69% 0.9[0.74,1.09]
Heterogeneity: Tau2=0; Chi2=0.56, df=2(P=0.76); I2=0%  
Test for overall effect: Z=1.06(P=0.29)  
   
Total (95% CI)       100% 0.86[0.74,1.01]
Heterogeneity: Tau2=0.08; Chi2=82.22, df=21(P<0.0001); I2=74.46%  
Test for overall effect: Z=1.81(P=0.07)  
Test for subgroup differences: Chi2=2.73, df=1 (P=0.26), I2=26.77%  
  100.1 50.2 20.5 1  
 
 
Analysis 2.9.   Comparison 2 Nonexperimental studies: highest
versus lowest green tea exposure, Outcome 9 Liver cancer.
Study or subgroup Cases Con-
trols/Non
cases
log[Risk
Ratio]
Risk Ratio Weight Risk Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
2.9.1 Cohort studies  
Inoue 2009b 73 6414 0.2 (0.318) 11.06% 1.18[0.63,2.2]
Inoue 2009b 37 12401 0.4 (0.517) 5.25% 1.48[0.54,4.08]
Nagano 2001 418 38540 -0.1 (0.163) 21.85% 0.95[0.69,1.31]
Nechuta 2012 133 67230 -0.1 (0.221) 16.92% 0.89[0.58,1.38]
Tamura 2018 172 30840 0.2 (0.25) 14.87% 1.25[0.77,2.04]
Ui 2009 247 41761 -0.5 (0.18) 20.33% 0.58[0.41,0.83]
Subtotal (95% CI)       90.28% 0.93[0.71,1.2]
Heterogeneity: Tau2=0.05; Chi2=9.27, df=5(P=0.1); I2=46.09%  
Test for overall effect: Z=0.57(P=0.57)  
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Study or subgroup Cases Con-
trols/Non
cases
log[Risk
Ratio]
Risk Ratio Weight Risk Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
2.9.2 Population-based case-control studies  
Mu 2003 204 415 -0.6 (0.349) 9.72% 0.55[0.28,1.09]
Subtotal (95% CI)       9.72% 0.55[0.28,1.09]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.71(P=0.09)  
   
Total (95% CI)       100% 0.88[0.68,1.14]
Heterogeneity: Tau2=0.05; Chi2=11.03, df=6(P=0.09); I2=45.6%  
Test for overall effect: Z=0.97(P=0.33)  
Test for subgroup differences: Chi2=1.95, df=1 (P=0.16), I2=48.59%  
  100.1 50.2 20.5 1  
 
 
Analysis 2.10.   Comparison 2 Nonexperimental studies: highest
versus lowest green tea exposure, Outcome 10 Pancreatic cancer.
Study or subgroup Cases Con-
trols/Non
cases
log[Risk
Ratio]
Risk Ratio Weight Risk Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
2.10.1 Cohort studies  
Khan 2004 25 3158 -0.7 (0.594) 3.04% 0.5[0.16,1.6]
Lin 2008 292 77850 0.2 (0.195) 9.88% 1.23[0.84,1.8]
Luo 2007 233 102137 0.2 (0.235) 8.8% 1.2[0.76,1.9]
Nagano 2001 122 38540 -0.2 (0.287) 7.49% 0.79[0.45,1.39]
Nakamura 2011 33 14241 0.6 (0.421) 4.95% 1.77[0.78,4.04]
Nakamura 2011 19 16585 -0.5 (0.512) 3.79% 0.59[0.22,1.61]
Nechuta 2012 131 67230 -0 (0.223) 9.1% 0.96[0.62,1.49]
Subtotal (95% CI)       47.05% 1.04[0.84,1.3]
Heterogeneity: Tau2=0.01; Chi2=6.5, df=6(P=0.37); I2=7.62%  
Test for overall effect: Z=0.38(P=0.7)  
   
2.10.2 Population-based case-control studies  
Goto 1990 71 142 -1.1 (0.346) 6.23% 0.34[0.17,0.67]
Ji 1997 246 1552 -0.1 (0.203) 9.65% 0.88[0.59,1.31]
Ji 1997 182 1552 -0.8 (0.252) 8.35% 0.47[0.29,0.77]
Wang 2012c 382 462 -0.4 (0.178) 10.34% 0.68[0.48,0.96]
Wang 2012c 526 605 0 (0.14) 11.37% 1.03[0.78,1.35]
Subtotal (95% CI)       45.94% 0.67[0.48,0.96]
Heterogeneity: Tau2=0.11; Chi2=14.55, df=4(P=0.01); I2=72.51%  
Test for overall effect: Z=2.22(P=0.03)  
   
2.10.3 Hospital-based case-control studies  
Mizuno 1992 124 124 0.7 (0.308) 7.01% 1.94[1.06,3.55]
Subtotal (95% CI)       7.01% 1.94[1.06,3.55]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.15(P=0.03)  
   
Total (95% CI)       100% 0.88[0.7,1.1]
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Study or subgroup Cases Con-
trols/Non
cases
log[Risk
Ratio]
Risk Ratio Weight Risk Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
Heterogeneity: Tau2=0.1; Chi2=32.75, df=12(P=0); I2=63.36%  
Test for overall effect: Z=1.11(P=0.27)  
Test for subgroup differences: Chi2=9.64, df=1 (P=0.01), I2=79.25%  
  100.1 50.2 20.5 1  
 
 
Analysis 2.11.   Comparison 2 Nonexperimental studies: highest
versus lowest green tea exposure, Outcome 11 Biliary tract cancer.
Study or subgroup Cases Con-
trols/Non
cases
log[Risk
Ratio]
Risk Ratio Weight Risk Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
2.11.1 Cohort studies  
Makiuchi 2016 271 89555 -0.4 (0.189) 49.93% 0.67[0.46,0.97]
Nagano 2001 122 38540 0.2 (0.305) 25.38% 1.2[0.66,2.18]
Nechuta 2012 82 67230 -0.3 (0.31) 24.69% 0.73[0.4,1.35]
Subtotal (95% CI)       100% 0.79[0.57,1.11]
Heterogeneity: Tau2=0.02; Chi2=2.68, df=2(P=0.26); I2=25.34%  
Test for overall effect: Z=1.33(P=0.18)  
   
Total (95% CI)       100% 0.79[0.57,1.11]
Heterogeneity: Tau2=0.02; Chi2=2.68, df=2(P=0.26); I2=25.34%  
Test for overall effect: Z=1.33(P=0.18)  
  100.1 50.2 20.5 1  
 
 
Analysis 2.12.   Comparison 2 Nonexperimental studies: highest
versus lowest green tea exposure, Outcome 12 Colorectal cancer.
Study or subgroup Cases Con-
trols/Non
cases
log[Risk
Ratio]
Risk Ratio Weight Risk Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
2.12.1 Cohort studies  
Khan 2004 15 1524 0.3 (0.772) 0.64% 1.3[0.29,5.9]
Khan 2004 14 1634 0.2 (0.663) 0.85% 1.2[0.33,4.4]
Kuriyama 2006 132 40530 0.1 (0.257) 3.41% 1.1[0.66,1.82]
Lee 2007 724 46023 -0 (0.151) 5.26% 0.96[0.71,1.29]
Lee 2007 434 50139 0 (0.192) 4.46% 1.02[0.7,1.49]
Nagano 2001 193 38540 0.3 (0.267) 3.27% 1.3[0.77,2.19]
Nagano 2001 432 38540 0 (0.156) 5.16% 1.03[0.76,1.4]
Nechuta 2012 579 67230 -0.1 (0.106) 6.15% 0.91[0.74,1.12]
Sun 2007 845 61320 0.1 (0.073) 6.72% 1.12[0.97,1.29]
Suzuki 2005 305 65915 -0 (0.169) 4.9% 0.97[0.7,1.35]
Suzuki 2005 211 65915 -0.2 (0.189) 4.53% 0.85[0.59,1.23]
Suzuki 2009 43 12251 -1 (0.804) 0.6% 0.36[0.07,1.74]
Yang 2011a 243 60567 -0.3 (0.138) 5.5% 0.77[0.59,1.01]
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Study or subgroup Cases Con-
trols/Non
cases
log[Risk
Ratio]
Risk Ratio Weight Risk Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
Subtotal (95% CI)       51.44% 1[0.92,1.08]
Heterogeneity: Tau2=0; Chi2=10.55, df=12(P=0.57); I2=0%  
Test for overall effect: Z=0.1(P=0.92)  
   
2.12.2 Population-based case-control studies  
Green 2014 854 948 -0 (0.239) 3.68% 0.99[0.62,1.58]
Ji 1997 426 1552 -0 (0.151) 5.26% 0.99[0.74,1.33]
Ji 1997 402 1552 -0.7 (0.183) 4.63% 0.51[0.36,0.73]
Ji 1997 459 1552 -0.3 (0.163) 5.01% 0.77[0.56,1.06]
Ji 1997 441 1552 -0.2 (0.151) 5.25% 0.82[0.61,1.1]
Kato 1990 91 578 0.3 (0.268) 3.25% 1.32[0.78,2.23]
Kato 1990 132 578 -0.5 (0.203) 4.27% 0.61[0.41,0.91]
Li 2011a 175 175 -0.5 (0.199) 4.35% 0.62[0.42,0.92]
Peng 2013 672 672 -0.6 (0.144) 5.4% 0.54[0.41,0.72]
Subtotal (95% CI)       41.11% 0.74[0.61,0.9]
Heterogeneity: Tau2=0.05; Chi2=20.82, df=8(P=0.01); I2=61.57%  
Test for overall effect: Z=3.03(P=0)  
   
2.12.3 Hospital-based case-control studies  
Gavrilas 2018 151 151 -2 (0.438) 1.68% 0.14[0.06,0.33]
Inoue 1998 362 21128 -0.3 (0.252) 3.48% 0.77[0.47,1.26]
Inoue 1998 266 21128 0.2 (0.356) 2.29% 1.25[0.62,2.51]
Subtotal (95% CI)       7.45% 0.53[0.17,1.6]
Heterogeneity: Tau2=0.84; Chi2=16.35, df=2(P=0); I2=87.77%  
Test for overall effect: Z=1.12(P=0.26)  
   
Total (95% CI)       100% 0.84[0.74,0.96]
Heterogeneity: Tau2=0.06; Chi2=68.44, df=24(P<0.0001); I2=64.93%  
Test for overall effect: Z=2.64(P=0.01)  
Test for subgroup differences: Chi2=8.53, df=1 (P=0.01), I2=76.55%  
  200.05 50.2 1  
 
 
Analysis 2.13.   Comparison 2 Nonexperimental studies: highest
versus lowest green tea exposure, Outcome 13 Colon cancer.
Study or subgroup Cases Con-
trols/Non
cases
log[Risk
Ratio]
Risk Ratio Weight Risk Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
2.13.1 Cohort studies  
Lee 2007 476 46023 -0.1 (0.188) 7.29% 0.92[0.64,1.33]
Lee 2007 284 50139 0.1 (0.231) 4.85% 1.1[0.7,1.73]
Nagano 2001 432 38450 0 (0.156) 10.62% 1.03[0.76,1.4]
Nechuta 2012 355 67230 -0 (0.131) 15.11% 0.96[0.74,1.24]
Oba 2006 102 16585 0.1 (0.246) 4.25% 1.09[0.67,1.76]
Oba 2006 111 14241 -0.3 (0.22) 5.34% 0.75[0.49,1.16]
Suzuki 2005 305 65915 -0 (0.169) 9.06% 0.97[0.7,1.35]
Yang 2011a 133 60567 -0.4 (0.182) 7.77% 0.69[0.48,0.98]
  100.1 50.2 20.5 1  
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Study or subgroup Cases Con-
trols/Non
cases
log[Risk
Ratio]
Risk Ratio Weight Risk Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
Subtotal (95% CI)       64.28% 0.93[0.82,1.05]
Heterogeneity: Tau2=0; Chi2=5.2, df=7(P=0.64); I2=0%  
Test for overall effect: Z=1.18(P=0.24)  
   
2.13.2 Population-based case-control studies  
Green 2014 281 948 -0.1 (0.32) 2.51% 0.95[0.51,1.78]
Green 2014 260 948 -0 (0.377) 1.82% 0.97[0.46,2.03]
Ji 1997 459 1552 -0.3 (0.163) 9.69% 0.77[0.56,1.06]
Ji 1997 426 1552 -0 (0.151) 11.37% 0.99[0.74,1.33]
Kato 1990 132 578 -0.5 (0.203) 6.27% 0.61[0.41,0.91]
Subtotal (95% CI)       31.65% 0.83[0.69,1]
Heterogeneity: Tau2=0; Chi2=4.24, df=4(P=0.37); I2=5.62%  
Test for overall effect: Z=2.01(P=0.04)  
   
2.13.3 Hospital-based case-control studies  
Inoue 1998 362 21128 -0.3 (0.252) 4.06% 0.77[0.47,1.26]
Subtotal (95% CI)       4.06% 0.77[0.47,1.26]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.04(P=0.3)  
   
Total (95% CI)       100% 0.89[0.8,0.98]
Heterogeneity: Tau2=0; Chi2=10.82, df=13(P=0.63); I2=0%  
Test for overall effect: Z=2.32(P=0.02)  
Test for subgroup differences: Chi2=1.36, df=1 (P=0.51), I2=0%  
  100.1 50.2 20.5 1  
 
 
Analysis 2.14.   Comparison 2 Nonexperimental studies: highest
versus lowest green tea exposure, Outcome 14 Rectal cancer.
Study or subgroup Cases Con-
trols/Non
cases
log[Risk
Ratio]
Risk Ratio Weight Risk Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
2.14.1 Cohort studies  
Lee 2007 150 50139 -0.2 (0.325) 5.5% 0.85[0.45,1.61]
Lee 2007 248 46023 0 (0.256) 7.91% 1.04[0.63,1.72]
Nagano 2001 193 38540 0.3 (0.267) 7.42% 1.3[0.77,2.19]
Nechuta 2012 224 67230 -0.2 (0.169) 13.24% 0.84[0.6,1.17]
Suzuki 2005 211 65915 -0.2 (0.189) 11.75% 0.85[0.59,1.23]
Yang 2011a 130 60567 -0.1 (0.21) 10.33% 0.89[0.59,1.34]
Subtotal (95% CI)       56.14% 0.92[0.77,1.09]
Heterogeneity: Tau2=0; Chi2=2.45, df=5(P=0.78); I2=0%  
Test for overall effect: Z=0.95(P=0.34)  
   
2.14.2 Population-based case-control studies  
Green 2014 323 948 0 (0.354) 4.78% 1.05[0.52,2.1]
Ji 1997 402 1552 -0.7 (0.183) 12.15% 0.51[0.36,0.73]
Ji 1997 441 1552 -0.2 (0.151) 14.82% 0.82[0.61,1.1]
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Study or subgroup Cases Con-
trols/Non
cases
log[Risk
Ratio]
Risk Ratio Weight Risk Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
Kato 1990 91 578 0.3 (0.268) 7.37% 1.32[0.78,2.23]
Subtotal (95% CI)       39.12% 0.83[0.56,1.24]
Heterogeneity: Tau2=0.11; Chi2=10.04, df=3(P=0.02); I2=70.12%  
Test for overall effect: Z=0.9(P=0.37)  
   
2.14.3 Hospital-based case-control studies  
Inoue 1998 266 21128 0.2 (0.356) 4.74% 1.25[0.62,2.51]
Subtotal (95% CI)       4.74% 1.25[0.62,2.51]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.63(P=0.53)  
   
Total (95% CI)       100% 0.89[0.75,1.05]
Heterogeneity: Tau2=0.03; Chi2=15.21, df=10(P=0.12); I2=34.27%  
Test for overall effect: Z=1.39(P=0.16)  
Test for subgroup differences: Chi2=0.98, df=1 (P=0.61), I2=0%  
  100.1 50.2 20.5 1  
 
 
Analysis 2.15.   Comparison 2 Nonexperimental studies: highest versus
lowest green tea exposure, Outcome 15 Nasopharyngeal carcinoma.
Study or subgroup Cases Con-
trols/Non
cases
log[Risk
Ratio]
Risk Ratio Weight Risk Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
2.15.1 Population-based case-control studies  
Hsu 2012 368 317 -0.5 (0.204) 35.4% 0.61[0.41,0.91]
Subtotal (95% CI)       35.4% 0.61[0.41,0.91]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=2.42(P=0.02)  
   
2.15.2 Hospital-based case-control studiesCohort studies  
Ruan 2010 733 872 -0.8 (0.102) 64.6% 0.44[0.36,0.54]
Subtotal (95% CI)       64.6% 0.44[0.36,0.54]
Heterogeneity: Not applicable  
Test for overall effect: Z=8.02(P<0.0001)  
   
Total (95% CI)       100% 0.49[0.36,0.67]
Heterogeneity: Tau2=0.03; Chi2=2.05, df=1(P=0.15); I2=51.15%  
Test for overall effect: Z=4.51(P<0.0001)  
Test for subgroup differences: Chi2=2.05, df=1 (P=0.15), I2=51.15%  
  100.1 50.2 20.5 1  
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Analysis 2.16.   Comparison 2 Nonexperimental studies: highest
versus lowest green tea exposure, Outcome 16 Lung cancer.
Study or subgroup Cases Con-
trols/Non
cases
log[Risk
Ratio]
Risk Ratio Weight Risk Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
2.16.1 Cohort studies  
Khan 2004 10 1634 -0.4 (0.725) 0.98% 0.7[0.17,2.9]
Khan 2004 40 1524 -0.5 (0.354) 3.04% 0.6[0.3,1.2]
Kuriyama 2006 218 40530 0.2 (0.192) 5.64% 1.18[0.81,1.72]
Li 2008 302 41440 0.2 (0.163) 6.26% 1.17[0.85,1.61]
Li 2018 964 103010 0.6 (0.355) 3.03% 1.88[0.94,3.77]
Nagano 2001 436 38540 -0.2 (0.149) 6.57% 0.79[0.59,1.06]
Suzuki 2009 88 12251 0.2 (0.736) 0.96% 1.24[0.29,5.25]
Subtotal (95% CI)       26.48% 1.02[0.79,1.31]
Heterogeneity: Tau2=0.04; Chi2=9.75, df=6(P=0.14); I2=38.46%  
Test for overall effect: Z=0.15(P=0.88)  
   
2.16.2 Population-based case-control studies  
Han 2008 523 1924 -0.3 (0.221) 5.05% 0.73[0.48,1.13]
Jin 2013 799 2010 -0.2 (0.097) 7.68% 0.79[0.65,0.95]
Le Marchand 2000 582 82 -0.1 (0.294) 3.82% 0.9[0.51,1.6]
Xu 2013 1225 1234 -1.1 (0.394) 2.63% 0.33[0.15,0.72]
Zhong 2001 504 601 -0.4 (0.185) 5.78% 0.65[0.45,0.93]
Zhong 2001 145 74 -0.1 (0.437) 2.26% 0.94[0.4,2.22]
Subtotal (95% CI)       27.23% 0.73[0.61,0.87]
Heterogeneity: Tau2=0.01; Chi2=5.78, df=5(P=0.33); I2=13.47%  
Test for overall effect: Z=3.48(P=0)  
   
2.16.3 Hospital-based case-control studies  
Bonner 2005 122 121 -0.5 (0.43) 2.32% 0.59[0.25,1.37]
Kubik 2008 383 2178 0.1 (0.158) 6.37% 1.09[0.8,1.49]
Kubik 2008 403 708 -0.1 (0.201) 5.44% 0.93[0.63,1.38]
Kubik 2008 163 2178 -0.1 (0.187) 5.74% 0.88[0.61,1.27]
Kubik 2008 66 708 0.1 (0.335) 3.26% 1.08[0.56,2.08]
Lei 1994 792 792 -0.3 (0.258) 4.39% 0.71[0.43,1.18]
Lin 2012 170 340 -1.8 (0.412) 2.46% 0.17[0.08,0.39]
Takezaki 2001 240 1189 0.1 (0.317) 3.5% 1.14[0.61,2.12]
Takezaki 2001 367 2964 0.3 (0.241) 4.69% 1.33[0.83,2.13]
Takezaki 2001 381 2964 0.1 (0.251) 4.5% 1.08[0.66,1.77]
Takezaki 2001 57 1189 -0.7 (0.557) 1.55% 0.49[0.16,1.46]
Tewes 1990 200 200 1 (0.464) 2.07% 2.74[1.1,6.8]
Subtotal (95% CI)       46.29% 0.9[0.69,1.17]
Heterogeneity: Tau2=0.12; Chi2=29.77, df=11(P=0); I2=63.05%  
Test for overall effect: Z=0.79(P=0.43)  
   
Total (95% CI)       100% 0.88[0.76,1.02]
Heterogeneity: Tau2=0.07; Chi2=53.65, df=24(P=0); I2=55.27%  
Test for overall effect: Z=1.71(P=0.09)  
Test for subgroup differences: Chi2=4.89, df=1 (P=0.09), I2=59.12%  
  200.05 50.2 1  
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Analysis 2.17.   Comparison 2 Nonexperimental studies: highest
versus lowest green tea exposure, Outcome 17 Breast cancer.
Study or subgroup Cases Con-
trols/Non
cases
log[Risk
Ratio]
Risk Ratio Weight Risk Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
2.17.1 Cohort studies  
Dai 2010 614 72861 0.2 (0.159) 7.98% 1.18[0.86,1.61]
Iwasaki 2010a 581 67422 0.1 (0.169) 7.64% 1.12[0.8,1.56]
Key 1999 405 34759 -0.2 (0.174) 7.48% 0.86[0.61,1.21]
Nagano 2001 281 23557 0 (0.222) 6.08% 1.04[0.67,1.6]
Suzuki 2004 222 35004 -0.2 (0.198) 6.76% 0.84[0.57,1.24]
Subtotal (95% CI)       35.94% 1.01[0.86,1.19]
Heterogeneity: Tau2=0; Chi2=3.07, df=4(P=0.55); I2=0%  
Test for overall effect: Z=0.15(P=0.88)  
   
2.17.2 Population-based case-control studies  
Inoue 2008 380 662 0 (0.101) 9.88% 1[0.82,1.22]
Li 2011a 224 224 -0.5 (0.337) 3.73% 0.61[0.32,1.18]
Shrubsole 2009 3371 3380 -0 (0.098) 9.98% 0.97[0.8,1.18]
Wu 2003 501 594 -0.5 (0.215) 6.26% 0.61[0.4,0.93]
Subtotal (95% CI)       29.85% 0.87[0.7,1.08]
Heterogeneity: Tau2=0.02; Chi2=6.09, df=3(P=0.11); I2=50.78%  
Test for overall effect: Z=1.29(P=0.2)  
   
2.17.3 Hospital-based case-control studies  
Iwasaki 2014 405 405 0.2 (0.266) 5.01% 1.27[0.75,2.14]
Li 2016 756 789 0.2 (0.201) 6.66% 1.2[0.81,1.78]
Mizoo 2013 472 464 -0.3 (0.225) 5.99% 0.72[0.46,1.12]
Wang 2013a 157 314 -0.4 (0.204) 6.57% 0.65[0.44,0.97]
Zhang 2007 1009 1009 -0.6 (0.098) 9.98% 0.57[0.47,0.69]
Subtotal (95% CI)       34.21% 0.81[0.58,1.13]
Heterogeneity: Tau2=0.11; Chi2=16.69, df=4(P=0); I2=76.03%  
Test for overall effect: Z=1.24(P=0.22)  
   
Total (95% CI)       100% 0.88[0.75,1.02]
Heterogeneity: Tau2=0.05; Chi2=39.28, df=13(P=0); I2=66.9%  
Test for overall effect: Z=1.67(P=0.09)  
Test for subgroup differences: Chi2=2.12, df=1 (P=0.35), I2=5.64%  
  100.1 50.2 20.5 1  
 
 
Analysis 2.18.   Comparison 2 Nonexperimental studies: highest
versus lowest green tea exposure, Outcome 18 Gynaecological cancer.
Study or subgroup Cases Con-
trols/Non
cases
log[Risk
Ratio]
Risk Ratio Weight Risk Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
2.18.1 Cohort studies  
Shimazu 2008 117 53724 -0.3 (0.281) 7.9% 0.75[0.43,1.3]
Subtotal (95% CI)       7.9% 0.75[0.43,1.3]
Heterogeneity: Not applicable  
  1000.01 100.1 1  
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Study or subgroup Cases Con-
trols/Non
cases
log[Risk
Ratio]
Risk Ratio Weight Risk Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
Test for overall effect: Z=1.03(P=0.31)  
   
2.18.2 Population-based case-control studies  
Bandera 2010 397 373 -0.3 (0.236) 9.95% 0.76[0.48,1.21]
Gao 2005 965 1987 -0.2 (0.112) 19.29% 0.81[0.65,1.01]
Goodman 2003 164 194 -0.1 (0.3) 7.18% 0.9[0.5,1.62]
Kakuta 2009 152 285 -1.1 (0.419) 4.24% 0.33[0.15,0.75]
Leung 2016 104 471 -0.2 (0.223) 10.67% 0.84[0.54,1.3]
Nagle 2010 1368 1462 -0.2 (0.398) 4.61% 0.82[0.38,1.79]
Song 2008 781 1263 -0.8 (0.299) 7.21% 0.47[0.26,0.84]
Xu 2007 1204 1212 -0.2 (0.147) 16.14% 0.8[0.6,1.07]
Zhang 2002 254 261 -0.8 (0.189) 12.81% 0.43[0.3,0.63]
Subtotal (95% CI)       92.1% 0.68[0.56,0.84]
Heterogeneity: Tau2=0.04; Chi2=15.46, df=8(P=0.05); I2=48.25%  
Test for overall effect: Z=3.69(P=0)  
   
Total (95% CI)       100% 0.69[0.57,0.83]
Heterogeneity: Tau2=0.03; Chi2=15.49, df=9(P=0.08); I2=41.88%  
Test for overall effect: Z=3.94(P<0.0001)  
Test for subgroup differences: Chi2=0.1, df=1 (P=0.75), I2=0%  
  1000.01 100.1 1  
 
 
Analysis 2.19.   Comparison 2 Nonexperimental studies: highest
versus lowest green tea exposure, Outcome 19 Endometrial cancer.
Study or subgroup Cases Con-
trols/Non
cases
log[Risk
Ratio]
Risk Ratio Weight Risk Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
2.19.1 Cohort studies  
Shimazu 2008 117 53724 -0.3 (0.281) 8.9% 0.75[0.43,1.3]
Subtotal (95% CI)       8.9% 0.75[0.43,1.3]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.03(P=0.31)  
   
2.19.2 Population-based case-control studies  
Bandera 2010 397 373 -0.3 (0.236) 12.37% 0.76[0.48,1.21]
Gao 2005 965 1987 -0.2 (0.112) 45.43% 0.81[0.65,1.01]
Kakuta 2009 152 285 -1.1 (0.419) 4.09% 0.33[0.15,0.75]
Xu 2007 1204 1212 -0.2 (0.147) 29.21% 0.8[0.6,1.07]
Subtotal (95% CI)       91.1% 0.75[0.61,0.94]
Heterogeneity: Tau2=0.02; Chi2=4.36, df=3(P=0.23); I2=31.21%  
Test for overall effect: Z=2.57(P=0.01)  
   
Total (95% CI)       100% 0.77[0.65,0.91]
Heterogeneity: Tau2=0; Chi2=4.37, df=4(P=0.36); I2=8.52%  
Test for overall effect: Z=3.1(P=0)  
Test for subgroup differences: Chi2=0, df=1 (P=0.99), I2=0%  
  100.1 50.2 20.5 1  
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Analysis 2.20.   Comparison 2 Nonexperimental studies: highest
versus lowest green tea exposure, Outcome 20 Ovarian cancer.
Study or subgroup Cases Con-
trols/Non
cases
log[Risk
Ratio]
Risk Ratio Weight Risk Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
2.20.1 Population-based case-control studies  
Goodman 2003 164 194 -0.1 (0.3) 18.11% 0.9[0.5,1.62]
Leung 2016 104 471 -0.2 (0.223) 23.98% 0.84[0.54,1.3]
Nagle 2010 1368 1462 -0.2 (0.398) 12.78% 0.82[0.38,1.79]
Song 2008 781 1263 -0.8 (0.299) 18.16% 0.47[0.26,0.84]
Zhang 2002 254 261 -0.8 (0.189) 26.98% 0.43[0.3,0.63]
Subtotal (95% CI)       100% 0.64[0.45,0.9]
Heterogeneity: Tau2=0.07; Chi2=8.29, df=4(P=0.08); I2=51.74%  
Test for overall effect: Z=2.6(P=0.01)  
   
Total (95% CI)       100% 0.64[0.45,0.9]
Heterogeneity: Tau2=0.07; Chi2=8.29, df=4(P=0.08); I2=51.74%  
Test for overall effect: Z=2.6(P=0.01)  
  100.1 50.2 20.5 1  
 
 
Analysis 2.21.   Comparison 2 Nonexperimental studies: highest
versus lowest green tea exposure, Outcome 21 Prostate cancer.
Study or subgroup Cases Con-
trols/Non
cases
log[Risk
Ratio]
Risk Ratio Weight Risk Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
2.21.1 Cohort studies  
Allen 2004 193 18115 0.3 (0.219) 8.77% 1.29[0.84,1.98]
Kikuchi 2006 110 18961 -0.2 (0.265) 7.86% 0.85[0.51,1.43]
Kurahashi 2007 404 49920 -0.1 (0.157) 9.98% 0.89[0.65,1.21]
Montague 2012 298 27293 0.1 (0.16) 9.92% 1.08[0.79,1.48]
Severson 1989 174 7821 0.4 (0.203) 9.1% 1.47[0.99,2.19]
Subtotal (95% CI)       45.63% 1.09[0.89,1.32]
Heterogeneity: Tau2=0.01; Chi2=5.34, df=4(P=0.25); I2=25.09%  
Test for overall effect: Z=0.83(P=0.4)  
   
2.21.2 Population-based case-control studies  
Li 2014 250 500 -0.5 (0.198) 9.18% 0.59[0.4,0.87]
Subtotal (95% CI)       9.18% 0.59[0.4,0.87]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.66(P=0.01)  
   
2.21.3 Hospital-based case-control studies  
Berroukche 2012 160 160 -0.5 (0.309) 7.04% 0.6[0.33,1.1]
Jian 2004 130 274 -1.3 (0.264) 7.88% 0.28[0.17,0.47]
Lassed 2016 90 190 -0.9 (0.8) 2.16% 0.4[0.08,1.92]
Lee 2017 404 395 -0.5 (0.25) 8.15% 0.6[0.37,0.98]
Sonoda 2004 140 140 -0.4 (0.457) 4.8% 0.67[0.27,1.64]
  200.05 50.2 1  
Green tea (Camellia sinensis) for the prevention of cancer (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
196
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Study or subgroup Cases Con-
trols/Non
cases
log[Risk
Ratio]
Risk Ratio Weight Risk Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
Tse 2017 431 402 -0.6 (0.248) 8.2% 0.56[0.34,0.91]
Wu 2009a 142 142 -0.7 (0.314) 6.95% 0.52[0.28,0.96]
Subtotal (95% CI)       45.19% 0.5[0.39,0.63]
Heterogeneity: Tau2=0.01; Chi2=6.4, df=6(P=0.38); I2=6.28%  
Test for overall effect: Z=5.72(P<0.0001)  
   
Total (95% CI)       100% 0.73[0.56,0.94]
Heterogeneity: Tau2=0.15; Chi2=43.09, df=12(P<0.0001); I2=72.15%  
Test for overall effect: Z=2.44(P=0.01)  
Test for subgroup differences: Chi2=26.49, df=1 (P<0.0001), I2=92.45%  
  200.05 50.2 1  
 
 
Analysis 2.22.   Comparison 2 Nonexperimental studies: highest
versus lowest green tea exposure, Outcome 22 Renal cancer.
Study or subgroup Cases Con-
trols/Non
cases
log[Risk
Ratio]
Risk Ratio Weight Risk Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
2.22.1 Hospital-based case-control studies  
Wang 2012a 250 299 -1.1 (0.246) 100% 0.34[0.21,0.55]
Subtotal (95% CI)       100% 0.34[0.21,0.55]
Heterogeneity: Not applicable  
Test for overall effect: Z=4.39(P<0.0001)  
   
Total (95% CI)       100% 0.34[0.21,0.55]
Heterogeneity: Not applicable  
Test for overall effect: Z=4.39(P<0.0001)  
  100.1 50.2 20.5 1  
 
 
Analysis 2.23.   Comparison 2 Nonexperimental studies: highest
versus lowest green tea exposure, Outcome 23 Urinary tract cancer.
Study or subgroup Cases Con-
trols/Non
cases
log[Risk
Ratio]
Risk Ratio Weight Risk Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
2.23.1 Cohort studies  
Chyou 1993 96 7991 0.3 (0.27) 12.28% 1.34[0.79,2.27]
Kurahashi 2009 164 49566 -0.1 (0.242) 13.44% 0.9[0.56,1.45]
Kurahashi 2009 42 54874 0.8 (0.39) 8.25% 2.29[1.07,4.92]
Nagano 2001 122 38540 0.1 (0.315) 10.55% 1.13[0.61,2.1]
Subtotal (95% CI)       44.53% 1.24[0.87,1.76]
Heterogeneity: Tau2=0.04; Chi2=4.36, df=3(P=0.23); I2=31.13%  
Test for overall effect: Z=1.2(P=0.23)  
   
  100.1 50.2 20.5 1  
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Study or subgroup Cases Con-
trols/Non
cases
log[Risk
Ratio]
Risk Ratio Weight Risk Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
2.23.2 Population-based case-control studies  
Wilkens 1996 195 390 0.2 (0.343) 9.63% 1.17[0.6,2.3]
Wilkens 1996 66 132 -0.1 (0.551) 5.08% 0.88[0.3,2.6]
Subtotal (95% CI)       14.72% 1.08[0.61,1.92]
Heterogeneity: Tau2=0; Chi2=0.19, df=1(P=0.66); I2=0%  
Test for overall effect: Z=0.28(P=0.78)  
   
2.23.3 Hospital-based case-control studies  
Hemelt 2010 419 392 0 (0.19) 15.85% 1.02[0.7,1.48]
Wakai 2004 124 620 0.2 (0.449) 6.86% 1.24[0.51,2.99]
Wang 2013b 1007 1299 -0.5 (0.144) 18.05% 0.6[0.45,0.79]
Subtotal (95% CI)       40.75% 0.84[0.53,1.32]
Heterogeneity: Tau2=0.1; Chi2=6.43, df=2(P=0.04); I2=68.88%  
Test for overall effect: Z=0.77(P=0.44)  
   
Total (95% CI)       100% 1.04[0.79,1.37]
Heterogeneity: Tau2=0.09; Chi2=18.2, df=8(P=0.02); I2=56.03%  
Test for overall effect: Z=0.26(P=0.79)  
Test for subgroup differences: Chi2=1.8, df=1 (P=0.41), I2=0%  
  100.1 50.2 20.5 1  
 
 
Analysis 2.24.   Comparison 2 Nonexperimental studies: highest
versus lowest green tea exposure, Outcome 24 Hematopoietic cancer.
Study or subgroup Cases Con-
trols/Non
cases
log[Risk
Ratio]
Risk Ratio Weight Risk Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
2.24.1 Cohort studies  
Nagano 2001 188 38540 -0 (0.247) 48.52% 0.99[0.61,1.61]
Naganuma 2009 157 41761 -0.5 (0.229) 51.48% 0.58[0.37,0.91]
Subtotal (95% CI)       100% 0.75[0.45,1.27]
Heterogeneity: Tau2=0.09; Chi2=2.51, df=1(P=0.11); I2=60.22%  
Test for overall effect: Z=1.07(P=0.29)  
   
Total (95% CI)       100% 0.75[0.45,1.27]
Heterogeneity: Tau2=0.09; Chi2=2.51, df=1(P=0.11); I2=60.22%  
Test for overall effect: Z=1.07(P=0.29)  
  100.1 50.2 20.5 1  
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Analysis 2.25.   Comparison 2 Nonexperimental studies: highest
versus lowest green tea exposure, Outcome 25 Leukaemia.
Study or subgroup Cases Con-
trols/Non
cases
log[Risk
Ratio]
Risk Ratio Weight Risk Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
2.25.1 Cohort studies - acute myeloid leukaemia  
Ugai 2018 85 95807 0.2 (0.337) 19.86% 1.2[0.62,2.32]
Subtotal (95% CI)       19.86% 1.2[0.62,2.32]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.54(P=0.59)  
   
2.25.2 Population-based case-control studies - all leukaemia  
Kuo 2009 72 147 -0.3 (0.421) 14.21% 0.73[0.32,1.67]
Li 2011a 26 540 0.4 (0.476) 11.62% 1.55[0.61,3.94]
Subtotal (95% CI)       25.82% 1.03[0.5,2.14]
Heterogeneity: Tau2=0.08; Chi2=1.4, df=1(P=0.24); I2=28.34%  
Test for overall effect: Z=0.08(P=0.94)  
   
2.25.3 Hospital-based case-control studies - all leukaemia  
Liu 2017 442 442 -0.3 (0.222) 33.38% 0.71[0.46,1.1]
Zhang 2008 107 110 -0.7 (0.325) 20.94% 0.51[0.27,0.96]
Subtotal (95% CI)       54.32% 0.64[0.45,0.91]
Heterogeneity: Tau2=0; Chi2=0.71, df=1(P=0.4); I2=0%  
Test for overall effect: Z=2.45(P=0.01)  
   
Total (95% CI)       100% 0.81[0.57,1.15]
Heterogeneity: Tau2=0.05; Chi2=5.63, df=4(P=0.23); I2=28.95%  
Test for overall effect: Z=1.2(P=0.23)  
Test for subgroup differences: Chi2=3.38, df=1 (P=0.18), I2=40.76%  
  100.1 50.2 20.5 1  
 
 
Analysis 2.26.   Comparison 2 Nonexperimental studies: highest
versus lowest green tea exposure, Outcome 26 Lymphoma.
Study or subgroup Cases Con-
trols/Non
cases
log[Risk
Ratio]
Risk Ratio Weight Risk Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
2.26.1 Cohort studies  
Ugai 2017 411 95807 -0.1 (0.193) 100% 0.89[0.61,1.3]
Subtotal (95% CI)       100% 0.89[0.61,1.3]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.6(P=0.55)  
   
Total (95% CI)       100% 0.89[0.61,1.3]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.6(P=0.55)  
  100.1 50.2 20.5 1  
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Analysis 2.27.   Comparison 2 Nonexperimental studies: highest
versus lowest green tea exposure, Outcome 27 Multiple myeloma.
Study or subgroup Cases Con-
trols/Non
cases
log[Risk
Ratio]
Risk Ratio Weight Risk Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
2.27.1 Cohort studies  
Ugai 2017 138 95807 -0.3 (0.329) 41.25% 0.74[0.39,1.41]
Subtotal (95% CI)       41.25% 0.74[0.39,1.41]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.92(P=0.36)  
   
2.27.2 Hospital-based case-control studies  
Wang 2012b 220 220 -1 (0.174) 58.75% 0.38[0.27,0.53]
Subtotal (95% CI)       58.75% 0.38[0.27,0.53]
Heterogeneity: Not applicable  
Test for overall effect: Z=5.55(P<0.0001)  
   
Total (95% CI)       100% 0.5[0.26,0.95]
Heterogeneity: Tau2=0.15; Chi2=3.21, df=1(P=0.07); I2=68.8%  
Test for overall effect: Z=2.11(P=0.03)  
Test for subgroup differences: Chi2=3.21, df=1 (P=0.07), I2=68.8%  
  100.1 50.2 20.5 1  
 
 
Analysis 2.28.   Comparison 2 Nonexperimental studies: highest versus
lowest green tea exposure, Outcome 28 Non-melanoma skin cancer.
Study or subgroup Cases Con-
trols/Non
cases
log[Risk
Ratio]
Risk Ratio Weight Risk Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
2.28.1 Population-based case-control studies  
Hakim 2000 234 216 -0.2 (0.429) 100% 0.82[0.35,1.9]
Subtotal (95% CI)       100% 0.82[0.35,1.9]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.46(P=0.64)  
   
Total (95% CI)       100% 0.82[0.35,1.9]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.46(P=0.64)  
  100.1 50.2 20.5 1  
 
 
Analysis 2.29.   Comparison 2 Nonexperimental studies: highest
versus lowest green tea exposure, Outcome 29 Thyroid cancer.
Study or subgroup Cases Con-
trols/Non
cases
log[Risk
Ratio]
Risk Ratio Weight Risk Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
2.29.1 Cohort studies  
  100.1 50.2 20.5 1  
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Study or subgroup Cases Con-
trols/Non
cases
log[Risk
Ratio]
Risk Ratio Weight Risk Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
Michikawa 2011 26 48802 -0.3 (0.595) 14.76% 0.71[0.22,2.28]
Michikawa 2011 133 51705 -0.1 (0.248) 85.24% 0.91[0.56,1.48]
Subtotal (95% CI)       100% 0.88[0.56,1.37]
Heterogeneity: Tau2=0; Chi2=0.15, df=1(P=0.7); I2=0%  
Test for overall effect: Z=0.57(P=0.57)  
   
Total (95% CI)       100% 0.88[0.56,1.37]
Heterogeneity: Tau2=0; Chi2=0.15, df=1(P=0.7); I2=0%  
Test for overall effect: Z=0.57(P=0.57)  
  100.1 50.2 20.5 1  
 
 
Analysis 2.30.   Comparison 2 Nonexperimental studies: highest
versus lowest green tea exposure, Outcome 30 Brain cancer.
Study or subgroup Cases Con-
trols/Non
cases
log[Risk
Ratio]
Risk Ratio Weight Risk Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
2.30.1 Cohort studies  
Ogawa 2016 155 106324 0.1 (0.212) 100% 1.07[0.71,1.62]
Subtotal (95% CI)       100% 1.07[0.71,1.62]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.32(P=0.75)  
   
Total (95% CI)       100% 1.07[0.71,1.62]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.32(P=0.75)  
  100.1 50.2 20.5 1  
 
 
A D D I T I O N A L   T A B L E S
 
Study Country Target
cancer
Outcomes Partici-
pants
Intervention Duration
Bettuzzi
2006
Italy Prostate
cancer
Prostate cancer inci-
dence
LUTS
PSA values
QoL
Safety data
60 men Green tea total catechins
600 mg/day = EGCG: ˜300 mg/day
12
months
Dostal
2015
USA Breast
cancer
Breast cancer biomark-
ers
1075
women
Green tea total catechins:
1315 (± 116) mg/day
12
months
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Circulating F2-iso-
prostane levels
Oestrogen metabolite
levels
Non-melanoma skin
cancer
Uterine cancer
Safety data
= EGCG:
843 (± 44) mg/day
Dryden
2013
USA - Ulcerative disease ac-
tivity
QoL
Safety data
20 men
and
women
Green tea extracts: Polyphenon E =
EGCG:
200 mg or 400 mg/day
56 days
Garcia
2014
USA Cervical
cancer
Oncogenic HPV clear-
ance
CIN1 clearance
Safety data
98 women Green tea extracts: Polyphenon E =
EGCG: 800 mg/day
4 months
Garland
2006
USA Lung can-
cer
Biomarkers of oxidative
stress
Safety data
178 (89
men
and 89
women)
Green tea extracts: Polyphenon E =
ECGC 800 mg/day
6 months
Kumar
2015
USA Prostate
cancer
Prostate cancer inci-
dence
Safety data
97 men Green tea extracts: Polyphenon E =
EGCG: 400 mg/day
12
months
Lane 2018 UK Prostate
cancer
PSA levels
Clinical outcome
(weight and blood pres-
sure)
Safety data
88 men Green tea extracts = EGCG: 600 mg/
day
6 months
Micali
2017
Italy Prostate
cancer
Prostate cancer inci-
dence
PSA levels
QoL
Safety data
60 men Green tea extracts 600 mg = EGCG:
300 mg/day
12
months
Roshdy
2013
Egypt Uterine fi-
broids
Severity of symptoms
QoL
Safety data
39 women Green tea extracts = EGCG: ˜400 mg/
day
4 months
Sinicrope
2017
USA Colon
cancer
Change in rectal aber-
rant crypt foci
39 (14
men
Green tea extracts = EGCG: 400 mg/
day
6 months
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Safety data and 25
women)
Tsao 2009 Japan Oral can-
cer
Histological response
Safety data
41 (19
men
and 22
women)
Green tea extracts 500, 750 or 1000
mg/day
12 weeks
Shannon
2010
USA Prostate
cancer
Prostate cancer inci-
dence
Immunoistochemical
response
67 men
out of 120
planned
Green tea polyphenols = EGCG ˜600
mg/day)
12 weeks
NCT01496521China Oe-
sophageal
cancer
Oesophageal cancer in-
cidence
Occurrence of high
grade dysplasia
Invasive oesophageal
squamous cell carcino-
ma
Not re-
ported
Tea polyphenols 600 mg/day 12
months
EGCG: (–)-epigallocatechin-3-gallate; CIN: cervical intraepithelial neoplasia; HPV: human papillomavirus LUTS: lower urinary tract
symptoms; PSA: prostate-specific antigens; QoL: quality of life
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Study Country Cohort Cancer Outcome Partici-
pants
Cases
Allen 2004 Japan Life Span Study Prostate Incidence 18,115
men
193
Chyou 1993 USA Honolulu Hearth Program Bladder Incidence 7991 men 96
Dai 2010 China Shangai Women's Health
Study
Breast Incidence 72,861 614
Fujino 2002 in: Inoue
2009a
Japan JACC Study Stomach Incidence 44,930 379
Galanis 1998 USA Hawaii Health Surveillance
Program
Stomach Incidence 11,907 108
Hoshiyama 2002 in:
Inoue 2009a
Japan JACC Study Stomach Mortality 44,930 359
Ide 2007 Japan JACC Study Oral Incidence 50,221 37
Inoue 2009a Japan JACC, JPHC-I, JPHC-II, MIYAGI,
3-pref MIYAGI, and 3-pref AICHI
Studies
Stomach Incidence 219,080 3577
Inoue 2009b Japan JPHC-II Study Liver Incidence 18,815 110
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Ishikawa 2006 Japan MIYAGI and 3-pref MIYAGI Stud-
ies
Oesophageal Incidence 26,723 78
Iwai 2002 Japan JACC Study Any cancer Mortality 2855 31
Iwasaki 2010a Japan JPHC-I and JPHC-II Studies Breast Incidence 67,422 581
Iwasaki 2010b in:
Iwasaki 2010a
Japan JPHC-I and JPHC-II Studies Breast Incidence 67,422 144
Key 1999 Japan Life Span Study Breast Incidence 34,765 405
Khan 2004 Japan Public Health Centers in
Hokkaido Prefecture
Any cancer
Lung
Stomach
Colorectal
Pancreatic
Mortality 3158 243
51
51
29
25
Kikuchi 2006 Japan Ohsaki Cohort Study Prostate Incidence 18,961 110
Koizumi 2003 in:
Inoue 2009a
Japan MIYAGI and 3-pref MIYAGI Stud-
ies
Stomach Incidence 65,915 733
Kurahashi 2007 Japan JPHC-I and JPHC-II Studies Prostate Incidence 49,920 404
Kurahashi 2009 Japan JPHC-I and JPHC-II Studies Bladder Incidence 104,440 206
Kuriyama 2006 Japan Ohsaki Cohort Study Any cancer
Lung
Stomach
Colorectal
Mortality 40,530 1134
218
193
132
Lee 2007 Japan JPHC-I and JPHC-II Studies Colorectal Incidence 96,162 1158
Li 2008 Japan Ohsaki Cohort Study Lung Incidence 41,440 302
Li 2018 China Kailuan Cohort Lung Incidence 103,010 964
Lin 2008 Japan JACC Study Pancreatic Mortality 77,850 292
Liu 2016 China Chinese Prospective Smoking
Study
Any cancer Mortality 164,681 7002
Luo 2007 Japan JPHC-I and JPHC-II Studies Pancreatic Incidence 102,137 233
Makiuchi 2016 Japan JPHC-I and JPHC-II Studies Biliary tract Incidence 140,420 271
Michikawa 2011 Japan JPHC-I and JPHC-II Studies Thyroid Incidence 100,507 159
Montague 2012 China Singapore Chinese Health
Study
Prostate Incidence 27,293 298
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Nagano 2001 Japan Life Span Study Any cancer and
several specific
types
Incidence 38,540 4049
Naganuma 2009 Japan Ohsaki Cohort Study Hematopoitic Incidence 41,761 157
Nakachi 2000 Japan Saitama Prefecture Any cancer Incidence 8552 488
Nakamura 2011 Japan Takayama and Gigu Prefec-
tures
Pancreatic Mortality 30,826 52
Nechuta 2012 China Shangai Women's Health
Study
Digestive system Incidence 67,230 1239
Oba 2006 Japan Takayama and Gigu Prefec-
tures
Colon Incidence 30,836 213
Odegaard 2015 China Singapore Chinese Health
Study
Any cancer Mortality 52,584 4092
Ogawa 2016 Japan JPHC-I and JPHC-II Studies Brain Incidence 106,324 155
Saito 2015 Japan JPHC-I and JPHC-II Studies Any cancer Mortality 90,914 5327
Sasazuki 2004 in:
Inoue 2009a
Japan JPHC-I and JPHC-II Studies Stomach Incidence 72,943 892
Sauvaget 2005 in:
Nagano 2001
Japan Life Span Study Stomach Incidence 38,576 1270
Severson 1989 USA Honolulu Hearth Program Prostate Incidence 7821 174
Shimazu 2008 Japan JPHC-I and JPHC-II Studies Endometrial Incidence 53,724 117
Sun 2007 China Singapore Chinese Health
Study
Colorectal Incidence 61,320 845
Suzuki 2004 Japan MIYAGI and 3-pref MIYAGI Stud-
ies
Breast Incidence 35,004 222
Suzuki 2005 Japan MIYAGI and 3-pref MIYAGI Stud-
ies
Colorectal Incidence 65,915 516
Suzuki 2009 Japan Prospective Shizuoka Elderly
Cohort
Any cancer
Stomach
Lung
Colorectal
Mortality 12,251 400
68
88
43
Tamura 2018 Japan Takayama and Gigu Prefec-
tures
Liver Incidence 30,824 172
Tsubono 2001 in:
Inoue 2009a
Japan 3-pref MIYAGI Study Stomach Incidence 26,311 419
Ugai 2017 Japan JPHC-I and JPHC-II Studies Lymphoma Incidence 95,807 411
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Multiple myelo-
ma
138
Ugai 2018 Japan JPHC-I and JPHC-II Studies Acute myeloid
leukaemia
Incidence 95,807 85
Ui 2009 Japan Ohsaki Cohort Study Liver Incidence 41,761 247
Yang 2007 in:
Nechuta 2012
China Shangai Women's Health
Study
Colorectal Incidence 69,710 256
Yang 2011a China Shangai Men's Health Study Colorectal Incidence 60,567 243
Zhao 2017 China Shangai Women's Health
Study and
Shangai Men's Health Study
Any cancer Incidence 115,954 3210
Table 2.   Summary characteristics of cohort studies  (Continued)
 
 
Study Country Study
type
Cancer Cases/
Controls
Sex
Bandera 2010 USA PCC Endometrial 397/373 Women
Berroukche 2012 Algeria HCC Prostate 160/160 Men
Bonner 2005 China PCC Lung 122/121 Both
Chen 2011 China HCC Oesophageal 150/300 Both
Chen 2015 in: Chen 2017a China HCC Oral 203/572 Both
Chen 2016 in: Chen 2017a China HCC Oral 207/480 Women
Chen 2017a China HCC Oral 586/1024 Both
Fu 2013 China HCC Oral 723/857 Both
Gao 1994 China PCC Oesophageal 902/1312 Both
Gao 2005 China PCC Endometrial 955/1087 Women
Gavrilas 2018 Romania HCC Colorectal 151/151 Both
Goodman 2003 USA PCC Ovarian 164/194 Women
Goto 1990 Japan PCC Pancreatic 71/142 Both
Green 2014 Australia PCC Colorectal 854/948 Both
Hakim 2000 USA PCC Skin 243/216 Both
Han 2008 China PCC Lung 523/1924 Both
Table 3.   Summary characteristics of case-control studies 
Green tea (Camellia sinensis) for the prevention of cancer (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
206
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Hemelt 2010 China HCC Bladder 419/392 Both
Hoshiyama 1992 Japan PCC Stomach 251/483 Men
Hoshiyama 2004 in: Inoue
2009a
Japan Nested
case-co-
hort
Stomach 151/256 Both
Hsu 2012 China PCC Nasopharyngeal 368/317 Both
Huang 1999 Japan HCC Stomach 887/28,619 Both
Inoue 1994 in: Huang 1999 Japan HCC Stomach 668/668 Both
Inoue 1998 Japan HCC Oesophageal
Stomach
Colorectal
1706/21,128 Both
Inoue 2008 China PCC Breast 380/662 Women
Islami 2009 Iran PCC Oesophageal 266/571 Both
Iwasaki 2014 Japan HCC Breast 369/405 Both
Ji 1996 China PCC Stomach 1029/1347 Both
Ji 1997 China PCC Colorectal
Pancreatic
2156/1552 Both
Jia 2016 China CC Lung
Mesothelioma
53/106 Both
Jian 2004 China HCC Prostate 130/274 Men
Jin 2013 China PCC Lung 799/2020 Both
Kakuta 2009 Japan PCC Endometrial 152/285 Women
Kato 1990 Japan HCC Colorectal 221/578 Both
Kato 1990a in: Huang 1999 Japan HCC Stomach 427/3014 Both
Kono 1988 Japan PCC/HCC Stomach 139/278
139/2575
Both
Kubik 2004 in: Kubik 2008 Czech Repub-
lic
HCC Lung 435/1710 Women
Kubik 2008 Czech Repub-
lic
HCC Lung 1096/2966 Both
Kuo 2009 China PCC Leukaemia 93/223 Both
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Lassed 2016 Algeria HCC Prostate 90/190 Men
Lee 2017 China HCC Prostate 404/395 Men
Lei 1994 China HCC Lung 792/792 Both
Le Marchand 2000 USA PCC Lung 582/582 Both
Leung 2016 China PCC Ovarian 104/471 Women
Li 2011a China PCC/HCC Any cancer
Breast
Colorectal
Leukaemia
425/540
425/540
Both
Li 2011b in: Mu 2003 China PCC Liver 204/415 Both
Li 2014 China PCC Prostate 250/500 Men
Li 2016 China HCC Breast 756/789 Women
Lin 2012 China HCC Lung 170/340 Both
Liu 2010 China PCC Stomach 641/1847 Both
Liu 2017 China HCC Leukaemia 442/442 Both
Mao 2011 China HCC Stomach 200/200 Both
Mizoo 2013 Japan HCC Breast 472/464 Women
Mizuno 1992 Japan HCC Pancreatic 124/124 Both
Mu 2003 China HCC Stomach
Liver
Oespphagus
628/415 Both
Mu 2005 in: Mu 2003 China PCC Stomach 206/415 Both
Nagle 2010 Australia PCC Ovarian 1368/1462 Women
Oze 2014 Japan PCC Upper digestive system 922/2883 Both
Peng 2013 China PCC Colorectal 672/672 Both
Peng 2015 China PCC Oesphageal 285/570 Both
Ruan 2010 China HCC Nasopharyngeal 1355/1459 Both
Setiawan 2001 China PCC Stomach 133/433 Both
Shrubsole 2009 China PCC Breast 3371/3380 Women
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Song 2008 USA PCC Ovarian 781/1263 Women
Sonoda 2004 Japan HCC Prostate 140/140 Men
Tajima 1985 Japan HCC Stomach 93/93 Both
Takezaki 2000 Japan HCC Pharynx
Oesophageal
346/11,936 Both
Takezaki 2001 Japan HCC Lung 945/4153 Both
Tewes 1990 China HCC Lung 200/200 Women
Tse 2017 China HCC Prostate 431/402 Men
Wakai 2004 Japan HCC Bladder 124/620 Both
Wang 1999 China PCC Oesophageal and stomach 209/209 Both
Wang 2006 China PCC Oesophageal 107/107 Both
Wang 2007 China PCC Oesophageal 355/209 Both
Wang 2012a China HCC Renal 250/299 Both
Wang 2012b China HCC Multiple myeloma 220/220 Both
Wang 2012c China PCC Pancreatic 908/1067 Both
Wang 2013a China HCC Breast 157/314 Women
Wang 2013b USA HCC Bladder 1007/1299 Both
Wang 2015 China HCC Stomach 160/320 Both
Wilkens 1996 USA PCC Bladder 261/522 Both
Wu 2003 USA PCC Breast 501/594 Women
Wu 2009a China HCC Prostate 142/142 Men
Wu 2009b China PCC Oesophageal 1,502/3,879 Both
Xu 2007 China PCC Endometrial 1204/1212 Women
Xu 2013 China PCC Lung 1225/1234 Both
Yan 2016 China PCC Oral 593/1128 Both
Ye 1998 China PCC Stomach 272/544 Both
Yu 1995 China PCC Stomach 711/711 Both
Zhang 2002 China PCC/HCC Ovarian 254/261
254/340
Women
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Zhang 2007 China HCC Breast 1009/1009 Women
Zhang 2008 China HCC Leukaemia 107/110 Both
Zheng 1993 China HCC Oral 404/404 Both
Zhong 2001 China PCC Lung 649/675 Both
HCC: hospital-based case-control study; PCC: population-based case-control study
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References Detailed results
Bettuzzi 2006 Prostate cancer incidence
Bettuzzi 2006: one prostate cancer case in the treatment group and 9 cases in the placebo group
Brausi 2008 reported a longer follow-up on a subset of participants: 13 cases in the intervention
group and 9 in the placebo group, all after the suspension of the treatment. Further 3 cases of
prostate cancer were diagnosed, 1 in the treatment group and 2 cases in the placebo group
LUTS: a slightly higher decrease in IPSS was found in the treatment group from 11.12 to 9.12, than
in the placebo group, from 8.27 to 7.00
PSA levels: no substantial difference in the PSA levels between groups
QoL: QoL score assessed after 3 months decreased in the intervention group (from 2.06 to 1.76),
while slightly increased in the placebo group (from 1.30 to 1.47)
Safety data: 2 cases of diarrhoea in each arm, reported as very mild disorders
Dostal 2015 Dostal 2015
Follow-up: 59 participants (39 in the intervention and 20 in the control group) stopped taking study
product but remained in the study. Participants stopped mainly due to adverse symptoms (N = 50).
Dropout: 138 participants withdrew from the study due to request (N = 93), adverse event (N = 22),
protocol violation (N = 10), lost to follow-up (N = 10), investigator judgment (N = 3) and death (N =
1). 18 of 22 (82%) who withdrew to adverse events were in the intervention group.
Cancer incidence: 2 participants in the placebo group were diagnosed with uterine cancer after
randomisation, 1 woman 1 day after beginning study product (for this reason not included in the
risk analysis) and the other during the last month of participation. 2 women (1 in the treatment and
1 in the placebo group) reported a diagnosis of non-melanoma skin cancer during the study.
Safety data: total 1141 adverse events documented in the intervention group and 1031 in the
placebo group. The most common events were infections; gastrointestinal disorders (nausea, indi-
gestion, diarrhoea, constipation, vomiting, increased gassiness, abdominal pain, increased acid re-
flux); vascular disorders; respiratory, thoracic and mediastinal disorders; general disorders and ad-
ministration site condition; musculoskeletal and connective tissue disorders, mainly of grade 1 and
2 of severity. Higher adverse effects in intervention groups were skin and subcutaneous tissue dis-
orders (mainly rash or allergic skin reaction), ALT elevations and nausea and partially indigestion
and constipation. Groups did not differ in severity of adverse effects.
Yu 2017 in: Dostal 2015
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Follow-up: in the present report data on 513 men in the intervention group and 508 women in the
control group are reported, due to missing data of ALT at baseline (N = 3) or during follow-up (N =
51).
Treatment increased both ALT and AST, whereas no increase was reported in the control group.
AKP and total bilirubin did not increase in both treatment and control group.
Webster 2018 in: Dostal 2015
QoL: data on overall QoL of recruited women. QoL assessed using MENQOL scale showed overall
scores higher in women aged 50-54.9 years
Dryden 2013 Follow-up: 10 participants randomised in cohort 1:8 to treatment group (low-dose) and 2 to place-
bo: 10 participants randomised in cohort 2: 8 to treatment group (high-dose) and 2 in placebo
Safety data: no participants required termination due to serious adverse event. 1 participant in the
treatment group required hospitalisation due to disease progression. Higher incidence of heart-
burn, increased thirst and increased diarrhoea were found in treatment group.
QoL: measured with the Inflammatory Bowel Disease Questionnaire, QoL generally inversely corre-
lated with the activity of the disease.
Garcia 2014 Follow-up: 82 participants (41 in the intervention and 41 in the control group) analysed for primary
outcome
Primary outcome
Complete response (negative high-risk HPV and normal histopathology) was noted in 7 (17.1%) and
6 (14.6%) for the treatment and control group, respectively
Partial response (negative high-risk HPV and evidence of low-grade CIN) occurred more frequently
in the control group, 1 (2.4%) vs. 614.6%)
Progression/negative response (persistence of high-risk HPV+ and worsening of CIN or invasive
cancer) was more common in the treatment group, 6 (14.6%) vs 3 (7.3%)
No response (persistence of high-risk HPV+ with no progression similar to intervention and control
group, 27 (65.9%) vs. 26 (63.4%)
Secondary outcome
Safety data: 163 and 136 adverse events in the control and in the intervention group. 2 serious
events occurred in 1 participant in the placebo group. 1 and 2 participants in the control and in the
intervention group respectively discontinued the study due to adverse events
Adverse events were all Grade 1 and Grade 2, except 1 Grade 3 ALT elevation and one Grade 3 back
pain in the Polyphenon E arm and one Grade 3 ALT and AST elevation in the placebo arm. Nausea
was reported more frequently by participants receiving Polyphenon E compared to those receiving
placebo, 32.0% vs 18.8%, respectively, as well as elevated ALT/AST, 10.0%/8.0% and 2.1%/2.1%, re-
spectively, as well as was incidence of dizziness (14.0% vs 6.3%)
Garland 2006 Primary outcome
Urinary 8-hydroxydeoxyguanosine levels increased in Group A (+2.36) and B (+5.20), while de-
creased in Group C (−1.08)
Urinary 8-F2-isoprostanes levels decreased in both Group A (−39.87) and B (−35.80), with no change
in Group C (0.71)
Secondary outcome
Safety data: no significant adverse events were reported, including no liver toxicity, but higher fre-
quency of nausea, constipation and gastrointestinal reflux disease detected
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Kumar 2015 Prostate cancer incidence: total 14 cases at the end of the study (1 year): 5 prostate cancer cases in
the treatment group and 9 cases in the control group.
Prostate cancer + ASAP: total 13 (8 + 5) cases at the end of the study (1 year): 3 (3 + 0) prostate can-
cer cases in the treatment group and 10 (5 + 5) cases in the control group.
No significant differences between the treatment and placebo arms were observed in LUTS and
QoL scores from baseline to end of study.
Safety data: 26 adverse effects (14 in the treatment group and 12 in control group censored at 6
months due to adverse effects), 2 (1 + 1) between 6 and 12 months and 55 (29 + 26) adverse effects
at 12 months. Higher possible and probable events in the treatment arm, all but 1 of grade 1 and
2. Total 381 adverse effects, 212 in the treatment group and 169 in the control group. 11 and 7 in
treatment and control groups respectively met oG-study criteria due to adverse effects. Higher inci-
dence of coagulation toxicity, gastrointestinal and pain reported in the treatment group as well as
toxicity to skin and musculoskeletal/soK tissue.
Data on adverse effects also reported in Kumar 2016.
Data on body weight or abdominal obesity in Kumar 2017
Lane 2018 Primary outcome
Risk for prostate cancer NR
Secondary outcomes
PSA levels did not differ between green tea groups after 6 months of treatment
Safety data: most incident adverse events were nocturia and insomnia that were higher in green
tea drink (46% and 22%) and green tea capsules (50% and 21%) compared to placebo (33% and
8%). Hypertension was similar across groups, while fatigue was higher in green tea capsules (24%)
and placebo (18%) than green tea drink (5%). Less frequent adverse events were cramp, shortness
of breath, heartburn, headache and diarrhoea.
Micali 2017 Follow-up: 44 (22 in the intervention and 22 in the control group) completed the study. 16 partici-
pants (8 in the intervention and 8 in the control group) chose to withdraw from the study.
Primary outcome
Prostate cancer incidence
After 6 months, 2/22 (9%) and 4/22 (18%) prostate cancer occurred in the treatment and control
group, respectively. After 1 year total prostate cancer cases were 4/22 (18%) in both groups
Secondary outcomes
Safety data: only Grade 1 and 2 side effects occurred, including nausea, emesis, abdominal pain, in-
somnia, fatigue and diarrhoea
Mean (SD) PSA levels decreased from 5.9 (2.3) ng/mL to 3.8 (1.8) in treatment group and increased
from 4.7 (2.5) to 5.8 (2.6) in control group
LUTS and QoL scores reported to be improved after 1-year study but results were NR.
Roshdy 2013 Primary outcome
Total fibroid volume decreased by an average of 32.6% in the treatment group and increased by an
average of 24.2% in the placebo group
Secondary outcomes
HRQoL
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Scale 1: mean change in score for the intervention group of −25.28 (SD ± 17.38) mean change of 7.1
(SD ± 15.5) in placebo group
Scale 2: overall increase of 20.7 (SD ± 21) in the percentile scores for HRQoL in the treatment group
and 2.19 (SD ± 17.4) in the placebo group
Safety data: none of the participants reported any adverse events of any grade throughout the
whole study period.
Sinicrope 2017 Percent change in rectal ACF did not differ between the study arms after 6 months of treatment
Safety data: similar adverse events between the study arms. 1 participant in placebo arm reported
grade 3 adverse event and 2 participants (1 in each arm) reported grade 2+ adverse events, namely
elevated AST, ALT in the treatment group
Tsao 2009 Histological response
Higher response rate in the 3 combined GTE arms (50%) versus placebo (18.2%), with dose-depen-
dent effect: 58% in the combined higher-dose GTE arms (750 and 1000 mg/m2) versus 36.4% (GTE
at 500 mg/m2) and 18.2% (placebo)
Higher histological response rate in the 3 combined GTE arms (21.4%) vs placebo (9.1%), not dose-
dependent
Safety data: adverse events reported by 28 of the 30 (93.3%) participants in treatment groups and 9
of the 11 (81.8%) participants of control group
The most frequently reported adverse effects are grade 1 to 2, including insomnia, headache, nau-
sea and nervousness. The grade 3 toxicity was reported by 2 participants in Group B, namely in-
somnia, diarrhoea and oral/neck pain. Insomnia was the most frequent adverse event.
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References Detailed summary results The Newcastle-Ottawa
Scale (NOS)
Allen 2004 Reference category: lowest exposure
Prostate cancer
Intermediate exposure: RR 1.03 (95% CI 0.69-1.55)
Highest exposure: RR 1.29 (95% CI 0.84-1.98)
Low risk:
Selection: 3/4 stars since
the exposed population
is a highly selected group
(survivors of the atomic
bomb).
Comparability: 1/2 stars,
since the study did not
control for smoking
habits.
Outcome: 3/3 stars, low
risk
Total score: 7/9 stars,
moderate quality.
Chyou 1993 Urinary tract cancer
Reference category: lowest exposure
Highest exposure: RR 1.34 (95% CI 0.79-2.27)
Low risk:
Selection: 4/4 stars, low
risk
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Comparability: 2/2 stars,
low risk
Outcome: 3/3 stars, low
risk
Total score: 9/9 stars, high
quality.
Dai 2010 Reference category: lowest exposure
Breast cancer
Exposure assessment A: intake of green tea
Highest exposure: HR 1.04 (95% CI 0.88-1.26)
Exposure assessment B: dosage of green tea:
Intermediate exposure 1: HR 1.07 (95% CI 0.81-1.42)
Intermediate exposure 2: HR 0.98 (95% CI 0.75-1.29)
Intermediate exposure 3: HR 1.00 (95% CI 0.68-1.48)
Highest exposure: HR 1.18 (95% CI 0.86-1.61)
Low risk:
Selection: 4/4 stars, low
risk
Comparability: 2/2 stars,
low risk
Outcome: 2/3 stars, fol-
low-up < 5 years
Total score: 8/9 stars,
moderate quality.
Galanis 1998 Stomach cancer
Reference category: lowest exposure
All
Intermediate exposure: HR 1.3 (95% CI 0.7-2.1)
Highest exposure: HR 1.5 (95% CI 0.9-2.3)
Men
Intermediate exposure: HR 1.2 (95% CI 0.6-2.5)
Highest exposure: HR 1.6 (95% CI 0.9-2.9)
Women
Intermediate exposure: HR 1.3 (95% CI 0.6-2.9)
Highest exposure: HR 1.3 (95% CI 0.6-2.6)
Low risk:
Selection: 4/4 stars, low
risk
Comparability: 1/2 stars,
the study did not control
for smoking in the overall
analysis, only in men
Outcome: 2/3 stars, fol-
low-up < 5 years, low risk
Total score: 7/9 stars,
moderate quality.
Ide 2007 Reference category: lowest exposure
Oral cancer
All participants
Intermediate exposure 1: HR 0.65 (95% CI 0.22-1.94)
Intermediate exposure 2: HR 0.69 (95% CI 0.28-1.71)
Highest exposure: HR 0.44 (95% CI 0.19-1.04)
Men
Intermediate exposure 1: HR 0.79 (95% CI 0.18-3.57)
Intermediate exposure 2: HR 0.81 (95% CI 0.22-3.03)
Highest exposure HR 0.61 (95% CI 0.18-2.06)
Women
Intermediate exposure 1: HR 0.51 (95% CI 0.10-2.68)
Low risk:
Selection: 4/4 stars, low
risk
Comparability: 2/2 stars,
low risk
Outcome: 3/3 stars, low
risk
Total score: 9/9 stars, high
quality.
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Intermediate exposure 2: HR 0.60 (95% CI 0.17-2.10)
Highest exposure: HR 0.31 (95% CI 0.09-1.07)
Inoue 2009a Reference category: lowest exposure
Stomach cancer
Men
All cohorts
Intermediate exposure 1: HR 0.97 (95% CI 0.83-1.12)
Intermediate exposure 2: HR 0.93 (95% CI 0.81-1.08)
Highest exposure: HR 1.06 (95% CI 0.86-1.30)
JPHC-I
Intermediate exposure 1: HR 0.85 (95% CI 0.62-1.17)
Intermediate exposure 2: HR 0.87 (95% CI 0.65-1.16)
Highest exposure: HR 0.97 (95% CI 0.73-1.28)
JPHC-II
Intermediate exposure 1: HR 1.11 (95% CI 0.82-1.52)
Intermediate exposure 2: HR 1.08 (95% CI 0.80-1.45)
Highest exposure: HR 1.06 (95% CI 0.78-1.43)
JACC
Intermediate exposure 1: HR 0.80 (95% CI 0.59-1.08)
Intermediate exposure 2: HR 0.75 (95% CI 0.57-1.00)
Highest exposure: HR 0.81 (95% CI 0.63-1.05)
MIYAGI
Intermediate exposure 1: HR 0.90 (95% CI 0.67-1.20)
Intermediate exposure 2: HR 0.87 (95% CI 0.65-1.17)
Highest exposure: HR 0.88 (95% CI 0.67-1.15)
3-pref MIYAGI
Intermediate exposure 1: HR 1.28 (95% CI 0.84-1.94)
Intermediate exposure 2: HR 1.20 (95% CI 0.79-1.80)
Highest exposure: HR 1.55 (95% CI 1.09-2.20)
3-pref AICHI
Intermediate exposure 1: HR 1.27 (95% CI 0.74-2.21)
Intermediate exposure 2: HR 1.22 (95% CI 0.73-2.03)
Highest exposure: HR 1.60 (95% CI 0.97-2.63)
Women:
Low risk:
Inoue 2009a
Selection: 4/4 stars, low
risk
Comparability: 2/2 stars,
low risk
Outcome: 3/3 stars, low
risk
Total score: 9/9 stars, high
quality.
Fujino 2002
Selection: 4/4 stars, low
risk
Comparability: 1/2 stars,
the study did not control
for smoking
Outcome: 2/3 stars, fol-
low-up < 90%.
Total score: 8/9 stars,
moderate quality.
Hoshiyama 2002
Selection: 4/4 stars, low
risk
Comparability: 2/2 stars,
low risk
Outcome: 2/3 stars, fol-
low-up < 90%
Total score: 8/9 stars,
moderate quality.
Hoshiyama 2004
Selection: 4/4 stars, low
risk
Comparability: 2/2 stars,
low risk
Outcome: 2/3 stars, fol-
low-up < 90%.
Total score: 8/9 stars,
moderate quality.
Sasazuki 2004
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All cohorts:
Intermediate exposure 1: HR 0.90 (95% CI 0.73-1.10)
Intermediate exposure 2: HR 0.92 (95% CI 0.76-1.11)
Highest exposure: HR 0.79 (95% CI 0.65-0.96)
JPHC-I
Intermediate exposure 1: HR 0.75 (95% CI 0.45-1.25)
Intermediate exposure 2: HR 0.90 (95% CI 0.58-1.42)
Highest exposure: HR 0.58 (95% CI 0.36-0.95)
JPHC-II
Intermediate exposure 1: HR 0.93 (95% CI 0.56-1.56)
Intermediate exposure 2: HR 1.18 (95% CI 0.74-1.86)
Highest exposure: HR 0.74 (95% CI 0.45-1.20)
JACC
Intermediate exposure 1: HR 1.04 (95% CI 0.71-1.53)
Intermediate exposure 2: HR 0.85 (95% CI 0.60-1.19)
Highest exposure: HR 0.88 (95% CI 0.64-1.21)
MIYAGI
Intermediate exposure 1: HR 0.81 (95% CI 0.53-1.26)
Intermediate exposure 2: HR 0.89 (95% CI 0.59-1.35)
Highest exposure: HR 0.67 (95% CI 0.44-1.02)
3-pref MIYAGI
Intermediate exposure 1: HR 0.82 (95% CI 0.45-1.49)
Intermediate exposure 2: HR 0.72 (95% CI 0.41-1.27)
Highest exposure: HR 0.83 (95% CI 0.51-1.35)
3-pref AICHI
Intermediate exposure 1: HR 1.20 (95% CI 0.49-2.95)
Intermediate exposure 2: HR 1.29 (95% CI 0.59-2.80)
Highest exposure: HR 1.54 (95% CI 0.72-3.28)
Stratified data available by sex and further stratified by smoking status (never
smokers and current smokers)
Stratified data available by subsite (proximal and distal stomach cancer)
Previous reports
Fujino 2002
Stomach cancer mortality
Reference category: lowest exposure
Selection: 4/4 stars, low
risk
Comparability: 2/2 stars,
low risk
Outcome: 3/3 stars, low
risk
Total score: 9/9 stars, high
quality.
Tsubono 2001
Selection: 4/4 stars, low
risk
Comparability: 2/2 stars,
low risk
Outcome: 3/3 stars, low
risk
Total score: 9/9 stars, high
quality.
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Men
Intermediate exposure: RR 0.82 (95% CI 0.41-1.64)
Highest exposure: RR 1.11 (95% CI 0.75-1.63)
Women
Intermediate exposure: RR 1.74 (95% CI 0.71-4.26)
Highest exposure: RR 1.43 (95% CI 0.78-2.62)
Hoshiyama 2002
Reference category: lowest exposure
Stomach cancer mortality
Men
Intermediate exposure 1: RR 1.6 (95% CI 0.9-2.9)
Intermediate exposure 2: RR 1.1 (95% CI 0.6-1.9)
Intermediate exposure 3: RR 1.0 (95% CI 0.5-2.5)
Highest exposure: RR 1.0 (95% CI 0.5-2.0)
Women
Intermediate exposure 1: RR 1.1 (95% CI 0.5-2.5)
Intermediate exposure 2: RR 1.0 (95% CI 0.5-2.5)
Intermediate exposure 3: RR 0.8 (95% CI 0.4-1.6)
Highest exposure: RR 0.7 (95% CI 0.3-2.1)
Hoshiyama 2004
Reference category: lowest exposure
Stomach cancer
Intermediate exposure 1: RR 1.3 (95% CI 0.6-2.8)
Intermediate exposure 2: RR 1.0 (95% CI 0.5-1.9)
Intermediate exposure 3: RR 0.8 (95% CI 0.4-1.6)
Highest exposure: RR 1.2 (95% CI 0.6-2.5)
Koizumi 2003
Stomach cancer
Intermediate exposure 1: HR 1.01 (95% CI 0.80-1.27)
Intermediate exposure 2: HR 0.89 (95% CI 0.70–1.13)
Highest exposure: HR 1.06 (95% CI 0.86–1.30)
Stratified data available by histological subtype (differentiated and nondifferenti-
ated)
Stratified data available by subsite (cardia, body and antrum)
Tsubono 2001
Stomach cancer
All participants
Intermediate exposure 1: RR 1.2 (95% CI 0.8-1.8)
Intermediate exposure 2: RR 1.0 (95% CI 0.7–1.5)
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Highest exposure: RR 1.4 (95% CI 1.0-1.9)
Men
Intermediate exposure 1: RR 1.2 (95% CI 0.7-1.9)
Intermediate exposure 2: RR 1.2 (95% CI 0.7-1.9)
Highest exposure: RR 1.5 (95% CI 1.0-2.3)
Women
Intermediate exposure 1: RR 1.2 (95% CI 0.6-2.3)
Intermediate exposure 2: RR 0.7 (95% CI 0.4-1.5)
Highest exposure: RR 1.1 (95% CI 0.6-2.0)
Sasazuki 2004
Reference category: lowest exposure
Men
Stomach cancer
Intermediate exposure 1: RR 0.95 (95% CI 0.74–1.21)
Intermediate exposure 2: RR 0.89 (95% CI 0.71–1.13)
Highest exposure: RR 0.97 (95% CI 0.77–1.22)
Subsite
Upper-third including cardia cancer
Intermediate exposure 1: RR 1.07 (95% CI 0.53–2.17)
Intermediate exposure 2: RR 0.88 (95% CI 0.44–1.75)
Highest exposure: RR 1.24 (95% CI 0.65–2.35)
Distal cancer
Intermediate exposure 1: RR 0.88 (95% CI 0.65–1.17)
Intermediate exposure 2: RR 0.85 (95% CI 0.64–1.12)
Highest exposure: RR 0.88 (95% CI 0.67–1.16)
Women
Stomach cancer
Intermediate exposure 1: RR 0.93 (95% CI 0.61–1.41)
Intermediate exposure 2: RR 1.10 (95% CI 0.75–1.60)
Highest exposure: RR 0.70 (95% CI 0.47–1.05)
Subsite:
Upper-third including cardia cancer
Intermediate exposure 1: RR 2.28 (95% CI 0.56–9.33)
Intermediate exposure 2: RR 0.70 (95% CI 0.13–3.62)
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Highest exposure: RR 1.74 (95% CI 0.44–6.86)
Distal cancer
Intermediate exposure 1: RR 0.92 (95% CI 0.58–1.47)
Intermediate exposure 2: RR 1.05 (95% CI 0.69–1.60)
Highest exposure: RR 0.53 (95% CI 0.33–0.85)
Inoue 2009b Reference category: lowest exposure
Liver cancer
Men
Intermediate exposure: HR 1.20 (95% CI 0.64-2.23)
Highest exposure: HR 1.18 (95% CI 0.63-2.20)
Women
Intermediate exposure: HR 2.58 (95% CI 1.01-6.59)
Highest exposure: HR 1.48 (95% CI 0.54-4.08)
Low risk:
Selection: 4/4 stars, low
risk
Comparability: 2/2 stars,
low risk
Outcome: 3/3 stars, low
risk
Total score: 9/9 stars, high
quality.
Ishikawa 2006 Reference category: lowest exposure
Oesophageal cancer
Cohort 1 + cohort 2
Intermediate exposure 1: HR 1.03 (95% CI 0.46-2.28)
Intermediate exposure 2: HR 1.13 (95% CI 0.53-2.42)
Highest exposure: HR 1.67 (95% CI 0.89-3.16)
Cohort 1
Intermediate exposure 1: HR 0.69 (95% CI 0.17-2.91)
Intermediate exposure 2: HR 1.58 (95% CI 0.52-4.76)
Highest exposure: HR 1.78 (95% CI 0.66-4.82)
Cohort 2
Intermediate exposure 1: HR 1.22 (95% CI 0.47-3.19)
Intermediate exposure 2: HR 0.85 (95% CI 0.30-2.40)
Highest exposure: HR 1.61 (95% CI 0.71-3.66)
Low risk:
Selection: 4/4 stars, low
risk
Comparability: 2/2 stars,
low risk
Outcome: 2/3 stars, fol-
low-up rate < 90%
Total score: 8/9 stars,
moderate quality.
Iwai 2002 Reference category: lowest exposure
Total cancer mortality
Intermediate exposure: HR 0.93 (95% CI 0.51-1.70)
Highest exposure: HR 0.92 (95% CI 0.49-1.73)
Low risk:
Selection: 4/4 stars, low
risk
Comparability: 1/2 stars,
the study did not control
for smoking
Outcome: 3/3 stars, low
risk
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Total score: 8/9 stars,
moderate quality.
Iwasaki 2010a Reference category: lowest exposure
Breast cancer
Iwasaki 2010a
Intermediate exposure: HR 1.19 (95% CI 0.80-1.76)
Intermediate exposure 2: HR 1.13 (95% CI 0.72-1.75)
Intermediate exposure 3: HR 1.13 (95% CI 0.81-1.58)
Intermediate exposure 4: HR 1.17 (95% CI 0.85-1.62)
Highest exposure: HR 1.12 (95% CI 0.81-1.56)
Iwasaki 2010b
Highest exposure: OR 1.02 (95% CI 0.62-1.65)
Low risk:
Iwasaki 2010a:
Selection: 4/4 stars, low
risk
Comparability: 2/2 stars,
low risk
Outcome: 3/3 stars, low
risk
Total score: 9/9 stars, high
quality.
Iwasaki 2010b
Selection: 4/4 stars, low
risk
Comparability: 1/2 stars,
the study did not control
for smoking
Outcome: 3/3 stars, low
risk
Total score: 8/9 stars,
moderate quality.
Key 1999 Reference category: lowest exposure
Breast cancer
Intermediate exposure: RR 1.02 (95% CI 0.76-1.36)
Highest exposure: RR 0.86 (95% CI 0.62-1.21)
Low risk:
Selection: 3/4 stars, expo-
sure based on self-report
not within a structured in-
terview or questionnaire.
Comparability: 1/2 stars,
the study did not control
for smoking
Outcome: 3/3 stars, low
risk
Total score: 7/9 stars,
moderate quality.
Khan 2004 Reference category: lowest exposure
Men
Total cancer mortality
Highest exposure: RR 1.0 (955 CI 0.7-1.6)
Lung cancer mortality
Highest exposure: RR 0.6 (95% CI 0.3-1.2)
Stomach cancer mortality
Low risk:
Selection: 4/4 stars, low
risk
Comparability: 2/2 stars,
low risk
Outcome: 3/3 stars, low
risk
Total score: 9/9 stars, high
quality.
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Highest exposure: RR 1.1 (95% CI 0.4-2.5)
Colorectal cancer mortality
Highest exposure: RR 1.3 (95% CI 0.3-5.9)
Pancreatic cancer mortality
Highest exposure: RR not estimated
Women
Total cancer mortality
Highest exposure: RR 1.0 (955 CI 0.6-1.6)
Lung cancer mortality
Highest exposure: RR 0.7 (95% CI 0.2-2.9)
Stomach cancer mortality
Highest exposure: RR 0.7 (95% CI 0.2-1.9)
Colorectal cancer mortality
Highest exposure: RR 1.2 (95% CI 0.3-4.4)
Pancreatic cancer mortality
Highest exposure: RR 0.5 (95% CI 0.2-1.6)
Kikuchi 2006 Reference category: lowest exposure
Prostate cancer
Intermediate exposure 1: HR 0.77 (95% CI 0.42-1.40)
Intermediate exposure 2: HR 1.15 (95% CI 0.69-1.94)
Highest exposure: HR 0.85 (95% CI 0.50-1.43)
Low risk:
Selection: 4/4 stars, low
risk
Comparability: 2/2 stars,
low risk
Outcome: 3/3 stars, low
risk
Total score: 9/9 stars, high
quality.
Kurahashi 2007 Reference category: lowest exposure
Prostate cancer
Intermediate exposure 1: RR 0.96 (95% CI 0.68-1.35)
Intermediate exposure 2: RR 0.94 (95% CI 0.68-1.30)
Highest exposure: RR 0.89 (95% CI 0.65-1.21)
Low risk:
Selection: 4/4 stars, low
risk
Comparability: 2/2 stars,
low risk
Outcome: 3/3 stars, low
risk
Total score: 9/9 stars, high
quality.
Kurahashi 2009 Reference category: lowest exposure
Bladder cancer
Men
Low risk:
Selection: 4/4 stars, low
risk
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Intermediate exposure 1: HR 1.18 (95% CI 0.73-1.91)
Intermediate exposure 2: HR 0.71 (95% CI 0.43-1.18)
Highest exposure: HR 0.90 (95% CI 0.56-1.45)
Women
Intermediate exposure: HR 1.22 (95% CI 0.49-3.00)
Highest exposure: HR 2.29 (95% CI 1.06-4.92)
Analysis also available stratified by smoking status
Comparability: 2/2 stars,
low risk
Outcome: 3/3 stars, low
risk
Total score: 9/9 stars, high
quality.
Kuriyama 2006 Reference category: lowest exposure
All participants
Total cancer mortality
Intermediate exposure 1: HR 1.11 (95% CI 0.93-1.34)
Intermediate exposure 2: HR 1.16 (95% CI 0.97-1.38)
Highest exposure: HR 1.11 (95% CI 0.94-1.31)
Stomach cancer mortality
Intermediate exposure 1: HR 1.33 (95% CI 0.86-2.04)
Intermediate exposure 2: HR 1.00 (95% CI 0.64-1.58)
Highest exposure: HR 1.17 (95% CI 0.78-1.76)
Lung cancer mortality
Intermediate exposure 1: HR 1.03 (95% CI 0.67-1.58)
Intermediate exposure 2: HR 1.05 (95% CI 0.69-1.59)
Highest exposure: HR 1.18 (95% CI 0.81-1.72)
Colorectal cancer mortality
Intermediate exposure 1: HR 1.04 (95% CI 0.59-1.82)
Intermediate exposure 2: HR 1.45 (95% CI 0.87-2.42)
Highest exposure: HR 1.10 (95% CI 0.67-1.82)
Men
Total cancer mortality
Intermediate exposure 1: HR 1.02 (95% CI 0.82-1.28)
Intermediate exposure 2: HR 1.18 (95% CI 0.95-1.46)
Highest exposure: HR 1.11 (95% CI 0.90-1.36)
Stomach cancer mortality
Intermediate exposure 1: HR 1.29 (95% CI 0.78-2.16)
Intermediate exposure 2: HR 1.19 (95% CI 0.71-2.00)
Highest exposure: HR 1.20 (95% CI 0.74-1.95)
Low risk:
Selection: 4/4 stars, low
risk
Comparability: 2/2 stars,
low risk
Outcome: 3/3 stars, low
risk
Total score: 9/9 stars, high
quality.
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Lung cancer mortality
Intermediate exposure 1: HR 0.88 (95% CI 0.54-1.42)
Intermediate exposure 2: HR 0.97 (95% CI 0.61-1.54)
Highest exposure: HR 1.14 (95% CI 0.75-1.73)
Colorectal cancer mortality
Intermediate exposure 1: HR 1.09 (95% CI 0.57-2.09)
Intermediate exposure 2: HR 1.23 (95% CI 0.66-2.29)
Highest exposure: HR 0.88 (95% CI 0.47-1.63)
Women
Total cancer mortality
Intermediate exposure 1: HR 1.27 (95% CI 0.93-1.74)
Intermediate exposure 2: HR 1.09 (95% CI 0.79-1.49)
Highest exposure: HR 1.07 (95% CI 0.80-1.44)
Stomach cancer mortality
Intermediate exposure 1: HR 1.32 (95% CI 0.59-2.94)
Intermediate exposure 2: HR 0.64 (95% CI 0.26-1.63)
Highest exposure: HR 1.08 (95% CI 0.50-2.33)
Lung cancer mortality
Intermediate exposure 1: HR 1.83 (95% CI 0.68-4.96)
Intermediate exposure 2: HR 1.46 (95% CI 0.54-3.95)
Highest exposure: HR 1.59 (95% CI 0.63-4.05)
Colorectal cancer mortality
Intermediate exposure 1: HR 0.98 (95% CI 0.32-2.97)
Intermediate exposure 2: HR 1.96 (95% CI 0.78-4.95)
Highest exposure: HR 1.49 (95% CI 0.60-3.71)
Lee 2007 Reference category: lowest exposure
Men
Colorectal cancer
Intermediate exposure 1: RR 0.80 (95% CI 0.57-1.06)
Intermediate exposure 2: RR 1.00 (95% CI 0.73-1.35)
Intermediate exposure 3: RR 1.04 (95% CI 0.78-1.40)
Highest exposure: RR 0.96 (95% CI 0.71-1.29)
Colon cancer
Intermediate exposure 1: RR 0.73 (95% CI 0.47-1.14)
Low risk:
Selection: 4/4 stars, low
risk
Comparability: 2/2 stars,
low risk
Outcome: 3/3 stars, low
risk
Total score: 9/9 stars, high
quality.
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Intermediate exposure 2: RR 1.09 (95% CI 0.75-1.59)
Intermediate exposure 3: RR 1.06 (95% CI 0.74-1.53)
Highest exposure: RR 0.92 (95% CI 0.63-1.33)
Rectal cancer
Intermediate exposure 1: RR 0.93 (95% CI 0.53-1.67)
Intermediate exposure 2: RR 0.81 (95% CI 0.47-1.39)
Intermediate exposure 3: RR 1.01 (95% CI 0.60-1.67)
Highest exposure: RR 1.04 (95% CI 0.63-1.72)
Women
Colorectal cancer
Intermediate exposure 1: RR 1.01 (95% CI 0.67-1.52)
Intermediate exposure 2: RR 0.81 (95% CI 0.55-1.22)
Intermediate exposure 3: RR 0.96 (95% CI 0.66-1.40)
Highest exposure: RR 1.02 (95% CI 0.70-1.47)
Colon cancer
Intermediate exposure 1: RR 0.97 (95% CI 0.57-1.63)
Intermediate exposure 2: RR 0.81 (95% CI 0.49-1.35)
Intermediate exposure 3: RR 0.99 (95% CI 0.62-1.57)
Highest exposure: RR 1.10 (95% CI 0.70-1.73)
Rectal cancer
Intermediate exposure 1: RR 1.09 (95% CI 0.56-2.13)
Intermediate exposure 2: RR 0.81 (95% CI 0.42-1.57)
Intermediate exposure 3: RR 0.92 (95% CI 0.49-1.71)
Highest exposure: RR 0.85 (95% CI 0.45-1.61)
Li 2008 Reference category: lowest exposure
Lung cancer
All participants
Intermediate exposure 1: HR 1.14 (95% CI 0.80-1.62)
Intermediate exposure 2: HR 1.18 (95% CI 0.83-1.66)
Highest exposure: HR 1.17 (95% CI 0.85-1.61)
Men
Intermediate exposure 1: HR 1.05 (95% CI 0.70-1.57)
Intermediate exposure 2: HR 1.21 (95% CI 0.82-1.79)
Highest exposure: HR 1.17 (95% CI 0.82-1.68)
Low risk:
Selection: 4/4 stars, low
risk
Comparability: 2/2 stars,
low risk
Outcome: 3/3 stars, low
risk
Total score: 9/9 stars, high
quality.
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Women
Intermediate exposure 1: HR 1.48 (95% CI 0.71-3.10)
Intermediate exposure 2: HR 1.11 (95% CI 0.52-2.37)
Highest exposure: HR 1.30 (95% CI 0.65-2.60)
Li 2018 Reference category: lowest exposure
Lung cancer
Highest exposure: HR 1.88 (95% CI 0.93-3.77)
Low risk:
Selection: 3/4 stars, expo-
sure based on self-report
not within a structured in-
terview or questionnaire.
Comparability: 2/2 stars,
low risk
Outcome: 3/3 stars, low
risk
Total score: 8/9 stars,
moderate quality.
Lin 2008 Reference category: lowest exposure
Pancreatic cancer mortality
All participants
Intermediate exposure 1: RR 1.04 (95% CI 0.67-1.60)
Intermediate exposure 2: RR 1.14 (95% CI 0.80-1.63)
Intermediate exposure 3: RR 0.99 (95% CI 0.69-1.42)
Highest exposure: RR 1.23 (95% CI 0.84-1.80)
Men
Intermediate exposure 1: RR 0.79 (95% CI 0.42-1.51)
Intermediate exposure 2: RR 1.09 (95% CI 0.65-1.83)
Intermediate exposure 3: RR 0.88 (95% CI 0.53-1.48)
Highest exposure: RR 0.95 (95% CI 0.5-1.65)
Women
Intermediate exposure 1: RR 1.32 (95% CI 0.73-2.38)
Intermediate exposure 2: RR 1.20 (95% CI 0.73-1.97)
Intermediate exposure 3: RR 1.08 (95% CI 0.66-1.78)
Highest exposure: RR 1.54 (95% CI 0.91-2.60)
Low risk:
Selection: 4/4 stars, low
risk
Comparability: 2/2 stars,
low risk
Outcome: 3/3 stars, low
risk
Total score: 9/9 stars, high
quality.
Liu 2016 Reference category: highest exposure
Total cancer mortality
Intermediate exposure 1: HR 0.93 (95% CI 0.85-1.01)
Intermediate exposure 2: HR 0.91 (95% CI 0.85-0.98)
Lowest exposure: HR 0.86 (95%CI 0.79-0.93)
Available also stratified analysis by smoking status, alcohol drinking, rural and
urban locality
Low risk:
Selection: 4/4 stars, low
risk.
Comparability: 2/2 stars,
low risk.
Outcome: 3/3 stars, low
risk.
Total score: 9/9 stars, high
quality.
Luo 2007 Reference category: lowest exposure Low risk:
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Pancreatic cancer
All participants
Intermediate exposure 1: HR 1.1 (95% CI 0.6-1.9)
Intermediate exposure 2: HR 1.1 (95% CI 0.7-1.9)
Intermediate exposure 3: HR 1.2 (95% CI 0.7-2.0)
Highest exposure: HR 1.2 (95% CI 0.7-1.9)
Men
Intermediate exposure 1: HR 1.3 (95% CI 0.6-2.9)
Intermediate exposure 2: HR 1.4 (95% CI 0.7-2.9)
Intermediate exposure 3: HR 1.5 (95% CI 0.7-3.1)
Highest exposure: HR 1.4 (95% CI 0.7-2.8)
Women
Intermediate exposure 1: HR 0.9 (95% CI 0.4-2.1)
Intermediate exposure 2: HR 0.9 (95% CI 0.4-1.8)
Intermediate exposure 3: HR 0.9 (95% CI 0.5-1.9)
Highest exposure: HR 1.0 (95% CI 0.5-2.0)
Selection: 4/4 stars, low
risk
Comparability: 2/2 stars,
low risk
Outcome: 3/3 stars, low
risk
Total score: 9/9 stars, high
quality.
Makiuchi 2016 Reference category: lowest exposure
Biliary tract cancer
All participants
Intermediate exposure 1: HR 0.74 (95% CI 0.52-1.04)
Intermediate exposure 2: HR 0.86 (95% CI 0.62-1.21)
Highest exposure: HR 0.67 (95% CI 0.46-0.97)
Men
Intermediate exposure 1: HR 0.74 (95% CI 0.48-1.15)
Intermediate exposure 2: HR 0.89 (95% CI 0.58-1.37)
Highest exposure: HR 0.66 (95% CI 0.40-1.08)
Women
Intermediate exposure 1: HR 0.74 (95% CI 0.42-1.29)
Intermediate exposure 2: HR 0.84 (95% CI 0.49-1.44)
Highest exposure: HR 0.66 (95% CI 0.37-1.20)
Gallbladder
Intermediate exposure 1: HR 0.56 (95% CI 0.32-0.97)
Intermediate exposure 2: HR 0.88 (95% CI 0.54-1.45)
Highest exposure: HR 0.57 (95% CI 0.32-1.01)
Extrahepatic bile duct cancer
Intermediate exposure 1: HR 0.83 (95% CI 0.53-1.31)
Intermediate exposure 2: HR 0.79 (95% CI 0.50-1.26)
Highest exposure: HR 0.69 (95% CI 0.41-1.15)
Low risk:
Selection: 4/4 stars, low
risk
Comparability: 2/2 stars,
low risk
Outcome: 3/3 stars, low
risk
Total score: 9/9 stars, high
quality.
Michikawa 2011 Reference category: lowest exposure Low risk:
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Thyroid cancer
Men
Intermediate exposure 1: HR 1.13 (95% CI 0.39-3.27)
Intermediate exposure 2: HR 0.95 (95% CI 0.33-2.78)
Highest exposure: HR 0.71 (95% CI 0.22-2.28)
Women
Intermediate exposure 1: HR 0.64 (95% CI 0.37-1.14)
Intermediate exposure 2: HR 1.10 (95% CI 0.70-1.75)
Highest exposure: HR 0.91 (95% CI 0.56-1.48)
Selection: 4/4 stars, low
risk
Comparability: 2/2 stars,
low risk
Outcome: 3/3 stars, low
risk
Total score: 9/9 stars, high
quality
Montague 2012 Reference category: lowest exposure
Prostate cancer
Intermediate exposure 1: HR 1.07 (95% CI 0.73-1.56)
Intermediate exposure 2: HR 1.09 (95% CI 0.80-1.48)
Highest exposure: HR 1.08 (95% CI 0.79-1.48)
Low risk:
Selection: 4/4 stars, low
risk
Comparability: 2/2 stars,
low risk
Outcome: 3/3 stars, low
risk
Total score: 9/9 stars, high
quality.
Nagano 2001 Reference category: lowest exposure
Total cancer
Intermediate exposure: RR 1.0 (95% CI 0.93-1.1)
Highest exposure: RR 0.98 (95% CI 0.89-1.1)
Total solid cancer
Intermediate exposure: RR 1.0 (95% CI 0.92-1.1)
Highest exposure: RR 0.98 (95% CI 0.88-1.1)
Stomach cancer (also reported in Sauvaget 2005)
Intermediate exposure: RR 1.0 (95% CI 0.82-1.2)
Highest exposure: RR 0.95 (95% CI 0.76-1.2)
Colon cancer
Intermediate exposure: RR 1.0 (95% CI 0.76-1.4)
Highest exposure: RR 1.0 (95% CI 0.76-1.4)
Rectal cancer
Intermediate exposure: RR 1.3 (95% CI 0.80-2.0)
Highest exposure: RR 1.3 (95% CI 0.77-2.1)
Liver cancer
Intermediate exposure: RR 1.1 (95% CI 0.80-1.4)
Low risk:
Nagano 2001
Selection: 3/4 stars, expo-
sure based on self-report
not within a structured in-
terview or questionnaire.
Comparability: 2/2 stars,
low risk
Outcome: 3/3 stars, low
risk
Total score: 8/9 stars,
moderate quality.
Sauvaget 2005
Selection: 3/4 stars, expo-
sure based on self report
not within a structured in-
terview or questionnaire.
Comparability: 2/2 stars,
low risk
Outcome: 3/3 stars, low
risk
Total score: 8/9 stars,
moderate quality.
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Highest exposure: RR 0.95 (95% CI 0.69-1.3)
Gallbladder cancer
Intermediate exposure: RR 0.9 (95% CI 0.57-1.7)
Highest exposure: RR 1.2 (95% CI 0.66-2.2)
Pancreatic cancer
Intermediate exposure: RR 0.8 (95% CI 0.51-1.4)
Highest exposure: RR 0.79 (95% CI 0.45-1.4)
Lung cancer
Intermediate exposure: RR 0.78 (95% CI 0.60-1.0)
Highest exposure: RR 0.79 (95% CI 0.59-1.1)
Breast cancer
Intermediate exposure: RR 1.2 (95% CI 0.86-1.8)
Highest exposure: RR 1.0 (95% CI 0.67-1.6)
Bladder cancer
Intermediate exposure: RR 1.1 (95% CI 0.62-2.0)
Highest exposure: RR 1.1 (95% CI 0.6-2.1)
Haematopoietic cancer
Intermediate exposure: RR 1.2 (95% CI 0.75-1.8)
Highest exposure: RR 0.99 (95% CI 0.61-1.7)
Sauvaget 2005:
Reference category: lowest exposure
Stomach cancer:
Intermediate exposure: IRR 1.03 (95% C 0.89–1.19)
Highest exposure: IRR 1.06 (95% CI 0.89–1.25)
Naganuma 2009 Reference category: lowest exposure
All participants
Haematopoietic cancer
Intermediate exposure 1: HR 0.88 (95% CI 0.57-1.38)
Intermediate exposure 2: HR 0.90 (95% CI 0.59-1.39)
Highest exposure: HR 0.58 (95% CI 0.37-0.89)
Lymphoid cancer
Intermediate exposure 1: HR 1.00 (95% CI 0.61-1.65)
Intermediate exposure 2: HR 0.92 (95% CI 0.56-1.52)
Highest exposure: HR 0.52 (95% CI 0.31-1.87)
Low risk:
Selection: 4/4 stars, low
risk
Comparability: 2/2 stars,
low risk
Outcome: 3/3 stars, low
risk
Total score: 9/9 stars, high
quality.
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Myeloid cancer
Intermediate exposure 1: HR 0.57 (95% CI 0.20-1.64)
Intermediate exposure 2: HR 0.91 (95% CI 0.37-2.23)
Highest exposure: HR 0.76 (95% CI 0.32-1.78)
Men
Hematopoietic cancer
Intermediate exposure 1: HR 0.75 (95% CI 0.41-1.35)
Intermediate exposure 2: HR 0.82 (95% CI 0.47-1.46)
Highest exposure: HR 0.57 (95% CI 0.32-1.00)
Women
Hematopoietic cancer
Intermediate exposure 1: HR 1.09 (95% CI 0.55-2.16)
Intermediate exposure 2: HR 1.01 (95% CI 0.52-1.99)
Highest exposure: HR 0.58 (95% CI 0.29-1.16)
Nakachi 2000 Reference category: lowest exposure
Total cancer
All participants
Intermediate exposure: RR 0.81 (95% CI 0.52-1.27)
Highest exposure: RR 0.59 (95% CI 0.35-0.98)
Men
Intermediate exposure: RR 1.00 (95% CI 0.50-2.04)
Highest exposure: RR 0.54 (95% CI 0.22-1.34)
Women
Intermediate exposure: RR 0.92 (95% CI 0.64-1.31)
Highest exposure: RR 0.57 (95% CI 0.34-0.98)
Low risk:
Selection: 4/4 stars, low
risk
Comparability: 2/2 stars,
low risk
Outcome: 3/3 stars, low
risk
Total score: 9/9 stars, high
quality.
Nakamura 2011 Pancreatic cancer mortality
Reference category: lowest exposure
Men
Intermediate exposure: HR 2.02 (95% CI 0.61-6.63)
Highest exposure: HR 1.77 (95% CI 0.78-4.04)
Women
Intermediate exposure: HR 0.31 (95% CI 0.04-2.59)
Highest exposure: HR 0.59 (95% CI 0.21-1.61)
Low risk:
Selection: 4/4 stars, low
risk
Comparability: 2/2 stars,
low risk
Outcome: 3/3 stars, low
risk
Total score: 9/9 stars, high
quality.
Nechuta 2012 Reference category: lowest exposure Low risk:
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Digestive system cancer
Highest exposure: HR 0.86 (95% CI 0.75-1.00)
Stomach cancer
Highest exposure: HR 0.79 (95% CI 0.58-1.07)
Stomach and oesophageal cancer
Highest exposure: HR 0.77 (95% CI 0.57-1.03)
Colorectal cancer
Highest exposure: HR 0.91 (95% CI 0.74-1.12)
Colon cancer
Highest exposure: HR 0.96 (95% CI 0.74-1.24)
Rectal cancer
Highest exposure: HR 0.84 (95% CI 0.60-1.17)
Liver cancer
Highest exposure: HR 0.89 (95% CI 0.58-1.38)
Pancreatic cancer
Highest exposure: HR 0.96 (95% CI 0.62-1.49)
Gallbladder and bile duct cancer
Highest exposure: HR 0.73 (95% CI 0.40-1.35)
Yang 2007:
Colorectal cancer
Highest exposure: RR 0.63 (95% CI 0.45-0.88)
Further divided in:
Highest exposure A: RR 0.70 (95% CI 0.47-1.02)
Highest exposure B: RR 0.56 (95% CI 0.32-0.98)
Nechuta 2012
Selection: 4/4 stars, low
risk
Comparability: 2/2 stars,
low risk
Outcome: 3/3 stars, low
risk
Total score: 9/9 stars, high
quality.
Yang 2007
Selection: 4/4 stars, low
risk
Comparability: 2/2 stars,
low risk
Outcome: 3/3 stars, low
risk
Total score: 9/9 stars, high
quality.
Oba 2006 Reference category: lowest exposure
Colon cancer
Men
Intermediate exposure: RR 0.99 (95% CI 0.61–1.63)
Highest exposure: RR 0.75 (95% CI 0.49–1.16)
Women
Intermediate exposure: RR 1.00 (95% CI 0.53–1.86)
Highest exposure: RR 1.08 (95% CI 0.67–1.76)
Low risk:
Selection: 4/4 stars, low
risk
Comparability: 2/2 stars,
low risk
Outcome: 3/3 stars, low
risk
Total score: 9/9 stars, high
quality.
Odegaard 2015 Reference category: lowest exposure
Total cancer mortality
Low risk:
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Intermediate exposure 1: HR 1.00 (95% CI 0.92-1.08)
Intermediate exposure 2: HR 0.95 (95% CI 0.83-1.09)
Highest exposure: HR 1.10 (95% CI 0.97-1.25)
Selection: 4/4 stars, low
risk
Comparability: 2/2 stars,
low risk
Outcome: 3/3 stars, low
risk
Total score: 9/9 stars, high
quality.
Ogawa 2016 Reference category: lowest exposure
Brain cancer
All participants
Intermediate exposure: HR 0.96 (95% CI 0.58-1.59)
Highest exposure: HR 1.07 (95% CI 0.70-1.62)
Men
Intermediate exposure: HR 1.19 (95% CI 0.59–2.40)
Highest exposure: HR 0.96 (95% CI 0.51–1.81)
Women
Intermediate exposure: HR 0.74 (95% CI 0.35–1.55)
Highest exposure: HR 1.17 (95% CI 0.66–2.06)
Glioma
Intermediate exposure: HR 1.12 (95% CI 0.51–2.43)
Highest exposure: HR 1.05 (95% CI 0.54–2.05)
Meningioma
Intermediate exposure: HR 0.89 (95% CI 0.38–2.12)
Highest exposure: HR 1.01 (95% CI 0.49–2.08)
Low risk:
Selection: 4/4 stars, low
risk
Comparability: 2/2 stars,
low risk
Outcome: 3/3 stars, low
risk
Total score: 9/9 stars, high
quality.
Saito 2015 Reference category: lowest exposure
Total cancer mortality
Men
Intermediate exposure 1: HR 1.09 (95% CI 0.97-1.22)
Intermediate exposure 2: HR 1.03 (95% CI 0.92-1.16)
Highest exposure: HR 1.04 (95% CI 0.93-1.17)
Women
Intermediate exposure 1: HR 0.86 (95% CI 0.73-1.01)
Intermediate exposure 2: HR 0.93 (95% CI 0.80-1.07)
Highest exposure: HR 0.87 (95% CI 0.75-1.01)
Low risk:
Selection: 4/4 stars, low
risk
Comparability: 2/2 stars,
low risk
Outcome: 3/3 stars, low
risk
Total score: 9/9 stars, high
quality.
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Severson 1989 Prostate cancer
Reference category: lowest exposure
Highest exposure: RR 1.47 (95% CI 0.99-2.19)
Low risk:
Selection: 4/4 stars, low
risk
Comparability: 1/2 stars,
the study did not control
for smoking
Outcome: 3/3 stars, low
risk
Total score: 8/9 stars,
moderate quality.
Shimazu 2008 Reference category: lowest exposure
Endometrial cancer
Intermediate exposure 1: HR 1.04 (95% CI 0.62-1.74)
Intermediate exposure 2: HR 0.79 (95% CI 0.47-1.35)
Higest exposure: HR 0.75 (95% CI 0.44-1.30)
Low risk:
Selection: 4/4 stars, low
risk
Comparability: 2/2 stars,
low risk
Outcome: 3/3 stars, low
risk
Total score: 9/9 stars, high
quality.
Sun 2007 Reference category: lowest exposure
Colorectal cancer
All participants
Exposure assessment A: green tea intake
Highest exposure: RR 1.12 (95% CI 0.97–1.29)
Exposure assessment B: green tea intake
Intermediate exposure 1: RR 1.05 (95% CI 0.84–1.31)
Intermediate exposure 2: RR 1.11 (95% CI 0.92–1.35)
Highest exposure: RR 1.18 (95% CI 0.97–1.45)
Men
Exposure assessment A: green tea intake
Highest exposure: RR 1.31 (95% CI 1.08–1.58)
Exposure assessment B: green tea intake
Intermediate exposure 1: RR 1.32 (95% CI 0.98–1.78)
Intermediate exposure 2: RR 1.25 (95% CI 0.98–1.61)
Highest exposure: RR 1.36 (95% CI 1.06–1.74)
Women
Exposure assessment A: green tea intake
Low risk:
Selection: 4/4 stars, low
risk
Comparability: 2/2 stars,
low risk
Outcome: 3/3 stars, low
risk
Total score: 9/9 stars, high
quality.
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Highest exposure: RR 0.89 (95% CI 0.71–1.12)
Exposure assessment B: green tea intake
Intermediate exposure 1: RR 0.79 (95% CI 0.56–1.13)
Intermediate exposure 2: RR 0.96 (95% CI 0.71–1.31)
Highest exposure: RR 0.91 (95% CI 0.63–1.32)
Reported stratified analysis in colon cancer and rectal cancer, only in men.
Reported stratified analysi by localised and advanced disease.
Reported nondrinkers vs. drinkers:
Men with colon cancer
Localised
Highest exposure: RR 1.23 (95% CI 0.81–1.87)
Advanced
Highest exposure: RR 1.75 (95% CI 1.24–2.46)
Men with rectal cancer:
Localised
Highest exposure: RR 1.17 (95% CI 0.75–1.81)
Advanced
Highest exposure: RR 1.32 (95% CI 0.90–1.91)
Suzuki 2004 Reference category: lowest exposure
Breast cancer
Intermediate exposure 1: RR 0.87 (95% CI 0.57-1.32)
Intermediate exposure 2: RR 1.07 (95% CI 0.73-1.57)
Highest exposure: RR 0.84 (95% CI 0.57-1.24)
Low risk:
Selection: 4/4 stars, low
risk
Comparability: 2/2 stars,
low risk
Outcome: 3/3 stars, low
risk
Total score: 9/9 stars, high
quality.
Suzuki 2005 Reference category: lowest exposure
All participants
Colon cancer
Intermediate exposure 1: RR 1.06 (95% CI 0.74-1.52)
Intermediate exposure 2: RR 1.10 (95% CI 0.78-1.55)
Highest exposure: RR 0.97 (95% CI 0.70-1.35)
Rectal cancer
Intermediate exposure 1: RR 0.85 (95% CI 0.56-1.29)
Intermediate exposure 2: RR 0.70 (95% CI 0.45-1.08)
Low risk:
Selection: 4/4 stars, low
risk
Comparability: 2/2 stars,
low risk
Outcome: 3/3 stars, low
risk
Total score: 9/9 stars, high
quality.
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Highest exposure: RR 0.85 (95% CI 0.58-1.23)
Men
Colon cancer
Intermediate exposure 1: RR 1.32 (95% CI 0.83-2.10)
Intermediate exposure 2: RR 1.35 (95% CI 0.86-2.12)
Highest exposure: RR 1.12 (95% CI 0.72-1.74)
Rectal cancer
Intermediate exposure 1: RR 0.85 (95% CI 0.50-1.45)
Intermediate exposure 2: RR 0.58 (95% CI 0.32-1.04)
Highest exposure: RR 0.62 (95% CI 0.38-1.02)
Women
Colon cancer
Intermediate exposure 1: RR 0.78 (95% CI 0.43-1.40)
Intermediate exposure 2: RR 0.78 (95% CI 0.45-1.35)
Highest exposure: RR 0.79 (95% CI 0.49-1.29)
Rectal cancer
Intermediate exposure 1: RR 0.81 (95% CI 0.40-1.66)
Intermediate exposure 2: RR 0.95 (95% CI 0.48-1.89)
Highest exposure: RR 1.30 (95% CI 0.70-2.42)
Suzuki 2009 Reference category: lowest exposure
All participants
Total cancer mortality
Intermediate exposure 1: RR 0.63 (95% CI 0.34–1.16)
Intermediate exposure 2: RR 0.76 (95% CI 0.42–1.37)
Highest exposure: RR 0.82 (95% CI 0.45–1.50)
Stomach cancer mortality
Intermediate exposure 1: RR 0.49 (95% CI 0.11–2.28)
Intermediate exposure 2: RR 0.78 (95% CI 0.19–3.30)
Highest exposure: RR 0.81 (95% CI 0.18–3.54)
Lung cancer mortality
Intermediate exposure 1: RR 0.85 (95% CI 0.19–3.74)
Intermediate exposure 2: RR 1.13 (95% CI 0.27–4.68)
Highest exposure: RR 1.24 (95% CI 0.29–5.25)
Colorectal cancer mortality
Low risk:
Selection: 4/4 stars, low
risk
Comparability: 2/2 stars,
low risk
Outcome: 3/3 stars, low
risk
Total score: 9/9 stars, high
quality.
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Intermediate exposure 1: RR 0.47 (95% CI 0.10–2.18)
Intermediate exposure 2: RR 0.35 (95% CI 0.08–1.55)
Highest exposure: RR 0.36 (95% CI 0.07–1.74)
Men
Total cancer mortality
Intermediate exposure 1: RR 0.61 (95% CI 0.32–1.17)
Intermediate exposure 2: RR 0.69 (95% CI 0.37–1.27)
Highest exposure: RR 0.82 (95% CI 0.44–1.55)
Women
Total cancer mortality
Intermediate exposure 1: RR 1.14 (95% CI 0.15–8.82)
Intermediate exposure 2: RR 1.85 (95% CI 0.25–13.57)
Highest exposure: RR 1.31 (95% CI 0.17–10.01)
Tamura 2018 Reference category: lowest quartile
Liver cancer
Intermediate exposure 1: HR 1.36 (95% CI 0.86-2.16)
Intermediate exposure 2: HR 1.08 (95% CI 0.60-1.94)
Intermediate exposure 3: HR 0.75 (95% CI 0.51-1.11)
Highest exposure: HR 1.25 (95% CI 0.77-2.04)
Low risk:
Selection: 4/4 stars, low
risk
Comparability: 2/2 stars,
low risk
Outcome: 3/3 stars, low
risk
Total score: 9/9 stars, high
quality.
Ugai 2017 Reference category: lowest exposure
Malignant lymphoma
All participants
Intermediate exposure 1: HR 0.84 (95% CI 0.53–1.31)
Intermediate exposure 2: HR 1.38 (95% CI 0.92–1.94)
Intermediate exposure 3: HR 1.10 (95% CI 0.76–1.59)
Highest exposure: HR 0.89 (95% CI 0.61–1.29)
Men
Intermediate exposure 1: HR 0.81 (95% CI 0.44–1.50)
Intermediate exposure 2: HR 1.45 (95% CI 0.87–2.39)
Intermediate exposure 3: HR 1.21 (95% CI 0.73–2.00)
Highest exposure: HR 1.08 (95% CI 0.65–1.79)
Women
Intermediate exposure 1: HR 0.87 (95% CI 0.45–1.69)
Low risk:
Selection: 4/4 stars, low
risk
Comparability: 2/2 stars,
low risk
Outcome: 3/3 stars, low
risk
Total score: 9/9 stars, high
quality.
Table 5.   Detailed summary results of included nonexperimental cohort studies  (Continued)
Green tea (Camellia sinensis) for the prevention of cancer (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
235
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Intermediate exposure 2: HR 1.21 (95% CI 0.70–2.11)
Intermediate exposure 3: HR 0.96 (95% CI 0.56–1.67)
Highest exposure: HR 0.67 (95% CI 0.38–1.19)
Multiple myeloma
All participants
Intermediate exposure 1: HR 0.98 (95% CI 0.47–2.03)
Intermediate exposure 2: HR 0.84 (95% CI 0.43–1.66)
Intermediate exposure 3: HR 1.18 (95% CI 0.64–2.20)
Highest exposure: HR 0.74 (95% CI 0.38–1.41)
Men
Intermediate exposure 1: HR 0.81 (95% CI 0.29–2.28)
Intermediate exposure 2: HR 0.77 (95% CI 0.31–1.94)
Intermediate exposure 3: HR 1.13 (95% CI 0.49–2.61)
Highest exposure: HR 0.55 (95% CI 0.22–1.37)
Women
Intermediate exposure 1: HR 1.18 (95% CI 0.41–3.44)
Intermediate exposure 2: HR 0.93 (95% CI 0.34–2.53)
Intermediate exposure 3: HR 1.25 (95% CI 0.50–3.15)
Highest exposure: HR 0.92 (95% CI 0.36–2.38)
Ugai 2018 Reference category: lowest exposure
Acute myeloid leukaemia
All participants
Intermediate exposure 1: HR 0.91 (95% CI 0.44–1.90)
Intermediate exposure 2: HR 1.19 (95% CI 0.62–2.31)
Highest exposure: HR 1.20 (95% CI 0.62–2.32)
Men
Intermediate exposure 1: HR 0.66 (95% CI 0.24–1.76)
Intermediate exposure 2: HR 1.26 (95% CI 0.56–2.84)
Highest exposure: HR 0.86 (95% CI 0.36–2.06)
Women
Intermediate exposure 1: HR 1.53 (95% CI 0.50–4.69)
Intermediate exposure 2: HR 1.08 (95% CI 0.34–3.44)
Highest exposure: HR 1.96 (95% CI 0.68–5.67)
Low risk:
Selection: 4/4 stars, low
risk
Comparability: 2/2 stars,
low risk
Outcome: 3/3 stars, low
risk
Total score: 9/9 stars, high
quality.
Ui 2009 Reference category: lowest exposure Low risk:
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Liver cancer
All participants
Intermediate exposure 1: HR 0.78 (95% CI 0.54–1.12)
Intermediate exposure 2: HR 0.98 (95% CI 0.69–1.37)
Highest exposure: HR 0.58 (95% CI 0.41–0.83)
Men
Intermediate exposure 1: HR 0.83 (95% CI 0.53–1.30)
Intermediate exposure 2: HR 1.11 (95% CI 0.73–1.68)
Highest exposure: HR 0.63 (95% CI 0.41–0.98)
Women
Intermediate exposure 1: HR 0.68 (95% CI 0.35–1.31)
Intermediate exposure 2: HR 0.79 (95% CI 0.44–1.44)
Highest exposure: HR 0.50 (95% CI 0.27–0.90)
Selection: 4/4 stars, low
risk
Comparability: 2/2 stars,
low risk
Outcome: 3/3 stars, low
risk
Total score: 9/9 stars, high
quality.
Yang 2011a Reference category: lowest exposure
Exposure assessment A: intake of green tea
Colorectal cancer
Highest exposure: HR 0.77 (95% CI 0.59-1.01)
Colon cancer
Highest exposure: HR 0.69 (95% CI 0.48-0.98)
Rectal cancer
Highest exposure: HR 0.89 (95% CI 0.59-1.34)
Exposure assessment B: consumption of green tea
Intermediate exposure: HR 0.66 (95% CI 0.46-0.93)
Highest exposure: HR 0.85 (95% CI 0.62-1.15)
Data also available stratified by smoking status (non-smokers and smokers)
Low risk:
Selection: 4/4 stars, low
risk
Comparability: 2/2 stars,
low risk
Outcome: 3/3 stars, low
risk
Total score: 9/9 stars, high
quality.
Zhao 2017 Reference category: lowest exposure
Total cancer mortality
All participants
Exposure assessment A: intake of green tea
Highest exposure: HR 1.01 (95% CI 0.93–1.10)
Exposure assessment B: consumption of green tea
Intermediate exposure: HR 0.98 (95% CI 0.87-1.10)
Highest exposure: HR 1.04 (95% CI 0.95-1.14)
Men
Low risk:
Selection: 4/4 stars, low
risk
Comparability: 2/2 stars,
low risk
Outcome: 3/3 stars, low
risk
Total score: 9/9 stars, high
quality.
Table 5.   Detailed summary results of included nonexperimental cohort studies  (Continued)
Green tea (Camellia sinensis) for the prevention of cancer (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
237
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Exposure assessment A: intake of green tea
Highest exposure: HR 1.06 (95% CI 0.94-1.19)
Exposure assessment B: consumption of green tea
Intermediate exposure: HR 1.06 (95% CI 0.92-1.22)
Highest exposure: HR 1.06 (95% CI 0.93-1.21)
Women
Exposure assessment A: intake of green tea
Highest exposure: HR 0.97 (95% CI 0.86–1.08)
Exposure assessment B: consumption of green tea
Intermediate exposure: HR 0.82 (95% CI 0.67-1.01)
Highest exposure: HR 1.03 (95% CI 0.91-1.17)
Table 5.   Detailed summary results of included nonexperimental cohort studies  (Continued)
 
 
References Detailed summary results The Newcastle-Ottawa Scale (NOS)
Bandera 2010 Reference category: lowest exposure
Endometrial cancer
Intermediate exposure: OR 1.04 (95% CI 0.72-1.50)
Highest exposure: OR 0.76 (95% CI 0.48-1.21)
Low risk:
Selection: 4/4 stars, low risk
Comparability: 2/2 stars, low risk
Exposure: 2/3 stars, difference in response rate be-
tween cases and controls or no designation
Total score: 8/9 stars, moderate quality.
Berroukche 2012 Reference category: lowest exposure
Prostate cancer
Intermediate exposure 1: OR 1.4 (95% CI 0.8-2.2)
Intermediate exposure 2: OR 0.9 (95% CI 0.5-1.4)
Highest exposure: OR 0.6 (95% CI 0.3-1.1)
Low risk:
Selection: 3/4 stars, hospital controls
Comparability: 2/2 stars, low risk
Exposure: 3/3 stars, low risk
Total score: 8/9 stars, moderate quality.
Bonner 2005 Reference category: lowest exposure
Lung cancer
Intermediate exposure: OR 0.84 (95% CI 0.38-1.85)
Highest exposure: OR 0.59 (95% CI 0.26-1.37)
Low risk:
Selection: 3/4 stars, no description of source of con-
trols
Comparability: 2/2 stars, low risk
Exposure: 2/3 stars, low risk
Total score: 7/9 stars, moderate quality.
Chen 2011 Oesophageal cancer
Reference category: lowest exposure
Intermediate exposure 1: OR 1.27 (95% CI 0.72-1.89)
Low risk:
Selection: 3/4 stars, hospital controls
Comparability: 2/2 stars, low risk
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Intermediate exposure 2: OR 0.97 (95% CI 0.59-2.56)
Highest exposure: OR 0.92 (95% CI 0.49-2.32)
Exposure: 3/3 stars, low risk
Total score: 8/9 stars, moderate quality.
Chen 2017a Oral cancer
Reference category: lowest exposure
Chen 2015
Highest exposure: OR 0.48 (95% CI 0.28-0.82)
Chen 2016
Highest exposure: OR 0.501 (95% CI 0.284-0.883)
Chen 2017a
non-smokers
Highest exposure: OR 0.515 (95% CI 0.323-0.821)
Former/current smokers
Highest exposure: OR 0.849 (95% CI 0.556-1.298)
Non-alcohol drinkers
Highest exposure: OR 0.551 (95% CI 0.372-0.817)
Former/current alcohol drinkers
Highest exposure: OR 0.934 (95% CI 0.934-1.563)
Low risk:
Chen 2015
Selection: 4/4 stars, low risk
Comparability: 2/2 stars, low risk
Exposure: 3/3 stars, low risk
Total score: 9/9 stars, high quality.
Chen 2016
Selection: 3/4 stars, hospital controls
Comparability: 2/2 stars, low risk
Exposure: 3/3 stars, low risk
Total score: 8/9 stars, moderate quality.
Chen 2017a
Selection: 3/4 stars, hospital controls
Comparability: 2/2 stars, low risk
Exposure: 3/3 stars, low risk
Total score: 8/9 stars, moderate quality.
Fu 2013 Oral cancer
Reference category: lowest exposure
Men
Intermediate exposure: OR 0.82 (95% CI 0.69-1.07)
Highest exposure: OR 0.72 (95% CI 0.54-0.93)
Women
Intermediate exposure: OR 1.00 (95% CI 0.80-1.25)
Highest exposure: OR 0.93 (95% CI 0.74-1.26)
Low risk:
Selection: 3/4 stars, hospital controls
Comparability: 2/2 stars, low risk
Exposure: 3/3 stars, low risk
Total score: 8/9 stars, moderate quality.
Gao 1994 Oesophageal cancer
Reference category: lowest exposure
Exposure assessment A: intake of green tea
Men
Highest exposure: OR 0.80 (95% CI 0.58-1.09)
Women
Highest exposure: OR 0.50 (95% CI 0.30-0.83)
Exposure assessment B: green tea consumption
Low risk:
Selection: 3/4 stars, hospital controls
Comparability: 2/2 stars, low risk
Exposure: 2/3 stars, non-response rate difference be-
tween cases and controls or NR
Total score: 7/9 stars, moderate quality.
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Men
Intermediate exposure: OR 0.79 (95% CI 0.53-1.17)
Highest exposure: OR 0.79 (95% CI 0.56-1.13)
Women
Intermediate exposure: OR 0.77 (95% CI 0.39-1.53)
Highest exposure: OR 0.34 (95% CI 0.17-0.69)
Gao 2005 Reference category: lowest exposure
Endometrial cancer
Highest exposure: OR 0.81 (95% CI 0.65-1.00)
Low risk:
Selection: 4/4 stars, low risk
Comparability: 1/2 stars, the study did not control for
smoking.
Exposure: 2/3 stars, nonresponse rate different be-
tween cases and controls or NR
Total score: 7/9 stars, moderate quality.
Gavrilas 2018 Colorectal cancer
Reference category: lowest exposure
Intermedaite exposure 1: OR 0.34 (95% CI 0.15-0.76)
Intermediate exposure 2: OR 0.03 (95% CI 0.01-0.10)
Highest exposure: OR 0.14 (95% CI 0.05-0.34)
Low risk:
Selection: 3/4 stars, no description of controls
Comparability: 2/2 stars, low risk
Exposure: 2/3 stars, non-response rate NR
Total score: 7/9 stars, moderate quality.
Goodman 2003 Ovarian cancer
Reference category: lowest exposure
Highest exposure: OR 0.9 (95% CI 0.6-1.5)
Highest exposure A: OR 1.0 (95% CI 0.6-1.9)
Highest exposure B: OR 0.9 (95% CI 0.5-1.6)
Low risk:
Selection: 4/4 stars, low risk
Comparability: 1/2 stars, the study did not control for
smoking
Exposure: 3/3 stars, low risk
Total score: 8/9 stars, moderate quality.
Goto 1990 Pancreatic cancer
Reference category: lowest exposure
Highest exposure: OR 0.34 (95% CI 0.17-0.67)
Low risk:
Selection: 3/4 stars, no description of source of con-
trols
Comparability: 2/2 stars, low risk
Exposure: 2/3 stars, non-response rate different be-
tween cases and controls or NR
Total score: 7/9 stars, moderate quality.
Green 2014 Reference category: lowest exposure
Colorectal cancer
Intermediate exposure 1: OR 0.99 (95% CI 0.64-1.52)
Intermediate exposure 2: OR 1.15 (95% CI 0.62-2.13)
Low risk:
Selection: 4/4 stars, low risk
Comparability: 2/2 stars, low risk
Exposure: 2/3 stars, non-response rate different be-
tween cases and controls or NR
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Highest exposure: OR 0.99 (95% CI 0.62-1.58)
Proximal colon cancer
Intermediate exposure 1: OR 1.36 (95% CI 0.76-2.41)
Intermediate exposure 2: OR 0.61 (95% CI 0.20-1.83)
Highest exposure: OR 0.95 (95% CI 0.50-1.78)
Distal colon cancer
Intermediate exposure 1: OR 0.75 (95% CI 0.38-1.46)
Intermediate exposure 2: OR 1.31 (95% CI 0.55-3.10)
Highest exposure: OR 0.97 (95% CI 0.47-2.03)
Rectal cancer
Intermediate exposure 1: OR 0.91 (95% CI 0.48-1.71)
Intermediate exposure 2: OR 1.49 (95% CI 0.67-3.32)
Highest exposure: OR 1.05 (95% CI 0.53-2.10)
Total score: 8/9 stars, moderate quality.
Hakim 2000 Skin cancer
Reference category: lowest exposure
Highest exposure: OR 0.82 (95% CI 0.35-1.90)
Low risk:
Selection: 4/4 stars, low risk
Comparability: 1/2 stars, the study did not control for
smoking.
Exposure: 3/3 stars, low risk
Total score: 8/9 stars, moderate quality.
Han 2008 Reference category: lowest exposure
Lung cancer
Exposure assessment 1:
Highest exposure: OR 0.520 (95% CI 0.392-0.691)
Exposure assessment 2:
Intermediate exposure 1: OR 0.222 (95% CI
0.127-0.390)
Intermediate exposure 2: OR 0.687 (95% CI
0.448-1.052)
Highest exposure: OR 0.734 (95% CI 0.476-1.132)
Low risk:
Selection: 4/4 stars, low risk
Comparability: 2/2 stars, low risk
Exposure: 2/3 stars, non-response rate different be-
tween cases and controls or NR
Total score: 8/9 stars, moderate quality.
Hemelt 2010 Bladder cancer
Reference category: lowest exposure
Exposure assessment 1:
Highest exposure: OR 0.95 (95% CI 0.68-1.32)
Exposure assessment 2:
Intermediate exposure: OR 0.83 (95% CI 0.54-1.27)
Low risk:
Selection: 3/4 stars, hospital controls
Comparability: 2/2 stars, low risk
Exposure: 2/3 stars, non-response rate different be-
tween cases and controls or NR
Total score: 7/9 stars, moderate quality.
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Highest exposure: OR 1.02 (95% CI 0.71-1.48)
further divided by cups/d: < 4 cups/d OR 1.23 (95% CI
0.76-1.97);
> 4 cups/d OR 0.83 (95% CI 0.53-1.28)
Hoshiyama 1992 Reference category: lowest exposure
Single stomach cancer
Intermediate exposure: OR 1.2 (95% CI 0.8-1.7)
Highest exposure: OR 0.9 (95% CI 0.6-1.3)
Multiple stomach cancer
Intermediate exposure: OR 1.5 (95% CI 0.6-3.5)
Highest exposure: OR 1.6 (95% CI 0.7-3.9)
Low risk:
Selection: 4/4 stars, low risk
Comparability: 2/2 stars, low risk
Exposure: 3/3 stars, non-response rate different be-
tween cases and controls or NR
Total score: 8/9 stars, moderate quality.
Hsu 2012 Reference category: lowest exposure
Nasopharyngeal carcinoma
Intermediate exposure: OR 0.58 (95% CI 0.35-0.98)
Highest exposure: OR 0.61 (95% CI 0.40-0.91)
Low risk:
Selection: 4/4 stars, low risk
Comparability: 2/2 stars, low risk
Exposure: 2/3 stars, non-response rate different be-
tween cases and controls or NR
Total score: 8/9 stars, moderate quality.
Huang 1999 Huang 1999
Reference category: lowest exposure
Stomach cancer
Intermediate exposure 1: OR 0.88 (95% CI 0.73-1.05)
Intermediate exposure 2: OR 1.08 (95% CI 0.90-1.24)
Highest exposure: OR 0.90 (95% CI 0.73-1.11)
Inoue 1994
Reference category: lowest exposure
Stomach cancer (total)
Highest exposure: OR 1.09 (95% CI 0.83-1.43)
Subsite
Cardia
Highest exposure: OR 1.12 (95% CI 0.70-1.79)
Middle
Highest exposure: OR 1.06 (95% CI 0.73-1.54)
Antrum
Highest exposure: OR 1.10 (95% CI 0.78-1.57)
Kato 1990a
High risk:
Huang 1999
Selection: 3/4 stars, hospital controls
Comparability: 2/2 stars, low risk
Exposure: 2/3 stars, non-respondent described
Total score: 7/9 stars, moderate quality.
Kato 1990a
Selection: 2/4 stars, potential bias in selection of cas-
es and hospital controls
Comparability: 1/2 stars, the study did not control for
smoking.
Exposure: 2/3 stars, self-reported exposure not within
a structured interview or questionnaire.
Total score: 5/9 stars, low quality.
Inoue 1994
Selection: 3/4 stars, hospital controls
Comparability: 1/2 stars, the study did not control for
smoking.
Exposure: 2/3 stars, self-reported exposure not within
a structured interview or questionnaire.
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Reference category: lowest exposure
Stomach cancer
Men
Intermediate exposure: RR 1.14 (95% CI 0.82-1.60)
Highest exposure: RR 1.01 (95% CI 0.70-1.47)
Women
Intermediate exposure: RR 0.71 (95% CI 0.45-1.14)
Highest exposure: RR 0.81 (95% CI 0.51-1.27)
Total score: 6/9 stars, low quality.
Inoue 1998 Reference category: lowest exposure
Oesophageal cancer
Intermediate exposure 1: OR 1.02 (95% CI 0.50-2.10)
Intermediate exposure 2: OR 1.07 (95% CI 0.58-2.00)
Intermediate exposure 3: OR 0.96 (95% CI 0.50-1.83)
Highest exposure: OR 1.14 (95% CI 0.55-2.34)
Stomach cancer (also reported in Inoue 1994 in:
Huang 1999 and Inoue 2009a)
Intermediate exposure 1: OR 1.00 (95% CI 0.77-1.44)
Intermediate exposure 2: OR 0.96 (95% CI 0.70-1.32)
Intermediate exposure 3: OR 1.01 (95% CI 0.74-1.39)
Highest exposure: OR 0.69 (95% CI 0.48-1.00)
Colon cancer
Intermediate exposure 1: OR 0.62 (95% CI 0.36-1.05)
Intermediate exposure 2: OR 0.64 (95% CI 0.42-1.00)
Intermediate exposure 3: OR 0.76 (95% CI 0.49-1.17)
Highest exposure: OR 0.77 (95% CI 0.47-1.26)
Rectal cancer
Intermediate exposure 1: OR 1.41 (95% CI 0.70-2.83)
Intermediate exposure 2: OR 1.04 (95% CI 0.55-1.98)
Intermediate exposure 3: OR 1.42 (95% CI 0.75-2.69)
Highest exposure: OR 1.25 (95% CI 0.62-2.51)
Low risk:
Selection: 3/4 stars, hospital controls
Comparability: 2/2 stars, low risk
Exposure: 2/3 stars, self-reported exposure not within
a structured interview or questionnaire.
Total score: 7/9 stars, moderate quality.
Inoue 2008 Reference category: lowest exposure
Breast cancer
Intermediate exposure: OR 0.65 (95% CI 0.45-0.94)
Highest exposure: OR 1.00 (95% CI 0.82-1.22)
Low risk:
Selection: 4/4 stars, low risk
Comparability: 1/2 stars, the study did not control for
smoking
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Exposure: 2/3 stars, non-response rate different be-
tween cases and controls
Total score: 7/9 stars, moderate quality.
Islami 2009 Reference category: lowest exposure
Oesophageal cancer
Highest exposure: OR 0.89 (95% CI 0.38-2.09)
Low risk:
Selection: 4/4 stars, low risk
Comparability: 2/2 stars, low risk
Exposure: 2/3 stars, non-respondents described
Total score: 8/9 stars, moderate quality.
Iwasaki 2014 Reference category: lowest exposure
Breast cancer
Intermediate exposure: OR 0.86 (95% CI 0.53-1.41)
Highest exposure: OR 1.27 (95% CI 0.75-2.14)
Low risk:
Selection: 3/4 stars, hospital controls
Comparability: 2/2 stars, low risk
Exposure: 2/3 stars, non-respondents described
Total score: 7/9 stars, moderate quality.
Ji 1996 Reference category: lowest exposure
Stomach cancer
Men
Exposure assessment A: green tea drinking status
Highest exposure: OR 0.96 (95% CI 0.77-1.21)
Exposure assessment B: consumption of green tea
leaves
Intermediate exposure 1: OR 1.06 (95% CI 0.76-1.49)
Intermediate exposure 2: OR 1.15 (95% CI 0.82-1.61)
Intermediate exposure 3: OR 0.88 (95% CI 0.55-1.24)
Highest exposure: OR 0.76 (95% CI 0.55-1.27)
Women
Exposure assessment A: green tea drinking status
Highest exposure: OR 0.77 (95% CI 0.52-1.13)
Exposure assessment B: consumption of green tea
leaves
Intermediate exposure: OR 0.74 (95% CI 0.45-1.21)
Highest exposure: OR 0.81 (95% CI 0.46-1.43)
Low risk:
Selection: 4/4 stars, low risk
Comparability: 2/2 stars, low risk
Exposure: 2/3 stars, non-response rate different be-
tween cases and controls or NR
Total score: 8/9 stars, moderate quality.
Ji 1997 Reference category: lowest exposure
Men
Colon cancer
Exposure assessment A: green tea drinking habit
Low risk:
Selection: 4/4 stars, low risk
Comparability: 2/2 stars, low risk
Exposure: 2/3 stars, non-respondents described
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Highest exposure: OR 0.99 (95% CI 0.74-1.33)
Exposure assessment B: green tea consumption
Intermediate exposure 1: OR 1.13 (95% CI 0.80-1.61)
Intermediate exposure 2: OR 0.92 (95% CI 0.62-1.37)
Highest exposure: OR 0.82 (95% CI 0.52-1.28)
Exposure assessment C: lifetime green tea consump-
tion
Intermediate exposure 1: OR 0.93 (95% CI 0.63-1.35)
Intermediate exposure 2: OR 1.06 (95% CI 0.72-1.56)
Highest exposure: OR 1.01 (95% CI 0.67-1.51)
Rectal cancer
Exposure assessment A: green tea drinking habit
Highest exposure: OR 0.82 (95% CI 0.61-1.10)
Exposure assessment B: green tea consumption
Intermediate exposure 1: OR 0.99 (95% CI 0.69-1.41)
Intermediate exposure 2: OR 0.66 (95% CI 0.43-0.99)
Highest exposure: OR 0.72 (95% CI 0.46-1.13)
Exposure assessment C: lifetime green tea consump-
tion
Intermediate exposure 1: OR 0.88 (95% CI 0.60-1.27)
Intermediate exposure 2: OR 0.75 (95% CI 0.50-1.13)
Highest exposure: OR 0.80 (95% CI 0.53-1.23)
Pancreatic cancer
Exposure assessment A: green tea drinking habit
Highest exposure: OR 0.88 (95% CI 0.60-1.31)
Exposure assessment B: green tea consumption
Intermediate exposure 1: OR 1.23 (95% CI 0.79-1.92)
Intermediate exposure 2: OR 0.57 (95% CI 0.32-1.03)
Highest exposure: OR 0.63 (95% CI 0.34-1.17)
Exposure assessment C: lifetime green tea consump-
tion
Intermediate exposure 1: OR 1.11 (95% CI 0.69-1.79)
Intermediate exposure 2: OR 0.86 (95% CI 0.51-1.45)
Highest exposure: OR 0.59 (95% CI 0.32-1.07)
Women
Total score: 8/9 stars, moderate quality.
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Colon cancer
Exposure assessment A: green tea drinking habit
Highest exposure: OR 0.77 (95% CI 0.56-1.06)
Exposure assessment B: green tea consumption
Intermediate exposure: OR 0.83 (95% CI 0.57-1.21)
Highest exposure: OR 0.67 (95% CI 0.41-1.10)
Exposure assessment C: lifetime green tea consump-
tion
Intermediate exposure: OR 0.87 (95% CI 0.60-1.27)
Highest exposure: OR 0.62 (95% CI 0.38-1.02)
Rectal cancer
Exposure assessment A: green tea drinking habit
Highest exposure: OR 0.51 (95% CI 0.36-0.73)
Exposure assessment B: green tea consumption
Intermediate exposure: OR 0.51 (95% CI 0.33-0.79)
Highest exposure: OR 0.57 (95% CI 0.34-0.97)
Exposure assessment C: lifetime green tea consump-
tion
Intermediate exposure: OR 0.54 (95% CI 0.35-0.84)
Highest exposure: OR 0.52 (95% CI 0.30-0.89)
Pancreatic cancer:
Exposure assessment A: green tea drinking habit
Highest exposure: OR 0.47 (95% CI 0.29-0.77)
Exposure assessment B: green tea consumption
Intermediate exposure: OR 0.47 (95% CI 0.25-0.89)
Highest exposure: OR 0.53 (95% CI 0.25-1.09)
Exposure assessment C: lifetime green tea consump-
tion
Intermediate exposure: OR 0.59 (95% CI 0.32-1.10)
Highest exposure: OR 0.38 (95% CI 0.18-0.82)
Jia 2016 Reference category: lowest exposure
Lung cancer + mesothelioma mortality
Intermediate exposure 1: OR 0.88 (95% CI 0.66-0.87)
Intermediate exposure 2: OR 2.18 (95% CI 0.96-3.50)
Highest exposure: OR 0.70 (95% CI 0.57-0.86)
Low risk:
Selection: 4/4 stars, low risk
Comparability: 1/2 stars, the study did not control for
smoking
Exposure: 2/3 stars, interview not blinded to case/
control status
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Total score: 7/9 stars, moderate quality.
Jian 2004 Prostate cancer
Reference category: lowest exposure
Exposure assessment A: green tea drinking habits
Highest exposure: OR 0.28 (95% CI 0.17-0.47)
Exposure assessment B: intake of green tea
Intermediate exposure: OR 0.53 (95% CI 0.30-0.94)
Highest exposure: OR 0.27 (95% CI 0.15-0.48)
Low risk:
Selection: 3/4 stars, hospital controls
Comparability: 2/2 stars, low risk
Exposure: 3/3 stars, low risk
Total score: 8/9 stars, moderate quality.
Jin 2013 Reference category: lowest exposure
Lung cancer
Exposure assessment A: green tea drinking habits
Highest exposure: OR 0.78 (95% CI 0.65-0.95)
Exposure assessment B: consumption of green tea
Intermediate exposure 1: OR 0.76 (95% CI 0.54-1.07)
Intermediate exposure 2: OR 0.84 (95% CI 0.66-1.08)
Highest exposure: OR 0.74 (95% CI 0.56-0.99)
Low risk:
Selection: 4/4 stars, low risk
Comparability: 2/2 stars, low risk
Exposure: 3/3 stars, low risk
Total score: 9/9 stars, high quality.
Kakuta 2009 Reference category: lowest exposure
Endometrial cancer
Intermediate exposure 1: OR 0.77 (95% CI 0.37-1.58)
Intermediate exposure 2: OR 0.61 (95% CI 0.30-1.23)
Highest exposure: OR 0.33 (95% CI 0.15-0.75)
Low risk:
Selection: 3/4 stars, hospital controls
Comparability: 2/2 stars, low risk
Exposure: 3/3 stars, low risk
Total score: 8/9 stars, moderate quality.
Kato 1990 Reference category: lowest exposure
Colon cancer
Highest exposure: RR 0.61 (95% CI 0.41-0.91)
Rectal cancer
Highest exposure: RR 1.32 (95% CI 0.78-2.23)
High risk:
Selection: 3/4 stars, potential for selection bias in cas-
es
Comparability: 1/2 stars, the study did not control for
smoking
Exposure: 2/3 stars, self-reported exposure not within
a structured interview or questionnaire.
Total score: 6/9 stars, low quality.
Kono 1988 Stomach cancer
Reference category: lowest exposure
Population controls
Highest exposure: OR 0.3 (95% CI 0.1-0.7)
Hospital controls
High risk:
Selection: 4/4 stars when using population controls
and 3/4 when using hospital controls
Comparability: 2/2 stars, low risk
Exposure: 1/3 stars, different methods of exposure as-
certainment in cases and controls and self-reported
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Highest exposure: OR 0.5 (95% CI 0.3-1.1) exposure not within a structured interview or ques-
tionnaire.
Total score: 7/9 stars, moderate quality and 6/9 stars
low quality.
Kubik 2008 Kubik 2008
Reference category: lowest exposure (OR for trend on-
ly reported)
Lung cancer
Men nonsmokers
Highest exposure: OR 1.08 (95% CI 0.56-2.08)
Men smokers
Highest exposure: OR 0.93 (95% CI 0.63-1.38)
Women nonsmokers
Highest exposure: OR 0.88 (95% CI 0.61-1.27)
Women smokers
Highest exposure: OR 1.09 (95% CI 0.80-1.49)
Data on former smokers who quit from 10 to < 20
years were excluded from the reported analysis. Pre-
vious report on fewer female cases reported in Kubik
2004.
Kubik 2004
Reference category: lowest exposure
Lung cancer
Intermediate exposure: OR 0.97 (95% CI 0.69-1.38)
Highest exposure: OR 1.02 (95% CI 0.74-1.40)
Also analysis available stratified by smoking habits
Subsequent report in Kubik 2008 with longer recruit-
ment of women from the same area
Low risk:
Kubik 2004
Selection: 3/4 stars, hospital controls
Comparability: 2/2 stars, low risk
Exposure: 2/3 stars, non-response rate different be-
tween cases and controls or NR
Total score: 7/9 stars, moderate quality.
Kubik 2008
Selection: 3/4 stars, hospital controls
Comparability: 2/2 stars, low risk
Exposure: 2/3 stars, non-response rate different be-
tween cases and controls or NR
Total score: 7/9 stars, moderate quality.
Kuo 2009 Leukaemia
Green-tea-only consumption compared to no-tea con-
sumption
Cases exposed = 9, controls exposed = 24, cases not
exposed = 63, controls not exposed = 123
OR 0.73 (95% CI 0.32-1.67)
Consumption of green tea with other types of tea
compared to no-tea consumption
Cases exposed = 17, controls exposed = 61, cases not
exposued = 63, controls not exposed = 123
High risk:
Selection: 4/4 stars, low risk
Comparability: 0/2 stars, only crude analysis without
adjustment for confounding factors
Exposure: 2/3 stars, non-response rate different be-
tween cases and controls or NR
Total score: 6/9 stars, low quality.
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OR 0.54 (95% CI 0.29-1.01)
Lassed 2016 Reference category: lowest exposure
Postate cancer
Intermediate exposure: OR 0.64 (95% CI 0.36-1.15)
Highest exposure: OR 0.40 (95% CI 0.08-1.92)
High risk:
Selection: 3/4 stars, hospital controls
Comparability: 0/2 stars, crude analysis with no ad-
justment for confounding factors
Exposure: 3/3 stars, low risk
Total score: 6/9 stars, low quality.
Le Marchand 2000 Reference category: lowest exposure
Lung cancer
Intermediate exposure 1: OR 1.0 (95% CI 0.6-1.7)
Intermediate exposure 2: OR 0.7 (95% CI 0.4-1.3)
Highest exposure: OR 0.9 (95% CI 0.5-1.6)
Low risk:
Selection: 4/4 stars, low risk
Comparability: 2/2 stars, low risk
Exposure: 3/3 stars, low risk
Total score: 9/9 stars, high quality.
Lee 2017 Reference category: lowest exposure
Prostate cancer
Exposure assessment A
Highest exposure: OR 0.60 (95% CI 0.37-0.98)
Exposure assessment B
Intermediate exposure 1: OR 1.53 (95% CI 0.39-5.93)
Intermediate exposure 2: OR 0.16 (95% CI 0.01-2.22)
Highest exposure: OR 0.34 (95% CI 0.02-6.05)
Low risk:
Selection: 3/4 stars, hospital controls
Comparability: 2/2 stars, low risk
Exposure: 2/3 stars, non-response rate different be-
tween cases and controls or NR
Total score: 7/9 stars, moderate quality.
Lei 1994 Reference category: lowest exposure
Lung cancer
Highest exposure: OR 0.71 (95% CI 0.43-1.18)
High risk:
Selection: 1/4 stars, no description of identification of
cases with potential selection bias and hospital con-
trols
Comparability: 1/2 stars, the study did not control for
smoking.
Exposure: 1/3 star, no description of exposure ascer-
tainment and non-response rate between cases and
controls NR
Total score: 3/9 stars, low quality.
Leung 2016 Reference category: lowest exposure
Ovarian cancer
Exposure assessment A
Highest exposure: OR 0.84 (95% CI 0.54-1.30)
Exposure assessment B
Intermediate exposure 1: OR 1.03 (95% CI 0.50-2.00)
Low risk:
Selection: 4/4 stars, low risk
Comparability: 2/2 stars, low risk
Exposure: 3/3 stars, low risk
Total score: 9/9 stars, high quality
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Intermediate exposure 2: OR 0.78 (95% CI 0.37-1.55)
Highest exposure: OR 0.77 (95% CI 0.39-1.46)
Li 2011a Reference category: lowest exposure
Results using population controls
All cancer
Exposure assessment A
Highest exposure: OR 0.78 (95% CI 0.60-1.01)
Exposure assessment B
Intermediate exposure: OR 0.71 (95% CI 0.47-1.08)
Highest exposure: OR 0.51 (95% CI 0.27-0.74)
Breast cancer
Exposure assessment A
Highest exposure: OR 0.61 (95% CI 0.32-1.18)
Exposure assessment B
Intermediate exposure: OR 0.60 (95% CI 0.24-1.50)
Highest exposure: OR 0.07 (95% CI 0.01-0.47)
Colorectal cancer
Exposure assessment A
Highest exposure: OR 0.62 (95% CI 0.42-0.92)
Exposure assessment B
Intermediate exposure: OR 0.55 (95% CI 0.28-1.06)
Highest exposure: OR 0.45 (95% CI 0.25-0.82)
Leukaemia
Exposure assessment A
Highest exposure: OR 1.55 (95% CI 0.61-3.96)
Exposure assessment B
Intermediate exposure: OR not estimable
Highest exposure: OR 0.57 (95% CI 0.07-4.79)
Results using hospital controls
All cancer
Exposure assessment A
Highest exposure: OR 0.77 (95% CI 0.59-1.00)
Exposure assessment B:
Intermediate exposure: OR 0.60 (95% CI 0.40-0.92)
Low risk:
Selection: 4/4 stars when using population controls
and 3/4 when using hospital controls, low risk
Comparability: 2/2 stars, low risk
Exposure: 2/3 stars, non-response rate different be-
tween cases and controls or NR
Total score: 8/9 stars and 7/9 stars, moderate quality.
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Highest exposure: OR 0.51 (95% CI 0.31-0.83)
Breast cancer
Exposure assessment A
Highest exposure: OR 0.55 (95% CI 0.28-1.06)
Exposure assessment B
Intermediate exposure: OR 0.54 (95% CI 0.22-1.33)
Highest exposure: OR 0.06 (95% CI 0.01-0.61)
Colorectal cancer
Exposure assessment A
Highest exposure: OR 0.67 (95% CI 0.45-0.99)
Exposure assessment B
Intermediate exposure: OR 0.51 (95% CI 0.26-0.99)
Highest exposure: OR 0.52 (95% CI 0.29-0.94)
Leukaemia
Exposure assessment A
Highest exposure: OR 1.46 (95% CI 0.55-3.84)
Exposure assessment B
Intermediate exposure: OR not estimable
Highest exposure: OR 0.65 (95% CI 0.08-5.63)
Li 2014 Reference category: lowest exposure
Prostate cancer
Highest exposure: OR 0.59 (95% CI 0.40-0.87)
Low risk:
Selection: 4/4 stars, low risk
Comparability: 1/2 stars, the study did not control for
smoking
Exposure: 2/3 stars, self-reported exposure not within
a structured interview or questionnaire.
Total score: 7/9 stars, moderate quality.
Li 2016 Reference category: lowest exposure
Breast cancer
Highest exposure: OR 1.20 (95% CI 0.80-1.78)
Low risk:
Selection: 3/4 stars, hospital controls
Comparability: 1/2 stars, the study did not control for
smoking
Exposure: 3/3 stars, low risk
Total score: 7/9 stars, moderate quality.
Lin 2012 Reference category: highest exposure
Lung cancer
Intermediate exposure: RR 3.01 (95% CI 1.13-8.05)
High risk:
Selection: 3/4 stars, hospital controls
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Lowest exposure: RR 6.34 (95% CI 2.69-14.91) Comparability: 1/2 stars, the study did not control for
smoking.
Exposure: 2/3 stars, self-reported exposure not within
a structured interview or questionnaire.
Total score: 6/9 stars, low quality.
Liu 2010 Reference category: lowest exposure
Stomach cancer:
Highest exposure: OR 0.42 (95%CI 0.32-0.55)
Low risk:
Selection: 4/4 stars, low risk
Comparability: 2/2 stars, low risk
Exposure: 3/3 stars, low risk
Total score: 9/9 stars, high quality.
Liu 2017 Reference category: highest exposure
Leukaemia
Lowest exposure: OR 0.71 (95% CI 0.46-1.07)
Low risk:
Selection: 3/4 stars, hospital controls
Comparability: 2/2 stars, low risk
Exposure: 3/3 stars, low risk
Total score: 8/9 stars, moderate quality.
Mao 2011 Reference category: lowest exposure
Stomach cancer
Exposure assessment A: green-tea drinking status
Intermediate exposure: OR 0.58 (95% CI 0.46-5.03)
Highest exposure: OR 1.02 (95% CI 0.70-1.64)
Exposure assessment B: green tea consumption
Intermediate exposure 1: OR 0.88 (95% CI 0.57-1.36)
Intermediate exposure 2: OR 1.15 (95% CI 0.76-2.35)
Highest exposure: OR 1.13 (95% CI 0.52-2.67)
High risk:
Selection: 2/4 stars, hospital controls with no descrip-
tion
Comparability: 2/2 stars, low risk
Exposure: 2/3 stars, self-reported exposure not within
a structured interview or questionnaire.
Total score: 6/9 stars, low quality.
Mizoo 2013 Reference category: lowest exposure
Breast cancer
Intermediate exposure 1: OR 0.97 (95% CI 0.71-1.33)
Intermediate exposure 2: OR 0.63 (95% CI 0.43-0.93)
Highest exposure: OR 0.72 (95% CI 0.46-1.12)
Low risk:
Selection: 3/4 stars, hospital controls
Comparability: 1/2 stars, the study did not control for
smoking
Exposure: 3/3 stars, low risk
Total score: 7/9 stars, moderate quality.
Mizuno 1992 Reference category: lowest exposure
Pancreatic cancer
Highest exposure: OR 1.94 (95% CI 1.06-3.55)
High risk:
Selection: 3/4 stars, hospital controls
Comparability: 1/2 stars, the study did not control for
smoking
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Exposure: 2/3 stars, self-reported exposure not within
a structured interview or questionnaire.
Total score: 6/9 stars, low quality.
Mu 2003 Reference category: lowest exposure
Stomach cancer (Mu 2005)
Intermediate exposure 1: OR 1.09 (95% CI 0.53-2.23)
Intermediate exposure 2: OR 0.44 (95% CI 0.19-1.01)
Highest exposure: OR 0.40 (95% CI 0.14-1.09)
Exposure assessment B: green tea intake
Highest exposure: OR 0.59 (95% CI 0.34-1.01)
Liver cancer (Li 2011b)
Intermediate exposure 1: OR 1.21 (95% CI 0.62-2.36)
Intermediate exposure 2: OR 0.76 (95% CI 0.38-1.51)
Highest exposure: OR 0.55 (95% CI 0.28-1.09)
Oesophageal cancer
Intermediate exposure 1: OR 1.13 (95% CI 0.67-1.92)
Intermediate exposure 2: OR 0.78 (95% CI 0.46-1.34)
Highest exposure: OR 0.58 (95% CI 0.35-0.97)
Low risk:
Li 2011b
Selection: 4/4 stars, low risk
Comparability: 2/2 stars, low risk
Exposure: 2/3 stars, non-response rate different be-
tween cases and controls or NR
Total score: 8/9 stars, moderate quality.
Mu 2003
Selection: 3/4 stars, potential selection bias for cases
Comparability: 2/2 stars, low risk
Exposure: 2/3 stars, non-response rate different be-
tween cases and controls or NR
Total score: 7/9 stars, moderate quality.
Mu 2005
Selection: 4/4 stars, low risk
Comparability: 2/2 stars, low risk
Exposure: 2/3 stars, non-response rate different be-
tween cases and controls or NR
Total score: 8/9 stars, moderate quality.
Nagle 2010 Reference category: lowest exposure
Ovarian cancer
Intermediate exposure 1: OR 0.77 (95% CI 0.61-0.98)
Intermediate exposure 2: OR 0.85 (95% CI 0.63-1.15)
Intermediate exposure 3: OR 0.80 (95% CI 0.54-1.19)
Intermediate exposure 4: OR 0.92 (95% CI 0.57-1.49)
Highest exposure: OR 0.82 (95% CI 0.38-1.79)
Low risk:
Selection: 4/4 stars, low risk
Comparability: 2/2 stars, low risk
Exposure: 2/3 stars, non-response rate different be-
tween cases and controls or NR
Total score: 8/9 stars, moderate quality
Oze 2014 Reference category: lowest exposure
Upper aerodigestive tract cancer
Intermediate exposure 1: OR 1.25 (95% CI 0.98–1.60)
Intermediate exposure 2: OR 1.02 (95% CI 0.77–1.34)
Highest exposure: OR 1.39 (95% CI 1.13–1.70)
Subsite
Low risk:
Selection: 4/4 stars, low risk
Comparability: 2/2 stars, low risk
Exposure: 2/3 stars, self-reported exposure not within
a structured interview or questionnaire.
Total score: 8/9 stars, moderate quality.
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Oesophageal cancer
Intermediate exposure 1: OR 1.20 (95% CI 0.82–1.77)
Intermediate exposure 2: OR 1.00 (95% CI 0.65–1.55)
Highest exposure: OR 1.31 (95% CI 0.95–1.81)
Oral, pharyngeal and laryngeal cancer
Intermediate exposure 1: OR 1.34 (95% CI 0.97–1.86)
Intermediate exposure 2: OR 1.03 (95% CI 0.71–1.50)
Highest exposure: OR 1.47 (95% CI 1.12–1.93)
Available also stratified analysis by smoking status
(never, ever) and alcoholic drinker
Peng 2013 Reference category: lowest exposure
Colorectal cancer
Highest exposure: OR 0.54 (95% CI 0.41-0.72)
Low risk:
Selection: 4/4 stars, low risk
Comparability: 1/2 stars, the study did not control for
smoking.
Exposure: 2/3 stars, self-reported exposure not within
a structured interview or questionnaire.
Total score: 7/9 stars, moderate quality
Peng 2015 Reference category: lowest exposure
Oesophageal cancer
Highest exposure: OR 0.63 (95% CI 0.45-0.91)
Low risk:
Selection: 4/4 stars, low risk
Comparability: 2/2 stars, low risk
Exposure: 2/3 stars, self-reported exposure not within
a structured interview or questionnaire.
Total score: 8/9 stars, moderate quality.
Ruan 2010 Reference category: lowest exposure
Nasopharyngeal cancer
Highest exposure: OR 0.44 (95% CI 0.36–0.54)
Low risk:
Selection: 3/4 stars, hospital controls
Comparability: 1/2 stars, the study did not control for
smoking
Exposure: 3/3 stars, low risk
Total score: 7/9 stars, moderate quality.
Setiawan 2001 Reference category: lowest exposure
Stomach cancer
Exposure assessment A
Highest exposure: OR 0.52 (95% CI 0.29–0.94)
Exposure assessment B
Intermediate exposure: OR 0.70 (95% CI 0.36–1.36)
Low risk:
Selection: 4/4 stars, low risk
Comparability: 2/2 stars, low risk
Exposure: 2/3 stars, non-response rate different be-
tween cases and controls or NR
Total score: 8/9 stars, moderate quality.
Table 6.   Detailed summary results of included nonexperimental case-control studies  (Continued)
Green tea (Camellia sinensis) for the prevention of cancer (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
254
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Highest exposure: OR 0.39 (95% CI 0.15–1.01)
Shrubsole 2009 Reference category: lowest exposure
Breast cancer
Exposure assessment A
Highest exposure: OR 0.88 (95% CI 0.79–0.98)
Exposure assessment B
Intermediate exposure 1: OR 0.89 (95% CI 0.73–1.08)
Intermediate exposure 2: OR 0.93 (95% CI 0.77–1.12)
Intermediate exposure 3: OR 0.72 (95% CI 0.59–0.88)
Highest exposure: OR 0.97 (95% CI 0.80–1.16)
Stratified analysis also available in pre- and post-
menopausal women
Low risk:
Selection: 4/4 stars, low risk
Comparability: 1/2 stars, the study did not control for
smoking.
Exposure: 2/3 stars, self-reported exposure not within
a structured interview or questionnaire.
Total score: 7/9 stars, moderate quality.
Song 2008 Reference category: lowest exposure
Ovarian cancer
Intermediate category: OR 0.82 (95% CI 0.66-1.04)
Highest exposure: OR 0.46 (95% CI 0.26-0.84)
Low risk:
Selection: 4/4 stars, low risk
Comparability: 2/2 stars, low risk
Exposure: 2/3 stars, self-reported exposure not within
a structured interview or questionnaire.
Total score: 8/9 stars, moderate quality
Sonoda 2004 Reference category: lowest exposure
Prostate cancer
Intermediate exposure 1: OR 0.99 (95% CI 0.48-2.03)
Intermediate exposure 2: OR 0.79 (95% CI 0.38-1.63)
Highest exposure: OR 0.67 (95% CI 0.27-1.64)
Low risk:
Selection: 3/4 stars, hospital controls
Comparability: 2/2 stars, low risk
Exposure: 2/3 stars, self-reported exposure not within
a structured interview or questionnaire.
Total score: 7/9 stars, moderate quality.
Tajima 1985 Reference category: lowest exposure
Stomach cancer
Highest exposure: OR 0.64, CIs NR
Colon cancer
Highest exposure: OR 0.97, CIs NR
Rectal cancer
Highest exposure: OR 0.91, CIs NR
High risk:
Selection: 3/4 stars, hospital controls
Comparability: 1/2 stars, the study did not control for
smoking
Exposure: 2/3 stars, self-reported exposure not within
a structured interview or questionnaire.
Total score: 6/9 stars, low quality.
Takezaki 2000 Reference category: lowest exposure
Pharynx (hypopharynx) cancer
Intermediate exposure: OR 0.8 (95% CI 0.4-1.5)
Low risk:
Selection: 3/4 stars, hospital controls
Comparability: 2/2 stars, low risk
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Highest exposure: OR 0.8 (95% CI 0.3-2.3)
Oesophageal cancer
Intermediate exposure: OR 0.8 (95% CI 0.6-1.1)
Highest exposure: OR 0.7 (95% CI 0.4-1.2)
Analysis also reported for upper, middle and lower
third of the oesophagus
Exposure: 3/3 stars, low risk
Total score: 8/9 stars, moderate quality.
Takezaki 2001 Reference category: lowest quartile
Adenocarcinoma
Men
Intermediate exposure 1: OR 1.06 (95% CI 0.72-1.57)
Intermediate exposure 2: OR 1.11 (95% CI 0.74-1.66)
Highest exposure: OR 1.33 (95% CI 0.83-2.15)
Women
Intermediate exposure 1: OR 0.98 (95% CI 0.58-1.66)
Intermediate exposure 2: OR 1.14 (95% CI 0.68-1.93)
Highest exposure: OR 1.14 (95% CI 0.61-2.12)
Squamous cell and small-cell carcinoma
Men
Intermediate exposure 1: OR 0.99 (95% CI 0.67-1.47)
Intermediate exposure 2: OR 1.17 (95% CI 0.78-1.73)
Highest exposure: OR 1.08 (95% CI 0.66-1.75)
Women
Intermediate exposure 1: OR 0.36 (95% CI 0.14-0.93)
Intermediate exposure 2: OR 0.41 (95% CI 0.16-1.04)
Highest exposure: OR 0.49 (95% CI 0.17-1.46)
Low risk:
Selection: 3/4 stars, hospital controls
Comparability: 2/2 stars, low risk
Exposure: 3/3 stars, low risk
Total score: 8/9 stars, moderate quality.
Tewes 1990 Reference category: lowest exposure
Lung cancer
Highest exposure: OR 2.74 (95% CI 1.10-6.80)
Low risk:
Selection: 3/4 stars, case identification with no inde-
pendent validation
Comparability: 2/2 stars, low risk
Exposure: 2/3 stars, self-reported exposure not within
a structured interview or questionnaire.
Total score: 7/9 stars, moderate quality.
Tse 2017 Reference category: lowest exposure
Prostate cancer
Highest exposure: OR 0.56 (95% CI 0.34-0.91)
High risk:
Selection: 3/4 stars, hospital controls
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Comparability: 1/2 stars, the study did not control for
smoking.
Exposure: 2/3 stars, self-reported exposure not within
a structured interview or questionnaire.
Total score: 6/9 stars, low quality.
Wakai 2004 Reference category: lowest exposure
Bladder cancer
Intermediate exposure 1: OR 1.49 (95% CI 0.78–2.84)
Intermediate exposure 2: OR 2.79 (95% CI 1.49–5.23)
Highest exposure: OR 1.24 (95% CI 0.51–2.99)
Low risk:
Selection: 3/4 stars, hospital controls
Comparability: 2/2 stars, low risk
Exposure: 3/3 stars, low risk
Total score: 8/9 stars, moderate quality.
Wang 1999 Reference category: lowest exposure
Oesophageal cancer
Highest exposure: OR 0.20 (95% CI 0.06-0.67)
Other stomach cancer
Highest exposure: OR 0.28 (CIs NR)
Low risk:
Selection: 4/4 stars, low risk
Comparability: 2/2 stars, low risk
Exposure: 1/3 stars, no description of exposure ascer-
tainment and non-response rate different between
cases and controls or NR
Total score: 7/9 stars, moderate quality.
Wang 2006 Reference category: lowest quartile
Oesophageal cancer
Highest exposure: OR 0.13 (95% CI 0.03-0.62)
High risk:
Selection: 4/4 stars, low risk
Comparability: 0/2 stars, no information on con-
founders as smoking
Exposure: 2/3 stars, self-reported exposure not within
a structured interview or questionnaire.
Total score: 6/9 stars, low quality.
Wang 2007 Reference category: lowest exposure
Oesophageal cancer
Men
Highest exposure: OR 1.368 (95% CI 0.948-1.975)
Women
Highest exposure: OR 0.257 (95% CI 0.070-0.941)
Available analysis according green tea drinking dura-
tion (years)
Low risk:
Selection: 4/4 stars, low risk
Comparability: 1/2 stars, the study did not control for
smoking.
Exposure: 2/3 stars, self-reported exposure not within
a structured interview or questionnaire.
Total score: 7/9 stars, moderate quality.
Wang 2012a Reference category: lowest exposure
Renal cancer
Highest exposure: OR 0.34 (95% CI 0.21–0.55)
High risk:
Selection: 3/4 stars, hospital controls
Comparability: 1/2 stars, the study did not control for
smoking.
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Exposure: 2/3 stars, non-response rate different be-
tween cases and controls or NR
Total score: 6/9 stars, low quality.
Wang 2012b Reference category: lowest exposure
Multiple myeloma
Intermediate exposure 1: OR 0.94 (95% CI 0.52–1.72)
Intermediate exposure 2: OR 0.51 (95% CI 0.35-0.73)
Highest exposure: OR 0.27 (95% CI 0.13–0.58)
Overall exposure: OR 0.38 (95% CI 0.27-0.53)
Low risk:
Selection: 3/4 stars, hospital controls
Comparability: 1/2 stars, the study did not control for
smoking.
Exposure: 3/3 stars, low risk
Total score: 7/9 stars, moderate quality.
Wang 2012c Reference category: lowest exposure
Pancreatic cancer
Men
Exposure assessment A
Highest exposure: OR 1.02 (95% CI 0.78-1.35)
Exposure assessment B
Intermediate exposure 1: OR 0.99 (95% CI 0.71-1.40)
Intermediate exposure 2: OR 1.38 (95% CI 0.91-2.11)
Highest exposure: OR 0.91 (95% CI 0.65-1.27)
Women
Exposure assessment A
Highest exposure: OR 0.68 (95% CI 0.48-0.96)
Exposure assessment B
Intermediate exposure 1: OR 0.85 (95% CI 0.49–1.46)
Intermediate exposure 2: OR 0.64 (95% CI 0.37-1.11)
Highest exposure: OR 0.56 (95% CI 0.32-0.98)
Low risk:
Selection: 4/4 stars, low risk
Comparability: 2/2 stars, low risk
Exposure: 2/3 stars, non-response rate different be-
tween cases and controls or NR
Total score: 8/9 stars, moderate quality.
Wang 2013a Reference category: lowest exposure
Breast cancer
Highest exposure: OR 0.65 (95% CI 0.44–0.97)
Low risk:
Selection: 3/4 stars, hospital controls
Comparability: 1/2 stars, the study did not control for
smoking.
Exposure: 3/3 stars, low risk
Total score: 7/9 stars, moderate quality.
Wang 2013b Reference category: lowest exposure
Bladder cancer
Intermediate exposure: OR 0.82 (95% CI 0.61–1.11)
Low risk:
Selection: 3/4 stars, hospital controls
Comparability: 2/2 stars, low risk
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Highest exposure: OR 0.60 (95% CI 0.45–0.79) Exposure: 2/3 stars, non-response rate different be-
tween cases and controls or NR
Total score: 7/9 stars, moderate quality.
Wang 2015 Reference category: lowest exposure
Stomach cancer
Exposure assessment A: green tea intake
Highest exposure: OR 0.72 (95% CI 0.32-0.98)
Exposure assessment B: green tea consumption
Intermediate exposure: OR 0.87 (95% CI 0.43-1.81)
Intermediate exposure: OR 0.66 (95% CI 0.36-1.17)
Highest exposure: OR 0.53 (95% CI 0.23-0.97)
Low risk:
Selection: 3/4 stars, hospital controls
Comparability: 2/2 stars, low risk
Exposure: 2/3 stars, non-response rate different be-
tween cases and controls or not reported
Total score: 7/9 stars, moderate quality.
Wilkens 1996 Reference category: lowest exposure
Urinary tract cancer
Men
Intermediate exposure: OR 1.1 (95% CI 0.6-1.9)
Highest exposure: OR 1.1 (95% CI 0.6-2.3)
Women
Intermediate exposure: OR 0.8 (95% CI 0.3-2.1)
Highest exposure: OR 0.9 (95% CI 0.3-2.6)
Low risk:
Selection: 4/4 stars, low risk
Comparability: 2/2 stars, low risk
Exposure: 2/3 stars, non-response rate different be-
tween cases and controls or NR
Total score: 8/9 stars, moderate quality.
Wu 2003 Reference category: lowest exposure
Breast cancer
Intermediate exposure: OR 0.74 (95% CI 0.52-1.04)
Highest exposure: OR 0.61 (95% CI 0.40-0.93)
Low risk:
Selection: 4/4 stars, low risk
Comparability: 2/2 stars, low risk
Exposure: 3/3 stars, low risk
Total score: 9/9 stars, high quality.
Wu 2009a Reference category: lowest exposure
Prostate cancer
Highest exposure: OR 0.52 (95% CI 0.28-0.96)
Intermediate categories NR
High risk:
Selection: 2/4 stars, potential selection bias for cases
and hospital controls
Comparability: 1/2 stars, the study did not control for
smoking.
Exposure: 2/3 stars, non-response rate different be-
tween cases and controls or NR
Total score: 5/9 stars, low quality.
Wu 2009b Reference category: lowest exposure
Oesophageal cancer
Dafeng (high risk area)
Low risk:
Selection: 3/4 stars, potential for selection bias in cas-
es
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Highest exposure: OR 1.0 (95% CI 0.7-1.3)
Ganyu (low risk area)
Highest exposure: OR 1.3 (95% CI 0.9-1.7)
Comparability: 2/2 stars, low risk
Exposure: 3/3 stars, low risk
Total score: 8/9 stars, moderate quality.
Xu 2007 Reference category: lowest exposure
Endometrial cancer
Highest exposure: OR 0.8 (95% CI 0.6-0.9)
Low risk:
Selection: 4/4 stars, low risk
Comparability: 1/2 stars, the study did not control for
smoking.
Exposure: 3/3 stars, low risk
Total score: 8/9 stars, moderate quality.
Xu 2013 Reference category: lowest exposure
Lung cancer
Highest exposure: OR 0.333 (95% CI 0.154 -0.720)
High risk:
Selection: 1/4 star, no description of cases, potential
selection bias in cases, no description of controls
Comparability: 1/2 stars, the study did not control for
smoking.
Exposure: 2/3 stars, non-response rate different be-
tween cases and controls or NR
Total score: 4/9 stars, low quality.
Yan 2016 Reference category: lowest exposure
Oral cancer
Highest exposure: OR 0.58 (95% CI 0.42-0.79)
Low risk:
Selection: 4/4 stars, low risk
Comparability: 2/2 stars, low risk
Exposure: 2/3 stars, non-response rate different be-
tween cases and controls or NR
Total score: 8/9 stars, moderate quality.
Ye 1998 Reference category: lowest exposure
Stomach cancer
Highest exposure: OR 1.72 (95% CI 1.26-2.36)
Low risk:
Selection: 4/4 stars, low risk
Comparability: 1/2 stars, the study did not control for
smoking.
Exposure: 2/3 stars, self-reported exposure not within
a structured interview or questionnaire.
Total score: 7/9 stars, moderate quality.
Yu 1995 Reference category: lowest exposure
Stomach cancer
Highest exposure: OR 0.71 (95% CI 0.54-0.93)
Highest exposure A: OR 0.76 (95% CI 0.57-1.03)
Highest exposure B: OR 0.54 (95% CI 0.33-0.88)
Subsite
Low risk:
Selection: 4/4 stars, low risk
Comparability: 2/2 stars, low risk
Exposure: 2/3 stars, non-response rate different be-
tween cases and controls or NR
Total score: 8/9 stars, moderate quality.
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Cardia
Highest exposure: OR 0.95 (95% CI 0.51-1.77)
Highest exposure A: OR 0.94 (95% CI 0.47-1.87)
Highest exposure B: OR 0.98 (95% CI 0.34-2.89)
Pylori
Highest exposure: OR 0.29 (95% CI 0.13-0.68)
Highest exposure A: OR 0.30 (95% CI 0.13-0.73)
Highest exposure B: OR 0.24 (95% CI 0.05-1.17)
Antrum
Highest exposure: OR 0.67 (95% CI 0.41-1.08)
Highest exposure A: OR 0.79 (95% CI 0.48-1.31)
Highest exposure B: OR 0.29 (95% CI 0.12-0.71)
Other sites
Highest exposure: OR 0.82 (95% CI 0.41-1.65)
Highest exposure A: OR 0.83 (95% CI 0.40-1.73)
Highest exposure B: OR 0.76 (95% CI 0.15-3.87)
Site unknown
Highest exposure: OR 0.69 (95% CI 0.23-2.06)
Highest exposure A: OR 0.62 (95% CI 0.17-2.18)
Highest exposure B: OR 0.87 (95% CI 0.15-5.00)
Zhang 2002 Reference category: lowest exposure
Ovarian cancer
Intermediate exposure 1: OR 0.42 (95% CI 0.24-0.73)
Intermediate exposure 2: OR 0.40 (95% CI 0.23-0.70)
Highest exposure: OR= 0.43 (95% CI 0.30-0.63)
Low risk:
Selection: 3/4 stars, hospital controls
Comparability: 2/2 stars, low risk
Exposure: 2/3 stars, self-reported exposure not within
a structured interview or questionnaire.
Total score: 7/9 stars, moderate quality.
Zhang 2007 Reference category: lowest exposure
Breast cancer
Intermediate exposure 1: 0.85 (95% CI 0.68–1.05)
Intermediate exposure 2: 0.92 (95% CI 0.75–1.12)
Intermediate exposure 3: 0.57 (95% CI 0.38–0.85)
Highest exposure: 0.57 (95% CI 0.47–0.69)
Low risk:
Selection: 3/4 stars, hospital controls
Comparability: 2/2 stars, low risk
Exposure: 3/3 stars, low risk
Total score: 8/9 stars, moderate quality.
Zhang 2008 Reference category: lowest exposure
Leukaemia
Low risk:
Selection: 3/4 stars, hospital controls
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Exposure assessment A: intake of green tea
Highest exposure: OR 0.51 (95% CI 0.27–0.96)
Exposure assessment B: intake of green tea
Intermediate exposure: OR 0.40 (95% CI 0.14–1.14)
Highest exposure: OR 0.40 (95% CI 0.19–0.82)
Comparability: 2/2 stars, low risk
Exposure: 2/3 stars, self-reported exposure not within
a structured interview or questionnaire.
Total score: 7/9 stars, moderate quality.
Zheng 1993 Reference category: lowest exposure
Oral cancer
Highest exposure: HR 0.85 (95% CI 0.32–2.31)
Low risk:
Selection: 3/4 stars, hospital controls
Comparability: 2/2 stars, low risk
Exposure: 2/3 stars, self-reported exposure not within
a structured interview or questionnaire
Total score: 7/9 stars, moderate quality.
Zhong 2001 Reference category: lowest exposure
Lung cancer
Highest exposure: OR 0.65 (95% CI 0.45-0.93) in non-
smokers
Highest exposure: OR 0.94 (95% CI 0.40-2.22) in smok-
ers
Low risk:
Selection: 4/4 stars, low risk
Comparability: 2/2 stars, low risk
Exposure: 2/3 stars, non-response rate different be-
tween cases and controls or NR
Total score: 8/9 stars, moderate quality.
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Study Random
sequence
generation
Allocation
conceal-
ment
Blinding of participants
and personnel
Blinding of outcome as-
sessment
Incomplete outcome data Selective
reporting
Other bias
Bettuzzi
2006
Low risk Unclear risk Low risk (all outcomes) Low risk: PSA levels
Unclear risk: prostate cancer
and LUTS
Low risk: prostate cancer and
PSA levels
Unclear risk: LUTS
Unclear risk Low risk
Dostal 2015 Low risk Low risk Low risk (all outcomes) Low risk (all outcomes) Low risk (all outcomes) Low risk Unclear risk
Dryden 2013 Low risk Low risk Low risk (all outcomes) Low risk (all outcomes) Low risk (all outcomes) Low risk High risk
Garcia 2014 Low risk Low risk Low risk (all outcomes) Low risk (all outcomes) Low risk (all outcomes) Low risk Low risk
Garland
2006
Low risk Unclear risk Low risk (all outcomes) Low risk (all outcomes) High risk Low risk Unclear risk
Kumar 2015 Low risk Low risk Low risk (all outcomes) Low risk (all outcomes) Low risk: prostate cancer and
PSA levels
Unclear risk: LUTS
Low risk Unclear risk
Lane 2018 Low risk Low risk Low risk (all outcomes) Low risk (all outcomes) Unclear risk (all outcomes) High risk Unclear risk
Micali 2017 Low risk Unclear risk Low risk (all outcomes) Low risk (all outcomes) Low risk (all outcomes) Unclear risk High risk
Roshdy 2013 Low risk Low risk Low risk (all outcomes) Low risk (all outcomes) Unclear risk (all outcomes) Low risk Unclear risk
Sinicrope
2017
Low risk Unclear risk Low risk (al outcomes) Unclear risk (all outcomes) Low risk (all outcomes) Low risk Low risk
Tsao 2009 Low risk Low risk Low risk (al outcomes) Low risk: other outcomes
Unclear risk: oral lesions
Unclear risk (all outcomes) Unclear risk Low risk
LUTS: lower urinary tract symptoms; PSA: prostate-specific antigens
Table 7.   Methodological quality of experimental studies 
 
 
Cochrane
Library
Trusted evidence.
Inform
ed decisions.
Better health.
  
Cochrane Database of System
atic Review
s
Green tea (Cam
ellia sinensis) for the prevention of cancer (Review
)
Copyright ©
 2020 The Cochrane Collaboration. Published by John W
iley & Sons, Ltd.
264
Selection Com-
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OutcomeStudy
S1 S2 S3 S4 C1 C2 O1 O2 O3
To-
tal
(out
of
9)
Allen 2004 c(0) a(1) b(1) a(1) 1 0 b(1) a(1) a(1) 7
Chyou 1993 b(1) a(1) b(1) a(1) 1 1 b(1) a(1) a(1) 9
Dai 2010 a(1) a(1) b(1) a(1) 1 1 b(1) b(0) b(1) 8
Fujino 2002 in: Inoue 2009a a(1) a(1) b(1) a(1) 1 0 b(1) a(1) a(1) 8
Galanis 1998 b(1) a(1) b(1) a(1) 1 0 b(1) b(0) b(1) 7
Hoshiyama 2002 in: Inoue 2009a a(1) a(1) b(1) a(1) 1 1 b(1) a(1) c(0) 8
Hoshiyama 2004a in: Inoue 2009a a(1) a(1) a(1) a(1) 1 1 b(1) a(1) c(0) 8
Ide 2007 a(1) a(1) b(1) a(1) 1 1 b(1) a(1) a(1) 9
Inoue 2009a a(1) a(1) b(1) a(1) 1 1 b(1) a(1) b(1) 9
Inoue 2009b a(1) a(1) b(1) a(1) 1 1 b(1) a(1) a(1) 9
Ishikawa 2006 a(1) a(1) b(1) a(1) 1 1 b(1) a(1) c(0) 8
Iwai 2002 a(1) a(1) b(1) a(1) 1 0 b(1) a(1) b(1) 8
Iwasaki 2010a a(1) a(1) b(1) a(1) 1 1 b(1) a(1) b(1) 9
Iwasaki 2010b in: Iwasaki 2010a a(1) a(1) b(1) a(1) 1 0 b(1) a(1) b(1) 8
Key 1999 c(0) a(1) b(1) a(1) 1 0 b(1) a(1) a(1) 7
Khan 2004 a(1) a(1) b(1) a(1) 1 1 b(1) a(1) a(1) 9
Kikuchi 2006 a(1) a(1) b(1) a(1) 1 1 b(1) a(1) b(1) 9
Kurahashi 2007 a(1) a(1) b(1) a(1) 1 1 b(1) a(1) b(1) 9
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Kurahashi 2009 a(1) a(1) b(1) a(1) 1 1 b(1) a(1) b(1) 9
Kuriyama 2006 a(1) a(1) b(1) a(1) 1 1 b(1) a(1) a(1) 9
Lee 2007 a(1) a(1) b(1) a(1) 1 1 b(1) a(1) b(1) 9
Li 2008 a(1) a(1) b(1) a(1) 1 1 b(1) a(1) b(1) 9
Li 2018 c(0) a(1) b(1) a(1) 1 1 b(1) a(1) b(1) 8
Lin 2008 a(1) a(1) b(1) a(1) 1 1 b(1) a(1) a(1) 9
Liu 2016 a(1) a(1) b(1) a(1) 1 1 b(1) a(1) a(1) 9
Luo 2007 a(1) a(1) b(1) a(1) 1 1 b(1) a(1) b(1) 9
Makiuchi 2016 a(1) a(1) b(1) a(1) 1 1 b(1) a(1) b(1) 9
Michikawa 2011 a(1) a(1) b(1) a(1) 1 1 b(1) a(1) b(1) 9
Montague 2012 a(1) a(1) b(1) a(1) 1 1 b(1) a(1) b(1) 9
Nagano 2001 c(0) a(1) b(1) a(1) 1 1 b(1) a(1) a(1) 8
Naganuma 2009 a(1) a(1) b(1) a(1) 1 1 b(1) a(1) a(1) 9
Nakachi 2000 a(1) a(1) b(1) a(1) 1 1 b(1) a(1) a(1) 9
Nakamura 2011 a(1) a(1) b(1) a(1) 1 1 b(1) a(1) b(1) 9
Nechuta 2012 a(1) a(1) b(1) a(1) 1 1 b(1) a(1) a(1) 9
Oba 2006 a(1) a(1) b(1) a(1) 1 1 b(1) a(1) b(1) 9
Odegaard 2015 a(1) a(1) b(1) a(1) 1 1 b(1) a(1) b(1) 9
Ogawa 2016 a(1) a(1) b(1) a(1) 1 1 b(1) a(1) b(1) 9
Saito 2015 a(1) a(1) b(1) a(1) 1 1 b(1) a(1) b(1) 9
Sasazuki 2004 in: Inoue 2009a a(1) a(1) b(1) a(1) 1 1 b(1) a(1) b(1) 9
Table 8.   Methodological quality of nonexperimental cohort studies  (Continued)
Cochrane
Library
Trusted evidence.
Inform
ed decisions.
Better health.
  
Cochrane Database of System
atic Review
s
Green tea (Cam
ellia sinensis) for the prevention of cancer (Review
)
Copyright ©
 2020 The Cochrane Collaboration. Published by John W
iley & Sons, Ltd.
266
Sauvaget 2005 in: Nagano 2001 c(0) a(1) b(1) a(1) 1 1 b(1) a(1) a(1) 8
Severson 1989 a(1) a(1) b(1) a(1) 1 0 b(1) a(1) b(1) 8
Shimazu 2008 a(1) a(1) b(1) a(1) 1 1 b(1) a(1) b(1) 9
Sun 2007 a(1) a(1) b(1) a(1) 1 1 b(1) a(1) b(1) 9
Suzuki 2004 a(1) a(1) b(1) a(1) 1 1 b(1) a(1) b(1) 9
Suzuki 2005 a(1) a(1) b(1) a(1) 1 1 b(1) a(1) b(1) 9
Suzuki 2009 a(1) a(1) b(1) a(1) 1 1 b(1) a(1) b(1) 9
Tamura 2018 a(1) a(1) b(1) a(1) 1 1 b(1) a(1) b(1) 9
Tsubono 2001 in: Inoue 2009a a(1) a(1) b(1) a(1) 1 1 b(1) a(1) b(1) 9
Ugai 2017 a(1) a(1) b(1) a(1) 1 1 b(1) a(1) b(1) 9
Ugai 2018 a(1) a(1) b(1) a(1) 1 1 b(1) a(1) b(1) 9
Ui 2009 a(1) a(1) b(1) a(1) 1 1 b(1) a(1) b(1) 9
Yang 2007 in: Nechuta 2012 a(1) a(1) b(1) a(1) 1 1 b(1) a(1) b(1) 9
Yang 2011a a(1) a(1) b(1) a(1) 1 1 b(1) a(1) b(1) 9
Zhao 2017 a(1) a(1) b(1) a(1) 1 1 b(1) a(1) b(1) 9
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Bandera 2010 a(1) a(1) a(1) a(1) 1 1 b(1) a(1) c(0) 8
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Berroukche 2012 a(1) a(1) b(0) a(1) 1 1 b(1) a(1) a(1) 8
Bonner 2005 a(1) a(1) a(1) b(0) 1 1 c(0) a(1) a(1) 7
Chen 2011 a(1) a(1) b(0) a(1) 1 1 b(1) a(1) a(1) 8
Chen 2015 in: Chen 2017a a(1) a(1) a(1) a(1) 1 1 b(1) a(1) a(1) 9
Chen 2016 in: Chen 2017a a(1) a(1) b(0) a(1) 1 1 b(1) a(1) a(1) 8
Chen 2017a a(1) a(1) b(0) a(1) 1 1 b(1) a(1) a(1) 8
Fu 2013 a(1) a(1) b(0) a(1) 1 1 b(1) a(1) a(1) 8
Gao 1994 a(1) a(1) b(0) a(1) 1 1 b(1) a(1) c(0) 7
Gao 2005 a(1) a(1) a(1) a(1) 1 0 b(1) a(1) c(0) 7
Gavrilas 2018 a(1) a(1) c(0) a(1) 1 1 b(1) a(1) c(0) 7
Goodman 2003 a(1) a(1) a(1) a(1) 1 0 b(1) a(1) a(1) 8
Goto 1990 a(1) a(1) a(1) b(0) 1 1 b(1) a(1) c(0) 7
Green 2014 a(1) a(1) a(1) a(1) 1 1 b(1) a(1) c(0) 8
Hakim 2000 a(1) a(1) a(1) a(1) 1 0 b(1) a(1) a(1) 8
Han 2008 a(1) a(1) a(1) a(1) 1 1 b(1) a(1) c(0) 8
Hemelt 2010 a(1) a(1) b(0) a(1) 1 1 b(1) a(1) c(0) 7
Hoshiyama 1992 a(1) a(1) a(1) a(1) 1 1 b(1) a(1) c(0) 8
Hsu 2012 a(1) a(1) a(1) a(1) 1 1 b(1) a(1) c(0) 8
Huang 1999 a(1) a(1) b(0) a(1) 1 1 b(1) a(1) b(0) 7
Inoue 1994 in: Huang 1999 a(1) a(1) b(0) a(1) 1 0 d(0) a(1) a(1) 6
Inoue 1998 a(1) a(1) b(0) a(1) 1 1 d(0) a(1) a(1) 7
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Inoue 2008 a(1) a(1) a(1) a(1) 1 0 b(1) a(1) c(0) 7
Islami 2009 a(1) a(1) a(1) a(1) 1 1 b(1) a(1) b(0) 8
Iwasaki 2014 a(1) a(1) b(0) a(1) 1 1 b(1) a(1) b(0) 7
Ji 1996 a(1) a(1) a(1) a(1) 1 1 b(1) a(1) c(0) 8
Ji 1997 a(1) a(1) a(1) a(1) 1 1 b(1) a(1) b(0) 8
Jia 2016 a(1) a(1) a(1) a(1) 1 0 c(0) a(1) a(1) 7
Jian 2004 a(1) a(1) b(0) a(1) 1 1 b(1) a(1) a(1) 8
Jin 2013 a(1) a(1) a(1) a(1) 1 1 b(1) a(1) a(1) 9
Kakuta 2009 a(1) a(1) b(0) a(1) 1 1 b(1) a(1) a(1) 8
Kato 1990 a(1) b(0) a(1) a(1) 1 0 d(0) a(1) a(1) 6
Kato 1990a in: Huang 1999 a(1) b(0) b(0) a(1) 1 0 d(0) a(1) a(1) 5
Kono 1988a a(1) a(1) a(1) a(1) 1 1 b(1) b(0) b(0) 7
Kono 1988b a(1) a(1) b(0) a(1) 1 1 b(1) b(0) b(0) 6
Kubik 2004 in: Kubik 2008 a(1) a(1) b(0) a(1) 1 1 b(1) a(1) c(0) 7
Kubik 2008 a(1) a(1) b(0) a(1) 1 1 b(1) a(1) c(0) 7
Kuo 2009 a(1) a(1) a(1) a(1) 0 0 b(1) a(1) c(0) 6
Lassed 2016 a(1) a(1) b(0) a(1) 0 0 b(1) a(1) a(1) 6
Le Marchand 2000 a(1) a(1) a(1) a(1) 1 1 b(1) a(1) a(1) 9
Lee 2017 a(1) a(1) b(0) a(1) 1 1 b(1) a(1) c(0) 7
Lei 1994 c(0) b(0) b(0) a(1) 1 0 e(0) a(1) c(0) 3
Leung 2016 a(1) a(1) a(1) a(1) 1 1 b(1) a(1) a(1) 9
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Li 2011aa a(1) a(1) a(1) a(1) 1 1 b(1) a(1) c(0) 8
Li 2011ab a(1) a(1) b(0) a(1) 1 1 b(1) a(1) c(0) 7
Li 2011b in: Mu 2003 a(1) a(1) a(1) a(1) 1 1 b(1) a(1) c(0) 8
Li 2014 a(1) a(1) a(1) a(1) 1 0 b(1) a(1) b(0) 7
Li 2016 a(1) a(1) b(0) a(1) 1 0 b(1) a(1) a(1) 7
Lin 2012 a(1) a(1) b(0) a(1) 1 0 b(1) a(1) b(0) 6
Liu 2010 a(1) a(1) a(1) a(1) 1 1 b(1) a(1) a(1) 9
Liu 2017 a(1) a(1) b(0) a(1) 1 1 b(1) a(1) a(1) 8
Mao 2011 a(1) a(1) b(0) b(0) 1 1 b(1) a(1) b(0) 6
Mizoo 2013 a(1) a(1) b(0) a(1) 1 0 b(1) a(1) a(1) 7
Mizuno 1992 a(1) a(1) b(0) a(1) 1 0 b(1) a(1) b(0) 6
Mu 2003 a(1) b(0) a(1) a(1) 1 1 b(1) a(1) c(0) 7
Mu 2005 in: Mu 2003 a(1) a(1) a(1) a(1) 1 1 b(1) a(1) c(0) 8
Nagle 2010 a(1) a(1) a(1) a(1) 1 1 b(1) a(1) c(0) 8
Oze 2014 a(1) a(1) a(1) a(1) 1 1 b(1) a(1) b(0) 8
Peng 2013 a(1) a(1) a(1) a(1) 1 0 b(1) a(1) b(0) 7
Peng 2015 a(1) a(1) a(1) a(1) 1 1 b(1) a(1) b(0) 8
Ruan 2010 a(1) a(1) b(0) a(1) 1 0 b(1) a(1) a(1) 7
Setiawan 2001 a(1) a(1) a(1) a(1) 1 1 b(1) a(1) c(0) 8
Shrubsole 2009 a(1) a(1) a(1) a(1) 1 0 b(1) a(1) b(0) 7
Song 2008 a(1) a(1) a(1) a(1) 1 1 b(1) a(1) b(0) 8
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Sonoda 2004 a(1) a(1) b(0) a(1) 1 1 b(1) a(1) b(0) 7
Tajima 1985 a(1) a(1) b(0) a(1) 1 0 b(1) a(1) b(0) 6
Takezaki 2000 a(1) a(1) b(0) a(1) 1 1 b(1) a(1) a(1) 8
Takezaki 2001 a(1) a(1) b(0) a(1) 1 1 b(1) a(1) a(1) 8
Tewes 1990 b(0) a(1) a(1) a(1) 1 1 b(1) a(1) b(0) 7
Tse 2017 a(1) a(1) b(0) a(1) 1 0 b(1) a(1) b(0) 6
Wakai 2004 a(1) a(1) b(0) a(1) 1 1 b(1) a(1) a(1) 8
Wang 1999 a(1) a(1) a(1) a(1) 1 1 e(0) a(1) c(0) 7
Wang 2006 a(1) a(1) a(1) a(1) 0 0 b(1) a(1) b(0) 6
Wang 2007 a(1) a(1) a(1) a(1) 1 0 b(1) a(1) b(0) 7
Wang 2012a a(1) a(1) b(0) a(1) 1 0 b(1) a(1) c(0) 6
Wang 2012b a(1) a(1) b(0) a(1) 1 0 b(1) a(1) a(1) 7
Wang 2012c a(1) a(1) a(1) a(1) 1 1 b(1) a(1) c(0) 8
Wang 2013a a(1) a(1) b(0) a(1) 1 0 b(1) a(1) a(1) 7
Wang 2013b a(1) a(1) b(0) a(1) 1 1 b(1) a(1) c(0) 7
Wang 2015 a(1) a(1) b(0) a(1) 1 1 b(1) a(1) c(0) 7
Wilkens 1996 a(1) a(1) a(1) a(1) 1 1 b(1) a(1) c(0) 8
Wu 2003 a(1) a(1) a(1) a(1) 1 1 b(1) a(1) a(1) 9
Wu 2009a a(1) b(0) b(0) a(1) 1 0 b(1) a(1) c(0) 5
Wu 2009b a(1) b(0) a(1) a(1) 1 1 b(1) a(1) a(1) 8
Xu 2007 a(1) a(1) a(1) a(1) 1 0 b(1) a(1) a(1) 8
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Xu 2013 c(0) b(0) c(0) a(1) 1 0 b(1) a(1) c(0) 4
Yan 2016 a(1) a(1) a(1) a(1) 1 1 b(1) a(1) c(0) 8
Ye 1998 a(1) a(1) a(1) a(1) 1 0 b(1) a(1) b(0) 7
Yu 1995 a(1) a(1) a(1) a(1) 1 1 b(1) a(1) c(0) 8
Zhang 2002 a(1) a(1) b(0) a(1) 1 1 b(1) a(1) b(0) 7
Zhang 2007 a(1) a(1) b(0) a(1) 1 1 b(1) a(1) a(1) 8
Zhang 2008 a(1) a(1) b(0) a(1) 1 1 b(1) a(1) b(0) 7
Zheng 1993 a(1) a(1) b(0) a(1) 1 1 b(1) a(1) b(0) 7
Zhong 2001 a(1) a(1) a(1) a(1) 1 1 b(1) a(1) c(0) 8
Table 9.   Methodological quality of nonexperimental case-control studies  (Continued)
aPopulation controls considered; bHospital controls considered.
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1. MeSH descriptor: [Tea] explode all trees
#2. MeSH descriptor: [Camellia sinensis] this term only
#3. (green or antiox* or anti-ox* or matsu or mattsu* or gruner*) near/5 (tea* or tee* or thea* or cha*)
#4. camellia sinensis
#5. tea or thea or tee or matsu-cha or mattsu-cha
#6. #1 or #2 or #3 or #4 or #5
#7. MeSH descriptor: [Neoplasms] explode all trees
#8. cancer* or tumor* or tumour* or neoplas* or malignan* or carcinoma* or adenocarcinoma* or oncol*
#9. #7 or #8
#10. #6 and #9
Appendix 2. Medline Ovid search strategy
1. exp Tea/
2. Camellia sinensis/
3. ((green or antiox* or anti-ox* or matsu or mattsu* or gruner*) adj5 (tea* or tee* or thea* or cha*)).mp.
4. camellia sinensis.mp.
5. (tea or thea or tee or matsu-cha or mattsu-cha).mp. [mp=title, abstract, original title, name of substance word, subject heading word,
keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
6. 1 or 2 or 3 or 4 or 5
7. exp Neoplasms/
8. (cancer* or tumor* or tumour* or neoplas* or malignan* or carcinoma* or adenocarcinoma* or oncol*).mp.
9. 7 or 8
10. 6 and 9
11. randomized controlled trial.pt.
12. controlled clinical trial.pt.
13. randomized.ab.
14. placebo.ab.
15. clinical trials as topic.sh.
16. randomly.ab.
17. trial.ti.
18. exp case control studies/
19. exp cohort studies/
20. case control.tw.
21. (cohort adj (study or studies)).tw.
22. cohort analy*.tw.
23. (follow up adj (study or studies)).tw.
24. (observational adj (study or studies)).tw.
25. longitudinal.tw.
26. retrospective.tw.
27. cross sectional.tw.
28. cross-sectional studies/
29. 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28
30. (animals not (humans and animals)).sh.
31. 29 not 30
32. 10 and 31
key:
mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept,
rare disease supplementary concept, unique identifier
pt = publication type
ab = abstract
fs = floating subheading
Appendix 3. Embase Ovid search strategy
1. exp tea/
2. Camellia sinensis/
3. ((green or antiox* or anti-ox* or matsu or mattsu* or gruner*) adj5 (tea* or tee* or thea* or cha*)).mp.
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4. camellia sinensis.mp.
5. (tea or thea or tee or matsu-cha or mattsu-cha).mp.
6. 1 or 2 or 3 or 4 or 5
7. exp neoplasm/
8. (cancer* or tumor* or tumour* or neoplas* or malignan* or carcinoma* or adenocarcinoma* or oncol*).mp.
9. 7 or 8
10. 6 and 9
11. exp controlled clinical trial/
12. randomized.ab.
13. randomly.ab.
14. trial.ab.
15. groups.ab.
16. exp case control study/
17. exp cohort analysis/
18. case control.tw.
19. (cohort adj (study or studies)).tw.
20. cohort analy*.tw.
21. (follow up adj (study or studies)).tw.
22. (observational adj (study or studies)).tw.
23. longitudinal.tw.
24. retrospective.tw.
25. cross sectional.tw.
26. cross-sectional studies/
27. 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26
28. (animals not (humans and animals)).sh.
29. 27 not 28
30. 10 and 29
key:
[mp = title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade
name, keyword]
Appendix 4. Newcastle-Ottawa Scale for nonexperimental cohort studies
Note: a study can be awarded a maximum of one star for each numbered item within the selection and
outcome categories. A maximum of two stars can be given for comparability.
Selection
1. Representativeness of the exposed cohort
a. truly representative of the average general population in the community (*)
b. somewhat representative of the average general population in the community (*)
c. selected group of users eg nurses, volunteers
d. no description of the derivation of the cohort
2. Selection of the non exposed cohort
i. drawn from the same community as the exposed cohort (*)
ii. drawn from a diGerent source
iii. no description of the derivation of the non exposed cohort
3. Ascertainment of exposure
a. secure record (eg surgical records) (*)
b. structured interview or use of food frequency questionnaire (*)
c. written self-report
d. no description
4. Demonstration that outcome of interest was not present at start of study
a. yes (*)
b. no
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Comparability
1. Comparability of cohorts on the basis of the design or analysis
a. study controls for age and sex (when appropriate) (*)
b. study controls for any additional factor (*) smoking habits
Outcome
1. Assessment of outcome
a. independent blind assessment (*)
b. record linkage (e.g. cancer registry) (*)
c. self-report
d. no description
2. Was follow-up long enough for outcomes to occur
a. yes, more than 5 years (*)
b. no, less than 5 years
3. Adequacy of follow-up of cohorts
a. complete follow-up - all participants accounted for (*)
b. participants lost to follow-up unlikely to introduce bias - small number lost - > 90% (select an adequate %) follow up, or description
provided of those lost) (*)
c. follow-up rate < 90 % (select an adequate %) and no description of those lost
d. no statement
Appendix 5. Newcastle-Ottawa Scale for nonexperimental case-control studies
Note: a study can be awarded a maximum of one star for each numbered item within the selection and
exposure categories. A maximum of two stars can be given for comparability.
Selection
1. Is the case definition adequate?
a. yes, with independent validation (*)
b. yes, e.g. record linkage or based on self-reports
c. no description
2. Representativeness of the cases
a. consecutive or obviously representative series of cases (*)
b. potential for selection biases or not stated
3. Selection of controls
a. community/population controls (*)
b. hospital controls
c. no description
4. 4) Definition of controls
a. no history of disease (endpoint) (*)
b. no description of source
Comparability
1. Comparability of cases and controls on the basis of the design or analysis
2. study controls for age and sex (when appropriate) (*)
3. study controls for any additional factor (*) smoking status
Exposure
1. Ascertainment of exposure
a. secure record (eg surgical records) (*)
b. structured interview blinded to case/control status or use of food frequency quesionannaire (*)
c. interview not blinded to case/control status
d. written self-report or medical record only
e. no description
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2. Same method of ascertainment for cases and controls
a. yes (*)
b. no
3. Non-response rate
a. same rate for both groups (*)
b. nonrespondents described
c. rate diGerent and no designation
W H A T ' S   N E W
 
Date Event Description
18 July 2019 New search has been performed An updated search from January 2009 to January 2019 was con-
ducted and 93 new studies were added to 52 in the review.
18 July 2019 New citation required but conclusions
have not changed
We included an additional 130 references relating to 93 studies.
However the conclusions overall remain unchanged.
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Link with editorial base and co-ordination of contributions from co-reviewers (FB, MM, MV, TF)
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Identify relevant titles (FB, MM, TF)
Selection of included studies (MM, MV, TF)
Extraction of data from included studies (MM, TF)
Methodological quality assessment (AAI, FB, MM, MV, TF)
Interpretation of analysis (all authors)
DraKing final review (MV and TF, with contributions from all)
D E C L A R A T I O N S   O F   I N T E R E S T
TF: none known
MM: none known
FB: none known
AAI: none known
SF: none known
MH: none known
MV: none known
S O U R C E S   O F   S U P P O R T
Internal sources• Pilkington Family Trusts, UK.
External sources• AG Biologische Krebstherapie, Deutsche Krebshilfe, Bonn, Germany.• Cochrane Gyneacological Cancer Review Group, UK.• Nordic Cochrane Centre / ViFab, Denmark.
D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
In contrast to the previous version of this review (Boehm 2009), we included a quantitative assessment of cancer risk related to green tea
intake, adding a meta-analysis of all cancer outcomes whenever there were suGicient data available to perform the analysis.
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